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ABSTRACT 
The objective of this thesis is to find solutions to the access to medicine 
problem in Nigeria whilst still complying with the TRIPS Agreement.  The 
study reveals that apart from the high prices of medicines, there are other 
major domestic factors such as the lack of social amenities, the failure of the 
pharmaceutical industry to become self reliant, counterfeit drugs and lack of 
recognition for traditional medicines which have contributed to the lack of 
medicines for HIV/AIDS and other opportunistic diseases that are a major 
public health problem in Nigeria. 
 
In fulfilling the objective of this study, the thesis notes that many Nigerian 
laws are based on the British legal system; a historical analysis of the patent 
system in Britain and indeed Europe is therefore carried out. The historical 
analysis is relevant in recognizing how the patent concept developed and 
evolved into becoming one of the most powerful components of the multi- 
lateral trading system and why developing countries like Nigeria have 
struggled with the concept. 
 
The HIV/AIDS epidemic in Nigeria, neglected diseases and counterfeit drugs 
are also examined with key emphasis on the Nigerian governments’ position 
on tackling the access to medicines problem. In that section an examination of 
the human rights approach to confronting the access to medicines crisis is 
conducted with a view of encouraging the respect and protection of 
fundamental human rights whilst still complying with the TRIPS Agreement. 
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Ultimately a comparative analysis of the Nigerian and Indian pharmaceutical 
industry is carried out in order to extract lessons which may be useful to the 
Nigerian government when initiating public health policies and amending its 
intellectual property laws which are presently out-of-date. In the end the thesis 
stipulates ways in which Nigeria can take advantage of the flexibilities of 
compulsory licenses and parallel importation within the TRIPS Agreement to 
gain access to medicines.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my father and mother Zegetar and Torkwase Iyortyer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
5 
 
ACKNOWLEDGEMENTS 
I once read a PhD candidate’s acknowledgement who said it is customary to 
begin such acknowledgements with a bout of name dropping, so I choose to 
begin mine with Friedrich Nietzsche quote “what does not destroy me makes 
me stronger”.  
 
My thanks and gratitude goes to my supervisors Professor Deryk Berylevd and 
Dr Antonis Antoniadis for their invaluable help and support. To my first 
supervisor Professor Ronan Deazley, for giving me the opportunity to 
investigate and discover the plight of people in my own country who do have a 
voice because they live on the edges of oblivion.  To Dr Mike Adcook for his 
advice. To Colin Baxter, who taught me at the University of Hull that your 
research must always have a focus. To Diana Webb, my history teacher and all 
the staff at St’Mary’s School who taught me what kindness is when I arrived in 
Wantage, Oxfordshire from an entirely different culture.  
 
To Uwanaka the Principal of Federal Government Girls College, Bwari - who 
would have ever thought that one day I would be grateful for all the long hard 
years of hardship and discipline, without which I probably would have gone 
through life never truly knowing what it is like on the other side of the fence.  
To Professor Charles Wambebe who provided me with invaluable data and 
advice on how to tackle the access to medicines debate. To Mr Salihu Aliyu at 
the Ministry of Justice in Nigeria who welcomed me when I first went to 
Nigeria looking for data and information on this thesis. To Professor I. A 
Ayua, Senior Advocate of Nigeria (SAN) who has shown considerable interest 
in my work and progress.   
 
Thank you to my parents, Zegetar and Torkwase for their massive hearts. 
These two great figures have not only given me the gift of life, but have taught 
me how to think and believe in whatever is good, excellent and inspirational. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
6 
 
Whenever I found my strength lacking in the pursuit to deliver, they kept 
pushing and encouraging. As a matter of fact Zegetar has become an expert on 
the field, because we both combined forces in making this happen. For me, 
everything that I am and will ever be first began with the unconditional love 
and support they have showed me. Their love has never wavered and has never 
wandered. I love you. 
 
To my sisters Iwasen, Avershima and Iveren, you girls have filled my life with 
beautiful memories and lovely stories and I will always have fun memories 
when I think of all the wonderful and sometimes crazy times we shared. I wish 
you girls all the best. To my brother Bem, may God be your compass. To all 
my friends who have given me encouragement and support during this journey. 
 
To Peter, I know you are in a better place and you are smiling down on us. We 
love you and miss you. To Kamto, thank you for coming into our lives. You 
make the world beautiful  and all I have to do is look at your wonderful smile 
and I know that everything is possible. I love you pumpkin, keep shining. To 
Jeffrey Chidi, the man of my dreams, my partner, my husband and the love of 
my life, you are my mirror and have touched my life in so many ways. You 
have made many of my dreams and aspirations a reality.  I only wish we had 
begun this wonderful journey earlier, so here is a toast to our favourite word 
“connection” and another to a joyful and blessed forever with you. 
 
Most earnestly thank you God for making everything possible in my life 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
7 
 
    CONTENTS 
ABSTRACT                               2 
LIST OF CONTENTS                  7 
LIST OF ACRONYMS       12 
LISTS OF DIAGRAMS, CHARTS AND TABLES   18 
ACKNOWLDGEMENT        
DECLARATION        19 
  
1 INTRODUCTION  
 1.1 The Problem       20 
1.2 Statement of purpose      24 
1.3 Scope of Study       27 
1.4 Summary        29 
 
PART I 
2  THE TRIPS AGREEMENT AND ACCESS TO ESSENTIAL 
MEDICINES IN DEVELOPING COUNTRIES: AN OVERVIEW 
 
2.1  Introduction        30 
2.2 Cost of R&D       33 
2.3  The TRIPS Agreement      35 
2.4   Intellectual Property Rights before the WTO  38 
2.4.1 The Negotiation Process (1986-1994) From Punta Del 
Este to Marrakech     39 
2.4.2 Resistance from Developing Countries    41 
2.5 The Question       41 
2.5.1 World Intellectual Property Organisation  44 
  2.5.2 Problems with WIPO    45 
2.6   Summary       49 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
8 
 
3 THE JURISPRUDENCE OF INTELLECTUAL PROPERTY 
RIGHTS – A VALUABLE BACKDROP TO PATENTS 
3.1  Introduction        50 
3.2  History of the emergence of International Industrial 
Property        52 
3.3 What does the phrase Intellectual property rights means?
         54 
3.4 Patents       61 
3.4.1 The Venetian influence on Patents    62 
            3.4.2    Patents spread to other parts of Europe  66 
3.4.2.1 France  66 
3.4.2.2 Germany   69 
3.5 The Birth and Growth of the Early patent Doctrine in 
Britain.        73 
3.6 The Birth of the Modern Patent Doctrine   85 
3.7  Monopoly       88 
3.8  Justifications for Intellectual Property Rights – Patents  93 
3.8.1  Natural rights Theory    94 
3.8.2 The “incentive to invent” Theory   98 
3.8.3   To promote Investments    101 
3.9      Summary       104 
 
PART II 
4         HUMAN RIGHTS  
4.1  Introduction        105 
4.2 The Development of the Right to Health in International Law 111 
4.2.1 UNDR       112 
4.2.2 ICESCR      116 
4.3 Human Right Obligation of Multinational Corporations  125 
4.4 Summary        128 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
9 
 
 
5        HIV/AIDS IN EPIDEMIC IN NIGERIA  
 
5.1 Introduction       130 
5.2  Background of AIDS in Nigeria    131 
5.3  HIV/AIDS crisis in Nigeria put in Human Rights Perspective 138 
5.4  Violation of the Human Right to Health in Nigeria 140 
5.5  ARV Distribution in Nigeria    141 
5.6 Nigeria Response to HIV/AID Compared to other Countries 
that have successfully confronted the Diseases.    143 
5.7 The Nigerian Government National Response  150 
5.8 NACA        158 
5.9 Summary        160 
 
6 NEGLECTED DISEASES, DRUG COUNTERFEITING AND 
HUMAN RIGHTS 
 
6.1  Introduction       163 
6.2  Neglected diseases: a Symbol for Neglected People 165 
6.3  R& D for Neglected Diseases     168 
6.4  Tuberculosis       170 
6.5       Partnership Initiatives into R&D for Neglected Diseases  172 
6.6       Drug counterfeiting                                                              179 
6.6.1  The Need to have a Common Definition for 
counterfeit drug                          182 
6.6.2 Counterfeit Drugs: a Flourishing Business in 
Developing Countries in South America    184 
6.6.3    Counterfeit Drugs: a Flourishing Business in 
Developing Countries in Asia    187 
6.6.4   Counterfeit Drugs from India   189 
6.7    NAFDAC       191 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
10 
 
6.8  The Fight Against Counterfeit    202                                                                
            6.9      Summary                                                                                 209
  
PART III 
7 THE FLEXIBILITIES WITHIN THE TRIPS AGREEMENT 
EXPOSED  
7.1  Introduction        211 
7.2  What brought about the Doha declaration?  212 
7.3  Demands of the Developing countries during the Doha 
Declaration           217 
7.4  Compulsory Licenses     227 
7.5  Parallel Importation      234 
7.6  Limitations of the Doha Declaration   257 
7.7  TRIPS Plus       262 
7.8  Is there TRIPS Plus in the ECP? If so is this the Way Forward for 
Nigeria?                    269 
 7.9  Summary       273 
 
8 THE PHARMACEUTICAL INDUSTRY AND ESSENTIAL 
MEDICINES 
8.1  Introduction       274 
8.2  Proximity between India and Nigeria    276 
8.3   Evolution of the Modern Pharmaceutical Industry: A 
History of the Pharmaceutical industry    278 
8.4 Leading Pharmaceutical Companies in the World ($ 
Billions)        281 
8.5  Generic Pharmaceutical Industry    287 
8.6  The origins of the Nigerian pharmaceutical Industry and 
Practice         292 
8.6.1 Problems of the Pharmaceutical Industry  295 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
11 
 
8.6.2 Nigeria’s National Health Plan    296 
8.6.3 Nigeria’s National Drugs Policy   299 
8.6.4  Essential Drug List (EDL)/ Nigeria’s Essential Drugs List  
(NEDL)       302 
8.6.5 Supply Systems     305 
8.6.6 The Present Status of the Nigerian Pharmaceutical 
Industry and Practice     309 
8.7  Background of the Indian Pharmaceutical Industry  312 
8.7.1 India’s National Drug Policy   315 
8.7.2 Disadvantages of the Indian Indigenous Firms pre-
1970 and how they were   overcome   318 
8.7.3  Product Patents and not Process Patents  320 
8.7.4 Indian Patent Act 1970    323 
8.8 Nigeria’s Patent and Design Act 1970   326 
 
 
9  CONCLUSION AND RECOMMENDATIONS: WAY FORWARD 
FOR NIGERIA                           331 
10 BIBLIOGRAPHY                 334 
 
 
 
 
 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
12 
 
LIST OF ACRONYMS 
 
 
AAIN  ActionAid International Nigeria 
ACHPR            African Commission on Human and Protection Rights  
ACP   African, Caribbean and Pacific 
ACTA    Anti Counterfeiting Trade Agreement (ACTA 
AFPAC  Armed Forces Programme on AIDS Control 
AIDS              Acquired Immuno-deficiency Syndrome 
AIPO                African Intellectual Property Organisation 
AITIC               Agency for International Trade Information and Cooperation  
 APEC   Asia-Pacific Economic Cooperation  
APIN                AIDS Prevention Initiative in Nigeria  
APOC               African Programme for Onchocerciasis Control 
ARIPO             African regional intellectual property organization 
ART   Anti-Retroviral Therapy 
ARV    Anti-Retroviral 
ASINFAR        Association of Colombian Pharmaceutical Industries  
BCPW    Bengal Chemical and Pharmaceutical Works 
BFAD  Bureau of Food and Drug  
BIRPI    Bureaux for the Protection of Intellectual Property  
CAFC Court of Appeals for the Federal Circuit 
CAFTA    Central American Free Trade Agreement 
CBD    Convention on Biological Diversity  
CBOs     Community-Based Organizations  
CDC   Centre for Disease Control and Prevention (US) 
CEDAW       Convention on the Elimination of Discrimination Against Women 
CHAN               Christian Health Association of Nigeria 
CIDA    Canadian International Development Agency 
CISNHAN   Civil Society Network for HIV/AIDS in Nigeria 
CSO  Civil Society Organizations 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
13 
 
DALE    Disability adjusted life expectancy 
DCG               Donor Coordination Group on HIV/AIDS 
DFID Department for International Development 
DIGEMID Directorate of Medicines, Supplies and Drugs  
DMA Danish Medical Agency  
DNDi   Drugs for Neglected Diseases initiative 
DPCO    Drug Price Control Authority 
DPHC    Department of Primary Health care  
DRC Democratic Republic of Congo  
ECJ    European Court of Justice 
ECOSOC   Economic and Social council 
ECOWAS   Economic Community of West African States 
EDL    Essential Drug List 
EFCC     Economic and Financial Crimes Commission  
EPA    Economic Partnership Agreement 
EPO    European Patent Office  
EU   European Union 
FBOs   Faith-Based Organizations 
FCT    Federal Capital Territory  
FDI   Foreign Direct Investment 
FERA    Foreign Exchange Regulation Act 
FHI    Family Health International 
FLE   Family Life Education  
FMIGA          Federal Ministry of Inter-governmental Affairs 
FMOE   Federal Ministry of Education 
FMOH    Federal Ministry of Health 
FTA                 Free Trade Agreement 
GAAP  Greater Access to Affordable Pharmaceuticals Act  
GATT  General Agreement on Tariff and Trade 
GDP  Gross Domestic Product 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
14 
 
GFATM  Global Fund to fight AIDS, Tuberculosis and Malaria 
GHAIN  Global HIV/AIDS Initiative Nigeria  
GIPA     Greater Involvement of People Living With HIV/AIDS 
GMP   Good Manufacturing Practices  
HAART           Highly Active Antiretroviral Therapy 
HAF   HIV/AIDS Fund 
HEAP  HIV/AIDS Emergency Action Plan 
HHS   Health and Human Services 
HIV  Human Immuno-deficiency Virus 
ICCPR  International Covenant on Civil and Political Rights 
ICESCR  International Covenant on Economic, Social and Cultural Rights  
IIPA  International Intellectual Property Alliance 
ILO International Labour Organization 
ILPIC  Industrial Licensing Policy Committee 
IMPACT  International Medical Products Anti-Counterfeiting Taskforce 
INVIMA         National Institute for the Supervision of Foods and Medication 
IPC                  Intellectual Property Committee  
IPMG              International Pharmaceutical Manufacturers Group  
IPRs   Intellectual Property Rights 
JAAIDS          Journalists Against AIDS  
LACA             Local Action committee on AIDS 
LASUTH Lagos State University Teaching Hospital 
LDC  Least Developed Countries 
LGA  Local Government Authorities 
MAP Multi-country AIDS Program 
MDGs  Millennium Development Goals 
MNCs  Multinational Corporations 
NACA  National Action Committee on AIDS  
NAFDAC National Agency for Food and Drug Administration and 
Control 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
15 
 
NASCP           National AIDS and STDs Control Program   
NASCP National HIV/AIDS/STI Control Programme 
NASSRA National Assembly Response to AIDS  
NEACA           National Expert Advisory Committee on AIDS  
NEDL   Nigeria’s Essential Drugs Policy 
NEEDS  National Economic Empowerment and Development Strategy 
NEPAD  New Economic Partnership for Africa Development  
NEPWHAN  Network of People Living with HIV/AIDS in Nigeria 
NERB   National Ethical Review Board 
NERDC           Nigerian Educational Research and Development Council  
NGO  Non-Governmental Organization 
NHIS  National Health Insurance Scheme 
NIPRD National Institute for Pharmaceutical Research and Development  
NNMDA Nigeria Natural Medicine Development Agency  
NNRIMS         Nigerian National Response Information Management System  
NOP               NNRIMS Operational  Plan 
NPC   National Planning Commission 
NQCL              National Quality Control Laboratories  
NSF   National Strategic Framework 
NUP    Nigerian Union of Pharmacist  
OCP                  Onchocerciasis Control Program  
OECD   Organization for Economic Cooperation and Development 
OEPA               Onchocerciasis Elimination Program for the Americas  
 
OI   Opportunistic Infections 
OPS   Organized Private Sector 
OVC      Orphans and Vulnerable Children 
OVD                Optically Variable Devices 
PEPFAR  President's Emergency Plan For AIDS Relief   
PhRMA  Pharmaceutical Research and Manufacturers of America 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
16 
 
PIJIP  Program on information Justice and Intellectual property  
PLWAs People Living With AIDS 
PLWHA People living with HIV and AIDS 
PMA  Pharmaceutical Manufacturers’ Association  
PMTCT    Prevention of Mother-To-Child Transmission 
PSN  Pharmaceutical Society of Nigeria  
PSRHH Promoting Sexual and Reproductive Health for HIV/AIDS 
Reduction 
R&D  Research & Development  
RFID               Radio Frequency Identification Technology  
RTIs                Reverse Transcriptase Inhibitors  
SACA             State Action Committee on AIDS 
SACU  Southern African Customs Union 
SECURE Standards Employed by Customs for Uniform Rights Enforcement 
SEEDS State Economic Empowerment and Development Strategy 
SNR  Strengthening the National Response to HIV/AIDS  
STA    State Trading Corporation  
STIs  Sexually Transmitted Infections 
STOP  US Strategy on Targeting Organised Piracy 
SUS                 Sistema Único de Saúde 
SWAA             Society Women and AIDS in Africa  
TB-DOTS    Tuberculosis Direct Observation Treatment Scheme 
TRIPS   Trade Related aspects of Intellectual Property Rights 
NOTAP  National Office for Technology Acquisition and Promotion 
UAFTA            US-Australia Free Trade Agreement 
UDHR   Universal Declaration of Human Rights 
UN   United Nations. 
UNAIDS  Joint United Nations Programme on AIDS 
UNCTAD   United Nations Conference on trade and Development  
UNDP   United Nations Development Programme 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
17 
 
UNICEF          United Nations Children’s Fund 
USAID United States Agency for International Development 
USFDA           US Food and Drug Administration  
VCT    Voluntary Counselling and Testing 
WCO   World Customs Organisation 
WB  World Bank 
WHO    World Health Organization 
WIPO  World Intellectual Property Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
18 
 
LISTS OF DIAGRAMS, CHARTS AND TABLES 
Diagram 1: National HIV Prevalence 1991 -2008    129 
Diagram 2: HIV Prevalence According to Age Group and Gender.  130 
Diagram 3: Awareness of HIV/AIDS      133 
Diagram 4: HIV Prevalence by sex and Zone in Nigeria, FMOH 2007 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
19 
 
 
DECLARATION 
In accordance with the Regulations for Higher Degrees by Research, I hereby 
declare that the whole thesis now submitted for the candidature of Doctor of 
Philosophy is a result of my own research and independent work except where 
reference is made to published literature. I also hereby certify that the work 
embodied in this thesis has not already been submitted in any substance for any 
degree and is not being concurrently submitted in candidature for any degree 
from any other institute of higher learning. I am responsible for any errors and 
omissions present in the thesis. 
 
 
    
  
 
 
 
 
 
 
 
 Candidate_____________________ 
      Hembadoon Iyortyer  
 
 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
20 
 
1.  INTRODUCTION  
1.1 The Problem 
On most days when you open the newspapers in Nigeria, there is always some 
news about the lack of medicines in the country. The difficulty of access to 
medicines in Nigeria has been compounded by numerous factors which have 
made the search for a solution more complicated. Some of these problems 
include inadequate infrastructure,  high rates of morbidity and mortality due to 
diseases, lack of technical assistance to existing laboratories and guidance on 
setting up new laboratories for improved medical/ scientific research and 
diagnosis in the country, lack of funding for the treatment of major diseases 
such as HIV/AIDS, tuberculosis and malaria, lack of human and institutional 
capacity which has affected the quality of healthcare delivery, lack of political 
will, the presence of counterfeit medicines in the Nigerian market and indeed 
around the globe, weak traditional medicine practice and an underdeveloped 
pharmaceutical industry.  All these factors have presented a very gloomy 
picture in the quest to finding a solution for access to medicines in Nigeria. 
 
Other domestic issues that have contributed towards the lack of access to 
medicine are the lack of electricity, telephone, water and transport. Indeed one 
Nigerian commentator wrote “If we can’t get electricity right, forget Nigeria”. 
Such proclamations are a regular occurrence in the daily newspapers of Nigeria 
and they signify the high level of disappointment that the indigenes feel about 
the inability of the Nigerian government to provide basic utilities that are 
essential for the major sectors of the Nigerian economy to function effectively. 
Indeed the same commentator wrote that Nigeria “lacks the collective will, to 
provide uninterrupted power supply to meet her domestic and industrial needs 
[and may therefore lose] her locus standi as a modern nation”.1  As a matter of 
                                                            
1 Tunde Fagbenle. If We Can’t Get Electricity Right, Forget Nigeria. 
http://www.nairaland.com/nigeria/topic-232182.0.html 7 February 2009 
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fact every aspect of a modern industrialized world needs a steady supply of 
electricity if it is to thrive.  
 
The problem of access to medicines is further compounded by Nigerian’s large 
population and the fact that the Nigerian government is genuinely struggling to 
meet the healthcare needs of its population; a problem which has been 
inflamed by the government’s failure to increase its national health 
expenditure. The last Nigerian population census result which was produced in 
March 2006 showed that Nigeria has a population of over 140 million people, 
nevertheless a report released by Actionaid showed that Nigeria is among the 
world’s 25th poorest nations and over 69 million of its people live in abject 
poverty.2 Without financial assistance from the national government and other 
international organisations and charities around the world the future for many 
Nigerians in accessing life saving medicines seem pretty bleak.  
 
Another major problem which has contributed to the lack of access to 
medicines in Nigeria is the fact that intellectual property is still not a well 
developed area, thus there is no up to date legal framework on the subject of 
intellectual property law. Indeed I spoke to many legal practitioners in Nigeria 
during the course of my research that struggled with the concept and had little 
knowledge about the law in this area.  It follows that although the Nigerian 
government is aware of the need to develop the law in the area of intellectual 
property if it is to compete with other countries who through their intellectual 
property laws have been able to develop their pharmaceutical industry to the 
level of producing and manufacturing medicines for its population, it must be 
acknowledged that there is still a very long way to go in making this aspiration 
a reality.  
 
                                                            
2 Ayegba Isreal Ebije, “69 million Nigerians in Abject Poverty”. Daily Trust, Wednesday, 
November 26, 2008. 
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Another complex issue which has compounded the access to the medicines 
problem is the fact that the TRIPS Agreement which has been in force since 
1995 introduced global minimum standards for the protection and enforcement 
of nearly all forms of intellectual property rights, including those on patents. 
The TRIPS Agreement requires all WTO members (to which Nigeria is a 
party) to implement the Agreement with different implementation deadlines 
depending on each country’s economic development. Nigeria like many other 
developing countries had a deadline of 2005 to become TRIPS compliant. 
Being TRIPS-compliant includes granting pharmaceutical patents for both 
process and products, however Nigeria has not yet amended its intellectual 
property laws to meet the required standards. Some of the reasons for this 
shortcoming include the fact that the growth and development of intellectual 
property rights in Nigeria has been slow when compared to countries like India 
or Brazil; lack of institutional capacity and the absence of appropriate IP-related 
technical assistance.3 The complexity however lies in that it is important for 
Nigeria to adapt its intellectual property laws to become TRIPS compliant if it 
is to take advantage of the flexibilities within the TRIPS Agreement and ensure 
that its populace have access to medicines in the short and long term.   
 
Some of the flexibilities within the TRIPS Agreement that WTO members can 
take advantage of, which have also been affirmed by the Doha Declaration in 
2001 include: (i) compulsory licences which permits 3rd parties to use an 
invention, without the patents holder’s consent (ii) government use which 
allows government agencies to use an invention for public non-commercial 
purposes (iii) parallel import which allows the importation and resale of patent 
products in other countries; other flexibilities which the government can take 
advantage of include making use of  measures such as (iv) the Bolar exception 
and the (v) Paragraph 6 system which allows import and export of generic 
                                                            
3 The pharmaceutical industry in Nigeria can gain from lose intellectual property rights laws 
and reverse engineer many medicines than stricter intellectual property rights. India was able 
to take advantage of this before the TRIPS Agreement came into place. 
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medicines under compulsory licences. The importance of incorporating these 
flexibilities into the Nigerian national law is that they will allow a degree of 
elasticity for the Nigerian government to accommodate their own patent needs, 
intellectual property systems and developmental need. If on the other hand 
Nigeria does not comply with the TRIPS Agreement or in becoming TRIPS-
compliant uses words inappropriate in the national legislation it may be forced 
to initiate TRIPS-Plus measures in the form of Free Trade Agreements (FTAs)4 
or the inclusion of data exclusivity into the Nigerian legislation.5 
 
Thus a state begins to set off TRIPS-Plus measures when it carries out 
activities that are aimed at giving right holders a level of protection that is 
higher than what is stipulated in the TRIPS Agreement. Such measures have 
the effect of reducing the ability of developing countries to protect their public 
interest. Such measures can be adopted at the multilateral, plurilateral, regional 
or national level. Sometimes they have the effect of impacting adversely on the 
healthcare delivery system by delaying the introduction of cheap medicines. 
This in the long term compounds the already existing problem of access to 
medicine which is  a major problem in many developing countries. It is with 
this backdrop at the forefront that this thesis finds its purpose and mission in 
seeking to find a solution to the access to medicines issue in Nigeria. 
 
1.2 Statement of Purpose  
The primary quest of this thesis is to find ways of conquering the access to 
medicine problem in Nigeria by finding ways of ensuring that the government 
                                                            
4 Note that some commentators have suggested that what the USA cannot accomplish through 
trade policies and behind the scene trade threats it tries to accomplish through technical 
assistance provided by USAID and by WIPO. In  See Brook K Baker. Pharma’s Relentless 
Drive for Profits. Health GAP. December 10, 2002. 
http://www.globalpolicy.org/component/content/article/209-bwi-wto/43688.html 
5 Note that data exclusivity is a means of preventing generic competition, which greatly 
restricts access to medicines. The TRIPS agreement does not refer to data exclusivity at all. It 
only refers to data protection against "unfair commercial use".    
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in becoming TRIPS compliant makes full use of all the flexibilities within the 
Agreement. This thesis will show that the Nigerian government need to adopt 
national policies that will develop the local pharmaceutical industries if it is to 
eradicate the access to medicine problem. In order to accomplish the foregoing, 
this thesis will analyze specific subject matters that shed light on the 
complexity of the issues stated above. It will conduct an in-depth analysis of 
other developing countries that  have successfully initiated the TRIPS 
Agreement and draw on their experiences and struggles in a bid to ensure that 
the Nigeria government can improve its own intellectual property rights policy 
initiatives in the future. This thesis is consequently divided into three main 
parts. 
 
Part I will provide a historical and jurisprudential background that is essential 
to understanding the key elements that continuously resound throughout the 
thesis.  Chapter Two explores the birth of the TRIPS Agreement and exposes 
the pressures that developing countries faced throughout the negotiation 
process in the Uruguay Rounds that lasted between September 1986 and April 
1994. It also exposes the initial fears that developing countries had; fears that 
were based on the belief that a stricter intellectual property system would 
impact adversely on public health. The chapter also goes further to discuss the 
gains that developing countries had at the Uruguay rounds, gains that seem 
very little when compared with those of the bloc of developed countries. The 
comparison is essential in appreciating the suitability of the multilateral trading 
system in our modern day society.  
 
Chapter Three expounds a jurisprudential examination of the patent regime and 
its historical heritage in Europe. The importance of this chapter to the entire 
structure of this thesis is it seeks to analysis the importance of the patent 
system and how it came into being. The different justifications of the concept 
of owing knowledge, inventions and ideas are developed in this chapter, whilst 
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the advantages and disadvantages of intellectual property rights as a whole are 
also explored here. The aim of the foregoing is to set the scene towards 
understanding the usefulness of patents as an incentive to driving Research and 
Development (R&D) into new discoveries for innovative new medicines.  
Chapter three is also useful in showing that the concept of patents has evolved 
for centuries in Europe and taken shape, whilst on the contrary the idealisms 
and principles of patents are not so established in many countries in the sub-
Sahara where ownership is based on communal ownership. For example in 
many parts of Africa, knowledge is seen more as a communal commodity 
rather than a product belonging to a particular individual.  This reveals certain 
aspect of why developing countries have encountered many obstacles in 
accepting and implementing the TRIPS Agreement. The chapter further 
explores the theory of natural rights, incentive to invent and investments as a 
foundation to the justification of intellectual property rights which are key 
issues in the access to medicine debate.  
 
Part II then follows by providing a revision of wide-ranging aspects of human 
rights as it relates to TRIPS and the access to Medicines debate. Chapter four 
gives a general overview of the origins of human rights, the interaction 
between human rights and trade, the human rights obligations of Multinational 
Corporations (MNC) and developed/ countries in alleviating the public health 
crisis of lack of medicines in developing countries. Chapter four is also 
significant as it examines the development of international law with regards to 
UDHR, ICESCR and the ICCPR in a bid to shade more light on the quest of 
access to medicines. 
 
Chapter five focuses specifically on HIV/AIDS as a human rights issue in 
Nigeria; it analyses the problem of HIV/AIDS in the country with an in-depth 
examination of how the Federal Government of Nigeria has responded to the 
problem.  It examines the efforts that have been made by the government in 
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procuring antiretroviral medicines in the past and whether such programs have 
been successful or not. The chapter discusses the Nigerian government’s 
national response in tackling the HIV/AIDS crisis through grass root support 
and international projects.   The Nigerian’s Agency for the Control of AIDS is 
particularly examined with major emphasis on how it has partnered with other 
international donors such as HEAP, Global funds, DFID, FHI and PEPFAR to 
pay for the high prices of medicines.  The chapter also goes further to provide 
an insight into how a few other countries including Uganda, Brazil, and South 
Africa has handled its HIV/AIDs epidemic and how Nigeria can draw lessons 
from it.  
 
Chapter six examines other important issues that shed more light on access to 
medicine as an important human rights issue. These issues include ‘neglected 
diseases’ and the refusal of the pharmaceutical industry to invest in producing 
medicines for diseases that affect mainly poor people who cannot afford to pay 
for their own medication. The chapter goes further to establish the link 
between diseases, development and terrorism as an urgent matter that needs 
immediate attention from the international community. Another important 
human rights issue that is further tackled in this chapter is drug counterfeiting. 
The trade in counterfeit drugs has continued to grow and not only does it affect 
countries like Nigeria, but industrialised countries as well. The trade in 
counterfeit medicines has caused the deaths of many unsuspecting victims and 
many human rights activist have called upon the international community to 
recognise that the trade in counterfeit medicines that causes grievously bodily 
harm (GBH) or death is a clear violation of human rights under Articles 3, 5 
and 25 of the UDHR.  
 
Part III subsequently provides a comparative analysis, with Chapter seven 
presenting a comparative analysis of the way that the UK and US have used 
the flexibilities within the TRIPS Agreement: namely compulsory licenses and 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
27 
 
parallel importation to gain access to cheaper medicines. The chapter also 
evaluates the successes and limitations of the Doha Declaration with a view of 
ascertaining what progress has been made since 2001 when the Declaration 
was announced. The Chapter concludes by evaluating whether in becoming 
TRIPS complaint Nigeria is at risk of becoming TRIPS-plus. 
 
Chapter eight concludes by conducting a comparative analysis of the 
pharmaceutical industry in Nigeria with India. Although much of the 
discussion is focused on India, the chapter presents a historical analysis of the 
pharmaceutical industry in both India and Nigeria .The analysis seeks to show 
that with the right policies Nigeria has the potential to increase the production 
of medicines for its populace thereby improving access to medicines. The 
chapter concludes by asserting that traditional medicines are the way forward 
for the development of the pharmaceutical industry in Nigeria. 
 
1.3 Scope of Study 
Although Nigeria is ultimately the central focus of this thesis, other countries 
play a very important role in the study. The reason for this are listed below: 
Nigeria has not yet developed its intellectual property rights laws, therefore it 
is necessary to  discuss how other states have developed their intellectual 
property rights laws to ascertain if there are specific policies or lessons that 
Nigeria can adopt  when attempting to develop its own intellectual property 
rights policies and legislations.  Another reason why the scope of this thesis 
extends to analysing  intellectual property laws in other countries is so to 
establish that  the TRIPS Agreement is not only harmless; but if implemented 
in the right way can promote the transfer of technology and FDI  which will 
inadvertently impact positively on the public health sector of Nigeria in the 
long run. 
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The scope of the study extends to cover a historical analysis of the patent 
system in Europe. The importance of carrying out a historical analysis on the 
evolution of the patent system in Europe lies in the fact that the concept of 
patents originated in Europe and spread throughout the world. It is therefore 
important to understand why the principle was established in the first place and 
what it intended to achieve.  This will enable one to determine whether patents 
as a whole fit into our modern day economy or not. The historical analyses of 
patents are also important because patents are a central theme of this study and 
they have been blamed for higher prices of medicines. 
 
A discussion of the Indian pharmaceutical industry also occupies a large 
section of this study. The usefulness of this lies in the fact that India has a 
similar history to Nigeria. They are both former colonies of Britain; they both 
have huge populations, rich cultures and a history of using traditional 
medicines (in the case of India -ayurveda medicines). Whilst India has 
developed its pharmaceutical industry to become one of the most prominent 
suppliers of generic medicines, Nigeria is still lacking behind.  The importance 
of this analysis is for the Nigerian government to learn from India how to 
succeed in implementing policies that have promoted their pharmaceutical 
industry and adopt the same strategy if possible. Indeed India played a very 
important role at the Uruguay and has always been at the forefront of the fight 
for access to medicines; they provide the cheapest ARVs and have saved many 
lives through its unwavering efforts in promoting access to medicines. 
 
The scope of the thesis also extends to other countries such as Brazil, South 
Africa, Kenya, USA, Liberia, China and other Asian and South American 
countries. It attempts to touch on other countries in order to deduce lessons for 
Nigeria to follow so that it can make full use the flexibilities of the TRIPS 
Agreement in the fight for access to medicines.  
1.4 Conclusion 
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At the end of this thesis the reasons why Nigeria has faced problems with 
regards to gaining access to medicines and whether it should become TRIPS 
compliant will become clear. The TRIPS Agreement is a very important part of 
the struggle for access to medicines in the sense that it increases the prices of 
some medicines, but what will also become clear is that there are other 
domestic issues that have contributed to making medicines inaccessible in 
many developing countries including Nigeria. Although the concluding chapter 
will be geared towards making recommendations in the sphere of legally 
inclined policies and laws; the thesis will ultimately end with making 
suggestions that I believe is the way forward for the Nigerian government in its 
quest for access to medicines.   
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PART I 
2  THE TRIPS AGREEMENT ACCESS TO ESSENTIAL 
MEDICINES IN DEVELOPING COUNTRIES: AN 
OVERVIEW 
 
2.1  Introduction  
The Agreement on Trade-Related Aspects of Intellectual Property Rights, 
(TRIPS)6 is the most important International Intellectual Property Agreement 
of the 21st century for the following reasons:  it extends the principles 
underpinning the world trading system to intellectual property rights and it 
ensures that there is adequate enforcement for it. However it remains the most 
controversial agreement in international commercial jurisprudence.7 In the 
access to essential medicine debate the criticisms against the TRIPS 
Agreement are essentially that it is a product of duress by powerful and 
developed states against the weak and under-developed states, rather than a 
bargain struck by equal sovereigns. The Agreement has also been condemned 
by some as being part of a hard bargain in which developing countries received 
very few reciprocal gains, thereby giving more to developed countries than 
they got in return.8 Some commentators have questioned whether developing 
countries really understood the implication of the TRIPS Agreement before 
agreeing to it. Indeed others have asserted that the US use of Special 301 
contributed in coercing developing countries to agree to the TRIPS Agreement 
regardless of their reluctance.9  And thirdly the implementation of the TRIPS 
                                                            
 
6 Hereinafter called The TRIPS Agreement, TRIPS or the Agreement. 
7 See: Drahos P and Braithwaite J (2002) Proceedings of the 2002 Access to Medicine in the 
Developing World: International Facilitation or Hindrance?  25 Hous. J. Int’l L. 229.  
8 Finger J. Michael (2007) Implementation and imbalance: dealing  with hangover from 
Uruguay Round. Oxford Review of Economic Policy  23(3):440-460; 
doi:10.1093/oxrep/grm020 
9  See Matthews, D (2002)  Globalising Intellectual Property Rights: The TRIPS Agreement  
(London: Routledge) 
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Agreement has been castigated for impacting adversely on the economies and 
health care delivery systems of developing countries.10  
 
The TRIPS Agreement stipulates the transition periods for all member states of 
the World Trade Organisation (WTO) to ensure that their national laws adhere 
to minimum standards of intellectual property protection by specific deadlines. 
For developed countries, they had to adapt to the minimum standards of 
intellectual property as early as 1995.  Accordingly the transition periods as 
stipulated in the TRIPS Agreement varies for each member state depending on 
the sort of obligation in question and the level of development of that country.  
Interestingly the WTO does not have a definition for “developed” and 
“developing” countries. Members announce for themselves whether they are 
“developed” or “developing” countries. 11 Although it is important to note that 
being a developing country brings with it certain rights such as the ability to 
receive technical assistance.12 Nevertheless the World Bank prefers to group 
all low- and middle- income countries as "developing". For example in 2008, 
all countries with a GNI per capita below US$11,905 were grouped as 
developing. The UN on the other hand defines (LDCs) as a group of states that 
are deemed to be ‘highly disadvantaged in their development process (many of 
them for geographical reasons), and facing more than other countries the risk 
of failing to come out of poverty’.13 
 
As such the initial date set for developing countries to adhere fully with the 
TRIPS Agreement was 1 January 2000; this was later postponed to 1 January 
                                                            
10 Note that in Nigeria, health care delivery (which means health care provision)  is the 
responsibility of the federal, state and local government. The federal government responsibility 
is to the university teaching hospitals, whilst the state government manages the general 
hospitals. The local government is in charge of the dispensaries. Note also that private 
providers of health care are active in the delivery of health care in Nigeria. 
11 Note that, this announcement is subject to being accepted by all WTO bodies, also note that 
other  members can challenge the decision of a member to make use of provisions available to 
developing countries. http://www.wto.org/english/tratop_e/devel_e/d1who_e.htm 
12 Ibid 
13 http://www.unctad.org/Templates/Page.asp?intItemID=3618&lang=1 
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2005. Least-developed countries (LDC) on the other hand had until 31 
December 2005 to comply fully with the TRIPS Agreement, this date was later 
extended by 11 years (that is until) 2016.14 
 
With regards to the access to medicine debate, critics argued that insisting that 
developing countries adhere to the TRIPS Agreement in 2005 negatively 
affected public health and stalled their quest to halt the spread of HIV/AIDS 
and other opportunistic diseases. The way that it did this was by further putting 
antiretroviral (ARV) medicines out of the reach of majority of people living 
with HIV/AIDS in many developing countries. ARVs are very expensive and 
for most people living with HIV/AIDS in developing countries (PLWHA), 
there are no drug assistance programs and community resources do not pay for 
the cost of treatment.  For example in the UK, the National Health Services 
(NHS) provides healthcare for all UK citizens based on their need for 
healthcare rather than their ability to pay for it. Although the NHS in funded by 
taxes, it ensures that people who cannot afford to pay for very expensive 
treatments receive the care that they need. Unfortunately, such systems do not 
exist in many parts of the developing world. The problem is further 
compounded by the fact that pharmaceutical companies charge extremely high 
prices for bringing new drugs unto the market which they blame on the high 
cost of R&D. The costs for R&D include clinical testing on both people and 
product developments have been identified as one of the driving factors for the 
prohibitive prices of new drugs.15  
 
 
 
                                                            
14 In the event that a member state ceased to be a LDC, it had to comply fully with the TRIPS 
Agreement depending on which date came first. 
15 Love J, (2008)  Prizes, not prices, to stimulate antibiotic R&D. 
http://www.scidev.net/en/health/antibiotic-resistance/opinions/prizes-not-prices-to-stimulate-
antibiotic-r-d-.html (Accessed 23 June 2008) . See also Adams CP, Brantner VV (2006)  
Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs, 
25(2):420-8. 
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2.2 Cost of R&D 
The figures for the actual cost of R&D for producing a new drug differ and 
unfortunately there is no way of being certain what the actual cost is. Thus 
according to the pharmaceutical industry's trade group Pharmaceutical 
Research and Manufacturers of America (PhRMA), in the 1990’s US and 
foreign drug companies spent a staggering $139.8 billion on domestic R&D.16  
In order words for every new drug developed pharmaceutical companies claim 
to have spent $163 million on R&D. The Tufts Centre for the Study of Drug 
Development came up with a different figure, stating that the average total cost 
of R&D for new drugs in the late 1990s was $897 million;17 a figure much 
lower than PhRMA’s estimates. Another report by the Public Citizen puts the 
price much lower at $107 million before tax.18  Interestingly after the Public 
Citizen report was released, PhRMA released new figures putting the total cost 
of R&D at $771 million.19   A figure much lower than it had initially 
published.  
 
Needless to say that even if the cost of R&D is $107 million per drug as the 
Public Citizen Report asserts, pharmaceutical companies are not charity 
organisations, they have to make a profit if the industry must flourish. Profits 
mean charging the users of the drugs for consumption.  It therefore seems 
common sense that they should be allowed to recover the money invested into 
R&D if they must continue to find new drugs for the various ailments and 
diseases that plague the world today. The question however remains how can 
society strike a balance between what seems ethical (pharmaceutical 
companies’ responsibility of saving lives and working for the public good) and 
                                                            
16 Pharmaceutical Research and Manufacturers of America, “Annual Survey 2000,” List of 
Tables, 2001, http://www.phrma.org/publications/publications/profile00/. (Accessed 26 June 
2007) 
17 Mark Moran. (2003)  Cost of Bringing New Drugs to market rising Rapidly. Health Care 
Economics.  Psychiatric News  Vol 38, No 15 
18  Rx R&D Myths: The Case Against the Drug Industry’s R&D “Scare Card”. Public Citizen 
Congress Watch, July 2001. http://www.citizen.org/documents/acfdc.pdf  
19 Bob Huff. (2001)What Does R&D  Really Cost. 
http://www.thebody.com/content/art13514.html  (Accessed 30 March 2008) 
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the need to promote innovation by allowing pharmaceutical companies to reap 
the full benefits of their investment through profit making (if pharmaceutical 
companies are prevented from making profit the industry will die away, 
thereby eliminating the wealth of lifesaving drugs capable of curing sickness 
and disease around the world). 
 
Before the TRIPS Agreement came into being, developing countries were able 
to avoid paying the expensive prices charged by pharmaceutical companies for 
purchasing branded medicines. They could easily gain access to generic 
equivalents at a lower price. Generic medicines have the advantage of being 
less expensive when compared to branded medicines because they do not have 
all the risks and costs associated with R&D for manufacturing new medicines. 
Indeed generic companies essentially focus on the production of existing 
generic compounds and concentrate on finding which patents protection have 
expired rather than developing new medicines that are classified as new 
chemical entities (NCEs). When countries such as India who are the biggest 
supplier of cheap generic medicines to developing countries (with 67% of its 
exports going to developing world)20 had to comply with the TRIPS 
Agreement in 2005 they had to begin recognizing both product and process 
patents. This changed the entire landscape for access to cheap medicines all 
over the developing world.  After the Indian Patents Act 1970, India excluded 
pharmaceutical products from being patented,  this made it easier for their 
manufacturers to sometimes reverse engineer medical products cheaply and 
sell them at a cheaper price than their branded manufacturing counterparts. It 
was not until 2005 that they began to introduce product patents again.  Critics 
have therefore argued that the TRIPS Agreement brought with it the “transfer 
of benefits from the hands of the consumer, in the form of consumer surplus, 
                                                            
20 Oxfam Press Release .( 11/15/2006)  Rich countries betraying their obligations to help poor 
countries protect public health. http://www.payvand.com/news/06/nov/1179.html (Accessed 5 
July 2007) 
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into the hands of inventors, in the form of profits”.21 Indeed India’s national 
sentiment was best captured by Indira Gandhi’s statement at the World Health 
Organisation in 1982 when she said "The idea of a better-ordered world is one 
in which medical discoveries will be free of patents and there will be no 
profiteering from life and death." 
 
2.3  The TRIPS Agreement  
The TRIPS Agreement is a fundamental part of the constitution establishing 
the World Trade Organization (WTO).  It is one of the multilateral trade 
agreements which have a binding effect on all its members. The WTO has 153 
members and requires all its members to provide a higher level of protection 
for intellectual property than otherwise would have been required.22 The 
TRIPS Agreement also stipulates minimum standards to be adopted for the 
protection of Intellectual Property Rights (IPRs) for countries which are 
members of the WTO. These standards are considerably detailed, particularly 
in the patent field. The TRIPS agreement can only operate through the laws of 
individual countries as it is not an automatic universal law. It therefore needs 
the co-operation and commitment of individual national governments to be 
dedicated to the full implementation of the Agreement for it to be effective.  
The key directive with regards to patent can be found in article 27:1, it requires 
member states to make patents available for all inventions including products 
or processes in all fields of technology.23 This means that apart from the areas 
where the Agreement specifically exempts the granting of patents,24 member 
states must grant patent protection as required by the TRIPS Agreement. This 
                                                            
21 Lanjouw, Jean O (1996) The Introduction of Pharmaceutical Product Patent in India” 
‘Heartless Exploitation of the Poor and Suffering? NBER Working Paper No6366.  
22 See http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm 
23 Article 21:1 states that subject to paragraph 2 and 3, patents shall be available for any 
inventions, whether products or processes, in all fields of technology, provided they are new, 
involve an inventive step and are capable of industrial application 
24 Article 27:2 allows members to exclude inventions from patentability on broad grounds of 
public order or morality and an exclusion for diagnostic, therapeutic and surgical methods for 
the treatment of humans or animals. Article 27:3(b) permits members to exclude plants and 
animals other than micro-organisms and biological processes for the production of plants or 
animals other than non-biological processes. 
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in effect increases the scope of patentable subject matters from what it used to 
be. Thus the birth of the TRIPS Agreement is a major development in 
international intellectual property rights protection especially in sensitive areas 
such as pharmaceuticals which many countries had previously guarded 
jealously because of public health.25 
 
Although article 1 of the TRIPS Agreement indicates that states are not obliged 
to adopt higher standards or provide greater protection than those set out in the 
Agreement, thus leaving the modalities for the implementation of the TRIPS 
Agreement at the discretion of the member states; article 33 of the TRIPS 
Agreement obliges states to grant patent protection for a minimum of 20 years 
beginning from the day of filling.26 This gives patent holders monopoly right 
over products and processes for a 20 year period with the attendant power to 
charge whatever price they wish irrespective of the consumer’s (in the case of 
drugs, patient’s) ability to pay. 27  Despite the foregoing analysis it is important 
to note that it can sometimes take 8-12 years to bring a new drug to the 
market.28 In such a case, the patent holder only has 8-12 years to charge 
whatever price they wish. 
 
This has resulted in drug prices not corresponding to the market forces but to 
the buying power of the rich minority.29   Whilst 8, 12 or even 20 years may 
not seem a long term for proponents of a strong patent protection system, 
commentators have argued that when producers are permitted to charge and 
maintain prices at a higher cost than the marginal costs of production, even 5 
                                                            
25 Before TRIPS India did not grant patents in the pharmaceutical field. 
26 Article 33 states that the term of protection available shall end before the expiration of a 
period of twenty years counted from the filling date 
27 Sell K Susan (2002) Proceedings of the 2002 Conference Access to Medicines in the 
Developing World: International Facilitation or Hindrance? 20 Wis. Int'l L.J. 481 
28 See Y. Richard Wang. (2006)  Price Competition in the Chinese Pharmaceutical Market. Int 
J Health Care Finance Econ 6:119-129 
29. Nnadozie C Kent (2001) The Trips Agreement and Access to Essential Medicines in 
Nigeria”, being a Status Report on the IP Regime in Nigeria, Presented to the Coalition of 
Civil Society Groups on Access to Essential Medicines, (COCSAEM) in Nigeria. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
37 
 
years is  a very long time to discourage generic competitors in such sensitive 
and fast evolving field such as the pharmaceuticals industry which deals with 
medicines where availability determines who lives and who dies, considering 
that HIV/AIDS kills 8,200 people every day30   
 
Nevertheless there are flexibilities within the TRIPS Agreement which reduces 
the harshness of the 20 year patent rule and this include where a country is 
experiencing a “national emergency” or other situations of “extreme urgency” 
(such as public health crises, such the HIV/AIDS, tuberculosis, malaria and 
crisis facing most parts of the sub-Sahara).31  The TRIPS Agreement makes 
provisions for such situations by providing countries with the options of 
issuing compulsory license under Article 31 of the TRIPS Agreement or 
parallel importation under Article 6 of the Agreement.   
 
Compulsory licensing allows a party to exploit a patented invention without 
the permission of the patent holder; however the patent holder of the 
compulsory license is required to pay the patent holder “adequate 
remuneration”. Another flexibility which is line with the WTO rules on TRIPS 
is the Bolar exemption. The Bolar exemption is a policy that allows generic 
manufacturers to prepare production and regulatory procedures before a patent 
expire. The aim of such preparation is to ensure that products are ready for sale 
as soon as the patent ends, rather than having to go through the lengthy 
preparatory process after the patent period expires which may further delay the 
availability of urgently needed medicines. In my opinion from the foregoing 
analysis it is fair to say that the TRIPS Agreement has sought to insert 
flexibilities within the Agreement which allow member states to circumvent 
                                                            
30 See Dasgupta  S and  Srivastava  Y, (2003) Public Health Safeguard in TRIPS: A Domestic 
Legal Response  43 India Journal of International Law 661 and See Keith E. Maskus (2002).  
Proceedings of The 2002 Conference Access to Medicines in the Developing World: 
International Facilitation or Hindrance? : Panel #4: Access to Essential Medicines and 
Affordable Drugs: Ensuring Access to Essential Medicines: Some Economic Considerations, 
20 WIS. INT'L. L.J. 563, 564 and 590 . 
31 World Trade Organisation. Fourth Ministerial Conference. Doha 9- 14 November 2001 
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the harsh effects that the TRIPS Agreement might otherwise have had on 
public health in developing countries. For that it must be praised, the problem 
however goes beyond this. The major issue now is whether the flexibilities 
inserted into the TRIPS Agreement are in reality alleviating the public health 
crisis confronting the developing world in terms of gaining access to 
medicines.  
 
2.4   Intellectual Property Rights Before the WTO 
Before the TRIPS Agreement came into force in 1995, intellectual property 
was chiefly governed internationally by two Conventions namely The Paris 
Convention of 1883 which protects "industrial property" including patents 32 
and the Berne Convention of 1886 which protects "every production in the 
literary, scientific and artistic domain, [and] mode or form of its expression."33  
The problem however remained that multinational pharmaceutical companies 
were concerned that the Conventions did not do enough to protect intellectual 
property rights. 34 Thus it was becoming increasingly urgent that intellectual 
property rights (IPRs) be protected within the GATT, which is a predecessor of 
the WTO.  Two key issues that pushed the TRIPS agenda forward were 
firstly,35 the fundamental principle of "national treatment" was found to be 
lacking in the both conventions because it only worked well for countries that 
could provide more or less the same level of protection and worked poorly for 
                                                            
32 Paris Convention for Protection of Industrial Property, March 20, 1883, last revised at 
Stockholm, July 14, 1967, 21 U.S.T. 1583 ["Paris Convention" ]. 
33 Berne Convention for the Protection of Literary and Artistic Works, Sept. 9, 1886, last 
revised at Stockholm, July 14, 1967, 828 U.N.T.S. 221.[Berne Convention] 
34 Amy Au, (2000) National Treatment" and the International Recognition and Treatment of 
Trademarks  20 Wis. Int'l L.J. 
35 These persons are referred to as "nationals," but include persons, natural or legal, who have a 
close attachment to other members without necessarily being nationals. Art 1(3) Marrakesh 
Agreement Establishing the World Trade Organization, Annex 1C: Agreement on Trade-
Related Aspects of Intellectual Property Rights, Apr. 15, 1994 [hereinafter TRIPS], reprinted 
in The Results of the Uruguay Round of Multilateral Trade Negotiations -- The Legal Texts 6-
19, 365-403 (GATT Secretariat ed., 1994) [hereinafter Results of the Uruguay Round]. The 
texts of each of the agreements reached at the conclusion of the Uruguay Round in December 
of 1993 and the related decisions taken at the same time and those taken at the Ministerial 
Meeting in Marrakesh in April of 1994, are contained in Results of the Uruguay Round 
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countries that could not afford to give equal protection to their own citizens. 
Secondly there was no effective means of enforcement when a party defaulted 
in not upholding the National Treatment principle, in Article III (1) of the 
GATT.36 Indeed Part III of the TRIPS agreement deals with enforcement in the 
following ways; firstly it states that governments have to ensure that 
intellectual property rights are enforced under their laws. Secondly the 
penalties for infringement should be tough enough to deter further violations. 
Thirdly the procedures must be fair and equitable. Fourthly the procedures 
should not be unnecessarily complicated or costly. Fifthly that they are no 
unreasonable time-limits or unwarranted delays, and lastly that people 
concerned should be able to request that a court review an administrative 
decision or appeal a lower court’s ruling.  
 
2.4.1  The Negotiation Process (1986-1994) From Punta Del Este to 
Marrakech 
The TRIPS Agreement became the chief WTO instrument dealing with 
intellectual property. The gestation period of the Agreement was a seven year 
period that began in Punta del Este (in Uruguay) in September 1986 and was 
concluded at Marrakech (in Morocco) in April 1994.37 The TRIPS Agreement 
was concluded as part of the Uruguay Rounds of the Multilateral Trade 
Negotiations of the GATT. Under the Uruguay Rounds several groups were set 
up and the “Group of Negotiating on Goods” had fourteen negotiating groups 
under it. Out of the fourteen groups, intellectual property was discussed under 
“The Negotiating Group on Trade-Related Aspects of Intellectual Property, 
Including Trade in Counterfeit Goods”.38 
 
                                                            
36 Robert J. Gutowski  (1999) Marriage of Intellectual Property and International Trade in the 
TRIPs Agreement: Strange Bedfellows or a Match Made in Heaven? 47 Buff. L. Rev. 713, 
721-23 
37  See Christopher Arup.  (2000) The New World Trade Organization Agreements. Cambridge 
University Press  
38 Ibid 
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The stages of the negotiation were nevertheless fraught with difficulty and 
complexity, and one of the reasons why this was the case was the fact that 
several proposals where put forward by various blocs.  The US, the European 
Community, Japan and the bloc of developing countries all wanted their 
different agendas and concerns addressed at Uruguay; however the diversity of 
the agenda resulted in fractions that slowed the entire process down leading to 
several deadlines being abandoned.39  The US bloc was unwavering in their 
position that inadequate intellectual property protection leads to trade 
distortions and impairment of concession.40  The European Union had an extra 
agenda of trying to get geographic indications and appellations of origin 
included in the TRIPS Agreement; 41 whilst the Japanese were concerned about 
protecting their domestic computer chip industry.42 The keenest bloc however 
was the US who was prepared to use extreme measures such as Special 301 
threats to enter into bilateral agreements with individual countries in its 
ambition to push for stronger intellectual property rights.   
 
The irony however was whilst the US was pushing for stronger international IP 
protection, she had in the past ran foul of the GATT principles by offering 
domestic patent holders stronger enforcement procedures than foreign 
holders.43 The Mid-term Review of the Uruguay Round held in Montreal in 
December 1988 highlighted the tension between the positions of developing 
countries and developed countries.44 Developing countries led mostly by Brazil 
and India continued to question the implication of intellectual property as an 
                                                            
39 For a detailed history of the TRIPS see Emmert, F (1990)  Intellectual Property in the 
Uruguay Round – Negotiating strategies of the Western Industrialised countries.  Michigan 
Journal of International Law 11(4), 1317-99. 
40 Blakeney (1996b) Trade Related Aspects of Intellectual Property: A concise guide to TRIPS. 
Agreement: Sweet  and Maxwell. 3  
41 GATT Doc. No. MTN.GNG/NG11/W/26 (7July 1988) 
42 Doane, M.L. (1994)  TRIPs And International Intellectual Property Protection in an Age of 
Advancing Technology, American University Journal of International Law an Policy 9, 2:  475 
43 See section 310 U.S.C with regards to seizure of potentially infringing imports into the US 
markets. 
44 The Japanese Perspective on the  Toronto Economic Summit and the Uruguay Round. 
http://www.g7.utoronto.ca/scholar/kobayashi1988/kobaurug.htm 
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item on the GATT, and this reinforced their resistance to the terms of the 
Agreement. The significance of the foregoing in the access to medicines debate 
must not be lost on the reader, it shows that from the beginning of the 
negotiation many countries had their own different agenda that they wanted to 
protect. For many developing countries, their major concern was to ensure that 
their vulnerable industries were protected, that they still had access to cheaper 
medicines, and the protection of their public health systems would not vanish. 
 
2.4.2    Resistance from Developing Countries   
Initially developing countries resisted the TRIPS Agreement; they were 
concerned that increased protection of intellectual property rights would lead 
to adverse changes in their national patent laws. In the end they backed down 
after much pressure and the TRIPS Agreement was sealed. India and Brazil 
were  particularly interested in protecting its pharmaceutical industry from the 
repercussions of a stricter IP regime. They feared the TRIPS Agreement would 
ultimately deny them access to the much needed modern technology that they 
needed to promote their pharmaceutical industry.45 Another cause of concern 
for developing countries was the fear that the TRIPS Agreement would 
increase the ever widening gap between developed and developing countries; a 
gap enhanced by the arrival of the knowledge economy era.46 For the resistant 
bloc of developing countries, reductions in the transfer of technology and an 
increase in the cost of pharmaceutical products were concerns that rose 
suspicions about the benefits of the TRIPs Agreement.  
 
2.5   The Question  
If from the onset, developing countries were concerned and possibly aware of 
the potential repercussions that a stronger intellectual property regime in the 
                                                            
45 Ibid 
46 OECD.  (2004)  Knowledge Management. Innovation in the knowledge Economy. 
Implications for Education and Learning..  The Wikipedia defines knowledge economy as an 
an economy of knowledge focused on the production and management of knowledge in the 
frame of economic constraints, or to a knowledge-based economy.  
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crystallization of the TRIPS Agreement might have on their economies, many 
have wondered why they did not stand firm in resisting the idea that 
intellectual property had a place in the WTO forum. Various explanations have 
been put forward to account for the ultimate surrender of developing countries. 
One of them is that in the years leading up to the TRIPS negotiation, most 
dialogues were initiated in accordance with what some scholars have termed 
the “Green Room” pattern.47 The Green Room of the GATT is a building in 
Geneva where ministers hold meetings. The Green Room pattern required 
negotiators from all the countries involved in the Uruguay Round to engage in 
close discussion with one another. Traditionally, draft texts would be 
exchanged and differences reduced through consecutive versions.48 Many 
countries could be involved in the negotiation process, however from February 
1991 onwards; the Green Room approach was abandoned in favour of a “ten 
plus ten group” approach.  The “ten plus ten group” approach at the Uruguay 
involved a situation where ten developed countries along with ten developing 
countries would sit down together and come up with a decision.49  The ten plus 
ten group was headed by the chairman of the TRIPS Working Group where 
experts and negotiators on intellectual property from  ten developing countries 
which included India and Brazil would bring unto the discussion table their 
views and vice visa the developed countries.  What later became apparent was 
that members of the ten\ developed countries which comprised of the US, some 
members of the European Union, Japan and Canada were meeting in private 
and agreeing on what direction the negotiations would take before they met 
with the developing countries.50 This evidently put the developing countries at 
a disadvantage. Another reason why the group of developing countries were at 
a disadvantage was because at the time, many of them lacked the technical 
                                                            
47  Gorlin  J (1991) An Analysis of the Pharmaceuticals-Related Provisions of WTO TRIPS 
(Intellectual Property) Agreement (London: Intellectual Property Institute )  p4 and Matthew, 
D  (2002)  Globalising intellectual Property Rights The TRIPS Agreement (London  Routledge) 
48  Matthews, D (2002)  Globalising Intellectual Property Rights: The TRIPS Agreement  
(London: Routledge) pp38 
49 Ibid 
50 Ibid 
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capacity to participate actively in the TRIPS negotiation process.  The 
reduction of a huge number of players in the negotiation process allowed the 
bloc of developed countries spearheaded by the US to gain an upper hand in 
deciding the direction of the negotiations.   However despite the pressure 
developing countries continued to forge on in their quest to resist stronger 
protection of intellectual property rights in the TRIPS Agreement.51   
 
Another theory for the submission of the developing countries is that when the 
US responded by sanctioning headstrong developing countries through its 
Special 301 powers, this further split the alliance of developing countries.52  
The main US target was the Indian pharmaceutical industry whose export into 
the US was in the region of $60 million per annum.53Export into the US from 
India was very important for the India economy. India fearing reprisals and 
trade sanctions by the US felt pressurized to succumb and eventually agreed to 
the terms of the TRIPs Agreement in 1994.54 Without India there was no other 
country strong enough to resist pressure from the bloc of powerful 
industrialised countries 
 
Braithwaite has suggested that “negotiation fatigue” was the principle factor in 
the inability of developing countries to withstand the United States pressure 
until the end. Other factors such as a lack of information and technical experts 
on intellectual property issues on the part of developing countries also played a 
role in defeating the developing countries resistance.55   
                                                            
51 Ibid 
52 See Michael Bailey, Ruth Mayne & Dr. Mohga Smith (2001)  Fatal Side Effects: Medicine 
Patents under the Microscope, available at 
http://www.oxfam.org.uk/what_we_do/issues/health/fatal_side_effects.htm (Accessed  5 April  
2006) and  Sell, K Susan. Private Power, Public Law. The Globalization of Intellectual 
Property Rights. The George Washington  University. Cambridge University Press. 2003. 
http://assets.cambridge.org/97805218/19145/sample/9780521819145ws.pdf 
53 Sudip Chaudhuri. (2006) The WTO  and India’s Pharmaceutical Industry: Patent 
Protection, TRIPS and Developing Countries. Oxford University Press.  
54 Ibid 
55 See Braithwaite J and Drahos P (2000) Global Business Regulation (Cambridge: Cambridge 
University Press); Drahos, P (1995) Global Property Rights in Information: The Story of 
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2.5.1  World Intellectual Property Organisation 
One of the arguments that developing countries put forward in their opposition 
against the TRIPS Agreement was that World Intellectual Property 
Organization (WIPO) was the appropriate forum to discuss any issues or 
amendments related to intellectual property rights matters and not the GATT.56   
 
A background of WIPO is therefore required here. WIPO was established in 
1967, and in 1974 it was converted into a specialized agency of the United 
Nations to deal with intellectual property rights matters.57   WIPO has 184 
members and one of its primary roles include the promotion of creativity; this 
it does through the protection and promotion of what academics term “works 
of the mind”. WIPO also has the chief role of facilitating the transfer of 
technology to developing countries with a view to speeding up economic, 
social and cultural development.58 Note that some critics have argued that 
WIPO has not been very successful in achieving the latter. 
 
The need to have a body which protects intellectual property rights throughout 
the world was highlighted in 1873 when foreign exhibitors refused to attend 
the International Exhibition of Inventions in Vienna because they feared that 
their ideas would be stolen and exploited commercially in other countries.59 
Subsequently in 1883 the Paris Convention for the Industrial Protection was 
established to provide patent protection for new inventions. One of the key 
element in relation to patents in the Convention was a term called the “Paris 
Convention priority right”. The Paris Convention priority right clause 
stipulates that an applicant from one contracting State shall be able to use its 
                                                                                                                                                            
TRIPS at the GATT’, Prometheus, 13, 1: 6.; Drahos, P (2001) Bilateralism in Intellectual 
Property’, Oxford: Oxfam Policy Paper. 
56 Blakeney, M. (1995) Intellectual Property in World Trade, International Trade Law and 
Regulation and  Evans, G. E (1994) Intellectual Property as a Trade Issue,  The Making of the 
Agreement of Trade Related Aspects of Intellectual Property Rights’ World Competition:139 
57 Ibid 
58 Ibid 
59 http://www.wipo.int/treaties/en/general 
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first filing date (in one of the contracting State) as the effective filing date in 
another contracting State, provided that the applicant files another application 
within 12 months (in the case of patents).60 The implication of this was that for 
the first time a treaty for the international harmonization of industrial property 
was established setting the stage for the stronger enforcement of intellectual 
property in the structure of the TRIPs Agreement.   
 
In 1886, following in the footsteps of the Paris Convention, the Berne 
Convention was further developed and strongly influenced by the French ‘right 
of the author”, which means the copyrights of an author is immediately 
protected once they are created. Once the author registers his copyrights in any 
country that is a party to the convention, he automatically receives protection 
in other countries that are party to the convention. In other words foreign and 
domestic authors get the same rights to copyrighted materials in all countries 
that are party to the Convention. 
 
In 1893 both the Paris Convention and the Berne Convention were 
amalgamated to form the International Bureaux for the Protection of 
Intellectual Property (BIRPI). As the significance of intellectual property 
began to grow and many developed countries began to rely heavily on 
intellectual property for the growth of their economies, the structure and form 
of the BIRPI further evolved into WIPO in 1967. 
 
2.4.3         Problems with WIPO 
Despite the high hopes that the international committee had for WIPO, by the 
early 1970s it was becoming increasingly clear to many developed countries 
that WIPO did not have the power to put in place a strong global enforceable 
system for intellectual property rights protection.61 A strong enforcement 
                                                            
60 http://en.wikipedia.org/wiki/Paris_Convention_for_the_Protection_of_Industrial_Property 
61 Matthews, D (2002) Globalizing Intellectual Property Rights. The TRIPS Agreement.  
Routledge.  
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
46 
 
procedure for the protection of intellectual property was considered essential 
by many developed countries because without it, it would be impossible to 
combat the problems of international piracy and counterfeit. Particularly, 
corporate America was worried that piracy and counterfeits was costing the US 
industries billions of dollars.62 For example in 1984, the Automotive Parts and 
Accessories Association told the US House Sub-committee on Oversight and 
Investigation that the US industry had lost $12 billion from counterfeiting of 
spare parts.63 A year later, in 1985 the International Intellectual Property 
Alliance (IIPA) representing seven trade associations of copyright-related 
industries conducted a study of the copyright laws of Brazil, Egypt, Indonesia, 
Malaysia, Nigeria, Philippines, Republic of Korea, Singapore, Taiwan and 
Thailand revealing that lax copyright laws in the above mentioned countries 
were costing the American copyright industries $1.3 billion.64   
 
Subsequently in 1984 an attempt was made to amend both the Paris and Berne 
Convention in Geneva to improve the effectiveness of WIPO by giving it more 
enforcement powers. Developed countries had two major issues that they 
wanted resolved. Firstly, they wanted WIPO to set out clear rules on 
enforcement rights before national judicial organization on intellectual 
property matters; secondly they wanted the absence of an obligatory and 
effective mechanism to settle disputes between states on intellectual property 
matters resolved.   
 
Unfortunately, the two parties of developing countries and developed countries 
could not come to a common resolution. A premonition of what was to take 
place in the Uruguay rounds. Whilst developed countries were concerned about 
competing with mass-produced unauthorised copies of their patented, 
                                                            
62 Stewart, T.P. (ed) (1993) The GATT Uruguay Round: A negotiating history (1986-1992), 
Deventer, Netherlands: Kluwer Law International : 2254 
63 Unfair Foreign Trade Practices, Stealing American Intellectual Property: Imitation in Not 
Flattery, 98th Cong. 2nd Sess. 1-3 (1984) 
64 IIPA, Piracy of US Counterfeited Works in Ten Selected Countries (1985), 7. 
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trademarked and copyrighted goods in domestic and foreign markets;65 
developing countries on the other hand wanted a relaxed system of intellectual 
property so as to accomplish technological progression and economic growth. 
Both blocs were unyielding in their position and could not come to a common 
consensus thereby blocking any resolution that might have been.66   Pressure 
from US industries was steadily increasing and by 1986 the Intellectual 
Property Committee (IPC) dominated by the US research-based industry was 
founded.  One of the  major accomplishments of the IPC was that whilst it was 
one of the driving forces in the Uruguay round, it had successfully harmonized 
US industry position with the US government, and by so doing became 
extremely influential in pushing through its agenda in the GATT.67  Another 
major body that the US industries used to push some of its agenda of a stronger 
intellectual property regime in international circles was the Office of the 
United States Trade Representatives (USTR), who became the biggest driver 
of overcoming developing countries opposition during the Uruguay rounds.68  
As a matter of fact during the Uruguay negotiation the USTR was strongly 
influenced by the IPC who had a confidant in Edmund Pratt of Pfizer, who was 
at the time the chairman of the Advisory Committee for Trade Negotiations 
and an adviser to the US official Delegation.69  Note that the influence of US 
industries on the USTR has sustained itself even until today. For example the 
Program on information Justice and Intellectual property (PIJIP) 2008 Special 
Report showed that US Industry still has a strong influence on government 
policy. Majority of the countries placed on the Special 301 list70 were 
                                                            
65 Sell. K. Susan (1998) Power and Ideas: The North and South Politics of intellectual 
property and antitrust, New York: State University of New York:132 
66 Matthews, D. Globalizing Intellectual Property Rights. The TRIPS Agreement. 2002 
Routledge.  
67 The influential members at the time were Pfizer and IBM. 
68 Ryan M. P. (1998)  Knowledge Diplomacy: Global Competition and the Politics of 
Intellectual Property, Washington, DC: The Brookings Insitution:105 
69 Sell, K. Susan. (1998)  Private Power, Public Law, the Globalization of Intellectual 
Property Rights. Cambridge Studies in International Relations.  
70 The Special 301 is a mechanism that the USTR use to force countries to provide better 
protection for intellectual property rights by putting countries on either a Priority Watch List, 
Watch List or Section 306 Monitoring Status.  
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recommended by Pharmaceutical Research and manufacturers of America 
(PhRMA) or the IIPA, 86% of them were chosen by IIPA and 75% were 
chosen by PhRMA.71  
 
The key thing to note however is that, the adoption of the TRIPs Agreement in 
1995 signalled a turning point for intellectual property rights, because it 
established a higher level of intellectual property protection standard that was 
previously lacking in the Paris and Berne Convention. Although some have 
argued that the WTO replaced WIPO as the chief intergovernmental 
organization for intellectual property rights matters, this is not entirely true.  
Indeed, the TRIPs Agreement requires compliance with the Paris and Berne 
convention. 72 It still recognizes the importance of WIPO as a medium for 
negotiating treaties, especially those representing a "higher levels of protection 
of intellectual property rights."73 
 
Another important role WIPO took up after the WTO was established is 
evident in the WIPO-WTO Cooperation Agreement where the International 
Bureau of WIPO took on the role of providing legal technical to developing 
countries.74  Indeed the cooperation between WIPO and the WTO in sharing 
expertise created  a doppelganger intellectual property position.75 Helfer’s 
quote typifies WIPO and the WTO’s bond sufficiently when he states that 
‘Whereas the WTO emphasized implementation, enforcement, and dispute 
settlement, WIPO focused on generating new forms of intellectual property 
                                                            
71 PIJIP Snapshot of Industry Influence on the 2008 Special Report. 
http://216.239.59.132/search?q=cache:OOxozIHF46UJ:www.wcl.american.edu/pijip/downloa
d.cfm%3Fdownloadfile%3D9BA6937C-0260-01BA-
625C00EDD0AC29C6%26typename%3DdmFile%26fieldname%3Dfilename+influence+of+i
ndustry+on+USTR&hl=en&ct=clnk&cd=2&gl=uk 
72 With the exception of Article 6bis of the Berne Convention relating to moral rights. 
73 See TRIPs, supra note 4 
74 http://www.wipo.int/treaties/en/agreement/trtdocs_wo030.html 
75  See Abbott .M. Frederick  (2000) Distributed Governance at the WTO-WIPO: An Evolving 
Model for Open-Architecture Integrated Governance, 3 J. Int'l Econ. L. 63, 70  (asserting that 
WIPO and WTO have "entered into a symbiotic relationship that takes advantage of the 
strengths of each of them"). 
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protection, administering existing intellectual property agreements, and 
providing technical assistance to developing countries’.76  The question 
however remains, has the prominence of WIPO in dealing with intellectual 
property rights issues been usurped by the WTO to the disadvantage of the 
developing countries. Under Article 67 of the TRIPS Agreement, developed 
countries were promised additional measures would be put in place to assist 
them in their efforts to reform their domestic IPRs regimes. Some of which 
included “assistance in the preparation of laws and regulations on the 
protection and enforcement of intellectual property rights as well as on the 
prevention of their abuse”.77 
 
2.6   Summary 
The TRIPS Agreement changed the landscape for intellectual property by 
giving the WTO enforcement powers which had previously been lacking in 
WIPO.  It also gave the patent holder powers to charge whatever price he 
wished, and this in turn increased the prices of medicines and affected which 
developing countries gained access to medicines. Whilst many countries have 
kicked intensely against the TRIPS Agreement, some have welcomed it. It is 
with this background in mind that the next chapter will conduct a historical 
analysis of the patent system with a view of providing background information 
about the usefulness of it to the access to medicine debate.  
 
 
 
 
 
 
                                                            
76 Ibid 
77 Art 67 of TRIPS 
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3 THE JURISPRUDENCE OF INTELLECTUAL 
PROPERTY RIGHTS – A VALUABLE BACKDROP TO 
PATENTS 
 
3.1  Introduction  
A look at the past reminds us of how great is the distance, and how short, over 
which we have come.  The past makes us ask what we have done with us. It 
makes us ask whether our achievements are not ironical counterpoint and 
contrast to our fundamental failures. 
Robert Penn Warren 
 
History ... is, indeed, little more than the trigger of the crimes, follies, and 
misfortunes’ of mankind. But what experience and history teach is – that 
peoples and government have never learned anything from history, or acted on 
principles deduced from it. 
Georg Wilhelm Fredrich Hegel, The Philosophy of History, “Introduction,” 
1807 
 
History knows that it can wait for more evidence and review its older verdicts; 
it offers an endless series of courts of appeal, and is ever ready to reopen 
closed cases. 
William Stubbs 
 
This chapter inter alia explores the history of patents from the influence of 
royal prerogative, the Statute of Monopolies, Elizabethan grants to common 
law property rights.  It evaluates the birth of the concept of patents in Venice 
and captures the acceptance of the concept in Europe in order to show why the 
transition to a knowledge based economy has been easier for many developed 
countries.  The chapter also evaluates the legal history of “owing knowledge” 
and the foundation of why knowledge became property. The tenets of natural 
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law as a foundation for the modern day intellectual property rights are also 
considered with the aim of understanding why patents are important in our 
modern day society.  This chapter is important to the overall structure of this 
thesis for several reasons: by providing a historical analysis of intellectual 
property, it is possible to see why intellectual property laws fit into the legal 
systems of  many countries in the developed world. It is  easy  to see how 
patents have developed in Europe and spread to other developed countries like 
the US and this has made it suitable for their economies. It is also easy to see 
that intellectual property right laws fit into the economies of poorer developing 
countries; thus putting the developing countries opposition to stricter IPRs at 
the Uruguay rounds into perspective. .The chapter is also relevant in revealing 
the importance of monopoly and the role it plays in today’s modern patent 
system. This will help to facilitate a better understanding of the jurisprudence 
of patent and its eventual codification into the TRIPS Agreement. Indeed this 
chapter is important to the overall structure of this thesis is showing that whilst 
the journey for patents began in Europe, it successfully spread throughout the 
world and even states who did not previously have a background of granting 
patents found themselves struggling to ensure that they adhere to minimum 
standards of intellectual property as set out in the TRIPS Agreement (for 
patents see article 27-34 of the Agreement).  Of course the argument continues 
that historically patents have had negative effects, for example in the case of 
access to medicines where the increased prices of medicines (a result of patent 
grants) have put medicines out of the reach of people; yet it has also brought 
with it certain benefits in the shape of FDI and technology transfer. The abuse 
of patent privileges in 16th century England nevertheless highlights the fear 
that there is a propensity to sometimes erroneously grant such privileges/rights, 
and that is what the international community must guard against.   
 
Many developing countries have a common history of owing knowledge 
collectively, the idea of profiting from an idea or invention to the exclusion of 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
52 
 
others for a specified period of time may therefore have been harder for them 
to contend with in the multilateral trading system. The usefulness of this 
chapter to the overall structure of this thesis also lies in that it reveals the 
tension between the public’s claim that they should be able to benefit from the 
scientific and cultural rewards of innovation and the inventor’s claim of being 
rewarded for his efforts and intellect.  In some parts of this chapter the analysis 
will be centred on the Lockean theory and will examine whether the theory is 
consistent with the general pattern of positive law and modern intellectual 
property rights. This will facilitate an easier understanding of the overall 
discussion of the TRIPS Agreement and the access to medicines debate as 
discussed in other chapters with a view of appreciating how history has 
evolved to bind countries together in agreements that determine whether 
people live or die. 
 
3.2  History of the Emergence of International Industrial Property 
At the advent of the twenty first century there has been immense pressure to 
conform to international standards of harmonization around the globe. This 
pressure stems from the fact that the world has increasingly become a 
knowledge based society where information and knowledge are replacing 
capital and energy as the primary wealth-generating assets. Before capital and 
energy were replaced, land and labour were the primary source of wealth, 
78with that one can deduce that society is constantly evolving and bringing 
with it new challenges.  Bearing that in mind, Thomas Riley stated that the 
“knowledge economy is about how new technologies have transformed the 
way we think and act”.79    The free flow of ideas and information has therefore 
become one of the key factors in producing the “wealth of nations”,80 and this 
                                                            
78 Riley T. B (2003) An Overview of the Knowledge Economy. By Executive Director and 
Chair, Commonwealth Centre for Electronic Governance’. 
http://www.egovmonitor.com/features/riley07.html. Viewed 23 April 2008 
79 Ibid 
80  Adam Smith (1904)  An Inquiry into the Nature and Causes of the Wealth of Nations 5th 
edition. London: Methuen and Co., Ltd., ed. Edwin Cannan 
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has changed our understanding of the world as it is today.81 It follows that most 
developed countries generate their wealth by pursing high R&D investments 
into innovation and converting it into marketable products. Wakelin and 
Rodrigo have pointed out that one of the pre-requisites for the technology 
based economic growth of any country is the movement from low or no 
technology export to medium or high technology export.82 A theory which 
clearly applies to countries like China that have been identified as one of the 
fastest growing economies in the world, thus in 2001 China’s high technology 
export grew 25.4 % to 46.46% billion US dollars.83 
 
Economic research also showed that innovation plays a central role in the 
productive growth of any new knowledge economy.84 Indeed Robert Solow’s 
seminal paper 1957 demonstrates that approximately 80 percent of economic 
growth occurred in the United States between 1909 and 1949.85  In his work, 
he suggests that the driving force behind the growth was technology and 
innovation.86 Many commentators therefore agree that innovation is the key 
justification for maintaining and guarding the new patent system.  Fisher also 
states that “History plays an important part as it tells us that patents should not 
be taken for granted. They have a hard-won place in the modern economy”.87  
In order to understand the origins of why a patent holder has ownership in his 
                                                            
81Ibid’ 
82 Wakelin, E (1996) Trade and Innovation: Theory and Evidence, Edward Elger, 
Massachusetts, and  Rodrigo, G. C. (1996), in National Economies for Countries in Transition: 
Evidence from Eastern Europe and Asia Pacific (ed. Scholtes, P. R.), University Press, 
Cambridge, pp. 3–33. 
83 Rapid Growth of China’s high-Tech Exports. (Beijing Times), January 12, 2002. 
http://english.peopledaily.com.cn/200201/12/eng20020112_88493.shtml. Last viewed 01-01-
2009 
84 The New Economy Task Force. Rules of the Road: Governing Principles of the New 
Economy. New economy Task force Report. September 13, 1999 
http://www.ppionline.org/ppi_ci.cfm?contentid=1268&knlgAreaID=128&subsecid=174 
85 Solow  M  Robert (1957 )Technical change and the aggregate production function” Review 
of Economics and 
Statistics No)  
86 Ibid 
87  Fisher . M (2005) Classical Economics and Philosophy of the Patent System” I.P.Q: No1 
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invention, it is essential to examine the historical background of the evolution 
of intellectual rights and the role that it plays in our modern day society.88   
 
3.3 What does the Phrase Intellectual Property Rights Means? 
Intellectual property rights are a twentieth century generic term which refers to 
a group of legal regimes89 that regulate the usage, exploitation and utilization 
of creation of the mind. 90  Although the term is relatively new (the term was 
not in widespread use until the 1960s, when it was adopted by the WIPO) the 
concept is a development of the last middle ages.  There are various kinds of 
intellectual property rights and they include patents, copyrights, design, trade 
and service marks, rights in performance, designs, plant breeders’ rights, utility 
models, appellation of origins, layout designs and topography; 91 however one 
of the major characteristics of intellectual property is that it has the ability to 
establish possession over intangible things that are in the form of ideas, 
inventions and information.92 Thus they are sometimes referred to as 
knowledge reduced to practice.93  
 
Knowledge is an elusive commodity94 and the ability to use it proficiently in a 
production capacity is an essential necessity for economic development which 
                                                            
88 Dreyfuss Rochelle, Zimmerman, L.D  Harry First, H. (2001)  Expanding the Boundaries of 
Intellectual Property Innovation Policy for the Knowledge Society. Publication date. 
89 The term “Intellectual Property” refers to both industrial property and copyrights.  See A. 
Bogsch,. (1992) Brief History o the First 25 Years of the World Intellectual Property 
Organization” Geneva. 8 
90 Art 2, para. Viii, WIPO Convention (1967) ‘Intellectual Property’ includes the rights relating 
to literally, artistic and scientific works –performances and performing artists, photographs and 
broadcasts – inventions  in all fields of human endeavour – scientific discoveries –Industrial 
designs, - trade marks, services marks, and commercial names and designations- protection 
against unfair competition and all other rights resulting from intellectual activity in the 
industrial, scientific literary or artistic field.  
91 See Bently, L. and Sherman, B. (2004) Intellectual Property Law.  2nd ed. Oxford: Oxford 
University Press (95 -100 
92 Ibid pg 1 
93 Fisher. M  (2005) Classical Economics and Philosophy of the Patent System.  I.P.Q: No1 
94 See ECONOMIC COUNCIL OF CANADA, REPORT ON INTELLECTUAL AND 
INDUSTRIAL PROPERTY, 1-30 (1971); P. DASGUPTA& P. STONEMAN, ECONOMIC 
POLICY AND TECHNOLOGICAL PERFORMANCE (1987); G. YANKEY, 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
55 
 
is imperative for the growth of any nation.95  Braga describes knowledge as a 
public good,96 and public goods have the characteristics of being non-rivalrous 
and non-excludable. In other words the usage of knowledge by one person 
does not diminish the amount of knowledge available for usage by another 
person.97 A very useful illustration of this point is, if I have only one piece of 
chocolate and I eat it, there would be none left for anyone else to eat. This 
would make it a rival, excludable private good.98 On the other hand, the 
amount of air I breathe will not diminish the amount of air left for other people 
to breath; neither will other people be excluded from using air. So when 
intellectual property rights are described as public goods, this is what it means, 
although some commentators have argued that in the real sense, there is no 
such thing as an absolutely non-rival or non-excludable good.99 
 
Intellectual property rights create property in inventions by facilitating and 
imposing control of the knowledge that defines the invention, therefore 
enabling limitations to be placed on its supply and use.100  They have therefore 
been described in economic circles as free goods, this means the goods are not 
scarce and are reproducible at zero cost. Free goods can also be described as 
non-wasting assets as they involve no “additional economic cost, beyond the 
                                                                                                                                                            
INTERNATIONAL PATENT AND TECHNOLOGY TRANFERS TO LESS DEVELOPED 
COUNTRIES (1987). 
95 See Mansfield (1988)  Intellectual Property Rights, Technological Change, and Economic 
Growth, in INTELLECTUAL PROPERTY RIGHTS AND CAPITAL FORMATION IN THE 
NEXT DECADE  
C. Walker & M Bloomfield eds.  
96 Carlos Alberto Primo Braga. (1998)The Economics of Intellectual Property Rights and the 
GATT: A View from the South. 22 Vand. J. Transnat’l L. 243 
97 For the definition of public goods see  Hal R. Varian, Microeconomic Analysis (1992) W. 
W. Norton; 3rd edition and ; Mas-Colell, Whinston & Green (1995) Microeconomic Theory . 
Oxford University Press, USA  
98 Ibid 
99 Meir Perez Pugatch. (2006) The intellectual property debate : perspectives from law, 
economics and political economy. Cheltenham, UK; Northampton, MA : Edward Elgar 
100 Matthew Fisher.(2005)  Classical economies and philosophy of the patent system. IPQ  
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costs of communication and learning”.101 What makes intellectual property 
rights fascinating however is that it imposes a structure of artificial scarcity; 
some commentators have therefore argued  that the benefits of free goods 
increase with its usage102- a good example of this is recycled paper. Recycling 
involves making something new out of something old, in this way making sure 
nothing is wasted. Other commentators have however argued that the very 
nature of intellectual property rights is to prevent the limitless usage of an 
inventor’s idea so that he does not lose absolute rights to the information by 
disclosing it.103  The rationale behind this is that many inventions are usually 
capital intensive and expensive to produce, therefore the creator expects to be 
rewarded for the disclosure of information to society. Today, inventions will 
rarely be brought to the public domain free of charge. Any diversion from this 
norm, some have argued would discourage the information holder from sharing 
information to avoid it being used without recourse to the inventor of the 
idea.104  
 
Traditionally, the concept of property as an exclusive private assert has been 
interpreted as being dependent on government policies. Jeremy Bentham wrote 
that “property and law are born together and die together. Before laws were 
made there was no property; take away laws and property ceases”.105 However 
others have argued that the consensus about the perception of property was not 
the product of any one particular legislator or of an organized social group.106 
The concept arose as a result of an evolution of dialogues and ideas from 
                                                            
101 See Taylor and Silberston, (1973) The Economic Impact of the Patent System . Cambridge 
University Press, P. 24; quoting from Arrow, “Welfare Economics and Inventive Activity’,  in 
The Rate and Direction of Inventive Activity (NBER, Princeton, 1962). 
102  M. Fisher, (2004) Classical Economics and Philosophy of the Patent System  IPQ 
103 Dr Patricia Kameri-Mbote. (2005)  An Assessment of the Status of Laws, Research and 
Policy Analysis on Intellectual Property Rights in South Africa. IELRC Working Paper. and 
Karen W. Baer, (1995) A Theory of intellectual Property and the Biodiversity Treaty, 21 
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104 Ibid 
105 J. Bentham (1864) Theory and Legislation, Principles of the Civil Code. Pt 1, at 111-13 
(R.Hildreth trans., E. Dumont ed. 
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learned jurist in different parts of Europe.107   Interestingly, the economic value 
of property is shifting from tangible property such as real estate to intellectual 
and intangible property.108 The difficulty however lies in that  people cannot 
physically hold intangible property, the boundaries of where intellectual 
property rights should end has been hard for many to agree on. Thomas 
Jefferson challenges the idea of intangible goods as a form of property when he 
states that “If nature has made any one thing less susceptible than all other of 
exclusive property, it is the action of the thinking power called an idea, which 
an individual may exclusively possess as long as he keeps it to himself; but the 
moment it is divulged, it forces itself into the possession of everyone, and the 
receiver cannot dispossess himself of it.  Its peculiar character, too, is that no 
one possesses the less, because every other possesses the whole of it. He who 
receives an idea from me receives instruction himself without lessening mine; 
as he who lights his taper at mine, receives light without darkening me.  That 
idea should freely spread from one to another over the globe, for the moral and 
mutual instruction of man, and improvement of his condition, seems to have 
been peculiarly and benevolently designed by nature, when she made them, 
like fire, expansible over all space, without lessening their density at any point, 
and like the air in which we breath, move, and have our physical being, 
incapable of confinement or exclusive appropriation. Inventions cannot, in 
nature, be a subject of property”.109 
 
Before Jefferson’s theory of intellectual property rights as an essential tool for 
encouraging invention, Long argued that prehistoric laws were suspicious of 
intellectual property rights and did not recognize the concept of intellectual 
                                                            
107 See H. Maine (1901) Ancient Law 1-20. London 
108 See BRUCE A. ACKERMAN (1977)  PRIVATE PROPERTY AND THE CONSTITUTION 
98-100  and  Grey, C.T. (1980) The Disintegration of Property, in NOMOS XXII: PROPERTY 
69, 69 distinguishing thing- ownership and bundle-of-rights metaphors). Even after 
Ackerman's book, the "thingness" of property plays an underappreciated role in property 
theory. 
109 Barlow, J. B (1997) The Economy of Ideas: Everything You Know about Intellectual 
Property is Wrong, in Intellectual Property: Moral, Legal, and International Property: Moral, 
Legal, and International Dillemas 349 (Adam d. Moore ed) 
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property rights. Genius, it was believed is a gift from God, and therefore could 
not have commercial value because it was granted by grace from God.110  Long 
argues that the concept of the intellect as property only began to be recognized 
after two criteria were established; the first was the establishment of the 
understanding that inventions or ideas could and were the end product of 
human intellect rather than a gift from the gods or the gift of God: and 
secondly the product of the intellect in its intangible from could also have 
commercial value.111 Some commentators argue that the concept of intellectual 
property rights has existed for over 6,000 years.112 Initially it existed in the 
form of a marking to establish ownership of animals. Other markings included 
markings to identify the property of a certain clan or group of people and 
markings to identify specific wares and ownership of household goods.113 
Evidence further suggests that the Greeks were the first civilized society to 
have rewarded genius which in the end became the accolade of intellectual 
property rights. During the 4th and 5th century BC, the Greek culture of 
Simonides and other poets were recognized as intellectual entrepreneurs and as 
such were expected to perform on demand for a fee.114 Around the same time, 
the Sophists who were Greek lecturers, writers, and teachers travelled around 
the Greek speaking nations giving lessons on many subjects from household 
management to wrestling in exchange for a fee.115 These Sophist philosophers 
were all said to possess encyclopaedic knowledge which they offered for a 
price,116  thus began the rudimentary idea that the content of the mind could be 
sold as property. The Sophists had manuals which they carried around and 
                                                            
110 P. O Long, (1991) .Inventions, Authorship, “intellectual Property,’ and the Origins of 
Patents: Notes towards a Conceptual History.  32 Technology and Cultural at 858 
111 Ibid 
112  May. C and Sell. K. Susan (2006) INTELLECTUAL PROPERTY RIGHTS: A Critical 
History.  Lynne Rienner Publishers, Inc 
113 Gerald Ruston. On the Origin of Trademarks. The Trade-Mark Reporter 45:127-144 
114  May. C and  Sell. K. Susan (2006)  INTELLECTUAL PROPERTY RIGHTS: A Critical 
History. Lynne Rienner Publishers, Inc 
115 Ibid pg 45 
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taught men how to speak and debate in public places.117 Although some have 
argued that the work the Sophist carried out was in some way analogous to 
payment for intellectual knowledge, evidence points to the fact that the 
Sophists did not seem to regard the content of their teaching as a form of 
ownership.118  
 
Simonides lifetime (556BC to 468 BC) has also been identified as a landmark 
period when art began to become commercialized.  This is the period in which 
money first began to be circulated. Coincidently that was the same period in 
which poetry first became commercialized. As a result some have claimed that 
these are the events which led to the development of a rudimentary form of 
intellectual property. From that time onwards poets and artist alike signed their 
paintings and work as a “recognition of personal achievement, and a warning 
of ownership” thus began the recognition of individual talent and innovative 
capability as a proponent of intellectual property rights, although as stated 
above, the term intellectual property rights was never employed at the time.119   
 
The recognition of the need to codify intellectual property into a law however 
has its origins in the guilds of the Roman era. Under the Lex Cornelia de 
ininriis c.81 B.C., a person was prohibited from using another person’s name 
for profit.120  Whilst the law recognized that there is commercial value in craft 
knowledge and it ought to be protected. It also recognised a purchaser right to 
bring an action against the vendor of goods with a fraudulent mark who had 
the intent to deceive and defraud. The Roman publishing industry also 
emerged and flourished in the first century B.C because the environment 
                                                            
117 Jacqueline de Romily (Author), Janet Lloyd (Translator)  (1998) THE GREAT SOPHISTS 
IN PERICLEAN ATHENS. OXFORD UNIVERSITY PRESS. 
118 Masterson, Salathiel C.  (1940) Copyright: History and Development. California Law 
Review 28, no 5 (July): 620-632 (pg. 621) 
119 Vukmir, Mladen. 1992,  “The Roots of Anglo-American Intellectual Property Law in 
Roman Law.” IDEA- The Journal of Law and Technology 32, no. 2:123-154 (pg192) 
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encouraged authorship through the use of patronage and rewards.121  It is 
acknowledged that Marcus Tullius Cicero (January 3, 106BC- December 7, 43 
BC), the prominent Roman statesman, lawyer and philosopher who was one of 
the supreme writers and orators of prose had commercial interest in the sale of 
his books including those on humanism, philosophy and politics. The assertion 
therefore implies that even though they were no codified intellectual property 
laws then, they appeared to be the recognition that artists have justified rights 
over their works.122 
 
The transition from a rudimentary form of intellectual property into modern 
day intellectual property rights as we know it today took place during the Early 
Middle Ages. 123 As a result of which several statutes were passed across 
Europe covering different guilds from woollen textiles industry to weavers and 
goldsmiths.124 Guilds functioned by establishing ownership of marks so that 
nobody outside the guild could legitimately use them; as such guilds prevented 
non-guild members from selling products within the area of guild monopoly. 
125 The guild system established who had the right to produce certain goods; 
this had the effect of producing scarcity in the use of certain knowledge or 
ideas. 126 Although guilds were to protect and further the guild members; 
professional interests, it became a very important part of the economic and 
social fabric of that society.127   In the same way modern day guilds can be 
compared to early guilds which have rejuvenated itself as local organization 
for craftsmen in traditional skills. These guilds operate like small business 
                                                            
121 May. C and Sell. K. Susan (2006) INTELLECTUAL PROPERTY RIGHTS: A Critical 
History.  Lynne Rienner Publishers, Inc 
122 Ibid  
123 In European historiography, the term Dark Age(s) refers to the Early Middle Ages, the 
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124 Epstein. S, (1991) Wage Labor & Guilds In Medieval Europe.  University of North 
Carolina Press.  
125 McClure, D. M. (1979)  Trademarks and Unfair Competition : A Critical History of Legal 
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associations and are renowned for exercising very strong influence in their 
field. For example the Screen Actors Guild and Writers Guild of America are 
prominent for exercising very strong control in Hollywood because of the very 
robust and rigid structure of intellectual property rights there. Other examples 
of guilds such as the American Bar Association and the Air Pilots and Air 
Navigators suggest that such associations have an extremely strong political 
influence on the fabric of any nation. 
 
3.4 Patents 
A patent is a form of property right in inventions which is granted for a limited 
time in exchange for the disclosure of technological or scientific 
information.128 Patents (previously referred to as patent customs) can also be 
described as a form of limited monopoly which in the past involved privileges 
rather than property rights129. Although patents have existed for centuries and 
are perhaps the most essential legal mechanism for protecting intellectual 
property rights, the reality is that some commentators see it as a process in 
which government policy goals are implemented and enforced.130  The 
monopoly concept of a patent confers on the inventor the sole right to exclude 
others from economically exploiting the innovation for a limited time. The 
most important international agreement on patents  in the 20th century has been 
established in the form of the TRIPS Agreement which limits the patent period 
to a twenty year time frame. Article 33 states that “the term of protection 
available shall not end before the expiration of a period of twenty years 
counted from the filing date”131  
 
                                                            
128 E. Walterscheid  (1994) The Early Evolution of the United States Patent Law (Part 1) ) 76 
J. Pat & Trademark Off. Society at 697. 
129 Patents as a form of privileges will be discussed below 
130 Bently L and Sherman. B.  INTELLECTUAL PROPERTY LAW. 2nd Edition Oxford 
University Press. 2004 
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For an invention, whether it is a product or process to pass the patent test, it 
must meet the three-tier test in Article 27, it must be new, involve an inventive 
step and be capable of industrial application. (Note that Article 27.1 of TRIPS 
could be considered a flexibility, e.g. section 3(d) of the India Patents Act 
which interprets narrowly the novelty of pharmaceutical products.) It must be 
new or novel in the sense that the idea or information should not be in the 
public domain before the date of filing and should not have been patented 
before that date. The inventive step also implies that the invention must not be 
an obvious one; in other words the idea should not be common sense to any 
“person skilled in the art”. It must constitute nonobvious improvements over 
past inventions. Section 3 of the 1977 Patent Act and Article 56  of the EPC 
state that inventive step/obvious step is determined from the view of the 
average person who is skilled in the art.132  For a patent to be useful and 
applicable in the industry, the device must have a stated function and be 
capable of being used for the proposed function. A patent holder cannot patent 
the theory that light travels through transparent bodies in straight lines; 
however he can patent a machine which measures the distance that the light 
travels into space.133  Although note that in the United States, utility is a 
requirement that must be fulfilled before the patent test is fulfilled,  however 
with the European patent law, utility is not a pre-requisite for an invention to 
pass the patent test.  
3.4.1 The Venetian influence on Patents  
Mandich’s research points out that the earliest record of law in Venice which 
looks like a rudimentary form of patent was the decree adopted by the Major 
Council of Venice on 21, May 1297.134 The law regulated the making and 
                                                            
132 Brugger v. Medic Aid [1996] RPC 635, 653. See J. Bochnovic, (1982) The Inventive Step, 
59; J. Pagenberg  (1978) The Evaluation of the “Inventive Step” in the European Patent 
System: More Objectives Standards Needed” 9 IIC 1, 16-17; J. Tresansky, (1991)  PHOSITA: 
The Ubiquitous and Enigmatic Person in Patent Law 73 JPTOS 37. 
133 What can be patented is highly controversial. Consider the recent furor over patenting 
genetically manipulated animals or patenting computer programs. 
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selling of medicines, syrups, and confections which it confined to state run 
shops.  The law stated that “all medicines, syrups and confections are to be 
made from the best materials available and to be sold only by those 
licensed”.135 Other commentators have singled out the Venetian movement in 
the fourteenth and fifteenth century as the first to repetitively and 
consecutively apply specific rules of patents to invention.136  At that time 
glassmaking in Venice was restricted to only members of the Glassmakers 
Guild which was closely controlled by the Venetian commune. 137  However 
when the sale of its glass products spread throughout Europe, it convinced the 
Venetians about the great commercial importance of its glassworks.  With this 
knowledge came the realization that the craft know-how of the state and guild 
must be watched closely and protected as a whole.138  Although it must be 
noted that some have suggested that intellectual property rules did not emerge 
entirely from Venice, one thing is certain it began its systematic evolution from 
there. In fact, some have insisted that this formed the foundation of the ensuing 
development that would eventually culminate in a codified TRIPS Agreement 
which sets out the rules and procedures for patent application. 
 
The rules and procedures for granting patents in Venice in the fourteenth and 
fifteen century were extremely exhaustive and similar to the criteria that a 
patentee has to establish today before he is granted a patent. For a patent to be 
granted the invention had to be new, i.e. the invention has to be different from 
any existing prior art and should not have been described in any prior public 
disclosures. As stated above it has to be useful, i.e. the invention must be 
useful in ways that represent improvements over existing products and 
techniques.  In addition the patent also has to have a time limit in which the 
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patent would be protected. The state also had a right to grant compulsory 
licensing in exceptional circumstance,139 an exception which is also recognized 
in the TRIPS Agreement. These similarities are evident of the fact that the 
TRIPS Agreement is historically linked to this period. 
 
One of the most striking factors that the Venetian authorities took into 
consideration when granting patents is that private and public interest must be 
balanced, and complement each other.140 An argument that is commonly used 
nowadays to challenge intellectual property laws and agreements that some 
believe go too far in protecting multinational corporations without taking into 
consideration the plight of peoples public health needs.  A good example of 
this is when the Venetian legislators prohibited the glassmakers’ guild from 
taking a monopoly on eye glasses for reading. The rationale behind the move 
was the fact that the public benefit of people in society having wide and easy 
access to eye glasses at a time when the dissemination of knowledge through  
reading books was considered a key element of societal and cultural life far 
outweighed the absolute ownership of knowledge as a stimulus to encourage 
innovative activities.141 These are some of the key factors that many 
commentators have argued should be taken into consideration when 
considering whether patents should be granted for life saving pharmaceutical 
products in the face of the HIV/AIDS epidemic, malaria and tuberculosis 
which has ravaged families, communities and nations in the developing world. 
In this regard, the Venetian movement has many things in common with the 
modern day intellectual property rights. 
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The first patent that historians found in the archives of Venice dates back to 20 
February 1416. It was given to someone from the Greek island of Rhodes who 
introduced a new device into Venice whilst requesting for monopoly rights to 
go along with the invention.142  In 1444, another patent appears to have been 
given to Antonio Marini of France;143 more patents for inventions were granted 
in 1445, 1446 and 1450 in Venice for various things.144 In 1469, a patent was 
issued to John Speyer for printing, the following year another was issued for 
the construction of mills. Subsequently, another patent was also granted to 
Branchalion in 1471 for the making of unspecified cannons or other 
weapons.145 One of the most cited Venetian statute  enacted in 1474 states that 
“We have among us men of great genius, apt to invent and discover ingenious 
devices; and in view of the grandeur and virtue of our city, more such men 
come to us very day from divers parts.  Now, if provisions were made for the 
works and devices discovered by such persons, so that other who may see them 
could not build them and take the inventor’s honour away, more men would 
then apply their genius, would discover, and would build devices of great 
utility and benefit to our commonwealth. Therefore: Be it enacted that, by the 
authority of this council, every person who shall build any new and ingenious 
device in this city, not previously made in our Commonwealth, shall give 
notice of it to the office of our General Welfare Board when it has been 
reduced to perfection so that it can be used and operated. It being forbidden to 
every other person in any of  our territories and towns to make any further 
device conforming with and similar to said one, without the consent and 
license of the author, for the term of ten years. And if anybody builds it in 
violation hereof, the aforesaid author and inventor shall be entitled to have him 
summoned before any magistrate the said infringer shall be constrained to pay 
him [one] hundred ducats; and the device shall be destroyed at once. It being, 
however, within the power and discretion of the Government, in its activities, 
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to take and use any such device and instrument, with this condition however 
that no one but the author shall operate it”.146 
 
 
 3.4.2       Patents Spread to other Parts of Europe 
 3.4.2.1 France 
Accordingly the patent custom spread quickly to other European countries 
such as France, Germany and England.  During the reign of Louis XIV in the 
early seventeenth century to the early eighteenth century France was 
considered more or less one of the most advanced countries in Europe.147  
Domestic silk production and the printing/publishing industry grew to become 
one of the most vibrant industries in Europe at the time.148 In that sense France 
inevitably became one of the chief recipient of the immigration of artisans and 
craftsmen from Venice and other Italian city-states.149 Indeed the first 
monopoly patent known to have been granted by the French king was to an 
Italian, Theses Mutio in 1551 for making glassware in Venetian style.150 
However it must be noted that between 1550 and 1600, on average only one 
patent was granted in France every two years.151 There were three major causes 
for this change in events: firstly the massacre of Protestant Christians on the 
night of St Bartholomew in 1572 and the religious intolerance and distaste for 
non-Catholics; secondly the severe interference of parliament with the granting 
of monopolies which were generally under-served and worked;152 and thirdly 
the fact that  many inventors and artist fled the country to other countries such 
as Germany and England deprived France of the potential to establish and 
maintain one of the most thriving intellectual property economies of its time. 
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The important thing to note from the above discussion however is that between 
1551 and 1887 many similarities can be observed from the French evolution of 
their patent system and the modern day intellectual property formation. A body 
of capable and proficient experts were put in place to monitor patent 
applications; the two chief bodies mainly responsible for this role were the 
Partisan Academy of Science and the Royal Academy of Science. In 1699, a 
French statute was passed stating that “The Academy shall, on order of the 
king, examine all machines for which privileges are solicited from his majesty.  
It shall certify whether they are new and useful. The inventors of those which 
are approved shall leave a model thereof.” This was apparently the first statute 
enacted which explicitly provided for patent examination.153 This statute was 
significant because it provided a legal foundation for a patent examining 
convention in France in which innovation was seriously addressed.154  In 1730 
the government appointed scientists to work within the Bureau du Commerce 
to examine inventions. This signified a dedication by authorities to be more 
involved in the examination process and represented a complete revolution in 
the patent system in Europe.  
 
In the sphere of French statutes that revolutionised the intellectual property 
landscape in France,   the Design Property Statute 1711 is probably the most 
obvious. This statute was first enacted in Lyon and paved the way for the rest 
of France to expand its national policy of industrial property rights.155 What 
made these statutes remarkable was the concept that an idea could be stolen in 
the same way that an incorporeal or unprivileged “design” can be.156  The 
implication of this was that for the first time designs took on the character of 
property, a clear indication that intellectual property as a concept has continued 
                                                            
153 See F. D Prager. (1944) A History of Intellectual Property from 1545 to 1787.  26 Pat. Off. 
Soc’y 711   
154 Ibid 
155 Ibid 
156 Ibid  
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to grow and evolve in ways that seemed entirely new and innovative in 
eighteenth century Europe.  Other important Statutes worth mentioning are the 
1744 act which protected both old and new designs without a time limit. 
Furthermore in 1762, a Statute fixed the term of patents at 15 years.157 The 
distinctive characteristics of the patent were that it limited the option of being 
able to transfer patents. The rationale for this was so that the patent could be 
utilized promptly.158 Other characteristics of the patent grants that stand out are 
the social obligation undertone of the patent structure which made it all the 
more interesting.159 Another Act passed in 1787 added the additional 
administrative tool needed for establishing design inventions in a secure way 
and deliberately referred to designs as property.160 This was a significant 
milestone because no country had ever passed a statute refereeing to designs as 
property.161 
 
This wave of intellectual property revolution did not last very long. On the 5th 
of February 1776, an edict was passed by Louis XVI abolishing the guilds 
which subsequently became state controlled after it was reinstated that same 
year.162 As a result of the high level of instability that enveloped the country, 
public opinion was beginning to change. The king who had once described 
privileges as “grace founded upon favour” found that people no longer saw 
their hard work as grace or favour. They were beginning to see the profits that 
came with the ownership of intellectual property as an entitlement and a 
reward for hard work.163 Most of the textile manufacturers in France joined in 
demanding that designs, patents and copyrights be recognised as property.164 
After the French revolution in  July 1789  the guild system came to an abrupt 
                                                            
157 J. Isore, 1937 in Revue Hist. De Dr. Fr. Etr p..115 
158 Below p.57 
159  See F. D Prager. (1944) A History of Intellectual Property from 1545 to 1787.  26 Pat. Off. 
Soc’y 711   
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162 Below p 754 
163 A rationale commonly used by proponents of   the patent system 
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end and shortly after that a new statute on patent was passed in 1791 165 The 
1791 statute applied the principle of industrial property with registration to 
inventions and became one of the strongest intellectual property statements in 
France.166 Section 1 of the French law stated that “All new discoveries are the 
property of the author; to assure the inventor the property and temporary 
enjoyment of his discovery, there shall be delivered to him a patent for five, 
ten or fifteen years”. The significance of section 1 was it gave the inventor  
property in his discovery.   Ironically, less than a century later in 1887, the 
highest court in France declared that there is no such thing as intellectual 
property.167  Prager asserts that this was heavily influenced by Renouard and 
Olin-Picard168 who were at that time the chief authorities on copyrights and 
patents. They publically denounced intellectual property because they believed 
that it gave the author and the inventors’ limited character rights, which they 
did not agree with. Conclusively on the subject of the development of patent in 
France, the reader can appreciate that France had had connections with the idea 
of property rights in ideas, so the concept was not novel to them in the 20th 
century. Indeed some commentators have asserted that it contributed in 
shaping the intellectual property concept in the eighteenth century although 
this was destroyed in the nineteenth century. 
 
3.4.2.2       Germany  
Historically patents in Germany appear not to have been there initially; 
however when the concept and practice arrived and took shape, it operated for 
some time and then disappeared due to the dissemination of German society.169 
                                                            
165 Liana Vardi,  The Abolition of the Guilds during the French Revolution. French Historical 
Studies, Vol. 15, No. 4 (Autumn, 1988), pp. 704-717   
166 Below, p756 
167 Bull. Cour de Cassation., 1887, p. 321 
168 Renouard  
 Traite des Brevets, p25 
169 The Thirty Years' War (1618–1648) was a religious war principally fought in Germany, it 
involved most of the European powers. The conflict began between Protestants and Catholics 
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Although many commentators do not acknowledge that the Germans accepted 
the concept of the inventor’s right before the 16th century, evidence suggest 
that in fact the Germans had a well structured patent system that was not just 
based on the favours and whims of the king (as it was in England during the 
reign of Elizabeth I and James I which will be discussed later in this chapter), 
but was actually free from monopoly abuse and corruption.170 This system it is 
asserted encouraged patents, a potential patentee had to establish the following 
specifications that the patent was capable of - application and specification, 
novelty and would pass the test of operability.171 Patents in Germany also had 
to fulfil the requirements of being capable of  technical advancement for the 
public benefit of society. Additionally the patent holder  had to pay a fee 
tantamount to tax before he could operate his patent.  The penalties for 
infringement in Germany were pretty high and the patent licences could be 
transferred pretty easily.172 One of the first procedures that a patent holder had 
to follow in order to be granted a patent was to make an application in which 
the invention had to be described as accurately and clearly as possible.173 A 
requirement that is very similar to most patent applications today. For a legal 
or natural person to make an application, it must be made at a patent office 
which has the jurisdiction to grant a patent of the proposed invention. The 
application is usually made at the national patent office but can also be made at 
a regional organisation, such as the European Patent Office (EPO). For a 
successful application to be made, it must contain the patent specification, 
illustrating drawings and reveal the most effective way to make the 
invention.174 The latter being a specific requirement for patent application in 
                                                                                                                                                            
most of Europe. See Geoffrey Parker and Simon Adams . THE THIRTY YEARS’ WAR. 
1997. 2nd Edition 
170 Hansjoerg Pohlmann.  (1961) The Inventors’ Right in Early German Law, Materials of the 
Time from 1531 to 1700. 43 J. Pat. Off. Soc’y 121  
171 Ibid 
172 Ibid 
173 Ibid 
174 What are the steps in getting a patent?". Questions and Answers on Patents. Wolf, 
Greenfield & Sacks, P.C.. 
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the US.175 16th century German patent applications however were presided 
over by a board of members in the Imperial Councillor’s Chamber who 
examined patent applications. If patents or copyrights application was too 
complicated, experts were called upon to assist.176 The relevance of showing 
that Germany had a well sophisticated  patent system must not be understated, 
because it reveals the foundation, background and origins of the present day 
patent system. It shows that most of the major super world powers today have 
a historically link with the patent system, and the TRIPS Agreement are former 
policies and rules which have perhaps evolved into a multinational codified 
body of law. What appears evident throughout this analysis is that you will not 
find any deep rooted historical link of the patent system to many developing 
countries for reasons that will become apparent later on in this chapter. 
Another interesting fact worth nothing is that the patent system has many 
characteristics that are similar to the pharmaceutical industry and are vital to 
ensuring the success of the sectors’ business model. For example both have a 
very large market capital; R&D is the essential for the survival of both, both 
are high regulated and there is a huge reliance on R&D and is highly 
regulated.177 
Many applications and grants in 16th century Germany made explicit and direct 
reference to the notion of novelty being an essential requirement for a patent 
application to be successful. Nevertheless, some patents were actually granted 
for improvements over previous patent. When one considers the requirement 
that a patent can only be granted for inventions that are new, one may begin to 
question whether the requirement that should be clearly stipulated as part of 
the pre-requites of a patent grant is that an inventions should be incremental as 
opposed to new. In the writers opinion granting patents for mere improvements 
                                                            
175 Ibid 
176  Pohlmann, H. P  (1961) The Inventors Right in Early Germany Law, (1961) 43 J.P.O.S. 
121 (translated by F.D.Prager) 
177 The US Food and Drug Administration (FDA), for example, has an enormous set of rules 
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Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
72 
 
may set a bad precedence and in the case of pharmaecticals lead to 
‘evergreening’. Nevertheless examples of such patents were those given to 
vom Creutz in 1580, 1584, 1589 and 1600 for mere improvements over old 
patents. Even though as many as 100 patents were issued by the Emperor 
between 1530 and 1630,178 the German patent structure was such that 
documents have shown that many patent applications were rejected for not 
meeting the necessary requirements. Another major requirement that an 
applicant had to prove in order to be granted a patent was to pass the proof of 
operability test. If the new invention was a new machine or process, tests had 
to be carried out with a model presented to the council.  When Eyring, the 
owner of a patent for Saxony applied for an Imperial patent in 1588, the 
Emperor requested that a small model of the device be produced to enable the 
Emperor make a decision.179 
 
In order to successfully apply for a patent, the applicant had to establish that 
the new invention had advanced over prior arts, whether this was a legal 
requirement or not is not clear.180 Many patent application documents 
uncovered at the time suggest that one of the ways in which patent applications 
were determined is by evaluating  whether the invention was for the public 
benefit of the populace. Like the requirement of “advancement over prior art” 
one is not entirely sure whether this was a legal requirement or simply the 
norm of the day.181 Furthermore the inventor had to pay a fee synonymous to a 
tax for the patent.182. Usually this was the only payment required and the 
inventor did not have to pay any extra tithe or recurring tax. This suggests that 
Germany operated a very efficient patent system, free from all the corruption 
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and abuse that consumed the British courts and eventually led to the infamous 
Statute of Monopolies being passed in 1623.  
\ 
The origins of the patent system are very important for a variety of reasons. It 
shows the historically link between many European countries and why it 
seemed easier for them to conform to the TRIPS Agreement than it did for 
developing countries. Patents were not a complete novelty to many countries in 
Europe, even countries like Germany where previously it was though had no 
patent system in the 16th and 17th century actually had a thriving and vibrant 
intellectual property culture that only got eroded with the 30 years war. Of 
course the exact location where the patent system emerged from is still perhaps 
a little bit problematic, but from historically evidence it has been agreed that it 
indeed emerge from Venice. One thing however remains absolutely clear, it 
was deeply rooted within the social fabric of many European states and spread 
like a flame within Europe and merged with existing local practices, eventually 
integrating itself into the culture and beliefs of the people. 
 
3.5 The Birth and Growth of the Early patent Doctrine in Britain. 
The birth and evolution of patents as it relates to our modern day economy can 
hardly be successfully expended without discussing the evolution of the 
English patent system for two reasons.  Firstly the Statute of Monopolies 1623 
183 is often cited as the legal foundation of the English patent system, and 
although this has been taken over by Patents Act 1977 which harmonised UK 
Patent law with the European Patent convention,  the relevance of it cannot be 
overlooked. Secondly, most commonwealth countries have developed their 
patent system based on the English patent system, whilst some countries 
                                                            
183 See Fox, H.G (1947)  Monopolies: A Study of the History and Future of the Patent 
Monopoly .Toronto 
Monopoly practice, was variously known as “engrossing,” “regarding,” or “forestalling,” and 
was generally an offence at common law. 
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including New Zealand and Australia still derive their definition of what an 
“invention” from  the Statutes of Monopolies.184  
 
Historically, the Statute of Monopolies 1623 is often cited as the most 
important milestones in the long history of patents in the United Kingdom.  
What sometimes does not seem obvious is the fact that a rudimentary form of 
patent system already existed in England before then. The Kings and Queens 
of England issued letters patent185 as royal prerogatives or privileges to give 
their subjects monopoly powers to produce goods or provide services. These 
prerogatives or privileges to issue letters patent by the crown were used for a 
number of reasons: firstly it was used as a fundamental tool to confer 
privileges upon individuals in order to promote and enhance royal policies;186 
it was also used by the crown to bolster the industrial development of the early 
17th century by attracting foreign tradesmen and entrepreneurs to come to 
England and practice their trade.187  These earlier forms of letters patent 
operating in England were similar to royal charters granted by the crown 
authorizing the conduct of business in the state.188 Such grants resembling 
today’s modern day patents were divided into three types, namely royal 
charters, letters close and letters patent. A Royal charter is a kind of letters 
patent by the Sovereign on the advice of the Privy Council to legitimize an 
incorporated body, such as a city, company or a university. Letters close on the 
other hand were used for private individual, they were personal in nature and 
sealed so that only the recipient could read its contents. 
                                                            
184 Hulme, E Wyndham (1896)  The History of the Patent System under the Prerogative and at 
Common Law (1896)  Law Quarterly Review 141 
185  MacLeod,  C. (1988)  Inventing the Industrial Revolution, The English Patent System, 1660 
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Letters patent which are similar to today’s patents were public and directed to 
everyone. They were similar to legal instruments which were in the form of an 
open letter issued by a monarch or government. Letters patent were used to 
confer rights, monopoly, title, or status to a person or to some entity such as a 
corporation. Blackstone wrote that “The King’s grants are also matters of 
public record. These grants, whether of lands, honors, liberties, franchises, are 
contained in charters, or letters patents”.189   A well noted case in point that 
gives an insight into the rationale for letters patent is the grant of letters patent 
to John Kempe of Flanders by190  Edward III in 1331.191 The grant issued took 
John Kempe and his workers into the King’s protection. The letter stated that “ 
Know you that since John Kempe of Flanders, weaver of woollen cloths, will 
come to stay within our realm of England to exercise his mystery here, and to  
instruct and teach those wishing to learn therein, and will bring with him 
certain men, servants and apprentices and their goods and chattels into our 
special protection and defence”192 Following that in 1337, letters of protection 
were given to all foreign cloth workers to settle in England. Commentators 
have suggested that this was the “beginning of a deliberate and vigorous policy 
to expand English industry”. 193   
 
The expansion of the English industry continued in  Edward III reign when he 
instigated direct policy initiatives regarding the grant of letters patent to 
produce  wool in England. This policy worked so well that during the 13th 
century England became established for providing the best luxury woollens in 
                                                            
189  Vishwas Devaiah . A History of Patent Law” 
www.altlawforum.org/PUBLICATIONS/document.2004-12-18.0853561257 (Accessed 10-12-
2006) 
190 See  Kitzke, R.A  (1959) Historical Background of the English Patent Law, 41 J. PAT. 
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Prerogative and at Common Law,” Law Quarterly Review, Vol.12, p.142. 
191 Christine Macleod. (1988) Inventing the Industrial Revolution: the English Patent System, 
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Europe, in the writer’s opinion a premonition of the industrial success that was 
to follow. Consequently in 1449 when Edward III’s successor Henry VI 
granted John of Utynam letters patent to work all his arts and sciences without 
constraint it did not come as a surprise.  John of Utynam’s art of making 
coloured glass had never been practiced in England and part of the agreement 
between the crown and John of Utynam involved him training the King’s 
subject.  His contract also involved him fitting stained glass windows for Eton 
College and King’s College, Cambridge which Henry VI was in the process of 
establishing. This he did successfully; although none of these windows still 
exist today it was a testament to the successful instruction of a patent system 
that would flourish centuries later. The issuing of letters patent in the 
fourteenth and fifteenth century was done sporadically, as no letters patent 
were issued until over a hundred years later when Edward VI granted Henry 
Smyth a letters patent in 1552 to make Normandy glass.  
 
Henry Smyth was granted an exclusive 20 year letters patent to produce 
Normandy glass during which time “No manner of person or persons not 
licensed, or auctorized by the said Henry Smyth as is afore mentioned shall 
attempte or presume to make any kynde of the said brode glasse commonly 
wount to be called Normandy glasse or any other fytte for wyndowes upon 
peyne or forfayture of all the same glass by any of theym so to be made and as 
they and any of theym regarde our expresse comaundment and extende too 
avoyde that trouble and perell which shall earnestly and indelayedly insue in 
this behalfe”. The grant to Henry Smyth was significant because it marked the 
first time that the English tradition of granting monopolies for inventions 
began to regularise itself.194 What this also meant was that letters patent were 
not only issued on inventions but for entire industries as well, of which the 
Stationers also benefited from when they gained complete control of the 
publishing industry.  
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For a patent to have been issued during that time, the patentee had to meet 
three criteria; firstly he had to work the patent. In other words he had to 
establish a foreign trade within the kingdom. Secondly the trade was not to 
interfere with established industries, i.e., the trade was not be inconvenient to 
other subjects and thirdly he had to create a self sufficient industry through 
which English subjects could make a livelihood.195 These requirements were 
very similar to the requirements that the German Emperor required the 
inventor to establish before he could be given a patent, i.e it had to be novel, 
advance technology and be for the public benefit. Henry Smyth was able to 
meet all three requirements. The significance of Henry Smyth’s letters patent 
was that when Queen Elizabeth came into power she pursued these policy 
requirements for patent grants and implemented a system of policies that 
would continue to stimulate domestic production. 
 
Queen Elizabeth’s era has usually been cited as the period in which the English 
patent custom began to take firm roots. As a consequence of this the patent 
system flourished throughout her reign. When she came into power in 1558, 
she embarked on a strategy to encourage domestic production of goods 
imported from abroad by attracting advanced technology from Europe. In other 
to do this, like Edward III, she granted patent monopoly to entice foreigners to 
establish new trades in England. The new trade had to be established within a 
specific time, failure to do this would result in the withdrawal of the patent. 
Some analysts have asserted that modern day working of patents may have in 
fact emerged from this practice. By the time of Elizabeth’s death in 1603, she 
had in fact issued no less than 51 patents. 
 
Initially like some of her predecessors, Elizabeth I pursued a policy of not 
granting patent monopolies that acted as an  inconvenience to subjects by 
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displacing an already existing trade.196 One of the instances where this policy 
was applied was in the Matthey’s Case.  The patentee in that case was granted 
a patent for the sole making of “knives  with bona hafts and paltes of lattin” 
because he claimed that he was the first person to import the trade from 
abroad, however a company of cutlers claimed that they used knifes though not 
with hafts and therefore his patent was considered invalid. Similarly in Birots’s 
Case, a patent for preparing and melting lead ore was held to be invalid 
because it was considered as an improvement over an already existing practice. 
This consideration formed the key element as to whether a patent application 
would be accepted or not. The philosophy behind the refusal to issue patents 
for mere improvements was summed up by Lord Coke when he stated that ‘a 
mans trade is accounted his life, because it maintaineth his life; and therefore 
the monopolist that taketh away a man’s trade, taketh away his life, and 
therefore is so much the more odious.’197 
 
Lord Coke’s elucidation of the concept of the “undesirable effects” of 
monopoly  taking a way a man’s trade and livelihood conjures up images of 
the sometimes “undesirable effects” of Intellectual property rights. The case of 
bio-piracy198 where they has been a lack of effective protection for traditional 
knowledge199 is a good example of this. The Basmati case is often cited as a 
good example of when the protection of intellectual property rights or lack of it 
has the likelihood of going wrong. Basmati as a plant has been cultivated in 
India, Nepal and Pakistan for centuries, however in 1997, the U. S company 
“Rice Tec” applied for 16 patents on the generic variations of basmati of which 
the trademark “Texmati” is perhaps best known. Although, traditionally 
                                                            
196 Wyndham.  H. E (1897) On the Consideration of the Patent Grant, Past and Present. 13 
LQR. 313 to 318 
197 Coke Edward. 1644. 1797. Institute of the Laws of England 183 
198 The term bio piracy refers to the appropriation of biological resources and traditional 
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Basmati belongs to India, it had to acquire a license from “Rice Tec” as a 
consequence of the patents so as to protect itself from being sued if a WTO 
disagreement arose. Fortunately, this attempt failed because India was able to 
uphold its right to Basmati rice in court; the result of which 13 out of the 16 
patents were cancelled. This example is similar to the Birot’s Case because a 
community of people were already practicing a trade for centuries before the 
patent application was made.  
                                                                                                                                                                               
In 16th century England many people who applied for letters patent tried to 
justify the reason why they should be granted the privilege.  In 1559, an Italian, 
Jacobus Acontius explicitly invoked rights and labour as a basis for why he 
should be granted letters patent.  Thus he wrote to the Queen Elizabeth that he 
had found things that were useful to the public and therefore he should have 
the “fruits of [his] rights and labour as he had abandoned all other modes of 
gain and had undertaken experiments at great expenses and sustained loss 
which he could only recover if there were a penalty fixed for anyone who used 
his invention without his consent”.200 This is similar to the arguments used by 
the pharmaceutical industry for their justification of why the patent system is 
not only imperative but indispensible.  Developing and securing the 
endorsement for new drugs is an extremely risky and expensive business where 
reverse engineering is easy and the cost of manufacturing drugs is very low. 
Therefore it is argued that the patent system is essential to protect 
pharmaceutical companies against competition from the generic manufacturers 
otherwise they  would be unable to make a profit. The absence of a patent 
system would lead to the lack of incentive to invest in producing vaccines and 
treatment for diseases from which the whole of society benefits from201 
 
                                                            
200 See Fox, H. G (1947) Monopolies: A Study of the History and Future of the Patent 
Monopoly. Toronto  
201 The Patent System and Access to Medicine in Developing Countries: Possible Cures. 
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The arguments that patent monopolies should be issued as a reward for past 
labour was commonplace.  In the first decade of Queen Elizabeth’s reign she 
had the good intention of granting monopolies to promote the domestic 
industries of England, however a rundown crown exchequer and the desire to 
patronise and please her favourite courtiers led to many renewed or extended  
period for already established trades such as starch, salt and vinegar.202  
Patentees’ no longer had to meet the patent test that a practice had to meet the 
following requirements: be inventive, not interfere with local established 
industries and assist English subjects in making a livelihood in order to be 
issued a patent. As a matter of the fact, many patent applications were rejected 
even if they were real inventions; on the contrary patents were given to people 
as gifts and favours. For example a patent monopoly was given to Richard 
Matthew’s widow in consideration for her husband’s long and faithful services. 
 
In the end Queen Elizabeth I’s reign was perhaps best remembered for her 
abuse of letters patent. Many parliamentarians saw the Queen’s actions as an 
abuse of power; however she challenged them by asserting that members of 
Parliament were set on taking away her prerogative.203 In 1571 she addressed 
parliament saying “her Majesty hoped that her dutiful and loving Subjects 
would not take away the Prerogative, which is the chiefest Flower in her 
Garden, and the principal and head Pearl in her Crown and Diadem; but that 
they will rather leave that to her Disposition. And as her Majesty hath 
proceeded to Trail of them already, so she promiseth to continue, that they 
shall all be examined, to abide the Trail and true Touchstone of the Law.’204  
 
                                                            
202 See generally Edward C. Walterscheid, “The Early Evolution of the United States Patent 
Law: Antecedents” (Pt 2) (1994) 76 Journal of the Patent and Trademark Office Society 849 at 
851-852. 
203Alternative Law Forum – A History of Patent Law. 
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As such, Queen Elizabeth’s grants of monopolies reflected significant policy 
changes from earlier grant of letters patent which were aimed at encouraging 
the introduction of new trade and industries. The highpoint of Queen 
Elizabeth’s abuse or royal prerogative came in 1598 when Edward Darcy was 
granted letters patent for the sole manufacture, importation and sales of playing 
cards. The effect of such “odious monopoly” was disastrous for trade and the 
people, and provoked severe conflict and resentment. The House of Commons 
were infuriated and this led to a debate in 1601 between them and the crown.205 
In 1602 in the landmark case of Darcy v Allen, Edward Darcy sued Thomas 
Allen for infringing on his patent for playing cards and the courts were called 
upon to make a decision upon the validity of the patent. The facts of the case 
was that the monopoly on the importation of cards had initially be granted to 
Ralph Bowes and Thomas Bedingfield in 1576 and in 1588 it was reissued to 
Bowes alone. 10 years later when Ralph Bowes died in 1598 the patent was 
given to Edward Darcy. The court held that the patent was null and void at 
common law; it did not meet the criteria necessary to be granted a patent. 
Darcy’s grant of letters patent to import cards was described as an “odious 
monopolies”, which violated the liberty of the subjects to work in their 
respective trade. 206 The significance of this case lies in the fact that for the first 
time in English history patents was viewed as a legal right of the inventor 
rather than an unrestricted royal prerogative.  
 
Critics have also argued that the case of Darcy lead to the  against “odious 
monopolies” and the crystallization of the Statutes of Monopolies 1623. The 
Statute of Monopoly states that all Crown monopolies are illegal, except in the 
case of monopolies for inventions consistent with the Case of Monopolies.207 
                                                            
205 The 1601 debate in Parliament focused on a bill entitled “An Act for the Explanation of the 
Common Law in Certain Cases of Letters Patent” which clarified the common law limits of the 
Crown's power to grant monopolies. 
206 Ibid 
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These exceptions are the basis of modern day patent and can be found in 
section 6 of the Statute of Monopoly which states that: (a ) Provided also, that 
any declaration before mentioned shall not extend to any letters patents (b ) 
and grants of privilege for the term of fourteen years or under, hereafter to be 
made, of the sole working or making of any manner of new manufactures 
within this realm (c ) to the true and first inventor (d ) and inventors of such 
manufactures, which others at the time of making such letters patents and 
grants shall not use (e ), so as also they be not contrary to the law nor 
mischievous to the state by raising prices of commodities at home, or hurt of 
trade, or generally inconvenient (f ):the same fourteen years to be accounted 
from the date of the first letters patents or grant of such privilege hereafter to 
be made, but that the same shall be of such force as they should be if this act 
had never been made, and of none other (g ).208 
 
Interestingly, Sir Edward Coke, the Attorney General whose writings were the 
role models for the founders of the American constitution argued the case for 
the monopolist Edward Darcy. Although many saw the harm that despotic 
monopolies could bring, Darcy’s monopoly grant was upheld. The irony of the 
case was that Coke despised monopolies and believed that they would lead to 
frustration for the poor.  Indeed some have suggested Cook only acted as 
council to the defendant because he was duty bound to defend the queen’s 
prerogative. After the case he reported that such grants of monopoly went 
against the freedom of trade and the common law.209 Coke continued his 
lifelong campaign against monopolies and in 1603 when James I became King 
of England he was appointed Chief Justice of the Bench, a position which was 
at that time the highest legal title in England. James I was soon to regret this 
when Coke declared that “neither by the Great seal nor by the Little Seal nor 
by the Little Seal, justice shall be delayed, ergo the king cannot take any cause 
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out of any courts and give judgment upon it himself”. Coke believed that the 
common law must always take precedence over acts of parliament. Coke 
argued that “when an Act of Parliament is against common right and reason, or 
repugnant, or impossible to be performed, the common law will control it and 
adjudge such act to be void”210 
 
As a liberal thinker Coke viewed the common law thinking as equivalent to the 
very virtue of being human beings.211 Commentators have expanded on this 
and suggested that this is what Coke meant when he said that “reason is the life 
of the law; nay, the common law itself is nothing else but reason...the law 
which is perfection of reason.”212 Coke also believed that monopolies violated 
the Magna Carta which was the foundation of English liberties.213 He is also 
remembered for his assertion on the supremacy of the common law and the 
rule of law that no man is above the law; some of his beliefs also included the 
significance of economic liberty and his belief of the free market. Some 
commentators have in fact suggested that the eighteenth century principle 
purported by Jefferson that “all men are created equal,” was probably derived 
from this concept, although Jefferson was supposedly only referring to “all 
free, property owning males” as equals.214   
 
In a sense the judgment in a later case the Clothworkers of Ipswich 1615 
marked the beginning of the end for odious monopolies. In this case, a group 
of tailors chartered by King James I to operate in Ipswich brought an action 
against a single tailor who was not part of the group but practising his trade in 
the town. The court held that the Crown could lawfully grant exclusive 
privileges of a new invention, a fresh discovery or a new trade within the 
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realm, for a limited time. Again the significance of this case lies in the 
doctrinal principles it sets out for issuing such patents namely: the invention 
must enables the introduction of a new industry, the training of the Englishmen 
in the trade and the fact that no monopoly patent can be issued for a pre-
existing trade. Another significance of this case was that it was clear that 
although the common law courts had taken over the responsibility of settling 
disputes over monopoly patents, they still viewed royal privileges to be for the 
fulfilment of royal policies and directions.215 This was to change shortly. 
 
The abuse of letters patent continued unabated under James I, even though he 
had promised in the Book of bounty to refrain from abusing royal prerogatives. 
In the 1620’s Parliament passed the Statutes of Monopolies to the King’s 
disappointment and displeasure.216 In a statement to Parliament, the king  said 
“I am grieved that you have called (my royal prerogatives to grant patents) ... 
and condemned them upon so short examination. I confess I might have passed 
some upon false suggestion and wrong information by the judges”.217 
Parliament asserted its authority and this action represented the final classic 
step towards the shift from royal prerogative to common law and legal rights in 
the sphere of letters patent.218 Along with this came the understanding that they 
was no need to implore an Emperor, King or Queen to have the “fruits of one’s 
labour”. In fact by the 18th century, John Locke’s labour theory of property had 
formed the basis for the justification of the protection of the patent system. 
With this came the erosion of the “odious monopoly” that had threatened to 
plague the English subjects.  
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The birth, growth and concretisation of patents in England and indeed many 
European countries reveals a lot when one considers that pharmaceutical 
patents is only a recent development in many European countries. For example  
before 1949, the  UK did not offer pharmaceutical patents, Italy too did not 
offer pharmaceutical patents until the 1970s. In the same light before Spain 
joined the EU in 1986, they did not provide product patent protection for new 
pharmaceutical products. As part of the Treaty of Accession, Spain was 
required to rectify this. The argument follows that before then most of 
continental Europe were keen on patenting only the processes of producing a 
medicine, while still allowing other companies to produce the medicine using a 
different process. Indeed the German Association of the Chemical industry 
points out that the same chemical products can be obtained by different 
processes, methods, materials or components. 219  Hence, there is social value 
in patenting a new process, as it rewards the innovator without preventing 
further innovation.220 Another classic example where patents were prohibited 
and led to the growth of the Industry is the Swiss Chemical Industry. This is in 
contrast to the French Patent laws which allowed chemical patents.221 
Imperative to note however is that most of Europe did not introduce patents 
until they had had the opportunity to develop their pharmaceutical industry 
 
3.6 The Birth of the Modern Patent Doctrine 
Before an exploration of the Locke theory and other professed theories of the 
justifications of patent system can be carried out, a modest elucidation of the 
foundation of the modern patent doctrine will be carried out here to set the 
scene for further erudition.  It follows that after the Statutes of Monopoly 1623 
was passed, they still existed some degree of uncertainty about the 
rationalization of the patent system. The thing that made the situation more 
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difficult was the lack of common law precedence.222 Thus in 1795 Lord Chief 
Justice Eyre lamented “patents rights are nowhere that I can find, accordantly 
discussed in our books”223  Mossoff comments that there is plenty of evidence 
in the late eighteenth century concerning the lack of precedence on the law of 
patent rights.224 The law of patents was thus created, defined and applied by 
later courts.  Many scholars have therefore investigated the theory that natural 
law philosophy influenced the development of the law of patent law principle 
particularly in the late eighteenth century. 
 
The ensuring years reflected the evolution of the law of patents, the emergence 
of new conditions and tenacity of the old concept of patents as royal grants.  
There was a consistent state of confusion as to whether patents grants were 
monopolies or inventions and it was during these periods that the conditions 
that patents must be novel, disclosed and be granted to the true inventor were 
final agreed upon and established.225 In the case of Yarranton in the late 1670s, 
an inventor petitioned the court to determine whether a patent had become 
invalid because the patentee had not worked on the grant many years earlier 
and if the patent was valid as similar work was being carried out by other 
people in the country.  With regards to “modern patents” this was perhaps one 
of the earlier cases which re-asserted the notion that for a patent to be valid: the 
patentee had to work the patent and not leave it unexplored.226  
 
In order to be granted a patent, the specification disclosure had to be carried 
out and this was reiterated in the case of Garill. Although the requirement of 
specification disclose was already being used in several jurisdictions in 
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Europe, it foretold the future development of the necessity of disclosure to 
either “prove or disprove” a patent application.227 The facts of the case are that 
in 1663, Garill applied for a patent “casting for the sole casting of gold and 
silver Ingot for Lace”.228 However his petition was contested by the officers of 
the Mint and the Goldsmith and wiredrawers of London, who maintained that 
this invention was already in use by some of the traders and that a patent would 
hurt the trade and deprive many people of their livelihood.229 The privy 
Council responded by asking Garill to disclose his new method for casting 
precious metal stones as wire, so as to determine if the method was new , but 
Garill refused to disclose the method and the matter was concluded. Garill was 
never granted the patent. 
 
Most of today’s prerequisites of a successful patent application continued 
compellingly to emerge and gain legal precedence during this time. A case in 
1719 exposed the mounting magnitude of the inherent concept of novelty as an 
essential element that would form the basis of future patent application. In this 
case a corporation of Silk Throwsters failed in their appeal to revoke a patent 
for “spinning organzine silk” because they were unable to prove that the 
engines used by the patentee were ever used before in the kingdom.230  Of 
course they were numerous cases that reflected the growing momentum 
towards the development of the patent doctrine in the modern sense of the 
concept,231 the point to note however is that  patent grants were evolving 
slowly in a way that was unprecedented.  
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The Privy Council was slowing relinquishing power to the common law courts 
thus patents were no longer being seen as a matter of royal favours, but as the 
“natural right” that belonged to innovators. Another landmark case establishing 
the shift of jurisdiction from the Privy Council in the case of patents was 
resolved in 1752. It involved a Chemist, Walker Baker who challenged a 
patent granted to Dr James for his invention of fever powder. Baker claimed 
that Dr James was not the inventor of the drug and therefore the patent should 
be voided.  The Privy Council rejected Baker’s petition and in 1753, Baker 
brought another case against Dr James accusing him of perjury. He petitioned 
the Privy Council to order its clerk to testify as to the affidavit filed by Dr 
James in support of his patents, in the end Baker was not successful. Some 
have however suggested that there was a deliberate conspiracy by the Privy 
Council to arrive at that decision.232  The important thing to note about this 
case is that although the Privy Council eventually prevailed in this case, the 
fact that innovators who felt that they had a natural right to be rewarded for 
their endeavours would stop at nothing to challenge the crown. 
 
3.7 Monopoly 
The word monopoly is derived from the Greek word monopolian, which means 
the right to exclusive sale, derived from monos, meaning alone, and polein 
meaning sell.  In England the word monopoly was understood by the public as 
the privilege of having the sole autonomy to sell a product or service even if 
the product or service has been in the public domain before.233 Rich contends 
that this disposed the public of some freedoms and liberties that they held very 
dear; and perhaps this was the reason why the public began to detest the 
concept of monopoly.  Robinson states that “patent privilege is a true 
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monopoly, granted in derogation of the common right.’234 Intellectual property 
has been described by some economists as a form of temporary monopoly.235 
Thus Stiglitz writes “an intellectual property regime rewards innovators by 
creating a temporary monopoly power, allowing them to charge far higher 
prices than they could if there were competition. In the process, ideas are 
disseminated and used less than they would be otherwise”.236  It further 
remains that commentators have contended that the exclusive rights granted by 
intellectual property laws are generally negative in nature, and subsequently 
gives the holder of intellectual property rights the ability to exclude third 
parties from infringing on their monopoly. Although note that these exclusive 
rights can be conferred or  transferred through license or mortgage to third 
parties.237  
 
Before the reign of Elizabeth I, the grant of monopolies appeared to have a 
legitimate function, i.e. to allow “genius” engage in business that would 
benefit the public and encourage the growth of industry in the realm. By the 
end of Elizabeth I’s reign, this doctrine had in effect lost its professed function.  
Patents were not only granted to people who had the intention of establishing a 
new trade and engaging in that trade, but were given in industries that were 
already flourishing.  Such grant of monopolies  was considered to be odious. 
The odiousness of monopolies derived itself from the fact that the rights, 
freedom, and liberty of the community to engage in activities that they were 
accustomed to enjoying were taken away from them collectively and given to a 
singular  person or corporation. An act which many thinkers believe is 
ludicrous.  Thus many people have interpreted the concept of monopoly as  
taking away from the community things that are invaluable and giving them to 
the monopolist, whilst the latter gives nothing in return. Although this stance is 
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debatable as the inventor in return for the monopoly gives the public 
something that they may not otherwise have had. The argument continues that 
if the  product or service that became monopolized was in the public domain 
before the grant of the monopoly, the monopoly is illegal and therefore odious.  
If the product or service was new and not obvious, a temporary monopoly was 
a fair price (quid pro quo) for society to pay as a reward of inducement to the 
inventor who had taken the financial risk of commercializing that product or 
service so that society can eventually benefit from the knowledge and 
inventiveness of the creator. 
 
Although economic power and exclusive rights are concepts that remain 
resonant in both monopolies and patents as a whole, patents are not 
monopolies and this distinction must be established. Thus Lord Chief Justice 
Coke declared that “all Grants of Monopolies are the ancient and Fundamental 
laws of the Kingdome”.238  Similarly Blackstone points out that the Statute of 
Monopolies [which is according to some the cornerstone of patents] did not 
declare monopolies to be contrary to law, certain exceptions must be made, 
some of which included patents for new inventions.239  Interestingly even when 
the Court of King’s Bench deliberated on the Clothworkers Case, it avoided 
calling a patent an exclusive privilege.240 In this regard, some questions that 
were raised in United States v. Dubilier 289 US 178 (1933) may be helpful in 
shading more light on the issue. In this case the US Supreme Court relied on 
the Webster Dictionary for the definition of monopoly which states that a 
monopoly is “the exclusive right, power or privilege of engaging in a particular 
traffic or business, or the resulting absolute possession or control; especially, in 
political economy, such control of a special thing, as a commodity, as enables 
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the person or persons exercising it to raise the price of it above its real value, or 
above the price it would bring under competition’.241 The unease with the idea 
that patents are regarded as “patent monopoly” was highlighted in the Court of 
Appeals for the Federal Circuit (CAFC) in several judgements in the late 20th 
century where the question whether patent rights should be referred to as 
“patent property” were brought into question.  
 
Chief Judge Markey of the Court of the Customs and Patent appeals quoted  a 
statement from the Supreme Court’s ruling in Dubilier that “a patent is not, 
accurately speaking, a monopoly.... [t]he term monopoly connotes the giving 
of an exclusive privilege for buying, selling, working or using a thing which 
the public freely enjoyed prior to the grant. Thus a monopoly takes something 
from the people. An inventor deprives the public of nothing which it enjoyed 
before his discovery, but gives something of value to the community by adding 
to the sum of human knowledge.... He may keep his invention secret and reap 
its fruits indefinitely." Accordingly under the statute, Title 35 U.S.C. section 
261, a patent is a form of property rights, and the right to exclude recognized in 
a patent is but the essence of the concept of property”.242 Rich is of the opinion 
that letter patents or patents should not be regarded as the  original documents 
by which all kinds legal and illegal patents were granted, but has encouraged 
the reader to think  of patents as they know today as grants for limited times of 
privileges to new inventions and discoveries.243 
 
Kitch has asserted that in the field of intellectual property, there continues to 
exist several persistent errors,244 of which one of the most common is that 
patents are monopolies. Kitch contends that the reason why patent is the 
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strongest case for this assumed claim is that patents confer monopoly market 
power, and even though these kinds of situations are rare, the presumption 
remains. Likewise he discusses the issue of patents (and other intellectual 
property rights) conferring economic monopoly which inevitably leads one to 
associate social welfare cost with monopoly. But the point remains that any 
system of property rights brings with it cost, be it the cost of “preventing 
trespass’ or arming oneself with the right tools to prevent one’s property from 
intrusion. The point to note however is that whether a particular right confers 
an economic monopoly is more of a practical question than a general 
presumption. Mark A Lemley has written “while some intellectual property 
right may in fact give their owner power in an economically relevant product 
market, most do not; they merely prevent others from competing to sell copies 
of a particular product not from selling different products that compete with 
the original”.245  Regardless of the foregoing, many people still believe 
intellectual property rights including patents confer monopolies.  
 
The Court in Atari Games Corp. v. Nintendo of Am., Inc., 897 F.2d 1572, 
1576 (Fed. Cir. 1990) noted that “The two bodies of law [competition laws and 
patent laws] are actually complementary” as both are aimed at encouraging 
innovation, industry and competition.  Although there are many circumstances 
where the protection of  the legitimate interests of a patent owner and antitrust 
law violation coincide, innovators  must be allowed to protect the property 
rights given to him under the patent laws. In a case where a patent owner takes 
the property rights granted by a patent and uses it to extend his power in the 
marketplace improperly, i.e. beyond the limits of what Congress intended to 
give in the patent laws; the patent given to him will not insulate him from the 
antitrust laws. The court went further to say a “patent is a ‘shield’ to protect an 
invention," "not a ‘sword’ to eviscerate competition unfairly.” Such assertions 
have been helpful in making a distinction between the average everyday 
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definitions of monopoly (to have exclusive or dominant possession of 
something) and the economic monopoly that the patent system brings which is 
to have the exclusive right to sell into a market for a limited period of time. 
 
Richard Epstein subsequently notes that “the patent system, in fact, 
undermines the economic power of the first patentee by giving incentives to 
rival inventors” to be more innovative.246 This declaration can be interpreted as 
encouraging competition, as opposed to preventing it. Whether this declaration 
applies to the case of poorer countries who lack the economic power and 
expertise to invest in R&D and engage in such activities is doubtful. Some of 
such poor countries have no resources, no skills, and no access to the 
technology, funds or support to undermine the economic power of the first 
patentee or any other patentee for that matter.  Some commentators have 
argued that patents must be upheld regardless of its effect on access to 
medicines. Solveig Singleton states that “those who suffer from illness does 
not constitute an argument against patent system”,247 a position which may 
seem very inhumane in many people’s opinions. 
 
3.8 Justifications for intellectual property rights – patents 
The struggle to justify the essence of the patent system has been ongoing since 
the birth of the concept, and this battle continues to rage in some anti-patent 
camps where property rights in the intangibles is still being questioned and 
abhorred. The reasons why intellectual property rights are difficult to justify 
are numerous, and one of the reasons why it is difficult to justify is that it is 
hard “enough to determine the appropriate kinds of ownership of corporeal 
objects (consider water or mineral rights): it is even more difficult to determine 
what types of ownership we should allow for noncorporeal, intellectual 
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objects”.248 Another reason why intellectual property rights are difficult to 
justify is its link with the corruption and abuse of power during Elizabeth that 
is associated with patents. Many people consider patents to be the cornerstone 
of intellectual property rights.  According to one author “patents are the heart 
and core of property rights, and once they are destroyed, the destruction of all 
other property rights will follow automatically,”249  hence the strong dislike for 
the patent system.  
 
The purpose of patents is to reward inventors for their inventions, however as 
stated above the fact that a patent is sometimes seen as a monopoly does it no 
justice, and has made the case against intellectual property rights stronger. One 
of the strongest arguments against patents however is the effect that it has had 
on access to medicines since the TRIPS Agreement came into being in 1995. 
Patents have led to higher prices for pharmaceuticals, which have in turn put 
them out of reach for poorer people living in developing countries.  Whether 
the flaws of the patent system outweighs its gains is debatable, however the 
value of having a patent system cannot and should not be denied.  Below are 
some of the justifications that writers, scholars and thinkers have come up with 
in their bid to support or in some cases denounce intellectual property rights. 
 
3.8.1  Natural Rights Theory 
The natural law hypothesis is based on the moral justification that individuals 
have a natural right in their ideas.250 The most well-known proponent of this 
doctrine is John Locke, who based his theory on the core principles that a 
person owns his body and therefore whatever he decided to do with it, 
including its labour belongs to him. If another person unauthorised by the 
owner of the labourer  uses the labour of the said person, he is in effect a thief. 
These are very profound and serious allegations that must not be taken for 
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granted if that is the case. Locke’s hypothesis is centred on the belief that 
humans are by their very own nature rational and good, and they should be 
able to carry such rights, including the right to property into the political 
society. This assumption that people are by nature good and rational is very 
optimistic indeed. Locke’s core proposition are based on six main summaries, 
namely: God has given the world to people in common; Everybody has a 
property right in his own person; A person’s labour belongs to him; whenever 
a person mixes his labour with something in the commons he makes it his own 
property; The right of property is conditional upon a person leaving in the 
commons enough and as good for the other commoners; A person cannot take 
more out of the commons than they can use to advantage.251 That being said, 
some commentators including Robert Nozick has questioned some of these 
core propositions, particularly the stance that when a person mixes his labour 
with something in the commons he makes it his own property. Nozick asks 
why a person by mixing his labour in the commons should not lose his labour 
instead of making it his own. The example which he uses drives home the 
point succulently, when he gives the example of a person pouring a can of 
tomato juice into the ocean. Should the person gain the ocean or lose his can of 
juice?252 
 
Locke’s “labour theory” is rooted in the idea that objects have little value until 
laboured upon, at some point Locke suggested that labour creates 99 percent of 
value, however Hettinger questions this stance by asking the reader to 
contemplate how an individual can add 99 percent of the total value of an 
object by merely labouring upon it, if he has to mix that labour with other 
things in the commons such as land and other natural resources.253 Hettinger 
also questions the labour theory by asserting that intellectual products are in 
fact social products. In other words, inventions (no matter how novel) do not 
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operate in a vacuum; a person’s thoughts depend on the ideas of the people 
before him. Thus he quotes “A person who relies on human intellectual history 
and makes a small modification to produce something of great value should no 
more receive what the market will bear than should the last person needed to 
lift a car receive full credit for lifting it”254 Opponents of the natural law theory 
have shared very strong opposition to this hypothesis as the justification for 
intellectual property rights, thus the Westminster Review castigated the idea by 
stating that to “talk of the natural rights of an inventor is to talk nonsense”.255 It 
must be noted however that during the time of  Locke’s writing it is doubtful if  
envisaged the idea that property in the intangible was part of a labourer’s 
natural rights. Locke’s philosophical ideas were more directed towards the 
enlightenment of corporeal, however this did not prevent proponents of the 
patent system in the 19th century from applying this theory to intellectual 
property and concluding that inalienable property rights indeed exist in 
ideas.256Regardless of the foregoing, Locke’s two treaties has been  used by 
some as a defence  for  the patent system.257 
 
Jean Jacques Rousseau attempted to merge the natural rights of the individual 
with the need for social unity and cooperation through the concept of the social 
contract.258 However the main elaboration of the natural rights came in the 
North American colonies. The writings of Thomas Jefferson, Samuel Adams, 
and Thomas Paine concentrated on the natural rights theory made it a 
commanding and authoritative justification for the American Revolution 
                                                            
254 Ibid 
255 The Patent laws, (1829) XXVI Westminster Review 329. John Farey was quoted as saying 
this before the 1829 Select Committee, at p21 of the report. 
256 See the case of International news Ser. V. Associated Press 248 U.S 215, 239 (1928) 
257See John Locke, TWO TREATIES OF GOVERNMENT OF GOVERNMENT 287-288 
(Peter Laslett ed., 2edition. 1967) 3rd edition, corrected by Locke) (bk.II&27) The Proviso is 
discussed in Part II(D0  
258 See Wright, B. F  (1931) American Interpretation of Natural Law ( repr. 1962); L. Strauss, 
(1957) Natural Right and History ; O. J. Stone, (1965) Human Law and Human Justice ;  
Tuck, R (1982) Natural Rights Theories (1982); L. L. Weinreb, Natural Law and Justice 
(1987); R. Hittinger, (1988) A Critique of the New Natural Law Theory  
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fought between 1775 and 1783.259 Interestingly some of the most powerful 
classic expressions of natural rights are the English Bill of Rights (1689), the 
American Declaration of Independence (1776), the French Declaration of the 
Rights of Man and the Citizen (1789), the first 10 amendments to the 
Constitution of the United States (known as the Bill of Rights, 1791), and the 
Universal Declaration of Human Rights of the United Nations (1948). The 
French patent law of 1791 amended in 1800 and 1844 states that “every novel 
idea whose realization or development can become useful to society belongs 
primarily to him who conceived it, and that it would be a violation of the rights 
of man in their very essence if an industrial invention were not regarded as the 
property of its creator”.260 Machlup contended that French lawyers passed this 
legislation because they preferred to speak of natural property rights as a 
substitute theory for monopoly rights, because such privileges were so 
unpopular.261 Machlup’s theory may be acceptable to some, however it must be 
noted that most American and English writers have dismissed the natural law 
theory as having played any part in the development of the modern patent 
laws. Webster summed up 18th and 19th century opinion when he stared that 
“those who believe the inventor to have a natural right ... must have an entire 
misconception as to what it is the inventor really achieves”.262  
 
In 1996 Odili suggested in his article that natural rights theory has been a 
major driving force in making the international community adhere to an 
international standard of intellectual property in order to protect people against 
piracy and international theft.263 Some of the basis of his argument was that the 
                                                            
259 Bernard Bailyn (1967) The Ideological Origins of the American Revolution. Harvard 
University Press. 
260 Ibid 
261 Malcup and Penrose,  (1950) The Patent Controversy in the Nineteenth Century. 10 Journal 
of economic History 1 at 10-26 
262 Webster, Law and Practice of Letters Patents for Inventions (London, 1841), p3 quoted 
from Dutton , (1982) The Patent System and Invention Activity during the Industrial 
Revolution 1790-1852(Manchester University Press  pp.17-92 
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“natural rights” theory holds that an individual goes into society with certain 
basic rights and that no government can refute these rights.264 In other words 
people, as creatures of nature and God, should live their lives and organize 
their society on the basis of rules and precepts laid down by nature or God.265 
Individuals have a natural property right in their ideas and therefore countries 
must recognize the natural property entitlement of the inventor.266  Any 
unauthorized use by others without consent from the inventor would therefore 
be considered illegal. Odili however acknowledges that developing countries 
may not be so enthusiast to accept the intellectual property based on a natural 
rights theory, considering that if one was to go by the natural law theory the 
United States and many developed countries were at one time or the other 
“thieves” during the era of their industrialization. There are indeed many flaws 
that make the natural rights theory unworkable in the 21st century, however 
there is also strong evidence to suggest that it played a huge part in the 
development of how patents are perceived today and what justifications are 
appropriate when attempting to rationalize it. Other questions that may be 
raised to disqualify the natural rights theory is if for example an inventor has 
the “natural right” to his labour, and therefore his invention, why are patents 
given for only a limited time? Does it not make commonsense for the right to 
his labour to be perpetual?    
 
3.8.2 The “Incentive to Invent” Theory 
Some authorities have linked patents and economic development as a lever of 
industrial progress.267 Proponents of the patent regime have been instrumental 
in advancing one of the key arguments for the protection of the patent system 
in the 21st century.  The industrial revolution in Britain in the late 18th and 
early 19th centuries, where major changes in agriculture, manufacturing and 
transportation had a tremendous effect on the socioeconomic conditions has 
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266 Ibid  
267 Ibid 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
99 
 
frequently been cited as the perfect example of the patent system’s success in 
encouraging technological advancement.268 At that time England had a 
functioning patent system, thus Price wrote that the monopoly policy which 
began under Elizabeth had produced a system of patents for the encouragement 
of new inventions.269 Innovations were made in the textile industry with 
Richard Arkwright’s water frame (1762); James Hargreaves’s Spinning Jenny 
(1764) which facilitated the handling of large quantities of harvested cotton.270  
Other areas of innovation were the steam power and the iron founding 
industry. James watt’s steam engine was used for pumping mines and later 
powering machines; and the iron founding which saw iron being potted and 
stamped was patented in 1783 by Henry Colt. These represent three major 
sectors, in which patents encouraged key innovations, thereby resulting in the 
economic take off by which the Industrial Revolution is usually defined. The 
coincidence however lay in the boom that came with the industrial revolution 
and the need to have patents protect inventor’s rights and act as incentives and 
enticements.271 Although some commentators have been suspicious of the 
coincidence and suggest that the development of the English industry would 
still have occurred regardless of the patent system, others have acknowledged 
that the patent system assisted in catapulting the industrial revolution 
nevertheless.272 Thus Abraham Lincoln notably wrote that “the patent system 
added the fuel of interest to the fires of genius”.273  
 
The “incentive to invent” theory is one of the most recognised justification of 
the patent system in the 21st century. Many multinational companies assert that 
                                                            
268Wikipedia The Free Encyclopaedia.  http://en.wikipedia.org/wiki/Industrial_Revolution 
269 Price, The English Patents of Monopoly (Harvard University Press, Cambridge, mass, 
1913), p.3 
270Spinning Jenny- James Hargreaves.  
http://inventors.about.com/library/inventors/blspinningjenny.htm 
271 Fisher. M (2005) Classical economics and Philosophy of the Patent System. IPQ.  
272 Coulter, (1991) Property in Ideas: The Patent Question in Mid-Victorian Britain (Thomas 
Jefferson University press, Kirksville. 
273 Lincoln,(1859)  Discoveries, Inventions and Improvements, in The Complete Works of 
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without patents, they would have a problem securing sufficient capital to 
exploit their inventions. The invention process, they assert can be considerably 
expensive because it involves trial and error and numerous  testing.274 These 
procedures require facilities, labour, and supplies. This explanation is not a 
novel one and has been purported by inventors even in the 19th century, thus 
Siemens who was a Fellow of the Royal Society, and President of the Institute 
of Mechanical Engineers stated at the 1872 Select Committee that “the fact of 
there being no properly understood and regulated Patent Law in Germany 
[that] induced me to come to this country and make this my real home”.275 In 
Ziv M. Preis thesis, he argues that there is no empirical evidence to suggest 
that if patentees did not have the right to patents as most of them claim, it 
would discourage their incentive to invent and disclose their inventions. His 
assertion is based on an examination carried out on 54 Federal Trade 
Commission antitrust decrees from 1980 to 1999 which revealed that antitrust 
decrees with substantial compulsory licensing provisions weaken the 
motivation to invent.276 This research in a sense confirms some of Turners 
position that no incentive is required to induce invention.277 Although one must 
note that Turner was in fact a supporter of the natural rights theory. Thus Sir 
William Armstrong, president of the British Association for the Advancement 
of Science in 1863 said “seeds of invention exist, as it were, in the air, ready to 
germinate whenever suitable conditions arise, and no legislative interference is 
needed to ensure their growth in proper season”.278 
 
                                                            
274 The Patent Prospector. Jackass Kicked in Texas. 
http://www.patenthawk.com/blog/2005/04/patent_economics_part_4_incent.html (accessed 5 
April 20070 
275 Report of the 1872 Select Committee on Letters Patent, house of Commons Paper 1872 
(Command Paper No. 193), p.433 
276  Ziv M. Preis. The Incentive Theory of Patents in Action: The Effects of Patent Relief on the 
Incentive to Invent and the Incentive to Disclose” Dissertation. 
http://www.law.harvard.edu/academics/graduate/sjd_candidates/zivpreis/ Accessed 6 May 
2007 
277 Turner,(1850)  Counsel to Investors of Improvements in the Useful Arts .F. Elsworth, 
London. p.50 
278 The Opening address of the president, Report  of the 33rd Meeting of the British Association 
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It is important to note that many academics, committees and courts find it 
difficult to deny that patents to some extent instigate technological advance 
and growth in today’s modern day economy279, however Macfie proposes that 
inventors should be rewarded by monetary awards and cash subsidies and 
believes that they are less harmful than patents.280  The problem however with 
Macfie’s proposition is that if cash subsidies were awarded as the reward for 
new inventions, how would the cash subsidies be calculate? Would a national 
or international body be set up to determine how much an inventor should be 
paid? Would this open up the floodgates of litigation with disgruntled 
innovators asking the court to review settlements that had been made to them? 
Would this be an impossible task to embark on?  Different scholars and 
commentators have tried to come up with different solutions to the patent 
problem, however Grove’s (a devoted abolitionist)  statement sums it all up , 
he says :“the sole ground on which letters Patents can be held to be justifiable 
or permissible, is that they are beneficial to the public. If they are, and, so far 
as they are, keep them; if they are not, abolish them.”281 
 
3.8.3 To promote Investments 
Other scholars have come up with other justification for the patent system, and 
one of them is the idea that patents lead to increased investment and as 
Sherwood puts it succinctly “technology drives investment [and] is reluctant to 
                                                            
279 See Turner,   (1969)   The Patent System and Competitive Policy 44 New York University 
Law Review 451; Taylor and Silberston,(1973)  The Economic Impact of the Patent System. 
Cambridge University Press. comments of Lord Oliver in Asahi Kasei Kogyo [1991] R.P.C. 
485 at 523 where he states that: “ The underlying purpose of the Patent System is the 
encouragement of improvements and innovation” . See also comments of Jacob J. (as he was 
then) in Teva Pharmaceutical Industries Ltd v Instituto Gentili SpA [2003] F.S.R. 498 that “  
… Patents are provided to encourage research” . American judicial opinion is apt to voice this 
justification slightly more vociferously: “ Strong Patents protection is key to encouraging 
innovation, economic growth, and American competitiveness”  per Circuit Judge Linn in Festo 
Corp v Shoketsu Kinzoku Kogyo Kabushiki Co, 234 F.3d 558 (2000, CAFC, en banc ) at 621 
280 See Macfie, (1863) The Patent Question under Free Trade: A Solution of the Difficulties by 
Abolishing or Shortening the Inventor's Monopoly and Instituting National Recompenses . 2nd 
ed., W. Johnson, London; also Macfie, (1869) Recent Discussions on the Abolition of Patent  
for Inventions (Longmans, Green, Reader & Dyer, London. 
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flow where it is not protected”.282  Kitch also contends that strong intellectual 
property rights offers a framework within which firms in the developed 
countries can easily engage in  FDI and technology transfer to developing 
countries.283 Makus maintains that nations with stronger intellectual property 
rights (patents) have benefited from a greater willingness on the part of the 
developed countries to engage in FDI and technology transfer.284  Evidence 
suggest that indeed this is the status quo, for example stronger IPRs in 
industrializing economies such as China, Brazil, and India have produced 
significant growth bonus, indeed as  much as 0.5 percent per year through 
enhanced inflows of trade, foreign direct investment FDI, and licensing.285 
Likewise Primo Braga and Fink have argued that firms in developed countries 
are more prone to invest in countries with higher levels of intellectual property 
protection. 286 The argument centres on the fact that multinational companies 
in developed countries are unwilling to assist developing countries in projects 
that require significant transfer of proprietary knowledge, including technology 
intensive manufacturing processes.  The fear that firms in developing and LDC 
will steal the technology to produce and sell their own products to third parties 
at a lower price which may result in a loss of profit has been one of the key 
arguments for mainlining a strict and vibrant intellectual property regime. 
 
 Mansfield conducted a survey showing that increased protection for 
intellectual property rights leads to an increase in FDI. 287 His survey was 
based on the performance of executives of major US corporations and patent 
                                                            
282 See Robert M. Sherwood, (1988) the Benefits Developing Countries Gain from 
Safeguarding Intellectual Property, Paper for Intellectual Property Committee, Washington, 
D.C  
283 Edmund W Kitch  (1994) The Patent Policy of Developing Countries.  13 UCLA Pac. Basin 
L.J. 166, 167 -78  
284 Maskus, K.E (2000) Intellectual Property Rights in the Global Economy. Institute for 
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and Foreign Direct Investment. 9 Duke J. Comp. & Int'l L. 163, 166  
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Rating of Systems in Eighteen Developing Countries. 37 IDEA 261, 351-52  
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
103 
 
attorneys, where he found that there was a strong positive correlation between 
higher levels of intellectual property protection and FDI. 288  However 
Mansfield’s analysis did not show a positive correlation in higher levels of 
intellectual property protection and increased FDI in all industrial sectors.289  
Although Mansfield found that when a country enacts strong intellectual 
property rights, firms in the chemical, pharmaceutical, machinery, and 
electrical equipment industries increased their levels of foreign joint venture 
and FDI.  
 
Justifying the patent system with the need to promote investment is according 
to some school of thought the key to economic growth.290 Economic growth 
and the eradication of poverty which are core goals of the Millennium 
development Goals to be achieved in 2015 depend very much on investment in 
the form of capital accumulation; this requires investment in plant and 
machinery along with its drive to gain access to new ideas and technologies.291 
For developing countries and other economies in transition, the promotion of 
investment is imperative in order to enhance their core competencies and 
competitiveness. Although the flows of investment and technology to 
developing countries have not materialized to the extent that would eradicate 
extreme poverty and hunger, promote gender equality, empower women, 
combat HIV/AIDS, malaria and other diseases, ensure sustainable 
development and develop a partnership for development;292 hope is still 
centred that with the promotion of investment these goals can be achieved if 
not now than sometime in the future. Whether this will happen or not remains 
to be seen. 
 
                                                            
288 Mansfield, E. (1995) Intellectual Property Protection, Direct Investment, and Technology 
Transfer 2 (International Finance Corporation Discussion Paper No. 27 
289 See Ibid at 2-4. 
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3.9 Summary  
The patent concept has its admirers and its opponents; however one thing 
remains certain the concept has evolved rapidly and has a high place in today’s 
modern day economy.  Whilst it remains clear that the history of patents have 
its foundation in Europe, it has spread its tentacles to many developing 
countries and is enshrined in many multilateral agreements, its application and 
relevance is still questioned by many especially in the developing world.   It 
follows that in matters of life and death or in a situation where if a patent were 
granted it would take away the only source of livelihood of a person or 
community; the matter becomes a human right issue.  It is with the foregoing 
in mind that the next section puts the TRIPS Agreement into a human rights 
perspective with the ultimate aim of discussing the situation in  Nigeria. 
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PART II 
4         HUMAN RIGHTS  
4.1 Introduction  
Therefore, let us not despair, but instead, survey the position, consider 
carefully the action we must take, and then address ourselves to our common 
task in a mood of sober resolution and quite confidence, without haste and 
without pause’  
Arthur Henderson  
 
Men occasionally stumble over the truth, but most of them pick themselves up 
and hurry off as if nothing ever happened 
Sir Winston Churchill 
 
More than any other time in history, mankind faces a crossroads. One path 
leads to despair and utter hopelessness. The other, to total extinction. Let us 
pray we have the wisdom to choose correctly’. 
Woody Allen293 
 
The compatibility of the intellectual property rights and human rights can 
sometimes be seen as strange bed fellows.294 Activists and scholars alike have 
asserted that the TRIPS Agreement undermines the capacity of member states 
to achieve and implement important policy goals with regards to their human 
rights obligations.295 These policy goals include the obligation of states to 
respect, protect, advance and defend the fundamental human rights of the 
general population. The interaction between trade and human rights is not a 
novel concept. The economist Peter Temin noted that in ancient times, traders 
were constantly in fear of being captured and sold as slaves, or incarcerated by 
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294 Two premises are strange bedfellows if they are diagrammed as co-premises in one reason 
when in fact they belong to completely different reasons.  
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pirates at sea whilst carrying out trade.296  Thus as early as 432 BC, the Greeks 
used the Megarian Decree (the Megarian Decree can be compared to a modern 
trade embargo) to exclude Megara merchants from the markets and ports of 
Athens for the kidnapping of Aspasian women.297 Note that kidnapping is a 
pure violation of Article 3298, 4299 5300 and 12301 of the Universal Declaration 
of Human Rights (UDHR). The interesting point about the Decree was that 
trade embargos were relatively unheard of in peace times in that part of the 
world.302  The tension between trade and human rights issues has presented 
many problems for centuries, however some commentators have asserted that 
trade should not be mixed with human rights issues. The tension nevertheless 
persists even in the 21st century. For example when China joined the WTO, it 
agreed to improve its human rights record; the Chinese government claimed 
that trade would encourage more transparency, cross cultural communication 
which would give the Chinese people more access to education and freedom of 
speech. However the fact remains that China continues to suppress political 
and religious rights. 
 
Other examples of trade and human rights being interconnected is the approach 
that the EU takes in setting its criteria for EU membership. The Copenhagen 
                                                            
296 Peter Temin  Also see 4 and 5 of UNDR 
297 For a similar case of Kidnapping - see L.M. HANDRAHAN. (2000) Implications of 
International Human Rights Law and Bride Kidnapping in Kyrgyzstan. RAXIS The Fletcher 
Journal of Development Studies VOLUME XVI  
298 . Universal Declaration of Human Rights (UDHR), adopted 10 Dec. 1948, G.A. Res. 217A 
(III), U.N. 
GAOR, 3d Sess., (Resolution, part 1), at 71, U.N. Doc. A/810 (1948), reprinted in 43 AM. J. 
INT.L. L 
SUPP. 127 (1949), art. 3, art. 4, art. 5, art.9, art. 12, art. 16 (1, 2, 3), art 29 (1, 2, and 3),.art. 3. 
.Everyone has the right to life, liberty and security of person.. 
299 Art. 4..No one shall be held in slavery or servitude; slavery and the slave trade shall be 
prohibited in all their forms.. 
300 Art. 5. .No one shall be subjected to torture or to cruel, inhuman or degrading treatment or 
punishment.. 
301 Art. 12 .No one shall be subjected to arbitrary interference with his privacy, family, home 
or correspondence, nor to attacks upon his honour and reputation. Everyone has the right to the 
protection of the law against such interference or attacks 
302 Hufbauer, Gary Clyde et al. (1990), Economic Sanctions Reconsidered: History and 
Current Policy, second edition, Washington: Peterson Institute for International Economics; 
see Megarian Decree. http://www.livius.org/mea-mem/megara/decree.html 
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criteria requires  that a state puts in place institutions to preserve democratic 
governance, human rights and a functioning market economy before acceding 
into the EU. Thus whilst the EU supports a strong multilateral trading system 
and  is committed to ensuring that the European economy is open to the world, 
Article 6(1) of the EU Treaty  states that the “Union is founded on the 
principles of liberty, democracy, respect for human rights and fundamental 
freedoms, and the rule of law”.  Thus there are indeed numerous examples of 
legislations around the world that have linked trade and human rights issue. 
Another example is under section 51 of the US Tariff Act 1890, goods 
produced by convict labour were banned in the US and this caused a chain 
reaction with Great Britain, Australia and Canada following suit. 303  The 
testament not only goes to the fact that trade and human right issues go hand in 
hand, but the fact that national laws sometimes instigate international 
collaboration.  Francisco de Vitoria (one of the founders of international laws) 
states that the right to trade is “derived from the law of nations...Foreigners 
may carry on trade, provided they do no hurt to citizens.”304  Bearing the above 
in mind, it is important to note that trade has been used to lift people out of 
poverty, create strong economies; however it has also been used to enslave and 
destroy many communities. It has dispossessed people of their fundamental 
human rights and left many destitute.  It is with background in mind that this 
chapter will seek to evaluate the human rights obligations of developing 
countries and  Multinational Corporations (MNC) in view of the public health 
crisis facing poorer nations today.  
 
The concept of human rights in modern context is enshrined in John Locke’s 
natural rights notion which states that people possess certain rights by virtue of 
them being human beings.305 The Lockean natural rights ideology is not based 
                                                            
303  Susan Aaronson and Devin T. Stewart. 
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304 Irwin, Douglas A. (1996), Against the Tide: An Intellectual History of Free Trade, 
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on citizenship, law of the state ethnicity, cultural background or religious 
affiliation; it is indeed a right that should be available to all.306  As Justice B.N 
Bhagwati succinctly put it human rights are “not ephemeral, not alterable with 
time and space and circumstances.  They are not the product of philosophical 
whim or political fashion.  They have their origin in the fact of the human 
condition and because of this origin, they are fundamental and inalienable.  
More specifically constitutions, conventions or governments do not confer 
them.  These are the instruments, the testaments of their recognition; they are 
important, sometimes essential elements of the machinery for the protection 
and enforcement of human rights but they do not give rise to human rights. 
Human rights were born not of humans but with humans”.307 Human rights are 
therefore the “basic rights and freedoms, to which all humans are entitled”,308  
these rights include civil and political rights such as right to life, liberty, 
freedom of expression, equality before the law, right to food, culture, work, 
association, participation and education. It follows that most human rights are 
interrelated so that the right to health is interconnected to the exercise of other 
relevant human rights. Imperatively, human rights involve the relationship 
between the state and individuals and by and large the state has an obligation 
to ensure that the most vulnerable people in society are not neglected.309  
 
Bearing the above in mind, commentators have asserted that HIV/AIDS is one 
of the greatest human rights issue confronting the world today. The reason for 
this affirmation is that it raises questions about the patients’ other human rights 
such as the right to housing, medical care, health care and mental health 
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308 Houghton Miffin Company (2006) 
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care.310  In June 2001, the UN general Assembly –Special Session on 
HIV/AIDS advocated an extraordinary response based on a nation-wide, multi-
sector and gender sensitive approach to halting the spread of the HIV/AIDs 
epidemic311, this was verification that the epidemic has fundamentally affected 
all sectors of society globally. The economic effect of the  disease was so much 
so that Brainerd and Siegler compares the long term economic effects of the 
HIV/AIDS epidemic to the 1918 Influenza epidemic which killed between 20 
and 100 million people worldwide, an approximate equivalent of one third of 
the population of Europe.312  Another evidence that the HIV/AIDS epidemic is 
a global health problem that has affected all segment of society  can be found 
in the  Presidential Address to the Economic History Association in 2000, 
where Neal stated that his fellow economic historians would do the 
“economics profession, and the society at large, a big favor if [they] focused an 
increasing the share of  research efforts on shocks, rather than on longer 
periods of ‘normal’ economic change.”313 The economic facts of the effects of 
HIV/AIDS on the world are not conclusive, however research suggest that the 
likely effects of it on growth in African countries will decrease GDP by 15-25 
percent and per capita income by 0-10 percent in 2010.314   
                                                            
310 Nigeria, Access to Health Care for People Living with HIV and AIDS.  A Report by 
Physicians for Human Rights in Co-ordination with Future Groups with International/POLICY 
Project and Centre for the Right to Health. 
311 Report on the United Nations General assembly Special Session (UNGASS) on HIV/AIDS, 
June 2001. http://www.hc-sc.gc.ca/ahc-asc/pubs/int-aids-sida/ungass-eng.phpfc 
312  Brainerd Elizabeth and Siegler Mark V (2002) The Economic Effects of the 1918 Influenza 
Epidemic. June  http://birdflubook.com/resources/brainerd1.pdf and Keyfitz, N., and W. 
Flieger. (1968) World Population: An Analysis of Vital Data. Chicago: University of Chicago 
Press, 1968 
313 Larry. Neal, (2000) A Shocking View of Economic History. Journal of Economic History 60 
(2): 317-331. 
314 Cuddington, John T.  (1993) Modeling the Macroeconomic Effects of AIDS, With an 
Application to Tanzania.” The World Bank Economic Review 7 (2) 
173-189. and “Further Results on the Macroeconomic Effects of AIDS: The Dualistic, Labor-
Surplus Economy.” The World Bank Economic Review 7 
(3), 1993b: 403-417. 
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The Brazilian Health Minister once stated that “access to medicines is a basic 
human right”,315 however the birth of the TRIPS Agreement in 1995 has been 
criticized for dangerously curbing the availability of cheap patented medicines 
by increasing the prices of patented medicines in developing countries and by 
so doing denying people access to medicines. Many commentators have 
contested the injustice of the access to medicines between the rich and poor 
countries by highlighting HIV/AIDS, Malaria and Tuberculosis which has 
ravaged the developing world as one of the injustices of the international 
trading system.  Whilst it is easy to make the case for access to medicines  a 
fundamental human right that must be protected from the multinational trading 
system; protecting the  fundamental human right of  inventors from free-riders 
and piracy is equally at the forefront of international human rights obligations.  
The question then lies, which human right should take precedence in the face 
of such conflict? 
 
Article 15 of the International Covenant on Economic, Social and Cultural 
Rights (ICESCR) states that intellectual property right holders must have the 
right to enjoy the absolute “protection of the moral and material interests 
resulting from scientific, literary or artistic production”.316 In other words 
patent holders must be given the unequivocal right to have their works 
protected from unauthorised use by the public whilst at the same time making 
sure that the public benefits from the scientific and cultural progress that 
comes from the patent holder’s work.317 The complexity nonetheless lies in; 
where to strike a balance between the two human rights; how can society, 
governments and the international community reach an arrangement where the 
two rights can complement each other, as opposed to clashing with each other.  
                                                            
315 Paying the Price (Television Trust for the Environment, U.S. Release 2002). The transcript 
for the film is available at http:// www.tve.org/lifeonline/index.cfm?aid=1174. 
316 See Lipinski T. A.  and  Britz, J.J (2000) “Rethinking the ownership of information in the 
twenty first century: Ethical implications”, Ethics and Information Technology, Issue 2,  pp. 
49-71. 
317 http://www.eumap.org/journal/features/2004/infohr/infohr1/ipandhr 
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4.2   The Development of the Right to Health in International Law  
The right to health in international law has come leaps and bounds and is now 
used as an instrument to protect individuals’ rights and prevent the abuse of 
power by states. Oppenheim stated in his treaties on International Law in 1912 
that “Subjects of the rights and duties arising from the law of Nations are 
States solely and exclusively”.318 The argument continues that the status quo 
has changed. As such the United Nations Charter ushered in a remarkable era 
by establishing an international organization called the United Nations. By 26 
June 1945 the Charter was signed at the United Nations Conference on 
International Organization in San Francisco, California by 50 members.319 The 
Agreement entered into force on 24 October 1945. It was ratified by the five 
permanent members of the Security Council namely China, France, Russia, the 
United Kingdom,  the United States and other signatories as a deliberate effort 
to promote human rights internationally.  Thus Article 1(3) of the UN Charter 
states that its core objective is to ensure ‘international co-operation in solving 
international problems of an economic, social, cultural, or humanitarian, 
character and in promoting and encouraging respect for human rights and for 
fundamental freedoms for all without distinction as to race, sex, language, or 
religion’, values which have stood the test of time. 
 
The development of human rights has evolved into many other treaties. Some 
of the few which are relevant to our discussion on the right to health can be 
found in Article 25 and 27 of the Universal Declaration of Human Rights 
(UDHR), Article 7, 11 and 12 ICESCR, Article 10,12, and 14 of the 
Convention on the Elimination of All Forms of Discrimination Against 
Women,  Article 5 of the Convention on the Elimination of All Forms of 
Racial Discrimination, and Article 24 Convention on the Rights of the 
                                                            
318  Oppenheim, L (1912) International Law. A Treaties. Vol. 1. Peace. 2nd edn, 19. 
319 (Poland, the other original member, which was not represented at the conference, signed it 
later) 
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Child.320 However the major international treaties we shall be concentrating on 
in this chapter are the UDHR, ICESCR and the International Covenant on Civil 
and Political rights (ICCPR). 
 
4.2.1 UDHR 
Article 25:1 of UDHR lends support to the right of individuals to have access 
to essential medicines, by stating that “Everyone has the right to a standard of 
living adequate for the health and well-being of himself and of his family, 
including food, clothing, housing and medical care and necessary social 
services, and the right to security in the event of unemployment, sickness, 
disability, widowhood, old age or other lack of livelihood in circumstances 
beyond his control”. 
 
The UDHR is significant because it is one of the most authoritative 
proclamations on human rights. 321 Its language stems from the United Nations 
Charter of 1945 and the World Health Constitution of 1946 which states that 
“The enjoyment of the highest standard of health is one of the fundamental 
rights of every human being without distinction of race, religion, political 
belief, economic or social condition”.322 The significance of UDHR is so 
contemporary that it was unanimously adopted by the General Assembly in 
1948 against the backdrop of the violence and atrocities of World War II.323  
The Charter exemplifies the need to always have a general agreement that 
                                                            
320 Alexander,  B. C (2001)  Lack of Access to HIV/AIDS Drugs in Developing countries: Is 
There a violation of the International Human Rights? 8 Hum. Rts. Brief 12, 14  
321 Chapman. Audrey  (2002) Human Rights Implications of Intellectual Property protection.  
J.Int’l Econ. L. 861 
322 Constitution of the World Health Organization, opened for signature July 22, 1946, 
reprinted in World Health Organization, Basic Documents (40th ed. 1994), at 1; for a full 
discussion of the Preamble of the WHO Constitution 
323 See. Craven, M.C.R (1995)The International Covenant on Economic, Social, and Cultural 
Rights: A Perspective on Its Development 3 (pg. 6  For a history of UDHR where Craven states 
that ("As a reaction to events prior to and during the Second World War, the allies, and later 
the international community as a whole, came to the belief that the establishment of the new 
world order should be based upon a commitment to the protection of human rights and 
fundamental freedoms." 
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codifies basic human rights norms as a common standard to which all nations 
must aspire to reach.324  
 
Interestingly however is the fact that the UDHR is not a treaty but a General 
Assembly resolution that represents a statement of policy. It does not have any 
international binding force and is unlike international treaties which are signed 
and ratified by states.325 This has raised questions about the authority that the 
UDHR has on the international front and some have even called it the "most 
fragile basis on which to construct a doctrine of individual duties to respect 
human rights."326  Sohn however does not agree with this position, he asserts 
that the UNDR are the interpretations of the human rights provisions of the UN 
Charter.327 Sohn’s arguments are based on two reasons, firstly the International 
Conference on Human Rights at Teheran states that the UDHR is “an 
obligation for the members of the international community” and secondly state 
practice invoked UDHR as soon as it was passed.328 In order words the UDHR 
has all the backing of states and is fully acknowledges and accepted by the 
international community. 
 
The preamble of the UDHR is instrumental in declaring that the “recognition 
of the inherent dignity and of the equal and inalienable rights of all members of 
the human family is the foundation of freedom, justice and peace in the 
world… [the] disregard and contempt for human rights have resulted in 
barbarous acts which have outraged the conscience of mankind" and a 
proclamation of "freedom of speech and belief and freedom from fear and want 
                                                            
324. Kuszler, P.  C (2007)  Global Health and the Human Rights Imperative, 2 Asian J. WTO & 
Int’l Health L. & Pol’y 99 
325 George P. Smith (2005), Human Rights and Bioethics, Formulating a Universal Right to 
Health, Health Care or Health Protection?   38 VAND. J. TRANSNAT’L L. 1295, 1300 . 
326 Nigel S. Rodley, Can Armed Opposition Groups Violate Human Rights?, in Human Rights 
in the Twenty-First Century: Global Challenge 297, 306 (Kathleen E. Mahoney & Paul 
Mahoney eds., 1993) at 307 
327 See Article 55-56 of the UN Charter 
328 Sohn, L.B (1977) The Human rights Law of the Charter.  12 Tex Int’l L J 129 and Sohn, 
L.B  (1982-1983) The New International Law: Protection of the Rights of Individual Rather 
than States.  32 Am U L Rev 1, 16. 
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. . . as the highest aspiration of the common people."329 For dignity and 
equality to qualify as a human right, Article 22 must be adhered to, thus it 
states that “Everyone, as a member of society, has the right to social security 
and is entitled to realization, through national effort and international co-
operation and in accordance with the organization and resources of each State, 
of the economic, social and cultural rights indispensable for his dignity and the 
free development of his personality.” The interpretation of Article 22 is 
instrumental in pointing out that state governments have an obligation to 
ensure that its resources are used effectively to ensure that all its citizens have 
the highest quality of life to participate in the free development of their 
personality which includes medicines to treat illness when he needs it. 
 
Tragically however, despite the broad vision of incorporating a legal right to 
health in the UDHR, it has had a less dynamic effect on the conjuring up of 
human rights as a binding tool.  Some countries have nevertheless incorporated 
the human right to health in their constitution. A good example are the twenty 
Latin America states who as far back as the 1940s took the initiative to 
prioritize the right to health of its citizens.330 As a matter of fact during the 
drafting of the UDHR, delegates from Chile, Uruguay, and Panama had the 
foresight and presented a document which laid greater emphasis on the need to 
include a direct reference to provide health care for the sick, however the draft 
was never incorporated. The draft stated that “The State has a duty to maintain 
or to ensure that there are maintained, comprehensive arrangements for the 
prevention of sickness…and the provision of medical care and of 
compensation for the loss of livelihood”,331  a proposition which may have 
appeared too burdensome for the signatories to the UDHR to adhere to. 
                                                            
329 Universal Declaration of Human Rights, G.A. Res. 217A, art. 27(2), U.N. GAOR, 3d Sess., 
1st plen. mtg., U.N. Doc A/810 (Dec. 10, 1948) [hereinafter UDHR].Recital 1 &2 
330 See Glendon, M. A (2003) The Forgotten Crucible: The Latin American Influence on the 
Universal Human Rights Idea, 16 HARV. HUM. RTS. J 27, 31-32. 
331 American Law Institute, (1998) Statement of Essential Human Rights, in American Law 
Institute Seventy-fifth Anniversary, 1923-1998, at 285-86,  
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Ultimately the language of the UDHR has been embraced by many nations, 
incorporated into national constitutions, and received universal acclamation 
even though it has no legal obligation on the parties.332 
 
In 1966, the UN initiated additional efforts to promote the international 
advancement of human rights and drafted other  human rights instruments to 
refine and reformulate the rights enumerated in the UDHR,  the two 
instruments it used were the  ICESCR 333 and the ICCPR.334 The main 
difference between the ICESCR and the ICCPR is whilst the former is a 
positive right that requires action by the states in the form of a pledge to use its 
resources to achieve “economic, social and cultural” rights, the former 
involves civil and political obligations that do not require the state to pledge its 
financial resources in fulfilling its duty.335 Although commentators have 
argued that the distinction between civil and political and economic, social and 
cultural rights are not valid because civil and political rights sometimes contain 
positive obligations, whilst economic, social and cultural rights have a negative 
obligations in the form of the duty of a state to refrain from certain actions336 
The point however remains that both conventions deal directly with access to 
medicines and have a legally binding effect on member states that sign and 
ratify them.337 As of 2006 the ICESCR had 154 State Parties, of which 145 
were also members of the WTO, of the 145 members 123 had ratified the 
                                                            
332 Kuszler, P.C (2007)  Global Health and the Human Rights Imperative, 2 Asian J. WTO & 
Int’l Health L. & Pol’y 99 and  Dennis M.J  &  Stewart, D.P (2004) Justifiability of Economic 
Social and Cultural Rights: Should There be an International Complaint Mechanism to 
Adjudicate the Rights to Food, Water, Housing and Health?, 98 A.M.J.I.L. 462, 478  
333 International Covenant on Economic, Social and Cultural Rights, G.A. Res. 22001 (XXI), 
U.N. GAOR, 21st Sess., Supp. No. 16, U.N. Doc. A/6316, 993 U.N.T.S. 3 (1966). 
334 International Covenant on Civil and Political Rights, G.A. Res. 2200A (XXI), U.N. GAOR, 
21st Sess., Supp. No. 16, at 49, U.N. Doc. A/6316 (1966). 
335  Cranston, M (1973) What are Human Rights? and Holger Hestermeyer (2007)  Human 
Rights and the WTO; The Case of Patents and Access to Medicines. Oxford University Press.  
336 Koch, I.E  (2002)‘Social Rights as Components in the Civil Right to Personal Liberty: 
Another Step Forward in the Integrated Human Rights Approach?  20 Netherlands Q of Hum 
Rts 29. 
337 See Sofia Gruskin, (2004) SARS, Is There a Government in the Cockpit: A Passenger's 
Perspective or Global Public Health: The Role of Human Rights, 77 TEMP. L. REV. 313, 
319-20  
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convention (note however that both the US and South Africa have not ratified 
the ICESCR). On the other hand as of 2006 the ICCPR had been ratified by 
157 countries, making the ICCPR one of the most powerful human rights 
conventions of the 21st century (note that the US only ratified the ICCPR in 
1992) 
.   
4.2.2 ICESCR 
Access to medicine is protected by the ICESCR as an integral part of the 
human right to health. One of the strongest sources of this right is Article 12 of 
the ICESCR which states that: 
1. The States Parties to the present Covenant recognize the right of everyone to 
the enjoyment of the highest attainable standard of physical and mental health.  
2. The steps to be taken by the States Parties to the present Covenant to 
achieve the full realization of this right shall include those necessary for:  
(a) The provision for the reduction of the stillbirth-rate and of infant mortality 
and for the healthy development of the child;  
(b) The improvement of all aspects of environmental and industrial hygiene;  
(c) The prevention, treatment and control of epidemic, endemic, occupational 
and other diseases;  
(d) The creation of conditions which would assure to all medical service and 
medical attention in the event of sickness. Furthermore article 2(1) of the 
convention requires that state parties of the convention “undertakes to take 
steps, individually and through international assistance and co-operation, 
especially economic and technical, to the maximum of its available resources, 
with a view to achieving progressively the full realization of the rights 
recognized in the present Covenant by all appropriate means, including 
particularly the adoption of legislative measures.”  
 
In an ideal world, making sure that everyone enjoys the “highest attainable 
standard of physical and mental health” (which involves having access to 
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medicines) should be a task that all countries engage in freely, but the fact that 
we do not live in an ideal world makes the task more difficult to achieve. 
When one talks about access to medicines for people in the developing  world, 
there is a general presumption that they do not mean access to “feel good 
medicines” such as  sliming pills, sleeping pills, breast enlargement pills and 
sex enhancement medicines, the medicines they refer to are life saving 
medicines for diseases that kill if not treated. Such diseases include 
tuberculosis, malaria, cholera, HIV/AIDS. However the problem with the state 
obligation to provide such medicines in the developing world is that 
governments carry on the impossibilium nulla obligation (this means that there 
is no duty to perform the impossible). Many developing countries are poor and 
cannot afford to provide the level of health care that its citizens require. The 
ability of the state to perform its duty to provide medicines will therefore be 
limited to its financial resources and budgetary capacity. The ICESCR 
therefore limits the state obligation to providing the minimum amount of 
medicines that are considered essential for good health. Thus the ICESCR draft 
General Comment 14 Para 12(a) states that access to medicines should be 
limited to the definition of “essential drugs, as defined by the WHO Action 
Programme on Essential Drugs.”338 Thus access to medicines has been 
promoted and endorsed by WHO since it was established in 1948. WHO 
defines health as “a state of complete physical, mental and social well-being 
and not merely the absence of disease or infirmity.”339 Note that this does not 
require that a person attain the highest state of health, however another 
interpretation of it requires that states provide other interdependent socio-
economic rights such as housing and healthcare as essential components. WHO 
defines essential medicines as “those that satisfy the priority health care needs 
of the population [and] are selected with due regard to public health relevance, 
efficacy and safety and comparative cost effectiveness”.340 The state duty to 
                                                            
338 Committee on Economic, Social and Cultural Rights, general Comment No 14 (2000) 
339 WORLD HEALTH ORGANISATION. http://www.who.int/about/definition/en/print.html 
340 Essential drugs and medicines policy. http://www.who.int/countries/eth/areas/medicines/en/ 
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provide essential medicines is generally upheld by national courts. Thus in 
Minister of Health v Treatment Action Campaign,341 the South African 
Constitutional Court ruled that the government had to make nevirapine, a drug 
used to prevent mother to child transmission of HIV medicines widely 
available.342  Similarly the Tribunal Supremo de Jusicia de Venezuelan held 
that the government has an obligation to provide antiretroviral medicines to 
HIV infected patients in Venezuela.343 
 
The ICESCR imposes significant duties that a state has to meet before the right 
to health is achieved; this obligation requires the states to establish a 
reasonable action programme towards the full realization of the right to health 
for its citizens within a limited period.344 What this implies is that states must 
therefore take all necessary measures to realize the right to health at all levels 
of state action, such actions may include health policies, trade agreements, 
social security laws, and adjudication processes.345  State actions are not only 
limited to legislations but may include omissions such as the failure to put in 
place a national health policy, such actions can be interpreted to signify a 
violation of its obligation. On 29 October 1993 Nigeria  signed and ratified the 
ICESCR and is therefore obligated to play an active role toward the realization 
of the right to health for its citizens. As such under international law, the 
Nigeria government must endeavour not to violate its duty to provide the right 
to health for its citizens either through its omission or its actions. Questions 
have therefore arisen about some of Nigeria’s national policies which do not 
promote access to medicines.  
 
                                                            
341 Minister of Health al v. Treatment Action Campaign et al 2002 (5) SA 721 (CC); 2002 (10) 
BCLR 1033 (CC) (5 July 2002) 
342 Ibid 
343 Tribunal Supremo de Justicia de Venezuela. Cruz Bermudez  v Minsterio de Sanidad y 
Asistencia Social Case No 15.789, Decision 8No 916 (1999) 
344 Commission on Economic. Social and Cultural Rights, General Comment No 14 (2000) 
345 Holger Hestermeyer. (2007) HUMAN RIGHTS AND THE WTO. The Case of Patents and 
Access to Medicines. Oxford University Press. 
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 Eide’s three tier classification of state obligation consist of the duty to respect, 
protect and fulfil its human rights obligation. 346 The first duty for states to 
respect human rights requires that a state refrain from discriminatory practices 
that may limit or deny access to medicines. It is important to note that the 
states’ duty to protect health does not override the duty to protect property.347  
In the same way that the government is responsible for ensuring that everyone 
has access to property, meaning that government must protect us from theft is 
the same way that they have a duty to ensure that everyone has a right to 
health. Bearing that in mind some have argued that when a state adopts patent 
laws it limits the economic accessibility of medicines available to its citizens, 
and because developing countries can only achieve a positive duty by 
guaranteeing a realistic price level on medicines, price in this sense becomes 
imperative to ensuring the respect of human rights obligations.  
 
In Nigeria an average worker earns approximately N6,500 ($52) per month  
(section 2(1) of the National Minimum Wage (Amendment) Act 2000 states 
that it is the duty of every employer to pay a wage not less than National 
Minimum Wage of N5,500 ($44) per month to every worker).348 However in 
2006 the average cost of a first-line treatment  in most low income countries 
was between $ 123 per person per year for a fixed dose combination of 
combination of stavudine + lamivudine + nevirapine to $493 for the fixed-dose 
combination zidovudine + lamivudine plus a single dose of efavirenz;349  
whilst the Second-line treatment  in 2006 was in the region of between $1698  
                                                            
346 A. Eide, (1987) The New International Economic Order and the Promotion of Human 
Rights. Report on the Right to Adequate Food as a Human Right, UN Doc 
E/CN.4/Sub.2/1987/23 (1987) 
347 See Horacio M Spector. 1989. An Outline of a theory justifying intellectual and industrial 
property. European Intellectual Property Review; Harold Demsetz, (1967)‘ Toward a Theory 
of Property Rights’ , American Economic Review, LVII  (Papers and Proceedings of the 
Seventy-Ninth Annual Meeting of the American Economic Association). 
348 National Minimum Wage (Amendment) Act 2000. 2000 Act No . Laws of the Federation of 
Nigeria  
349 Summary of Global progress in priority Intervention areas see 
http://www.searo.who.int/LinkFiles/News_and_Events_UAPR_Summary.pdf  
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and $ 4735 for  a dosage of didanosine + abacavir + lopinavir/ritonavir, 350 
This places the  antiretroviral medicines which is an essential medicines under 
the WHO Model List out of the reach of many HIV patient in Nigeria who earn 
minimum wage. The question therefore arises is the state therefore under an 
obligation to prevent MNC from introducing prices for medicines that are 
outside the reach of its population? Or they under an obligation to subsidize the 
prices of these patented medicines to ensure that they become affordable to the 
people? To answer the question, Hestermeyer argues that when corporations 
are given the right to patent, the price of medicines go up. State obligation to 
protect the human rights of its citizens requires it to enact legislations that 
ensure “equal access to health and health related services provided by third 
parties  [and] ensure that privatization of the health sector does not constitute a 
threat to the availability, accessibility, acceptability and quality of health 
facilities”.351  
 
Eide’s second tier state duty to protect the right to health requires the State to 
take active measures to prevent third parties from interfering with Article 12 of 
the ICSECR.352 Commentators have therefore pointed out that the State is 
under an obligation to take measures that will ensure access to health care 
provided by third parties. This obligation is relevant to evaluate the status quo 
in Nigeria for a variety of reasons. Firstly in many countries health care is 
provided by the private sector alongside the state run institutions, For example 
in Lagos, the most populated city in Nigeria, seven percent of healthcare is 
provided by private hospital. In the first half of 2008, the state government had 
to shut down 184 private hospitals, clinics and laboratories for failure to meet 
the basic standards of hygiene and staff training; in the writer’s opinion, a clear 
                                                            
350 Ibid 
351 General Comment 14 
352 Professor Andrew Clapham and Mariano Garcia Rubio. (2002) Human and Health Rights 
Working Paper Series No 3. The Obligation of States with Regard to Non-State Actors in the 
Context of the Right to Health. http://www.who.int/hhr/Series_3%20Non-
State_Actors_Clapham_Rubio.pdf 
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fulfilment of Article 12 obligation to protect its people against ill health that 
might result from poor hygiene and treatment from unqualified staff.353 
Secondly, pharmaceuticals are almost entirely manufactured and marketed by 
the private sector, and because economic accessibility is a major part of the 
right to health, the state is responsible for ensuring that firms do not limit 
access to medicines through high prices. Thirdly, signatories to the ICESCR 
are under the obligation to abstain from “denying or limiting equal access for 
all persons...to preventive, curative and palliative health services”.354 Thus if a 
state “repeals or suspends legislation necessary for the continued enjoyment of 
the right or adopts legislation or policies that are manifestly incompatible with 
pre-existing domestic or international legal obligations relating to the right to 
health” it is in violation of its obligation to protect the human rights of its 
citizens.355  In other words when a country enters into bilateral or multilateral 
agreement with other states, it should not restrict access to medicines by 
increasing prices covertly or explicitly.356  The TRIPS Agreement authorizes 
WTO Members to “adopt measures necessary to protect the public health and 
nutrition and to promote the public interest in sectors of vital importance to 
their socio-economic and technological development”.357 Supportive of this 
stance the Ministerial Conference of the WTO held in Doha 2001 (Doha 
Declaration) instructs states to interpret the Multilateral TRIPS Agreement in a 
way which is “supportive of the WTO members’ right to protect the public 
health and, in particular, to promote access to medicines for all”.358 This 
includes the right of each member state to determine what constitutes a 
                                                            
353 Nigeria shuts down private hospitals. Science and Environment Online. October 9 2008. 
http://www.downtoearth.org.in/full6.asp?foldername=20080531&filename=fort&sec_id=5&si
d=5 
354 General Comment 14: The Right to the Highest Attainable Standard of Health, U.N. Comm. 
on Econ., Soc. & Cultural Rts., 20th Sess., P 12, U.N. Doc. E/C.12/2000/4 (2000). 
355 Ibid 
356 Ibid 50” 
357 The Limburg Principles on the Implementation of the International Covenant on Econ., Soc. 
and Cultural Rights, U.N. ESCOR, Comm'n. on H.R., 43d Sess., Annex, PP 46-57, U.N. Doc. 
E/CN.4/1987/17 (1987), reprinted in 9 Hum. Rts. Q. 122, 128-29 (1987). 
358 Declaration on the TRIPS Agreement and Public Health, adopted on Nov. 14, 2001, P 4, 
WT/MIN(01)/DEC/2 (Nov. 20, 2001)  
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“national emergency or other circumstances of extreme urgency”359 including 
public health crises such as “HIV/AIDS, tuberculosis, malaria and other 
epidemics”.360 Furthermore the ICESCR committee takes the position that a 
country violates its obligation to promote human rights when it fails to 
“regulate the activities of individuals, groups or corporations so as to prevent 
them from violating the rights to health of others”.361  
 
Eide’s third and final concept of state responsibility in fulfilling its human 
rights obligation compels her to put into place adequate legislative, budgetary 
and administrative procedures so that it can realize its human rights obligation 
.362  In doing so states have to adopt satisfactory national health policies, health 
insurance schemes and provide alternative medicines such as generic 
equivalents to patented medicines. By accessing generic equivalents of brand 
name drugs, states can access cheaper medicines. For example in 2006, the 
Indian government announced a fall in prices for 886 generic drugs leading to 
a price reduction ranging from 0.2 to 74 per cent for formulations such as anti-
diabetes drugs, painkillers, cough medications and hypertension drugs and 
other formulations such as paracetamol, cefadroxil and amoxicillin;363 thus 
setting a very good example for other developing countries like Nigeria to 
follow. Some commentators have therefore argued that states can better fulfil 
its human rights obligation by providing anti-competitive measures against 
multinational companies to prevent them from setting prices that are 
extensively higher than their generic equivalent.364  Such anti-competitive 
                                                            
359 Ibid. p. 5 (c). 
360 Ibid . P 5 ( 5). 
361 U.N. Comm. on Econ., Soc. & Cultural Rts., General Comment 14,  P 51. 
362 Koch, I.E (2002) Social Rights as Components in the Civil Right to Personal Liberty: 
Another Step Forward in the Integrated Human Rights Approach? 20 Netherlands Q of Hum 
Rts 29. 
363 http://www.hindu.com/2006/11/01/stories/2006110104121200.htm (Assessed 7 February 
2007) 
364 Yamin. A. E (2003) NOT JUST A TRAGEDY: ACCESS TO MEDICATIONS AS A RIGHT 
UNDER International law. 21 B.U. INT’L.J. 325 
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measures may come in the form of regulations, protectionist measures, tariffs 
and quotas.365 
 
The Policy briefing for Stop AIDS campaign in May 2006 stated that in order 
for the Universal access to treatment to be achieved by 2010 new generic 
versions of key drugs must become quickly accessible.366  This is because half 
of the people in the developing world who are on antiretroviral therapy rely on 
generic versions of the more expensive patented drugs. Furthermore it seems 
that generic medicines essentially offer HIV patients a better chance to prolong 
their lives by introducing “second line” treatments, needed for patients when 
they develop resistance to their first combination of medicines. Treatment for 
HIV generally involves three drugs taken together  WHO advocates that in 
most conditions a first line regimen ought to consist of two drugs from the 
nucleoside/nucleotide (NRTI) group and one drug from the non-nucleoside 
(NNRTI) group.367 Second-line treatments are currently under patent and 
priced overtly high, so are most new upcoming successful drugs that HIV 
patients need that come onto the market.368   
 
Generic medicines enable states to overcome the inconvenience of fixed-dose 
combination in cases where the various components are patented by different 
companies who are reluctant to work together. To clarify what fixed 
combinations mean to HIV patients, these medication consist of pills that 
contain two or three AIDS drugs in one tablet and they have been widely 
recognized as being a key element in efforts to scale up AIDS treatment in 
                                                            
365  Article 31 (K) 3states that ‘Members are not obliged to apply the conditions set forth in 
subparagraphs (b) and (f) where such use is permitted to remedy a practice determined after 
judicial or administrative process to be anti-competitive. The need to correct anti-competitive 
practices may be taken into account in determining the amount of remuneration in such cases. 
Competent authorities shall have the authority to refuse termination of authorization if and 
when the conditions which led to such authorization are likely to recur;) 
366 STOP AIDS CAMPAIGN.  Policy briefing: Access to Essential Medicines. May 2006. 
http://www.vso.org.uk/Images/stop_aids_campaign_drugpricingpolicy_tcm8-8152.pdf 
367 AVERT  http://www.avert.org/aidstreatment.htm .  See diagram below. 
368  STOP AIDS CAMPAIGN.  Policy briefing: Access to Essential Medicines. May 2006. 
http://www.vso.org.uk/Images/stop_aids_campaign_drugpricingpolicy_tcm8-8152.pdf 
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developing countries.369  The benefits of these medicines is the fact that they 
are generally more affordable than purchasing separate products, they are easy 
to use and reduce the risk of the drug becoming  which is one of the major 
problems that HIV patients encounter when using ARV drugs.370 Despite the 
advantages of generic medicines, proponents of the patent system argue that 
generic drugs are not needed because pharmaceutical companies already make 
cheaper versions of ARV in developing countries, an example which is often 
cited is the Meltrex tablet formulation of Kaletra (lopinavir/ritonavir) produced 
in Germany which has received full marketing approval from the European 
Medicines Agency  and is a second line treatment for the HIV virus. The main 
benefit of the new Kaletra tablet is that it does not need to be refrigerated.  
 
Previous studies have found that the old Kaletra capsules deteriorated fast in 
countries with hot climates and needed to be stockpiled and distributed with 
care. Other benefits of the new tablet include dosing with or without food (this 
can be a real problem in poorer countries with a low standard of living where 
feeding is a real problem) and a reduced pill count for those on standard dosing 
(400mg lopinavir/100mg ritonavir) twice daily. Nonetheless big patent holding 
manufacturers such as Abbot have been criticized in the past for not speeding 
up the registration of the new tablet in developing countries that are in urgent 
need to provide medicines needed to the fight HIV/AIDS. Although Abbot 
disputed these claims, stating that it has guaranteed that the new formulation 
will be sold at a reduced price of $500 a year to poorer countries.371 MSF 
disagrees with this claim, stating that Abbott could choose to export the drug 
from the United States, allowing quicker registration and therefore would not 
                                                            
369 TWO PILLS A DAY SAVING LIVES: FIXED DOSE COMBINATION OF FIXED-
DOSE COMBINATIONS.  
http://64.233.169.104/search?q=cache:l9_1Sysh29YJ:www.accessmed-
msf.org/documents/factsheetfdc.pdf+what+are+fixed-
dose+combinations&hl=en&ct=clnk&cd=12&gl=uk 
370 Ibid 
371 AIDSMAP NEWS.  http://www.aidsmap.com/en/news/BD54D18C-962B-46D4-8882-
3327471FBBA5.asp 
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need to wait for European approval, since many African regulatory authorities 
need a certificate of pharmaceutical production from the European Union. 
Such discontent are evidence that even if the pharmaceutical industry feels that 
it is doing much to provide access to medicines and not using the TRIPS to 
prevent such access, some activist feel that such measures are not sufficient, 
states have to do more to fulfil their human rights obligation. 
 
4.3 Human right Obligation of Multinational Corporations 
Conventionally, human rights have been regarded as being solely in the 
domain of states and not in the realm of individuals.372 However recent 
developments have changed the status quo. Many states have now privatised 
many of their public institutions that were previously controlled by the 
government and this has made the case for MNC being held accountable for 
human rights obligations more fervent,373 secondly MNC have become so 
powerful and rich that some of them are richer than many developing countries 
put together.374  In 2002 sales from Wal-Mart outdid the GDP of the many 
developing countries put together. Many commentators have argued that MNC 
should have as much human rights obligations to fulfil as states.375 Countries 
such as Portugal have enacted legislation to hold both private and public 
institutions responsible for human rights obligations.376 Wiesbrock suggest that 
the interpretation of human rights instruments suggest that rights protected by 
the Covenant such as the right to life and health care can be violated by 
individuals and corporations.377  To support this the preambles of the ICCPR 
and ICESCR states that “the individual, having duties to other individuals and 
to the community to which he belongs, is under a responsibility to strive for 
                                                            
372 See Nowak  J.E and Rotunda, R.D  (1995) Constitutional Law  5th ed 
373 Singer, P.W (2004) Corporate Warriors. The Rise of the Privatized Military Industry 
374 See McCorquodale R & Richard Fairbrother, (1999) Globalization and Human Rights, 21 
Hum. Rts. Q. 735, 742-58  
375 Wal-Mart (ed) Annual Report 2002. 
376 The Portuguese Constitution 2 April 1976. See also DM Chirwa,(2003) The Right to Health 
in International Law: Its Implication for the Obligation of States Actors in Ensuring Access to 
Essential Medicine 19 SAJHR 541, 564 
377  
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the promotion and observance of the rights recognised in the present 
Covenant’, thus Article 5(1) of the ICCPR states that “Nothing in the present 
Covenant may be interpreted as implying for any State, group or person any 
right to engage in any activity or perform any act aimed at the destruction of 
any of the rights and freedoms recognized herein or at their limitation to a 
greater extent than is provided for in the present Covenant”. It is widely 
accepted by academics that international human rights indirectly holds member 
states responsible for the acts of corporations (including pharmaceutical 
companies),378 Kinley and Tadaki assert that the fundamental treaty obligation 
imposed on members states requires that all non-state parties within its 
jurisdiction adhere to duties imposed in the instrument, and furthermore 
international human rights depends on domestic law to implement its 
provisions. 379 
 
In elucidation, the fact that MNC have become so powerful has led to a public 
outcry that they too must be held accountable for the violation of human rights. 
They are many examples of abuses by MNC, especially in the developing 
countries, where accountability is not as structured as those in the developed 
world.380 For example in Nigeria, oil trade in the Niger Delta region of the 
country produces about 90 per cent of the country’s budget.381 The activities of 
                                                            
378 See Clapham A&  Jerbi. S, (2001)  Categories of Corporate Complicity in Human Rights 
Abuses, 24 Hastings Int'l & Comp. L. Rev. 339, 341- 42, 346-47 . There is evidence to suggest 
that  the Inter-American Court of Human Rights and the European Court of Human Rights  has 
established a  way to states  responsible for the actions of non-state actors. See, in respect of 
the Inter-American Court, Velasquez Rodriguez v. Honduras, Case No. 4, Inter-Am. C.H.R., 
OEA/ser. C, PP 159-88 (1988), and in respect of the European Court of Human Rights, see 
Costello-Roberts v. United Kingdom, 247 Eur. Ct. H.R. (ser. A) (1993); Gustafsson v. 
Sweden, 22 Eur. Ct. H.R. 490, and A v. United Kingdom, 1998-VI Eur. Ct. H.R. 2692 (1998). 
379 Kinley D and  Tadaki, J (2004)  From Talk to Walk: The Emergence of Human Rights 
Responsibilities for Corporations at International Law  44 Va. J. Int’I L. 931. 
380 Multinational Corporations and the Ethics of Global Responsibility: Problems and 
Posssibilities (2003) 25 Hum Rts Q 965, 971ff, Multinational corporate social responsibility, 
ethics, interactions and Third World governments: An agenda for the 1990s. Journal of 
Business Ethics. Volume 12, Number 7 / July, 1993 
381 http://news.bbc.co.uk/1/hi/world/africa/6698433.stm, see Shell’s involvement in violations 
of the rights of the Ogoni people, Social and economic Rights Action Centre and the Centre for 
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oil companies such as Shell and Chevron has led to a severe case of oil 
spillages in the region which has resulted in environmental degradation, lack of 
livelihood for the fisher men and poor health which has extended to other areas 
such as poverty due to lack of social services such as hospitals, good drinking 
water and schools.382 Cases of oil pollution in the Niger Delta have raised 
many human rights issues because the oil industries have not always been 
prepared to face up to the negative effects that their activities has on the 
communities of the region. The tragedy of the actions of MNC is captured in 
the statement by Mr. Louis Nwanchukw "Shell has promised us several things, 
but have not done any. Apart from that, the issue of environmental devastation 
that is still threatening us. Two major spills have occurred between 1991 and 
1999 and Shell refuses to clean spills from our lands and rivers and pay 
compensation to us".383 Similar cases of MNC violation of human rights 
obligations is prevalent throughout the developing world, for example in 2006 
a Netherland based commodities company Trafigura Beheer dumped toxic 
waste in Abidjan, Cote d’Ivoire killing eight people and resulting in more than 
77,000 people needing medical attention.384385 
 
The history of MNC violating the human rights of individuals in developing 
countries is common. Cases of MNC and countries dumping hazardous waste 
are examples of how MNC have violated the human rights of people in some 
developing countries. In 1979 the American company, Nedlog Technology 
Group, Inc., offered Sierra Leone $25 million to use its territory for waste 
disposal. In the case of Nigeria, in 1987, an Italian waste broking firm Ecomar 
                                                                                                                                                            
Economic and Social Rights v Nigeria, Communication No 155/1996, 
ACHPR/COMM/A044/1 (27 May 2002) 
382 http://www.american.edu/TED/iko.htm 
383“Shell fails to clean spill, refuses to pay compensation"  FOR OIL SPILLS IN AMUSIA,  
RIVERS STATE OF NIGERIA'S NIGER DELTA.  Mr. Louis Nwanchukwu, chairman, 
Umusia Community development Committee (CDC). 
http://www.waado.org/Environment/OilSpills/NigerDelta/Amusia_Rivers.html 
384 Ivory Coast parliament open hearing into toxic waste scandal 
http://www.reliefweb.int/rw/RWB.NSF/db900SID/HMYT-6TYM8P?OpenDocument Last 
visited 12-03-07 
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and Jelly Wax signed a contract with a construction company where it would 
store its hazardous waste of 18,000 drums for approximately $100 a month. 
They have been numerous cases of gross human rights abuses, however some 
have argued that Covenants define the obligations on State Parties, but not 
individual.386 One of the strongest cases against individuals and corporations 
being held responsible for adhering to the human rights obligations is Article 2 
of the ICCPR and Article 2 of the ICESCR which make no mention of 
individuals being bound by the rights in the Covenants, and secondly state 
practices do not support individuals and corporations being bound by human 
rights obligations. The German Federal Constitutional Court stated that 
“outside the area of minimum human rights standards current general 
international law contains only few norms that create right or duties of private 
individuals”.387 Bearing this in mind international human law may have to 
undergo a constructional evolution to determine MNC’S accountability in 
relation to international law.388 The US suggested that the future Article 7 of 
the future ICCPR should be rephrased to “no one shall be subjected to torture” 
as opposed to “no state shall be subjected to torture”.389 This may broaden the 
umbrella in which human rights obligation applies to include both states and 
individuals because at the moment, there is no bold and clear evidence that 
MNCs can be held in violations for human rights obligations under the 
Covenant as state parties can. 
 
4.4 Summary   
The relationship between trade and human rights has caused a lot of tension in 
the access to medicines debate. Whilst some commentators have argued for the 
                                                            
386 Klein, E  (2000)The Duty to Protect and to Ensure Human Rights Under the International 
Covenant on Civil and Political Rights  in E Klein  (ed), The Duty to Protect and to Ensure 
Human Rights. Colloguium. Potsdam, 1-3 July 1999  
387 Memorandum for the United States as Amicus Curiae in Filartiga v Pena-Irala, at 21, 630 
F2d 876 (2nd Cir, 1980) 
388 See Kinley D &  McBeth, A (2003) Human Rights Trade and Multinational Corporations, 
in Business and Human Rights 52-68 (Rory Sullivan ed.,  
389 Holger Hestermeyer. (2007) HUMAN RIGHTS AND THE WTO. The Case of Patents and 
Access to Medicines. Oxford University Press 
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international recognition of the human right to health and access to medicines 
as fundamental human rights that must be protected by the state, the authority 
to back the assertion up has been debatable. Whilst the UDHR and other 
international human rights instruments such as the ICESCR and ICCPR can be 
used as authorities to back the assertion up, the matter has been left for the 
state governments to implement. It follows that most state are shielded by 
impossibilium nulla (meaning that the state is under no duty to perform the 
impossible). Many developing countries have a weak healthcare delivery 
system and the budget for their health care expenditure is not high enough to 
meet the medical expenses of ensuring that majority of it population receive 
the treatment or necessary medicines that they require. In my opinion, MNC 
have also played a part in preventing state governments from affording to meet 
their human rights obligations of ensuring that there is access to medicines. 
State governments have to enunciate  laws and national policies that will 
ensure that access to medicines and good health are a priority for their nations. 
It is with the foregoing in view that an in-depth analysis is conducted in the 
next chapter to ascertain the healthcare crisis in Nigeria with particular 
emphasis on the HIV/AIDS epidemic. 
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5   HIV/AIDS EPIDEMIC IN NIGERIA  
5.1 Introduction 
 
It is my aspiration that health finally will be seen not as a blessing to be wished 
for, but as a human right to be fought for. 
—United Nations Secretary-General Kofi Annan 
 
I cannot take that rubbish any longer. Can you believe it? I have never in my 
life heard such rubbish. Here we have a situation where the minister of health 
sends out a document, amongst others, that is Looney tunes, that suggests that 
the Illuminati have conspired with the aliens to bring about Aids to reduce the 
African population.  
A reporters’ response to Manto 
Tshabalala Msimang assertion that raw 
garlic, onion, lemon and beetroot are the 
best remedies for  HIV. 
 
Even if he can vote to choose his rulers, a young man with AIDS who cannot 
read or write and lives on the brink of starvation is not truly free… Larger 
freedom implies that men and women everywhere have the right to be 
governed by their own consent… without discrimination or retribution… They 
must also be free from want — so that the death sentences of extreme poverty 
and infectious disease are lifted from their lives — and free from fear…Indeed, 
all people have the right to security and to development."  
—United Nations Secretary-General Kofi Annan 
 
The HIV/AIDS epidemic is one of the leading challenges facing our modern 
day society. The severity of the epidemic comes from the fact that it threatens 
to undermine the millennium development goals to reverse the spread of 
HIV/AIDS by 2015.  In the twenty- eight years since HIV was first identified 
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there have been considerable advances in the understanding on how to prevent 
and treat HIV infection and by so doing alleviate the social, economic and 
financial impacts that the diseases has on individuals, families, and 
communities. Successful programs have been implemented to halt and slow 
down the rate of new infections among specific groups in many parts of the 
world. But despite such considerable progress the AIDS epidemic continues to 
gain momentum in a number of new countries where early intervention could 
have prevented its spread if more medicines were available. HIV/AIDS is 
clearly a major human rights issue, and the inability to pay for treatment 
because of the high cost set by MNC has further compounded the problem. In 
the case of Nigeria, the prevalence rate of the diseases continues to rise, while 
the people suffering from HIV/AIDS continue to face the pangs of 
discrimination and other human rights abuse. Whilst the government has set 
out programs to respond to the epidemic and ensure that people gain more 
access to medicines, some have argued that the governments are not doing 
enough. This chapter focuses on the HIV/AIDS epidemic in Nigeria with a 
view to showing that the inability to gain access to medicines is not so much an 
international problem caused by the TRIPS Agreement, but an internal one 
caused by domestic factors that make up the fabric of the Nigerian society. 
 
5.2  Background of AIDS in Nigeria 
The first case of HIV/AIDS in Nigeria was reported in 1985 by the Federal 
Ministry of Health (FMOH).390 Subsequently in the two decades since AIDS 
was first discovered in Nigeria, many individuals and communities are still 
adversely affected by the destructive forces of the disease.391 When the finding 
of FMOH was reported to the Nigerian government as far back as 1986, the 
government was thrown into a state of panic about the effect that the disease 
would have on the Nigerian economy. In 1987 the National Expert Advisory 
                                                            
390 Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development 
391 HIV/AIDS National Strategic Framework for Action 2005 -2009 NACA Published by the 
Society for Family Health. September 2005 
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Committee on AIDS (NEACA) was established to control and fight the 
disease. A year after that, the National AIDS and STDs Control Program 
(NASCP) was established to replace NEACA with the hope that it would be 
more effective in halting the AIDS epidemic in the country. In 1991, the 
NASCP program was expanded to include sexual transmitted infections (STIs), 
and today NASCP focus principally on the health sector responses to HIV and 
other STIs. Its work is centred mainly on the monitoring and surveillance of 
the epidemic, syndromic management of STIs, voluntary counselling and 
testing (VCT), prevention of mother-to-children of HIV transmission 
(PMTCT) and management of HIV/AIDS, including treatment of opportunistic 
infections, administration of antiretroviral (ARVs), and home based care.392  
 
In the 1980’s Nigeria was considered to be at a moderately early stage of the 
HIV/AIDS epidemic when compared to many countries in the East and South 
of Africa; however the prevalence of the disease continued to grow.393 Indeed 
the effects of HIV/AIDs have become so severe that many Nigerians are afraid 
that if not checked, the epidemic could spill into all other fabrics of society.394  
The most direct impact of AIDS in Nigeria however has been an increase in 
the number of infant mortality, reduced life expectancy and adult deaths.395 
Statistics show that the increase in the level of HIV prevalence in Nigeria 
indicates a rise from 1.8 % in 1991 to 3.8% in 1995, to 5.4% in 1999 to 5. 8% 
in 2001, and  4.6 % in 2008.396  These figures shows that because of the high 
level of HIV prevalence in Nigeria, 9.8 out of every 1000 people in the 
population is dying as a direct or indirect result of AIDS.397   
                                                            
392 Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development pg. 18 
393  Ibid  
394 Pew Research Center, 2002 Pew Research Center for The People and the Press, “What the 
World Thinks in 2002”, December 
395 HIV/AIDS: The Disease Burden and the level of Funding in Nigeria. A Publication of aids 
alliance in Nigeria 
396 2007 National HIV/AIDS and Reproductive Health Survey (NARHS Plus 2007) 
397 Epstein, B. G. (2005)  The Demographic Impact of HIV/AIDS, Chapter1: 1-40 
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Diagram 1: National HIV Prevalence 1991 -2008 
Source: NACA 
 
Disturbingly too is the fact that more than half of the people living with AIDS 
in Nigeria are women (58%), consequently statistics show that HIV prevalence 
among women is very high especially among young women between the age 
of 20 and 39 years.398  (See Diagram 2) The implication being that many 
women are getting ill and dying in their reproductive years, and there is also an 
increase in the number of children born with HIV.  It is no wonder that Nigeria 
has the highest number of AIDS orphans in sub-Sahara Africa aged between 0-
17 at an estimate of 1.3 million.399  
                                                            
398 UNAIDS, 2004b 
399 UNAIDS, 2004a 
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Diagram 2: HIV Prevalence According to Age Group and Gender. 
Source: NACA 
 
After South Africa and India, Nigeria has the third highest number of people 
living with HIV/AIDS. As of 2008 they were over 2.95 million people living 
with HIV/AIDS in Nigeria. 400 There are several factors that contribute to the 
spread of HIV/AIDS in Nigeria such as culture and religion. The marriage 
practices in Nigeria which are sometimes based on culture violate women’s 
rights and have been identified as one of the factors that contribute to the 
growing HIV prevalence among women and girls.401 In Nigeria there are three 
different legal systems, namely civil, customary, and Islamic laws.402  A 
Muslim man is allowed to marry as many as four wives. Previously in Nigeria 
there was no law as to the minimum age a girl could attain before she is given 
                                                            
400 2008 National HIV Sero-Prevalance sentinel Survey Among the Antenatal Clinic 
Attendees.  Preliminary Findings 
401  Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development pg. 30 
402 Center for Reproductive Law and Policy (CRLP). 2001. Women of the World: Laws and 
Policies Affecting their Reproductive Lives (Anglophone Africa). New York: CRLP. 
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away in marriage. Some young girls are married off as early as 10 years and 
may be married off to men who are more than 50 years older than they are.  
The northern part of Nigeria has some of the highest rates of early marriage in 
the world. The Child Rights Act, passed in 2003, rose the minimum age of 
marriage to 18 for girls. However, the Nigerian federal law can be 
implemented diversely at the state level (Nigeria has a three tiers of 
government system. The first which is the federal level includes the Executive, 
Legislative and Judiciary. The second tier contains 36 States of the federation, 
and the local government which has 774 local governments)   and up until now 
not many of the 36 states in the country have begun the process of 
implementing the law.403 Young girls are therefore at danger of contracting 
sexual transmittable diseases such as HIV/AIDS, and basically have no 
protection from the law from being married off at a very young age. (See 
Diagram 3) Statistics show that 20 percent of girls were married by age 15, and 
40 percent were married by the age of 18.404 Child marriage is extremely 
prevalent in some regions; in states such as Borno, Yobe, Jigawa and Gombe 
48 percent of girls were married by the age of 15.405 Young girls that are 
married at such a tender age do not only face the fear of being infected with 
HIV/AIDS and other STDs but face obstetric fistulas which are a result of 
prolonged and obstructed labour that is associated with girls giving birth at 
young ages.406 The FMOH indicates that between 200, 000 to 400,000 girls are 
presently living with fistulas, with 100,000 occurring annually.407Fistula is a 
medical condition where there is an abnormal connection between the rectum 
and the vagina.  The diseases can be extremely debilitating.408  
 
                                                            
403 Corinne Whitaker, personal communication, 2004. 
404 Ibid 
405 http://www.popcouncil.org/pdfs/briefingsheets/NIGERIA.pdf 
406 Yolah, Hajia Kindin.( 2001) Epilogue to childhood encounter,” http://www.unfpa.org/news/ 
news.cfm?ID =268&Language=1, accessed 20 April 2007 
407 Ibid 
408 Wikipedia. The Free Encyclopedia. http://en.wikipedia.org/wiki/Rectovaginal_fistula 
http://en.wikipedia.org/wiki/Rectovaginal_fistula 
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Statistics also show that girls between the ages of 15–24 are about twice as 
likely as boys the same age to be infected by HIV.409 Married girls due to their 
age, lack of education and low status in the Nigerian society usually have less 
knowledge about HIV than unmarried girls.  They are less likely to have heard 
of HIV and are less likely to know that HIV can be transmitted from mother to 
child.410  The prevalence rate for HIV varies from state to state with the highest 
statistic being Cross River (12.0%), Benue (9.3%) and Adamawa (7.5), 
however the elements that contributes to the spread of the disease is the same. 
(See Diagram 4) Consequently, the heterosexual route of infection accounts for 
82% of all transmission and despite the sexual behaviour of the population, sex 
is generally a “hush-hush” subject and many people do not discuss it freely.411  
Sex has in the past been perceived as something dirty or evil particularly by 
religious leaders who often view morality as being determined by a higher 
order from above.412 Although the FMOH and the Nigerian Educational 
Research and Development Council (NERDC) have added sexual education on 
school curriculums to improve the entire package of development as well as 
teacher training for schools and family-life programmes, effective sexual 
education has still remained elusive and almost unattainable in many parts of 
the country. The inability to implement sex education in some parts of Nigeria 
through free and open discussions  between adults and the younger generations 
has continued to foster myths and misconceptions about HIV/AIDS and hence 
and contributed to rising HIV transmission in some communities.413 
                                                            
409 Estimates range from 4.7 percent to 7.0 percent for girls aged 15–24, and from 2.4 percent 
to 3.6 percent for boys. UNAIDS. 2002. Report on the Global HIV/AIDS Epidemic 2002. 
Geneva: UNAIDS. 
410 NDHS 1999. Data are for 15–19-year-olds. 
411 Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development. pg 29 
412 Adepoju, Adunola, (2005) Sexuality and Life Skills Education. London: PenPress 
Publishers 
413   Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development pg 29 
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Diagram 3: Awareness of HIV/AIDS  
Source: NACA 
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Figure 14.1: HIV Prevalence by Sex and Zones in Nigeria, FMOH 2007
 
Diagram 4: HIV Prevalence by sex and Zone in Nigeria, FMOH 2007 
Source: NACA 
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5.3  HIV/AIDS crisis in Nigeria put in Human Rights Perspective 
Most people living with HIV/AIDS in Nigeria (PLWHA) have therefore been 
deprived of almost every fundamental human right because they are seen as the 
“outcast in society”, “the lepers”, “and the dead among the living”.  A person 
living with HIV/AIDS in Nigeria, especially in the rural parts of the country 
suffer hate, discrimination, rejection, neglect, harassment, humiliation and 
various acts of unprofessional conduct by health care workers such disclosure 
of patient records without their consent.  They have no one to turn to for 
reassurance and usually die alone rejected by society.  The trepidation of 
HIV/AIDS stems from the lack of medicines for people infected with the 
disease. A status quo, some have argued is compounded by the high cost of 
patented medicines; which is directly linked to article 33 of the TRIPS 
Agreement..414  This allows the patent holders charge whatever price they 
wish, even if the majority of customers cannot afford it. The stigma against the  
disease is so much so that they are various myths surrounding how to gain 
access to medicines or protect oneself against the disease. In 2002 a man in 
Johannesburg was sentenced to life in prison for raping a nine-month old baby. 
He allegedly raped the baby because he believed the myth that a person can be 
protected against AIDS if he has sex with a virgin, even if it is a baby.415 Such 
myths are not only exclusive to developing countries. Studies by the Henry J. 
Kaiser Foundation showed that one quarter of Canadians believe that HIV can 
be transmitted through kissing, mosquito bites, casual contact, coughing and 
sneezing.416  However by far the biggest myth that exacerbates such beliefs is 
that if a person is diagnosed with HIV/AIDS they  will die when in fact many 
people can and do live normal, happy, healthy productive lives with the right 
medical treatment.417  
                                                            
 
415  http://www.thebody.com/content/whatis/art20708.html July, 29, 2002. South Africa Man 
Jailed for Life for Baby Rape 
416 http://www.thebody.com/content/whatis/art11316.html One-Quarter of Canadians Believe 
HIV can be Transmitted Through Kissing, Mosquito Bites, Poll says. Accessed 3, December  
2005 
417 http://aids.about.com/cs/aidsfactsheets/tp/hivmyths.htm 
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Many people in Nigeria have no incentive to be tested for HIV or even 
informed about the result of their assessment if the result is positive, because 
they feel that they are not likely to have access to antiretroviral. The plight of a 
person living with HIV/AIDS in most parts of the developing world is very 
different from people in the developed world. Available medication has given 
those with HIV/AIDS in the developed world hope thereby prolonging their 
lives. Among the available medication is the availability of five different kinds 
of antiretroviral medicines in the form of a complex combination of cocktails. 
The first is the Reverse transcriptase inhibitors (RTIs), this targets the structure 
of the viral DNA by slowing down the activity of the reverse transcriptase, the 
second is the Protease inhibitors (PIs), this targets the viral structure by 
inhibiting the activity of protease, an enzyme used by HIV to reduce nascent 
proteins for the final assembly of new virons, the third is the Fusion inhibitors, 
this blocks HIV from fusing with a cell's membrane to come in and infect it. At 
present there is only one FDA-approved drug in this class, enfuvirtide, which 
is marketed as Fuzeon.  The fourth is the Integrase inhibitors, this stops the 
enzyme integrase, which is responsible for the integration of viral DNA into 
the DNA of the infected cell and lastly the Entry inhibitors which blocks HIV-
1 from the host cell by binding CCR5, a molecule on the host membrane 
termed a co-receptor that HIV-1 normally uses for entry into the cell together 
with a primary receptor. These antiretroviral drugs disrupt the setting in of the 
HIV infection, thereby allowing an infected person’s immune system to 
recover.418  The latter two anti-retroviral are currently under clinical trial and 
are not commercially available to the public as of yet.419 
 
 
 
                                                            
418 Gustin L.O & Hodge, J.G Jr (1998) The "Name Debate": The Case for National HIV 
Reporting in the United States, 61 Alb. L. Rev. 679, 700  
419 http://en.wikipedia.org/wiki/Antiretroviral_drug   
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5.4  Violation of the Human Right to Health in Nigeria 
Ever since the discovery of HIV in Nigeria, there has been widespread abuse 
of human rights and violation of fundamental liberties that are essential for a 
person to live with human dignity and equality.  Remarkably however is the 
fact that section 33 of the Nigerian Constitution 1999 guarantees the right to 
life of every citizen of the Federal Republic of Nigeria. Some have therefore 
interpreted this as including the right to healthcare. Section 17 (3) (d) provides 
that there shall be “adequate medical and health facilities for all persons”.  The 
Nigeria government has ratified most human rights treaties and instruments, 
including the African Charter on Human and People’s Rights (ACHPR)420 
which became domestic law by means of the African Charter on Human and 
People’s Rights (Ratification and Enforcement Act, Cap 10, LFN 1990). 421 
Article 16 of the Charter also stipulates that state parties to the Charter must 
take all necessary measures to protect the health of all citizens and ensure that 
they receive medical attention when they are sick.  Nigeria is also a member of 
the Organisation of African Union (OAU) and ECOWAS, and both regional 
treaties contain provisions protecting the basic rights of individuals as an 
essential part of the agreement; other international charters that Nigeria have 
subscribed to include the UN Charter and the WHO constitution. Both have 
human rights as their core obligation. In this regard it is fair to say that the 
right to health is a fundamental part of the fabric of the Nigeria society.  
 
Another violation of the right to health for PLWHA in Nigeria is the fact that is 
not unusual for people living with HIV/AIDS to be denied treatment because 
they are carrying the virus.  The stigma that comes with the disease means that 
a person with HIV/AIDS may sometimes be refused treatment by doctors and 
other health care workers because some medical staff are afraid of being 
exposed to the diseases. Expired ARVs is another major cause of concern in 
                                                            
420 This was ratified by Nigeria on 22 July 1983 
421 HIV/AIDS and Human Rights in Nigeria. Background Paper for HIV/AIDS Policy Review 
in Nigeria. Prepared by the Centre for the Right to Health for the Health for the POLICY 
Project. September 2003 
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Nigeria, thus access to medicines should mean access to the right drugs, for 
example in November 2003, a report showed that expired ARVs were found in 
64 per cent of health care facilities. The financial loss amounted to an 
estimated sum of 19,953,510 Naira422 (equivalent to $146,717).423    
 
5.5  ARV distribution in Nigeria 
The Nigeria government commenced procuring ARVs in 1997, and by 2003 
there were 25 ARVs that had been collected sporadically of which 9 were 
patented and 16 were generics.424 Indeed the effect of patents and the 
avalibility of medicines in Nigeria cannot be lost on the reader. Nigeria does 
not have a fully developed pharmaceutical industry like India or Brazil and 
must therefore rely on importation of ARVs from countries like India and 
China.   Indeed ARVs in Nigeria are procured by the government and stored at 
the Central Medical Store at Oshodi in Lagos, Nigeria, and on the Essential 
Medicine List for Nigeria are 8 antiretroviral drugs namely Diadanosine, 
Lamivudine, Stavudine, Zidovudine, Nerirapine, Indinavir, Nelfinavir and 
fixed dose combination of lamivudine, Stavudine and Nievirapine.425 Health 
facilities throughout the country are required to collect their share of the ARVs 
from the Central Medical stores in Lagos.  Although procurement of ARVs 
have been done mainly by the government, thus between 2001 and 2004, the 
Nigerian government spend a total of 2.1 billion naira ($19 million). Charity 
organisations, international organisations and institutions have also been 
instrumental in the fight to get ARVs to people suffering from HIV/AIDS. The 
World-Bank initiated a HIV/AIDS program Development Project to form the 
structure of the HIV/AIDS Emergency Action Plan (HEAP) for 2001-2004. 
The main purpose of the project has been to help Nigeria curtail the spread and 
lessen the impact of HIV/AIDS epidemic that was beginning to take a toll on 
                                                            
422 The US Dollar was equivalent to 136 Naira at the time of the study. 
423 Situation of ARV Drug Use in Nigeria. November 2003. The Federal Ministry of Health in 
coloration with World Health Organization. 
424 Ibid 
425 Ibid 
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the country. The total credit from the World Bank was US$90.3 million, this 
was to be shared proportionately between 18 (out of the 36) states and the 
Federal Capital Territory in Abuja, Nigeria.426 Although it must be noted that 
this has now been extended to the remaining 14 states. Another such initiative 
is the Global Fund for AIDS, Tuberculosis and Malaria which as of 2005 had 
committed $66.46 million Naira to halt and reverse the HIV/AIDS epidemic.  
427 The fund was initiated to expand the country’s ARV program, to develop 
six centres of excellence for the Prevention of Mother to Child Transmission 
(PMTCT), and to sponsor the successful contribution of the Nigerian Civil 
Society Organisations (CSOs) in the national response to HIV/AIDS.  
 
Britain’s Department for International Development (DFID) has also been a 
major force in providing access to medicines for people living with HIV/AIDS 
in Nigeria. It has in fact been at the forefront of two HIV/AIDS programme in 
Nigeria: Promoting Sexual and Reproductive Health for HIV/AIDS Reduction 
(PSRHH) and Strengthening the National Response to HIV/AIDS (SNR). The 
latter began in 2002 and will remain functional until 2009.428 The program 
aims at sexual and reproductive care among the poor, vulnerable and 
marginalised people in Nigeria.429 The programme has set up three agencies: 
Population Services, SFH, and Action Aid with Nigeria as their chief 
implementing bodies.  
 
SNR was established in Nigeria in 2004 and is a $25 million 5 year project.430 
Family Health International (FHI) is another program that has taken the lead to 
                                                            
426 World Bank. Nigeria: HIV/AIDS Program Development Project Appraisal Document, 
P070291. Washington, D.C: World Bank. 2001. 
427 Global Fund for AIDS, Tuberculosis and Malaria. Portfolio of Grants in Nigeria. Accessed 
at www.theglobalfund.org/search/portfolio.aspx?lang=en&countryID=NGA on July 1, 2005 
428 Department for International Development. DFID Programmes in Nigeria. London: 
Department for International Development, May 2005;14 
429 Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A NATION ON 
THE THRESHOLD. Harvard Center for Population and Development 
430 Department for International Development. DFID Programmes in Nigeria. London: 
Department for International Development, May 2005;14 
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work with Action Aid-Nigeria and other voluntary Services as collaborating 
partners in the halt of HIV/AIDS.  The program is being implemented in six 
high prevalence states with the goal of reducing “the impact of HIV/AIDS on 
the lives and livelihood of poor people in Nigeria.”431  The objective of these 
organisations and programs has been the continued effort to implement a 
multi-sectoral, human-rights-based Nigerian response to the epidemic, 
focusing on selected, high priority locations where DFID’s input has made a 
real difference to improve the situation. 
 
5.6 Nigeria’s Response to HIV/AID compared to other Countries that 
have successfully confronted the Diseases.  
Nigeria has set a target year of 2010 to reverse the spread of HIV by a 
minimum of 25%,432 the fact however remains that Nigeria needs more access 
to cheap affordable medicines and an unparalleled motivated national response 
to quieten the spread of HIV/AIDS. Appraising how some low and middle 
income countries have been successful in implementing programs and enacting 
legislation to curtail the spread of HIV/AIDS is a good starting point to 
evaluate the suitability of Nigeria’s response to HIV/AIDS. A good example of 
a country which has been able to implement a somewhat successful HIV/AIDS 
management program is Uganda who as early as 1986 developed a behavioural 
change strategy that has led to the reduction of the HIV prevalence.433 
President Yoweri Museveni434 was remarkable in instigating a policy that led 
to a complete revolution in the way HIV/AIDS is responded to and tackled in 
Uganda. He championed an open, honest and ingenuous discussion on the 
subject of HIV/AIDS and placed it on the political agenda as an issue to be 
                                                            
431 Ibid 
432 Federal Government of Nigeria. National Policy on HIV/AIDS. Abuja: Federal Government 
of Nigeria, 
2003. See also Adeyi. O, Kanki.P.J, Odutolu, O, Idoko, J.A  (2006) AIDS IN NIGERIA: A 
NATION ON THE THRESHOLD. Harvard Center for Population and Development 
433 Ibid 
434 who became the president of Nigeria since 29 January 1986 
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addressed and resolved.435  President Museveni also applied a policy where all 
pregnant women would be tested for HIV/AIDS, consequently one of the 
strategies implemented by Museveni to fight AIDS was the ABC program, 
which stands for “Abstain, Be faithful, or use Condoms if A and B are not 
practiced. This program was mainly headed by Janet Museveni, the wife of the 
Ugandan President as part of George Bush’s ABC strategy for curbing the 
spread of the epidemic who said  “Giving young people condoms is 
tantamount to giving them a licence to be promiscuous; it leads to certain 
death”. However this approach does not go without its criticisms, Hillary 
Benn, the UK’s International Development Secretary who was in charge of 
Britain’s fight against AIDS abroad,436 stated that the ABC program ignores 
the fact that HIV/AIDS has long been associated with several human rights 
abuses. For example, in many developing countries where women are 
considered subordinate in society, they face the dangers of rape and engaging 
in unsafe sex. Hillary Benn’s unease was made unequivocal in a statement in 
2006 when he said “I wish we could have been a bit more frank in our 
declaration about telling the truth that some groups – like sex workers, drug 
users and men who have sex with men [who] are more at risk… This is not a 
time for telling it straight because it is about saving people's lives”.437 Critics 
have asserted that any discriminatory allocation of medications or funding for 
medications would constitute a violation of the obligation to respect the right 
to health.  
 
In 2003 the Bush administration introduced the President’s Emergency Plan 
for AIDS Relief (PEPFAR) with the aim of saving the lives of people infected 
with HIV by providing them with essential medicines and implementing 
initiatives to curb the spread of AIDS.  However like the ABC programme it 
has been criticised for its emphasis on abstinence and faithfulness being the 
                                                            
435 Kaleeba N, Kadowe JN , Lalinaki D, Williams G. Open Secret; People Facing  
436 http://www.commondreams.org/headlines04/0711-03.htm 
437 UK Mission To the United Nations New York (2006) 'Statement by Mr. Hilary Benn MP - 
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core of the programme.  Surprising as it may seem, even in the  21st century 
many people still believe that HIV/AIDS is a punishment from God for sexual 
immorality and a reprimand against gay people from a higher authority, thus in 
“Launch a Jihad Against [people with] AIDS”, the author writes that “The 
AIDS pandemic should not be considered simply as a disease for which a cure 
may sooner or later be discovered; it must be viewed in general as a serious 
sign and a grave warning for adopting a lifestyle of sexual abandon and drug 
intake, and that even if a cure or vaccine is discovered, new viral mutations 
will almost certainly surface if rampant promiscuity, homosexuality and drug 
abuse are not checked.”438  Critics have argued that governments should stop 
adopting policies that are ideologically and morally based, and begin to adopt 
scientific and rights based policies that will encourage access to medicines as a 
human rights for people living with HIV/AIDS. Although it is important to 
note that in 2008, the Bush Administration passed another legislation pledging 
50billion in funding through PEPFAR for AIDS, tuberculosis and malaria over 
a five year program. The legislation removed the controversial abstinence 
clause that had previously been sown into the 2003 law. 
 
Evidence suggests that governments which have an open and all-inclusive 
access to medicines policy are more likely to reverse the spread of HIV/AIDS 
and other opportunistic diseases.  A good example of a country which has been 
successful in curbing the spread of HIV/AIDS is the Brazilian’s government 
with its policy on free and worldwide access to anti-retroviral medicines 
(ARVs) for people living with HIV/AIDS.439  Since 1996, the Brazilian 
government initiated a program where free generic AIDS drugs have been 
made available to Brazilian citizens and death rates have fallen by more than 
                                                            
438 http://www.sodomylaws.org/usa/wackos/wacko034.htm 
439 Galvão J. Brazilian. (2002) policy for the distribution and production of antiretroviral 
drugs: a privilege or a right? [in Portuguese.] Cad Saúde Pública. 18:213–219, Galvão J. 
Community mobilization and access to medicines: the Brazilian non-governmental responses 
for the HIV/AIDS epidemic. Text presented at: Harvard Forum on Human Rights in Brazil, 
Brazil Human Rights Series: Rights to Health; November 3, 2003; Boston, Mass. 
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half. Likewise opportunistic infection has fallen by 60 - 80 percent and 
continues to fall dramatically. 440 In 1997, an estimated 35,900 people infected 
with HIV/AIDS in Brazil were receiving treatment, this number increased to 
55,600 in 1998. By 2001 the number increased to 105,000, it further increased 
to 140,000 in 2004.441 What has made Brazil stand out as a champion for 
protecting, enhancing and encouraging human right to health and access to 
medicines is that although Brazil is a middle-income country with a far smaller 
gross domestic product (GDP) than countries like the US, and  lower per capita 
health expenditures and technological investments than the UK.19 The  
Brazilian government provides ARVs to its citizens free of charge, an act 
which signifies the government’s total commitment towards halting the spread 
of HIV/AIDS and making the right to health care in the world a priority.   
 
Previously in Brazil, access to health care including medicines was based on 
“regulated citizenship”,442 a system whereby social rights like retirement 
pensions and medical coverage were restricted to private sector workers who 
were paid regular wages. The Brazilian government had created a system of 
social security based on obligatory contributions by employers and employees 
that was restricted to those that had a job.443 By doing this the majority of the 
population were ignored including people in sectors like agriculture,444 what 
this inevitably meant was that Brazil  had to run a health care sector which 
resembled a private health sector. Thus the system was based on the Eloi 
Chaves Law, and this effectively limited universal and equal access to 
medicines, however in the 1980s several health care experts and health reform 
advocates got into government positions and began to reform the health care 
                                                            
440 See Stephen Buckley (2000) Brazil Becomes Model in Fight Against AIDS, Wash. Post,  at 
A22 
441 Avert:  http://www.avert.org/aidstarget.htm  
442 Santos WG. Cidadania e Justiça. Rio de Janeiro, Brazil: Campus; 1979. 
443 Paulo Eduardo M. Elias, PhD, and Amelia Cohn, PhD. Reform in Brazil: Lessons to 
Consider. 
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sector by way of decentralizing the health care system. Change came in 1988 
when the Brazilian public health system was reorganised with the adoption of a 
new constitution. 445 The new Constitution brought with it the Unified Health 
System (Sistema Único de Saúde [SUS]).446 The SUS was instrumental in 
offering free comprehensive health care to the entire population, regardless of 
employment status or access to other forms of health insurance.  To sustain this 
policy, the government had to limit the drug high cost by producing some 
ARVs domestically and by consulting with international pharmaceutical 
companies to import other ARVs.447 The Brazil government response to 
HIV/AIDS has been phenomenon and the steps it has taken are seen as bold 
and ambitious by many and this has resulted in domestic industries producing 
at least five generic HIV/AIDS medicines.448 Not only that, but recently Brazil 
also made full use of the flexibilities within the TRIPS Agreement in the form 
of compulsory license. 
 
 In April 2007 Brazil issued a statement stating that it would be issuing a 
compulsory license to import Merck’s Efavirenz from India. Note that it is 
estimated that 210,000 people live with HIV/AIDS in Brazil and 180,000 are 
receiving free antiretroviral from the government, 38 percent of them use 
Efaviirenz.449 Efavirenz had been identified as one of the best choices for the 
initial treatment of HIV Treatment.450  The Brazilian government’s strategy for 
                                                            
445 Elias PE, Cohn A. (2003) Health reform in Brazil: lessons to consider. Am J Public 
Health.;93:44–48. 
446 Mattos RA. Os sentidos da integral-idade: algumas reflexões acerca dos valores que 
merecem ser defendidos. In: Pinheiro R, Mattos RA, eds. Os Sentidos da Integralidade na 
Atenção e no Cuidado à Saúde. Rio de Janeiro, Brazil: IMS/UERJ/ABRASCO; 2001: 39–64., 
Souza RR. O Sistema Público de Saúde Brasileiro. Brasília, Brazil: Ministry of Health; 2002. 
Available at: http://dtr2001.saude.gov.br/editora/produtos/livros/pdf/02_0784_M.pdf. 
Accessed April 4, 2005. 
447 Oliveira-Cruz V, Kowalski J, McPake B. (2004) Viewpoint: the Brazilian HIV/AIDS 
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providing access to medicines and controlling the costs of HIV/AIDS 
medicines has not been without challenges from the US and pharmaceutical 
companies.  In 2001 Brazil was involved in an international dispute about its 
program of access to AIDS medicines. 451In that year, the World Trade 
Organization (WTO) accepted a request for a panel by the United States, which 
was challenging Brazil’s patent laws. These laws in a nutshell permitted the 
compulsory license of patents under special conditions. At its heart, the US 
challenge brought into question Brazil’s commitment to producing ARVs 
nationally. The United States was concerned about the likely patent violations 
that would occur as a result of Brazil’s program, the dispute was however 
resolved amicably. 
 
The South Africa government faced a similar upheaval in 1997 when it 
attempted to pass its Medicines and Related Substances Act in order to allow 
the governments regulate the marketing and distribution of medicines in South 
Africa.  The law sought to allow the use of compulsory licensing and parallel 
importation of cheaper drugs and generic substitution for brand name drugs 
from countries such as Brazil and India. At the time there were at least 4.2 
million people living with HIV/AIDS in South Africa 452and the price for 
antiretroviral cocktails could cost between $10,000 to $15,000 per year, a price 
which was far more than what an average person living with HIV in South 
Africa could afford to pay.453 The issue was compounded when the 
pharmaceutical companies refused to provide the drugs to South Africans at a 
lower price or to allow them manufacture cheaper generic versions. The group 
of pharmaceutical companies argued that the Medicines and Related 
Substances Act would violate their ownership of drug patents and their 
intellectual property rights. The pharmaceutical companies further argued that 
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such infringement could undermine the funding of future scientific research.454 
When the South African government went ahead and passed the law, the 
Pharmaceutical companies filed a law suit against the South African 
government to prevent them from implementing the Act. There was of course 
an international public uproar and pharmaceutical companies were forced to 
drop the law suit in order to preserve their public image.455 The concern of 
many activist at the time were twofold, firstly they sought to confront the 
effects that intellectual property was having on access to AIDS drugs. 
Secondly they wanted to see a situation where governments in developing 
countries would be allowed to use the flexibilities within the TRIPS 
Agreement to gain access to cheap drugs for all epidemics that were 
confronting their nations.   Access to medicines in this case became not only a 
human rights issue, but a constitutional one.   South Africans had the 
constitutional right to human dignity, life and health care. The South African 
government felt the need to meet its obligation of realizing its citizen’s right to 
health care. 
 
Nigeria has no manufacturing capacity to produce any of the antiretroviral for 
PLWHA and must therefore enter into agreements with countries that produce 
generic AIDS medicines such as Brazil and India. In 2001, Nigeria entered into 
an agreement with an India-based manufacturer to offer low priced treatment 
to many HIV/AIDS patients despite resistance from multinational 
pharmaceutical companies. 456 Nigeria faces a grave situation with its fight 
against HIV/AIDS hence of the 600,000 people who are in need of 
                                                            
454 Ibid at 271 
455 Barbara Noah (2003) AIDS and Antiretroviral Drugs in South Africa: Public Health, 
Politics, and Individual Suffering: A review of Brian Tilley’s my life. 31 J.L. Med. & Ethics 
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antiretroviral medicines only 20,000 is receiving it.457  Nigeria is still 
struggling to establish the appropriate policies and approaches to deal with the 
HIV/AIDS crisis, some commentators assert that it is the Nigerian 
government’s national response that has fuelled the HIV/AIDS epidemic and 
other opportunistic diseases rather than the TRIPS Agreement.  Senegal for 
example also recorded the presence of  HIV/AIDS in their nation in 1986, the 
same year that Nigeria did. However they have managed to keep their 
HIV/AIDS prevalence level at a low of 2%.458  
 
5.7 The Nigerian Government’s National Response 
The government’s national response has passed through different stages in 
Nigeria. Real efforts and government commitment began in 2001 after the 
Doha Declaration, when the government began to allocate human and financial 
resources to prevent of the halt the epidemic. The Nigerian civil society 
organisations (CSO) and other international organisations became involved in 
finding a solution to the health crisis. Consequently the HIV/AIDS Emergency 
Action Plan (HEAP)459  was established in 2001 which pursued a multisectoral 
national response to HIV/AIDS. The program provided for HIV prevention 
intervention, research efforts and demonstration service delivery projects 
which were at the time seen as the solution to a successful national response of 
any country HIV/AIDS management program.460  
 
The response was divided into a public and civil society national response. The 
public sector response to the HIV/AIDS epidemic began with the FMOH co-
ordinating the national response. The health sector HIV/AIDS strategy was co-
                                                            
457 AIDS Funding on the Ground in Nigeria 
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458 UNAIDS, UNAIDS report for 2003: most deaths and new infection ever; some good news. 
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459 Federal Government of Nigeria. National Policy on HIV/AIDS. Abuja: Federal 
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ordinated by the Department of Disease Control and the major focus was on 
prevention and health promotion (this involved offering support for the 
advancement of broad-based programs to teach the general population about 
HIV/AIDS, targeting intervention to high risk groups), treatment (this involved 
increasing access to services to diagnose and manage STIs) health standards 
and health systems (this involved setting up national standards for the public, 
private and community-based delivery of HIV/AIDS prevention, health 
promotion, and treatment and care) and  informed policy and strategic 
development (which consisted of establishing and strengthening and 
behavioural surveillance for HIV and other STIs and rallying communities, 
NGOs, People living with HIV and AIDS (PLWHAs), vulnerable groups, and 
other business sector). 
 
However the change of strategy came when the Nigerian government sought to 
concentrate on a multisectoral national HIV/AIDS response under HEAP 
2000-2004.  HEAP involved the development of national policies, monitoring 
HIV/AIDS and other sexual transmitted diseases, co-ordination of 
development partners, blood safety and more importantly access to medicines 
for people that were already living with HIV/AIDS as well as PMTCT. The 
HEAP was fundamentally successful because for the first time in Nigeria, 
political commitment and co-operation was given to alleviate the epidemic by 
the president, politicians and other governmental officials without question or 
reluctance. This was immediately after the re-establishment of democracy in 
the form of a civilian rule under President Olusegun Obasanjo in 1999. The 
president established the Presidential Committee on AIDS which include 
several governmental ministries and technical experts.  At the federal level 
National Action Committee on AIDS (NACA) dealt with HIV/AIDS 
prevention and control, at the state level co-ordination was done through state 
action committee on AIDS (SACAs) and on the local level this was managed 
by the local Action committee on AIDS (LACAs).  Some of the features that 
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made the HEAP successful were the development of skills and the availability 
of resources. Nigeria was able to attract funding from the World Bank, 
USAID, DFID, the Bill and Melinda Gates Foundation, and the Ford 
Foundation. The government was able to attract a budget to the tune of 
$236million, apart from the $40 million national government contribution that 
budgeted over a three to five year period.461 The fact that several international 
projects began in the country at the same time meant huge success and more 
access to ARVs for people with HIV/AIDS. Nevertheless HEAP was again 
reviewed in 2004 where many gaps were identified. Access to services for 
PMTCT and ARV treatment were found to be lacking; states were not 
adequately motivated to action, and co-ordination in the centre was 
insufficient. A new plan known as the National HIV/AIDS Strategic 
Framework was thereby established in 2005. Also worth noting is the Nigerian 
National Response Information Management System for HIV/AIDS 
(NNRIMS) which was set up by NACA to monitor, evaluate and report on 
HIV/AIDS initiatives and their impact on the country.  Such initiatives point to 
a struggling nation undergoing a “national emergency” and fighting to provide 
help to her citizens and access to medicines regardless of the cost of 
medication and health services. 462 
 
Mother to child transmission of HIV was and still is a huge major public health 
crisis in Nigeria. In 2001, the FMOH initiated a national PMTCT programme 
and the service provision began in July 2002 in eight tertiary institutions in the 
six geo-political zones of Nigeria (namely North West, North East, Central 
North, South East, South West, and South South) with the assistance of the 
AIDS Prevention Initiative in Nigeria (APIN) and United Nation Children 
Fund (UNICEF), although by 2005 and with the help of the United States, the 
                                                            
461 Ibid at 249 
462 Federal Ministry of Health. Nigeria National Response Information Management System 
(NNRIMS) Guidelines and Indicators.  Abuja: Federal Ministry of Health, 2004 
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number of sites had increased to 66 sites.463 The co-ordination of the program 
is principally done by the FMOH, the task team which comprises of obstetrics, 
gynaecologist, paediatrics and nurse, and core partners provide technical and 
financial assistance to the program. The program has one of the most efficient 
monitoring and evaluation systems and provides nevirapine prophylaxis which 
is essential in reducing transmission, although it has been suggested that ARV 
regimen has to be reconsidered in the breastfeeding population, whilst the use 
of the triple therapy –zidovudine, stavudine, and nevirapine of highly active 
antiretroviral therapy (HAART) for HIV positive women.   The goal of the 
National PMTCT Programme in Nigeria is to reduce the transmission of HIV 
from mother to child. The objectives of the programme include: to ensure that 
50% of HIV positive pregnant women and their babies access ARV by 2010 
for PMTCT; to increase access to obstetric practices that reduce the risk of 
mother to child transmission of HIV by 50% by 2010 and ensure that all HIV 
positive mothers, their partners and all HIV infant gain access to ARV.   
 
Interestingly, the Federal government response to HIV was considered to be 
efficient, so much so that by 2001, the national AIDS program in Nigeria was 
proclaimed the largest antiretroviral treatment program in Africa with an 
annual allocation of $3.7 million for the procurement of ARVs from India. 464 
In 2002 the Nigerian government started an ambitious ARV treatment 
programme to get 10,000 adults and 5000 children unto ARV within a year.465  
An initial $3.5 million worth of ARV were imported from India and delivered 
at subsidized monthly cost of $7 per person. In 2004, the programme suffered a 
major setback when it was hit by a shortage of drugs.  This meant that some 
                                                            
463 SCALE UP PLAN On Prevention of Mother to Child Transmission (PMTCT) of HIV in 
Nigeria. Federal Ministry of Health. 2005 
464 See Abantu for Development. Empowering Youth Through Comprehensive Reproductive 
Health Programs. London/Accra: Abantu for Development,( 2004) and ActionAid/Nigeria. 
Mapping Civil Society’s Involvement in HIV/AIDS Programmes in Nigeria. Abuja: Action 
Aid, 2001 
465 Odutolu, O, Ahonsi, B.A, Gboun, M & Jolayemi, O.M (2006) AIDS in Nigeria: A nation on 
the threshold’. Chapter 11: The National Response to HIV/AIDS. Harvard Centre for 
Population and Development Studies. 
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people did not receive treatment for up to three months.  Eventually, another 
$3.8 million drugs were then ordered and the programme resumed.  In 2001, 
Ranbury Nigeria, a subsidiary of Ranbury India, India’s largest pharmaceutical 
company signed an agreement with the Nigerian government to supply ARVs 
manufactured at its plant in Lagos. In the same light, in 2004 Archy 
Pharmaceutical also set up a plant to manufacture ARVs in Lagos.  These 
efforts were made to increase the availability of ARVs to people in Nigeria and 
other West African Countries.466 The significance of these establishments 
cannot be overstated because it shows a commitment to confronting the 
problem of a lack of medicines for people living with HIV/AIDS. Similarly 
developments have shown the possibility of a widespread therapy for 
HIV/AIDS in the country. The price of advanced antiretroviral (ARV) drugs 
which can effectively suppress the AIDS virus in infected people has fallen 
from $12,000 to under $200 per year.  In addition, ARV treatment regimens 
have been greatly simplified by decreasing dosing and monitoring requirement 
and decreased toxicity.  
 
The Nigerian government has in recent time’s demonstrated clear and solid 
commitment to providing antiretroviral (ARV) treatment to people living with 
HIV/AIDS.  Public health expenditure increased from 0.3 percent of GDP in 
1996, the lowest of any country in the world, to 0.5 percent of GDP in 
2000.467. However despite Nigeria’s staunch efforts in fighting the disease, 
there is still much to be done in scaling up HIV/AIDS services. AS at 2004, 
few Nigerians still had access to basic HIV/AIDS prevention, care, support or 
treatment services.  Around 520,000 people are estimated to require ART 
(antiretroviral therapy) and only 170,000 are currently receiving treatment.  As 
2004, there were 50 treatment sites for HIV/AIDS in Nigeria.468 According to 
Luppe’s report, patients lucky enough to be included in Nigeria’s national 
                                                            
466 Reuters News Media 2004 
467 (UNDP 2003) 
468 PlusNews, 2005 
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treatment programme paid 1,000 Naira (US $7) per month for their ARV 
drugs.469 However, this fee did not cover the cost of drugs required to treat 
opportunistic infections, nor frequent laboratory tests which were necessary 
and had to be paid for separately. Although, there have been substantial efforts 
from international organizations, one of such organisations is the Ford 
Foundation which has worked closely with national governments to create 
deep talent pools of professional and community leaders knowledgeable about 
the best practices for preventing and treating HIV/AIDS and supporting them 
in taking action to assist those living with the diseases; in so doing ensuring 
equal access to HIV prevention.470 Other international efforts to provide ARV 
to people living with HIV/AIDS include PEPFER’s pledge to put 120,000 
people on ARV between 2006 and 2011, and the Global Fund grant which has 
been instrumental in giving people living with HIV/AIDS hope.  
 
Another major channel through which Nigeria has sought to confront 
HIV/AIDS epidemic is through civil societal interventions. Such intervention 
has come mainly from faith-based and community based organisations that 
operate on a small-scale care and welfare system.471  Other interventions have 
come from Nigerian civil society organisations. A good example is the 
STOPAIDS which is a Lagos based CSO launched an HIV prevention 
education which branches in Onitsha, Lagos, and Port-Harcourt for long-
distance truck drivers.  The civil society areas of concentration have been 
mainly focused on condom use promotion, youth-focused intervention, people 
living with HIV/AIDS care and support, including organising for self-help and 
advocacy, HIV prevention and VCT among high-risk groups, mass media 
engagement, training and mobilization and legal reform advocacy and legal aid 
                                                            
469 Plus News, 2005 
470 FORD FOUNDATION. HIV/AIDS. http://www.fordfound.org/fields/hivaids/overview 
471 Ahanihu E. Closing Ranks: An Account of Nigeria’s Response to HIV/AIDs, 1986-2003. 
Ibadan: Spectrum Books. 2005 and Touray KS. Mapping of Support Groups for People Living 
with HIV/AIDS (PLWHAs) in Nigeria: National Report. Abuja: National Action Committee 
on AIDS, 2005 
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for people living with HIV/AIDS.  The Nigerian chapter of the Society Women 
and AIDS in Africa (SWAAN) has also provided prevention education, 
voluntary HIV counselling and community home-based HIV care service 
among low-income women across Nigeria, including sex workers.472  The 
media has also played a huge part in promoting access to medicines for people 
living with HIV/AIDS.  Also worth mentioning has been the work done by the 
Journalists Against AIDS (JAAIDS). JAAIDS was formed in 1997 and sought 
to contribute to the prevention, care and control of HIV in Nigeria by 
educating and building the skills of media professionals reporting on AIDS and 
pursing media-based advocacy.  The most significant advocacy campaign 
embarked by JAAIDS has focused on the issue of access to HIV treatment and 
community participation in stigma reduction. These efforts still have a long 
way to go in making a real difference when compared with the prevalence of 
HIV/AIDS in the sub-Sahara.473 
                                                            
472See  Mba ND. Youth for Youth, Gender and Development NGOs: Report of a mapping 
Exercise Prepared for the Ford Foundation. Ford Foundation, 2004 and Society for Women 
and AIDS in Africa Nigeria. SWAAN Profile. 2003 
473 Table below is from AVERT http://www.avert.org/subaadults.htm and it states that an 
estimated 22 million adults and children were living with HIV in sub-Saharan Africa at the end 
of 2007. The estimated number of adults and children living with HIV/AIDS, the number of 
deaths from AIDS, and the number of living orphans in individual countries in sub-Saharan 
Africa at the end of 2007 are shown below.  
Country 
People living 
with 
HIV/AIDS  
Adult 
(15-49) 
rate % 
Women with 
HIV/AIDS  
Children 
with 
HIV/AIDS 
AIDS 
deaths 
Orphans  
due to 
AIDS 
Angola 190,000 2.1 110,000 17,000 11,000 50,000 
Benin 64,000 1.2 37,000 5,400 3,300 29,000 
Botswana  300,000 23.9 170,000 15,000 11,000 95,000 
Burkina Faso 130,000 1.6 61,000 10,000 9,200 100,000 
Burundi 110,000 2.0 53,000 15,000 11,000 120,000 
Cameroon 540,000 5.1 300,000 45,000 39,000 300,000 
Central 
African 
Republic 
160,000 6.3 91,000 14,000 11,000 72,000 
Chad 200,000 3.5 110,000 19,000 14,000 85,000 
Comoros <200 <0.1 <100 <100 <100 <100 
Congo 120,000 3.5 43,000 6,600 6,400 69,000 
Côte d'Ivoire 480,000 3.9 250,000 52,000 38,000 420,000 
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Whilst both the public and private sector of Nigeria can be commended for its 
courageous and ambitious HIV/AIDS programs which have contributed to 
                                                                                                                                                            
Dem. Republic 
of Congo 
400,000- 
500,000 
1.2- 
1.5 
210,000- 
270,000 
37,000- 
52,000 
24,000- 
34,000 
270,000- 
380,000 
Djibouti 16,000 3.1 8,700 1,100 1,100 5,200 
Equatorial 
Guinea  11,000 3.4 5,900 <1,000 <1,000 4,800 
Eritrea 38,000 1.3 21,000 3,100 2,600 18,000 
Ethiopia 980,000 2.1 530,000 92,000 67,000 650,000 
Gabon 49,000 5.9 27,000  2,300 2,300 18,000 
Gambia 8,200 0.9 4,500 <1,000 <1,000 2,700 
Ghana 260,000 1.9 150,000 17,000 21,000 160,000 
Guinea 87,000 1.6 48,000 6,300 4,500 25,000 
Guinea-Bissau  16,000 1.8 8,700 1,500 1,100 6,200 
Kenya 1,500,000- 2,000,000 
7.1- 
8.5 
800,000- 
1,100,000 
130,000- 
180,000 
85,000- 
130,000 
990,000- 
1,400,000 
Lesotho  270,000 23.2 150,000 12,000 18,000 110,000 
Liberia 35,000 1.7 19,000 3,100 2,300 15,000 
Madagascar 14,000 0.1 3,400 <500 <1,000 3,400 
Malawi  930,000 11.9 490,000 91,000 68,000 560,000 
Mali 100,000 1.5 56,000 9,400 5,800 44,000 
Mauritania 14,000 0.8 3,900 <500 <1,000 3,000 
Mauritius 13,000 1.7 3,800 <100 <1,000 <500 
Mozambique 1,500,000 12.5 810,000 100,000 81,000 400,000 
Namibia 200,000 15.3 110,000 14,000 5,100 66,000 
Niger 60,000 0.8 17,000 3,200 4,000 25,000 
Nigeria  2,600,000 3.1 1,400,000 220,000 170,000 1,200,000 
Rwanda 150,000 2.8 78,000 19,000 7,800 220,000 
Senegal 67,000 1.0 38,000 3,100 1,800 8,400 
Sierra Leone  55,000 1.7 30,000 4,000 3,300 16,000 
Somalia 24,000 0.5 6,700 <1,000 1,600 8,800 
South Africa  5,700,000 18.1 3,200,000 280,000 350,000 1,400,000 
Swaziland  190,000 26.1 100,000 15,000 10,000 56,000 
Togo 130,000 3.3 69,000 10,000 9,100 68,000 
Uganda 1,000,000 6.7 520,000 110,000 91,000 1,000,000 
United Rep. Of 
Tanzania 940,000 5.4 480,000 130,000 77,000 1,200,000 
Zambia  1,100,000 15.2 560,000 95,000 56,000 600,000 
Zimbabwe 1,300,000 15.3 680,000 120,000 140,000 1,000,000 
Total sub-
Saharan Africa 22,000,000 5.0 12,000,000 1,800,000 1,500,000 11,600,000 
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reducing in ARV prices globally. Other challenges that Nigeria has had to face 
in providing access to medicines include budgetary shortfalls and 
discontinuous release of funds, inventory control and distribution problems, 
inadequate laboratory backstopping, human resource scarcity and training 
deficiencies, health care infrastructure deficits, inadequate involvement of 
people living with HIV/AIDS and related community groups, poor technical 
guidance, support and co-ordination for all treatment centres to forge a 
comprehensive ARV program474 and counterfeit medicines.475  
 
5.8 NACA 
One of the most recognised efforts that have been made by the Nigerian 
government to combat the HIV/AIDS epidemic is through the work of 
National Action Committee on AIDS (NACA). The advert of democracy in 
1999 in Nigeria brought with it a renewed commitment to tackle the public 
health problem of the nation and in 2001, the government set up a three-year 
HIV/AIDS Emergency Action Plan (HEAP). In the same year, the government 
hosted OAU’s first African Summit on HIV/AIDS, Tuberculosis, and Other 
Related Infectious Diseases476. Both gestures indicated an unprecedented 
national response to the HIV/AIDS epidemic that was ravaging the country at 
the time.  In 2004, NACA launched a five year behavioural change 
communication strategy to combat the spread of HIV/AIDS through the 
National Strategic Framework (2005-2009), NACA has also set up Nigerian 
National Response information Management System Operational Plan, which 
has 9 Specific Objectives that are listed below: 
                                                            
474 Ibid at pg 257 
475 This will be discussed in detail below. 
476 Adeyi et al. (2006) AIDS in Nigeria: A nation on the threshold’. Chapter 2: The 
epidemiology of HIV/AIDS in Nigeria. Harvard Center for Population and Development 
Studies. 
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1. 1. To develop the requisite infrastructure for monitoring and evaluation 
in Nigeria 
2. To develop the required human resource capacity across levels of the 
national response. 
3. To harmonize indicators and standardize data tools and collection 
systems. 
4. To coordinate and strengthen second generation surveillance and 
HIV/AIDS operational research. 
5. To develop a database or clearing house for all strategic information 
on the national response. 
6. To define clear roles and responsibilities in monitoring and evaluation 
across different levels and sectors of the system  
7. To facilitate efficient data transmission and feedback flow 
8. To outline how data collected by NNRIMS should be used 
9. To mobilize adequate financial and material resources to support full 
operationalization of the monitoring and evaluation plan (2007- 2010)  
NACA’s response to the HIV/AIDS has been nationwide and is done through a 
multi-sectoral platform of network activity which involves the National Policy 
on AIDS, the BBC Strategy, Work Place Policy, The Vaccine Plan, the Policy 
on Ethics for Human Research, the Policy Environment –Sectoral Plans, the 
Health Sector Plan, the Education Sector Plan, the AFPAC policy and Plan, the 
Ministry of Internal Affairs Plan –Prisons, Immigration and Civil Defence, the 
National Commitment, NEEDS and SEEDS.   
 
NACA also has the full support of other international organisations including: 
The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), The 
World Bank – MAP and the Malaria Initiative, US President’s Emergency Plan 
for AIDS Relief (PEPFAR) & US President Malaria programme, The Bill and 
Melinda Gates Foundation and other development partners - DFID, JICA, The 
French Cooperation, CIDA and other international bodies who are committed 
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to helping the Nigerian government reverse the Spread of HIV/AIDS in the 
country. 
 
NACA has also sought to raise awareness that AIDS is real through campaigns 
targeted at Behavioural  CHANGE including  FLHE, zip up, condom,. It has 
set up condom vending machine as well as voluntary counselling and testing; 
other efforts include PMTCT, providing treatment in the form of OIs, ARVs. 
 
NACA has promoted its campaign through the National Youth Network, 
CISHAN, NEPWHAN, Faith Based Advisory Council and the public sector  
which comprises of 28 line ministries and the Primary Health Care 
Development Agency. Interesting enough NACA has recorded results in 
Increasing 85% in both urban and rural areas. NACA has recorded behavioural 
changes, for example the ages in which young people are first having sexual 
intercourse has risen, the number of people using condoms when have extra 
marital sex has risen to 61%, sex workers have increased the usage of condoms 
to 83%, and there are  now over 160 ART Sites. Indeed the new government 
under the presidency of Umaru Musa Yar’Adua which began in 2007 has 
continued to work already began by the last administration of trying to tackle 
the HIV/AIDS epidemic. Whether the national response of the Nigerian 
government will amount to a reversal of the HIV/AIDS epidemic remains to be 
seen and will be judged by the target it has set itself of reducing HIV 
prevalence by 25% by 2010, preventing 55% of new HIV infections by 2010, 
placing 550,000 HIV positive persons on treatment by 2010 and providing care 
and support services for 1.6 million HIV positive persons by 2010. 
 
5.9 Summary  
The Nigerian government has struggled to come to terms with initiating ways 
of tackling the HIV/AIDS epidemic, nevertheless there continues to be a high 
percentage of people living with the diseases. The issue of HIV/AIDS is 
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clearly a human rights issue which is supported by section 17 (3) (d) and 33 of 
the Nigerian Constitution, however the government has in the past struggled to 
fulfil these obligation with regards to providing medicines for its citizens. 
Although the government must be commended for adopting a miltisectoral 
approach which has sought to get international bodies, private charities, NGOs, 
civil societies, private sectors and private individuals involved in the fight for 
access to medicines, it still has some way to go before it can reach its NACA 
objectives of reducing HIV prevalence by 25%, preventing 55% of new HIV 
infections, placing 550,000 HIV positive persons on treatment and providing 
care and support services for 1.6 million HIV positive persons by 2010 or the 
Millennium Development Goals (MDGs) of access to medicines for all 
HIV/AIDS patients by 2015. 
 
Empirical evidence of countries that have succeeded in drastically reducing the 
prevalence rate of the HIV/AIDS epidemic show that countries must put in 
place laws so that the rule of law and due process can be the cornerstone of all 
its policies and initiatives. This in turn enables the government to meet its 
obligation. The Brazilian government has succeeded in curbing the spread of 
HIV/AIDS with its policy on free and worldwide access to anti-retroviral 
medicines (ARVs) for people living with HIV/AIDS.477 To sustain this policy, 
the Brazilian government had to limit the drug high cost by producing some 
ARVs domestically and by consulting with international pharmaceutical 
companies to import other ARVs. Today Brazil domestic industries produce at 
least five generic HIV/AIDS medicines.  Although Nigeria relies on help from 
international organisations and donors in order to purchase ARV medicines, 
the question remains will it continue to rely on them to provide medicines for 
the millions of people that will need access to medicines? If Nigeria amended 
                                                            
477 Galvão J. (2002) Brazilian policy for the distribution and production of antiretroviral 
drugs: a privilege or a right? [in Portuguese.] Cad Saúde Pública.  18:213–219, Galvão J. 
Community mobilization and access to medicines: the Brazilian non-governmental responses 
for the HIV/AIDS epidemic. Text presented at: Harvard Forum on Human Rights in Brazil, 
Brazil Human Rights Series: Rights to Health; November 3, 2003; Boston, Mass. 
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its patent laws and became TRIPS compliant, it would be able to take 
advantage of the flexibilities within the TRIPS Agreement to meet its human 
rights obligations, which in my opinion is a great place to start to meet all other 
obligations that may arise with ensuring access to medicines for Nigerians.  
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6 NEGLECTED DISEASES, DRUG COUNTERFEITING 
AND HUMAN RIGHTS 
6.1 Introduction 
The human rights community is becoming increasingly aware of neglected 
diseases and addressing problems associated with access to drugs. 
Professor Paul Hunt 
 
The most dangerous goods on the market  are counterfeit drugs and ‘People are 
interested in getting a profit, but this is a human rights issue...the consequences 
of this business are really immense... a person with severe malaria: if he or she 
cannot access the genuine drug, then it means they may die. 
Edith Ngirwamungu, president of the Medical Association of Tanzania. 
 
This chapter seeks to address neglected diseases and counterfeit medicines as 
human rights issues in the access to medicine debate. It seeks to do this in 
order to identify whether these are the real obstacles to accessing medicines as 
opposed to the TRIPS Agreement. In doing this, the chapter examines what 
challenges other jurisdictions have encountered in solving the problem of 
neglected diseases as well as confronting the problem of counterfeit medicines.  
The way that it seeks to do this is by confronting the issues as two distinct 
international issues that need an all round response by both states and non-state 
actors such as NGOs and the private sector. By examining the problem of 
counterfeit medicines on a state by state level, the reader is able to better 
appreciate the access to medicine problem as an international problem which 
needs  international solution. 
 
Recently the international community has called for the issue of neglected 
diseases to be given more consideration and solutions found. Thus in April 
2003, the UN Commission and the UN General Assembly passed a human 
rights resolution on neglected diseases to specifically recognise the need for 
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“further international corporation and research to promote the development of 
new drugs, vaccines and diagnostic tools for diseases causing a heavy burden 
in developing countries, and stresses the need to support these countries in 
their efforts in this regard, taking into account that the failure of market forces 
to address such diseases has a direct negative impact on the progressive 
realization in these countries of the right of everyone to the highest attainable 
standard of physical and mental health”478 In the same manner the international 
community has called out for  solutions to be found for the global trading in 
counterfeit drugs which has claimed the lives of so many.  
 
Whilst many commentators have called for WHO to actively get involved in 
counterfeit medicines as a serious public health crisis, concerns that counterfeit 
can only be tackled as a violation of IP rights issue have remained unanswered. 
Paraguay on behalf of the Latin American and Caribbean countries 
(GRULAC) put it succulently when she said“ Counterfeit is an infringement of 
an IP right [and] injures a rights holder of a trademark ... the typification of this 
infringement does not include health criteria.”479  That being said the fact that 
counterfeit is a human right to health issue that cannot in my opinion be 
ignored. The confusion extends to the direction that the international law 
enforcement agency INTERPOL and IMPACT should be following in order to 
tackle the problem. Whilst reports shows that INTERPOL is investing more 
effort and attention to Africa as the main target markets for counterfeit traders 
because of  the high level of corruption, unregulated medicines and poverty, 
evidence point to the fact that most  counterfeit medicines come from China 
and other Asian countries where the penalty for trading in counterfeit 
medicines is not efficiently checked by the government. Whilst Nigeria has 
played a tremendous role in reducing the trade of counterfeit drugs in Nigeria 
through the work of NAFDAC and its active role in IMPACT, a lot still 
                                                            
478 
 
UN General Assembly, A/C.3/58/L.53, 17 November 2003, para.13.   
479 Mara. K (2008) Hope for Consensus on WHO And Counterfeits Moves To May Assembly. 
Intellectual Property Watch. 9 December 2008.  
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remains to be done in order to completely eradicate the trade in counterfeit 
drugs. The situation is made more serious by the fact that China is becoming a 
world power480 and has began to form strong ties with Nigeria and many other 
African countries.  Thus as Chinese government and companies sign more 
contracts with African leaders to build more roads, import goods and mine 
natural resources, the fear remains that there will be more avenues for the 
influx of counterfeit medicines if the situation is not tackled in the near future.  
It is with this background in mind that this chapter tackles the access to 
medicines problem. 
 
6.2  Neglected Diseases: a Symbol for Neglected People 
Neglected diseases are a group of tropical disease that are deadly and 
widespread, yet have no sufficient treatment and affect a large number of 
people who are often deprived and live in low income developing countries.481 
People suffering from neglected diseases often lack affordable or easy to use 
drug treatment because they are usually too poor and cannot afford to pay for 
medications.482  What makes the case for neglected diseases more disturbing is 
that most of the diseases that affect low income developing countries can be 
treated or prevented with medicines, however pharmaceutical companies have 
in the past been reluctant to conduct R&D into neglected diseases.483The 
inability for poor countries to pay for the medication generally has acted as  a 
deterrent for pharmaceutical companies who have no interest in investing in a 
market where they cannot make financial profits.484 Whilst the pharmaceutical 
industries have generally tried to stay away from investing in neglected 
diseases, they have found R&D into life-style drugs (life style drugs is a term 
                                                            
480 Reports show that China will rival US as world power by 2010. Chinadialy.com.cn. 
Updated 2006-06-02 . http://www.chinadaily.com.cn/china/2006-06/02/content_607496.htm 
481 Hunt, P. (2003)  Neglected Diseases, Social Justice and Human Rights: Some Preliminary 
Observations.  Health and Human Rights Working Paper Series No 4.  
482 Yamey. G. (2002) The world’s most neglected diseases Ignored by the pharmaceutical 
industry and by public-private partnerships. BMJ; 325:176-177 (27 July) 
483 J Drews, trans D Kramer (2003)  In Quests of Tomorrows Medicines : 234 
484 Neglected Diseases.  http://www.answers.com/topic/neglected-diseases 
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which is generally used by the media to target “medical conditions” which are 
considered unworthy of treatment. Lifestyles medicines includes medications 
which treat conditions such as baldness, impotence, wrinkles, and obesity) 
particularly attractive.485  
 
Pharmaceutical companies have also found it particularly attractive to invest in 
“evergreening”.  Thus the EGA report on patent-related barriers has expressed 
concern that the ‘evergreening’ technique can and is being used as a way to 
have follow-on patents and  keep generic competitors off the market. These 
follow-on patents are often weak or trivial and, upon careful examination 
should not be granted patents)486 and modification of chemical entities 
marketed by competitors to obtain a drug in an existing market.487 
 
Neglected diseases fall amongst the three categories of diseases affecting the 
world today. The other two are global diseases (like cancer, diabetes and 
cardiovascular diseases which affect people both in developed and developing 
nations and usually forms the major focus of pharmaceutical industries around 
the world) and most neglected diseases which are totally ignored by 
pharmaceutical companies and public- private partnerships.488 
 
Statistics show that between 1975 to 1999, only 13 drugs out of 1,393 New 
Chemical Entities (NCE) marketed were aimed at neglected diseases.489 Out of 
the 13 drugs, only 4 were for the treatment of malaria and nine for other 
neglected diseases.490 By 2003 only 26 NCE for neglected diseases had been 
                                                            
485 Wikipedia http://en.wikipedia.org/wiki/Lifestyle_drug.  
486 EGA REPORT | May 2008. Patent-related Barriers to Market Entry for Generic Medicines 
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487  Holmer, A.F  (31 May 2002) Innovation is Key Mission’ USA Today  
488  Yamey. G (2002) The world’s most neglected diseases Ignored by the pharmaceutical 
industry and by public-private partnerships. BMJ; 325:176-177 (27 July) 
489 Deficient market and a public-health policy failure.  See Trouiller, P. et al. (2002) Drug 
development for neglected diseases: a deficient market and a public-health. Lancet, 359, 2188–
2194: 
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developed from a total of 1556 NCEs produced between 1975 and 2004. It 
follows that investments in health R&D have never been higher nevertheless 
only a small percentage of that money has actually been spent on developing 
medicines for tropical diseases. This has raised much concern for human rights 
activists and academics alike. Similarly global spending on health research has 
increased from US$30 billion in 1990 to US$105.9 billion in 2001. Further 
statistics also show that tropical diseases which often fall in the category of 
neglected diseases account for 90% of the global disease burden, but only 10% 
of the world's health budget was spent on it.491  Of the 10%, kudos must go to 
India and China who have some of the biggest generic industries  because most 
of the NCEs were derived from  their efforts and the fact that they also face the 
same health issues and have had to find medicines for neglected diseases has 
added to their minor R&D interest. 
 
Although, India has demonstrated some interest in developing NCEs for 
neglected diseases through its strong innovative capabilities in developing 
manufacturing processes and has increased its R&D into new drug 
development. On the down side is the fact that India is not engaged in the 
entire process of drug development because they lack the skills and resources 
to do so.  This has made India follow the bandwagon of MNCs and made the 
Indian pharmaceutical companies focus on drugs that are targeted at diseases 
that affect high-income countries as opposed to neglected diseases that affect 
poor developing counties.492 Another major factor that has contributed to the 
lack of medicines for neglected diseases is the fact that the pharmaceutical 
environment is a highly competitive global market place and this has turned 
drugs from being used as a public health tool into a profit making 
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commodity.493 Thus the absence of R&D into medicines to treat diseases that 
affect mainly people in developing countries are evidence of the fact that the 
priorities of pharmaceutical companies  are highly guided by market prospects 
and benefits494  and the attitude of “no profit - no cure”  has become the 
norm.495    
 
6.3 R& D for Neglected Diseases  
 Drug production has been left mainly in the hands of the private sector has 
compounded the problem of lack of R&D for medicines that are needed in 
many poor countries.496  Jeffrey Sachs stated that “poor country governments 
lack the means to subsidize R&D, and patent protection means little when 
there is no significant marketer at the end of the process. The result is that the 
R&D for diseases specific to poor countries tends to be grossly underfinanced. 
The poor countries benefit from R&D mainly when the rich also suffer from 
the same diseases.”497 
 
 In the early twentieth century neglected diseases posed a constant threat to 
armies during the wars, foreign settlers, and European business communities 
who were stationed in developing countries were also at risk from tropical 
diseases. Overcoming tropical diseases was therefore a vital necessity that 
concerned the colonial ‘masters’. It was with this objective that the London 
and Liverpool Schools of Tropical Medicine were established in 1899 to study 
tropical disease to treat the many British citizens who were dying of tropical 
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diseases This case is clearly pointed out by the availability of medicines for 
malaria and tuberculosis (note the word used is availability not 
affordability).498For example many people in developing countries cannot 
afford to pay for malaria drugs, however most of the westerners that travel to 
developing countries can. In the same way, many people who have 
tuberculosis in developing countries may not be able to pay for treatment but 
there are sufficient patients in developed countries to persuade pharmaceutical 
companies to invest in medicines for tuberculosis. All the same, developing 
countries still find it difficult to gain access to medicines for diseases suffered 
in both developing and developed countries. Thus statistics show that 611,000 
people die from measles each year, 155,000 from syphilis, and 1,778,000 from 
diarrhea in developing countries. Note that in developed countries people 
rarely die from such diseases, they are more likely to die from global diseases 
such as cancer and heart diseases 499  The fact that people affected by neglected 
diseases are therefore at the mercy of the pharmaceutical industry that set the 
agenda for drug development and R&D is therefore undisputed. 
 
It follows that whilst HIV/AIDS, tuberculosis and malaria (known as the Big 
Three) receive a lot of media attention as neglected diseases which more R&D 
and the attention of the international community, the argument follows that 
other neglected diseases need the same level of media attention as well.  Thus  
Professor Molyneux argues that political and media attention over the last few 
years have led to resources to conduct R&D  being transferred to fight  the "big 
three" which only has  a limited chance of success, other  disease such as  
Kala-azar (Leishmaniasis),  African Sleeping Sickness (African 
trypanosomiasis), Chagas disease (American trypanosomiasis) , Lymphatic 
Filariasis (elephantiasis) , Onchocerciasis (river blindness) , Drancunculiasis 
(guinea worm) , helminthiases:, Ascariasis (roundworm) , Trichuriasis 
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(whipworm), Hookworm , Leprosy, Buruli ulcer and  Trachoma are  being 
ignored.  
 
6.4 Tuberculosis 
Tuberculosis is one of the most widespread diseases in the developing world 
and one of the leading infectious killers after HIV/AIDS, thus it puts the 
serious need to find medicines for neglected diseases into perspective. In 1993, 
WHO confirmed that tuberculosis presented a global health emergency, by 
2006 many developing countries including the federal government of Nigeria 
had declared the diseases a national emergency.500  The WHO Global 
tuberculosis Control Report in 2006 showed that they were approximately 9.2 
million new cases of tuberculosis,501 the same report showed that 1.7 million 
people had died of tuberculosis in 2006 of which 14% were HIV-positive.502  
 
Tuberculosis is the leading killer of people living with HIV/AIDS and the 
inadequacy of tools to diagnose and treat tuberculosis has been a major threat 
to the health and lives of HIV/AIDS and tuberculosis co-infected people.503 At 
the 17th International Conference in Mexico, respondents called for new 
strategies such as expanded screening in health care setting to have early 
diagnosis of HIV and tuberculosis.504 Reuters report notes that patients with 
HIV/AIDS are 50 times more likely to develop tuberculosis than those who do 
not have HIV, however the Report showed that only 314,394 people had been 
tested for tuberculosis out of the supposed 33 million HIV-positive people who 
had the disease worldwide.505 A report showed that $900 million needs to be 
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invested annually in the development of new tools for tuberculosis, but only 
$206 million was invested in 2005, and the funding gap is expected to widen 
over time.  As recently as 2008 a WHO report showed that in the US, only $20 
million was spent on clinical trials for drugs for tuberculosis, in comparison to 
the $300 million that was being spent on HIV drugs annually, this point out the 
disparity of the financial resources allocated to different diseases. Thus a report 
showed that a dramatic funding increase is needed to support R&D 
tuberculosis. Interestingly diseases like leishmaniasis, a parasitic and highly 
infectious disease spread by sand flies hardly gets any allocation even though it  
is endemic in 88 countries however the most commonly used drug is now 70-
years-old and toxic.506  
 
Many have expressed surprise at the lack of R&D into diseases that affect poor 
countries, stating that interpreted to suit developing countries, the TRIPS 
Agreement, at least in theory provides incentives that encourage R&D that 
ensures that drugs are manufactured to treat neglected diseases.  Article 7 of 
the TRIPS states that the “protection and enforcement of the intellectual 
property rights should contribute to the promotion of technological innovation 
and to the transfer and dissemination of technology, to the mutual advantage of 
producers and users of technological knowledge and in a manner conductive to 
social and economic welfare, and to a balance of rights and obligations”.507  
 
Whilst the TRIPS envisages that technological advances would increase the 
pharmaceutical industry’s ability to control infectious diseases worldwide, 
there has been little or no progress towards drug discovery and development 
aimed at neglected diseases in poor countries. It is therefore important that 
more is done to ensure collaboration among scientists, drug developers, care 
providers, and affected individuals in both developed and developing 
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countries, and develop a global priority research agenda to eradicate 
tuberculosis.  
 
 6.5     Partnership Initiatives into R&D for Neglected Diseases  
Regardless of the foregoing, many speculators have recorded some progress in 
confronting the lack of medicines for neglected diseases. In this regards, there 
has been  some positive response by the pharmaceutical industry and charitable 
organisations to bring medicines to the “neglected patients” of the world.  
Indeed there has been many diseases control initiatives by numerous 
international partnerships and many of these programs have been successful in 
curtailing tropical diseases.508 Until recently riverblindness was a major 
problem confronting the African continent but has gradually been eradicated 
with the help and cooperation of the pharmaceutical industry.509 By 1974, the 
first control program known as the Onchocerciasis Control Program (OCP) was 
launched and treated over 30 million people. By 1992 another control initiative 
program called the Onchocerciasis Elimination Program for the Americas 
(OEPA) was formed; subsequently in 1995, the African Programme for 
Onchocerciasis Control (APOC) was formed and provided medicines for 
millions of people living with Onchocerciasis.510 However by far the most far 
reaching strategy to eliminate the spread of Onchocerciasis was the initiative 
by Merck in 1988 which sought to provide ivermectin to millions of people in 
eleven countries, thus statistics suggest that at least 65 million people receive 
ivermectin annually and this has near enough brought the diseases under 
control.511   
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Similarly, other renowned pharmaceutical companies have begun to take note 
of the need to provide more medicines to fight neglected diseases.  For 
example Pfizer has partnered with the International Trachoma Initiative to 
donate azithromycin as part of a comprehensive program to eliminate 
trachoma.512 GlaxoSmithKline’s coalition with WHO, Merck, and the Global 
Alliance to eliminate lymphatic Filariasis has led to the control of lymphatic 
filariasis  which was a public health problem in Egypt, Samoa, and Zanzibar.513  
Patent pools are another way which pharmaceutical companies have sought to 
conduct more R&D into neglected diseases. A good example of this is the U.S 
FDA priority review voucher. This legislature was passed in order to create an 
incentive to register NCEs for most neglected diseases. Whilst there are no 
PRVs traded yet,  some have stated that a PRV is worth more than 300 million 
dollars.514  UNITAD has created a patent pool for second generation AIDS 
drugs whilst Gilead, J&J and Merck have agreed to negotiate with them.  
 
Interestingly GSK has taken a low profile on the UNITAID proposal and 
refused to plainly exclude  HIV/AIDS in their announcement and are limiting 
their proposal to an upstream R&D proposal. This has led many  public health 
experts to interpret this as a sign that GSK is not interested in the  model 
presented in the UNITAID patent pool. Nevetheless  it is important to note that 
GSK, AstraZeneca PLC,  Novartis AG and other major pharmaceutical 
companies have made commitments to tackle neglected diseases, and set up 
research institutes to specifically focus on neglected diseases. A recent report 
indicated that pharmaceutical companies have launched more than 60 projects 
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to treat neglected diseases and the report is optimistic that nine or ten 
medicines could become available by 2010.515  Whether or not this will 
become a reality remains to be seen. 
 
Apart from the partnership initiative, India’s pharmaceutical companies plays a 
very important role in global R&D for NCEs but most of their R&D is 
conducted into diseases affecting high-income countries. The India 
pharmaceutical industry  also faces the challenge of finding partners to 
collaborate with in order to undertake successful R&D investments in 
manufacturing new drugs. They have had to depend on its government, R&D 
institutions, academic institutions such as universities and colleges and 
international agencies to provide funding for R& D.  Chauduri points out that 
the government and the higher education sector account for 78 per cent of 
R&D expenditure, whilst the remaining 22 per cent comes from the private 
sector. Pharmaceutical R&D expenditure in India between 1998-1999 was 
estimated at 6000 million of which 63 per cent of it was contributed by the 
pharmaceutical industry.516 Commentators have therefore raised the question 
of why the pharmaceutical industry around the world, especially in the 
developed world have continuously lobbied to make stronger patent rules 
applicable in developing countries if they consider the markets in third world 
countries to be inconsequential and unprofitable. One of the best answers to 
this question is that MNC want to prevent price leakage of cheap 
pharmaceuticals from developing world into developed countries; a scenario 
which usually occurs with parallel importation.517  
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Commentators assert that the allocation of resources to R&D should be 
reformed to address the health crisis of the developing world in order to 
safeguard the economic, health and security interest of the developed world.518 
Questions such as whether  the profits of manufacturing a drug is more 
important than finding cures of diseases if they can be found have arisen in 
recent times.519 The idea that an era of globalisation should bring with it a level 
of integration in all sectors including health care that transcends countries and 
borders has added value to the access to medicines debate.520 Thus the increase 
in international travel and tourism has unavoidably increased the possibility 
that diseases will pass from developing countries to the developed world if not 
halted. Some of the most prevalent diseases that have had a spill over effect on 
developed countries are HIV/AIDS, Malaria and Tuberculosis, hence the 
situation is made more dire especially as new resistance to previous 
inoculations or treatments have become more pronounced;521  nevertheless 
there is the argument that the spill over effect of diseases from the developing 
world to the developed world only carries weight with diseases that are 
contagious. That argument does not hold when one considers the financial 
burden that neglected diseases have on the healthcare systems of many 
developed countries. 
 
In 2007, Jon Snow did a program on the BBC showing the effects of 
immigration on the UK. The program showed that it cost NHS millions of to 
treat tuberculosis, HIV/AIDS that came from developing countries. The lack of 
medicines to treat infections in developing countries has also been linked to the 
spread of terrorism in the developed world. Indeed poor health and 
underdevelopment are interrelated, thus commentators have argue that the 
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eradication of poverty in developing countries might diminish the threat of 
terrorism which some believe is a direct result of poverty and resentment. 
Branko Milanovic comments that “resentment breeds terrorism”522 Hatred of 
the west has been the bedrock of terrorist activities and this has led some to 
argue that this is fuelled by the “unfair trading system” between developing 
countries and developed countries. The genesis of this is usually affiliated with 
the key periods of European colonization between the 1500 and 1900s and the 
post- World War II era of decolonization manifested by an international 
structure in which Western dominance has been affixed in the power of the 
US.  
 
The US spends roughly 50 Billion dollars on pharmaceutical research per year, 
which is approximately half of the world expenditure on pharmaceutical 
research.523 However the question is not what the world spends on R&D but 
how much should it spend on R&D for neglected diseases for nations that 
cannot afford to pay for their own R&D.  For example the richest 1 percent of 
the world (50 million people) receives as much income as the bottom 57 per 
cent (2.7 billion) of the world.524  Such clear disparity promotes an inequality 
of global resources that could be targeted towards R&D for neglected diseases. 
This had led commentators to assert that R&D dollars should be allocated in 
the manner that will achieve results in the access to medicines problem for the 
majority of the world.  
 
In 2001 at the 37th Summit of the OAU (Organisation of African Unity) 
formally adopted the strategic framework document known as New Partnership 
for Africa’s Development (NEPAD). The NEPAD strategic framework 
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document arose from a mandate given to the five initiating Heads of State 
(Algeria, Egypt, Nigeria, Senegal, and South Africa). NEPAD was an 
undertaking by African leaders to maintain a common vision and a firm and 
shared conviction, that they have a pressing duty to eradicate poverty and to 
place their countries, both individually and collectively, on a path of 
sustainable growth and development and, at the same time, to participate 
actively in the world economy and body politic. The Programme is anchored 
on the determination of Africans to extricate themselves and the continent from 
the malaise of underdevelopment and exclusion in a globalising world. What 
stood out through the formation of NEPAD was that it constituted a bold and 
unprecedented declaration of African responsibility for Africa's future.525 
 
At Kananaskis in Canada, African leaders also presented the NEPAD 
document to the G8 for endorsement and support. The African leaders had a 
main objective of finding ways into inciting pharmaceutical research into  
neglected diseases. Although criticized for not dealing specifically with 
epidemic diseases, the NEPAD document recognizes that “unless the 
epidemics of AIDS, tuberculosis and malaria are brought under control, real 
gains in [African] development will remain an impossible hope.” Indeed, the 
African leaders have asserted that nothing short of a massive international 
initiative can even begin to contain and control HIV/AIDS, tuberculosis and 
malaria.  
 
Likewise other commendable efforts to tackle lack of R&D for neglected 
diseases include the DNDi (Drugs for Neglected Diseases initiative) which was 
set up in 2003 to promote co-operation between developing countries and 
developed countries in developing new drugs, raising awareness for neglected 
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diseases, and building public responsibility and leadership in addressing needs 
of patients. 526   Part of the DNDi’s agenda included developing new drugs by 
building a portfolio that will make better use of drugs, raise awareness of the 
need for R&D for neglected diseases and build up existing capacity in disease 
endemic countries.  It capitalized on existing, fragmented R&D capacity, 
especially in the developing world, and complemented it with additional 
expertise as needed.  
 
Amongst all the international efforts that has been put forward to tackle the 
issue of lack of medicines for people living with neglected diseases, one of 
efforts that stand out the most include  the product-development partnerships in 
drug R& D set up by certain individuals and philanthropic organisations. . A 
survey carried out in April 2005 showed that a total of US$212 million had 
been donated for R&D into neglected diseases, 78.5% of which  came from the 
Bill & Melinda Gates Foundation although public funding in R&D for 
neglected diseases was still as low as 16%.  Worthy of mention also is the fact 
that the British Government announced in March, 2006 that a substantial 
additional funding of 17 million pounds (or about $30 million) would be 
donated for R&D into neglected diseases,  a funding gap of several hundred 
million dollars is still needed in order for there to be adequate R& D into 
neglected diseases.527  
 
Lack of R&D is a serious issue that needs to be confronted so that people 
living in the developing world can have more hope for the future. Indeed most 
countries in the developing world have a population of people suffering from 
neglected diseases who have no access to medicines, it is also their 
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responsibility to ensure that their governments made concrete efforts to invest 
in developing their local pharmaceutical industries and improving the use of 
their traditional medicines for therapeutic purposes where applicable.528 A 
report by WHO's Commission on Intellectual Property Rights, Innovation, and 
Public Health, released April 3, 2005 urged WHO to develop a Global Plan of 
Action to secure enhanced and sustainable funding for developing and make 
accessible products to address diseases that disproportionately affect 
developing countries.529 The bitter reality nevertheless remains that although it 
may not make economic sense for pharmaceutical companies in the developed 
world to invest in R&D for medicines for neglected diseases, the terrible 
reality of people suffering around the world and the fact that half of the world 
population is perishing without access to medicines is a public responsibility 
for the governments of the world.  
 
6.6    Drug Counterfeiting 
WHO’s definition of a counterfeit drug is: “a medicine, which is deliberately 
and fraudulently mislabelled with respect to identity and/or source. 
Counterfeiting can apply to both branded and generic products and counterfeit 
products may include products with the correct ingredients or with the wrong 
ingredients, without active ingredients, with insufficient active ingredients or 
with fake packaging.”Note that  Article 51 of the TRIPS Agreement allows 
suspension of release by customs authorities of goods suspected to be 
counterfeit.  
 
                                                            
528 Sudip Chauduri. (2005) R&D for Development of New Drugs for Neglected Diseases. How 
Can India Contribute.  
529 WORLD HEALTH ORGANIZATION EXECUTIVE BOARD. EB117/9. 117th Session  
22 December 2005. Provisional agenda item 4.10  Intellectual Property rights, Innovation 
rights, Innovation and Public Health.,; Donor funding priorities for communicable disease 
control in the developing world. Shiffman Health Policy Plan...2006; 21: 411-420; Do Patents 
for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa? Attaran and 
Gillespie-White JAMA.2001; 286: 1886-1892. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
180 
 
Counterfeit drugs are a public health problem and therefore a serious hazard 
that endangers people’s lives and prevents access to genuine medicines in 
developing world. In 2003, the World Health Organisation (WHO) report 
showed that 10 % of all medicines worth $32 billion sold worldwide were fake 
and counterfeit drugs. Other studies have also showed that the pharmaceutical 
industry losses approximately $46 billion a year to counterfeit drugs.530 The 
harms of counterfeit drugs in Nigeria and other developing countries cannot be 
underestimated, thus the former Director General of National Agency for Food 
and Drug Administration Control (NAFDAC), Dr Dora Akunyili compared 
counterfeit drugs to “terrorism against public health [and] an act of economic 
sabotage”.531  The Center for Medicines in the Public Interest predicted that 
counterfeit drug sales will reach $75 billion globally by 2010, a more than 90 
percent increase from 2005.  One of the major reasons for this is that the laws 
and enforcement agencies in many countries are so lax that in Argentina for 
example, it is not a crime to change the expiration date on a drug unless it is 
proven that doing so will damage someone’s health. There is strong evidence 
to suggest that counterfeit drugs are slowing leaking into the supply chains of 
western countries, thus there are 70,000 packages of counterfeit drugs hidden 
inside legitimate medicines that are smuggled into the United States through 
the JFK and Miami airports every day.532 Similarly in February 2009, over 
70,000 packets of fake medicines which originated from China were 
discovered to have been distributed by the NHS.533 
 
The developing world is where most counterfeit drugs are manufactured and 
where most victims live. Statistics show that in some of these countries up to 
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532 Ibid 
533 Joel Taylor. Thousand given fake drugs by NHS. METRO newspaper. February 3, 2009 
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half the drugs are counterfeit.534 Majority of these counterfeit medicines are 
produced in countries like China, India and other parts of South East Asia. The 
destructive nature of the unlawful trade in counterfeit drugs are well 
recognized, thus the report from the EC states that “the marketing of fake 
goods does considerable damage to [patent] rights holders, as well as law-
abiding manufacturers and traders and more and more attention is being drawn 
to the dangers to the consumers' health and safety." Counterfeit drugs cause 
serious injury and death and lead to drug resistance which inevitably 
undermine the effectiveness of legitimate drugs. All these are a basic violation 
of the right to medical care under Article 25 of the UDHR and the right to 
health under 12 of the ICESCR. What makes the situation more poignant is 
that people in the developing world already face a host of public health 
problems and do not have the economic power to purchase medicines, however 
counterfeit drugs worsens the existing burden of poverty. 
 
Counterfeit drugs have killed a lot of people in Nigeria. Dr Dora Akunyili 
stated that “The evil of fake drugs is worse than the combined scourge of 
malaria, HIV/AIDS and armed robbery put together. This is because malaria 
can be prevented, HIV/AIDS can be avoided and armed robbery may kill a few 
at a time, but counterfeit/fake drugs kill in mass. The social problem posed by 
hard drugs, cocaine, heroine etc. cannot also be compared with the damage 
done by fake drugs, because illicit drugs are taken out of choice, and by those 
that can afford them, but fake drugs are taken by all and anybody can be a 
victim”.535 Thus Nigeria has a long history of problems with counterfeit drugs. 
The first well reported case of deaths caused by counterfeit medicines was in 
                                                            
534 International Policy Network. (IPN) 
http://www.policynetwork.net/main/press_release.php?pr_id=103 .   
535Prof. Dora N. Akunyili (D.G of NAFDAC) Strategies employed in combating Drug 
Counterfeiting in Nigeria, A workshop organised by World Health Organisation (WHO) in 
Collaboration with Italian Medicines Agency (AIFA) and the International Federation of 
Pharmaceutical Manufacturers and Association (IFPMA), held in Rome, Italy, 16th-18th 
February. 2006  
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the 1980’s when the malaria drug for children, chloroquine syrup killed many 
children in the University of Nigeria Teaching Hospital in Enugu. In 1990, 109 
children died in Ibadan and Jos from taking paracetamol syrup which 
contained a poisonous substance ethylene. Similarly in 1996, a clinical trial 
was conducted in Kano by Pfizer for Trovan during the outbreak of the 
meningicoccal meningitis during which 200 people died. It was further 
reported that at least 15,000 Africans died as a direct result of the clinical trial 
conducted by Pfizer.  
 
Pfizer’s illegal clinical trial in Nigeria was also a violation of Nigerian law and 
the international Declaration of Helsinki that regulates ethical medical research 
and the U.N. Convention on the Rights of the Child.536 The Nigerian Federal 
Government consequently filed a law suit against them demanding for N890bn 
($6.9bn) damages, however the case was eventually settled out of court in 
2007.  Another case of counterfeit drugs causing deaths took place in 2003, 
when the counterfeit cardiac stimulant (adrenaline) killed 3 children during an 
open heart surgery. In 2004, hospitals in Nigeria also reported that 4 Nigerian 
companies were producing contaminated infusions; further investigation 
confirmed that the infusions produced by the companies were contaminated 
with microorganisms. In the case of fake antiretroviral medicines there were 
reports of counterfeit antiretroviral in Zidovudine, Lamivudine, Indinavir in 
Cote d”Ivoire in 2003. Regardless of the foregoing by far the most common 
counterfeit drugs in Nigeria are antibiotics, malaria drugs and vitamins. 
 
6.6.1  The Need to have a Common Definition for Counterfeit Drug 
Commentators have asserted that in order to fight the war against counterfeit 
drugs successfully, there should be a consensus on the definition of the term 
counterfeit drugs. There should also be an effective collection and comparison 
of data with the goal of implementing the necessary measures to combat 
                                                            
536 http://www.washingtonpost.com/wp-
dyn/content/article/2006/05/06/AR2006050601338.html 
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counterfeit drugs.  Under Nigerian law counterfeit and fake drugs are defined 
as " any product which is not what it purports to be; or b) any drug or drug 
product which is coloured, coated powdered or polished that the damage is 
concealed or which is made to appear to be better or of greater therapeutic 
value than it really is, which is not labelled in the prescribed manner or which 
label or containers or any thing accompanying the drug bears any Statement, 
design or device which makes a false claim for the drug or which is false or 
misleading; or c) any drug or drug product whose container is so made, formed 
or filled as to be misleading; or d) any drug product whose label does not bear 
adequate direction for use and such adequate warning against use in those 
pathological conditions or by children where its use may be dangerous to 
health or against unsafe usage or methods or duration of use; or e) any drug 
product which is not registered by the agency in accordance with the 
provisions of the Food, Drugs and Related Products Decree 1993, as 
amended."  
 
Pakistan's Manual of Drug Laws defines a counterfeit as  "a drug, the label or 
outer packing of which is an imitation of, resembles or so resembles as to be 
calculated to deceive the label or outer packing of a drug manufacturer” 
 
The US defines counterfeit drugs as :  "a drug which, or the container or 
labelling of which, without authorization, bears the trademark, trade name, or 
other identifying mark, imprint, of device or any likeness thereof, of a drug 
manufacturer, processor, packer, or distributor, other than, the person or 
persons who in fact manufactured, processed, packed, or distributed such drug 
and which thereby falsely purports or is represented to be the product of, or to 
have been packed or distributed by, such other drug manufacturer, processor, 
packer, or distributor."  
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The Philippines definition of counterfeit medicines is similar to WHO’s 
definition, it states that  "...medicinal products with correct ingredients but not 
in the amounts as provided there under, wrong ingredients, without active 
ingredients, with insufficient quantity of active ingredients, which results in the 
reduction of the drug's safety, efficacy, quality, strength or purity, а counterfeit 
drug is deliberately and fraudulently mislabelled with respect to identity and/or 
source or with fake packaging, and can apply to both branded and generic 
products”537 
 
 All the various definitions of counterfeit drugs have led some commentators to 
suggest that there is need for an international convention on counterfeiting of 
pharmaceuticals, just as there is a common consensus on the definition of 
narcotics and psychotropic substances. This it is believed will ensure a 
harmonized regulation of pharmaceutical products in international commerce. 
It follows that the severity of the problems of counterfeit medicines is a huge 
international problem that must be tackled collectively, if it is to be tackled 
effectively and  trans-national counterfeiters caught and persecuted sooner than 
later 
 
6.6.2 Counterfeit drugs: a Flourishing Business in Developing Countries in 
South America 
The trade in counterfeit is particularly attractive for criminals and this has 
enabled the trade flourish and provide a lucrative venture for fraudsters. One of 
the reasons why the business of counterfeits drugs is growing is because most 
regulatory oversight and law enforcement agencies in developing countries are 
weak.538According to Peru’s Association of Pharmaceutical Laboratories in 
Peru the sale of counterfeit drugs rose from an estimated US$ 40 million in 
                                                            
537 The Republic Act No. 82036 
538 Deadly Imitations.  http://www.paho.org/English/DD/PIN/Number23_article3.htm  
(Accessed 23 April 2008) 
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2002 to a US$ 66 million.539  Evidence gathered from South American 
countries reports that recent developments in Pan American Health 
Organizations (PAHO) show a high activity in counterfeit drugs. These data 
comprise drugs that enter the country as contraband, contaminated, expired, 
counterfeits with altered or mislaid labels and those stolen from warehouses.540 
In the Dominican Republic, roughly 50 per cent of all medicines operate 
illegally. Thus in 2005, 10 percent of medicines imported were counterfeits.541  
In Lima the numbers of illegal pharmaceutical stores dealing in counterfeit 
medicines in 2002 were estimated to be as high as 18,000. Thus trading in 
counterfeit medicines was so rampant that the Lima General Directorate of 
Medicines, Supplies and Drugs of the Department of Health seized 
approximately 460,000 expired medicines in 2005.   
 
Mexico has also had to tackle the problem of counterfeit drugs infiltrating the 
markets. In the case of Mexico, the case for counterfeit medicines is more 
crucial because of the thousands of Americans who cross the border every year 
to buy medicines in order to save money buying prescription drugs in the 
US.542 For this reason trading in pharmaceuticals is an extremely lucrative 
business in Mexico, and the estimated total sales to foreigners exceeds two 
hundred million dollars annually. In 2002, the number of illegal pharmacies 
selling counterfeit medicines increased from approximately 200 to 1,800.  In 
2004, Mexican federal agents apprehended 60 tons of stolen, expired, and 
counterfeit medicines in two states - Michoacán and Jalisco. That same year 
                                                            
539 WHO. See 
http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/index1.html 
(Accessed 25 April 2008) 
540 Deadly Imitations http://www.paho.org/English/DD/PIN/Number23_article3.htm 
(Accessed 12th April 2008) 
541 According to the Ministry of Public Health.. Deadly Imitations 
http://www.paho.org/English/DD/PIN/Number23_article3.htm (Accessed 23 April 2008) 
542 The People’s guide to Mexico. 
http://www.peoplesguide.com/1pages/chapts/health/buymed/cheapmed1.html (Accessed 23th 
June 2008) 
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reports indicated that counterfeit medicines represented approximately 10 
percent of the pharmaceutical market nationally. 
 
 El Salvador, one of the smallest countries in Central America also has the 
problem of counterfeit drugs turning up in the market. The fact that there was a 
civil war in the country that ended in 1992 made the situation worse. The irony 
in the case of El Salvador is  the fact that there is only one school of pharmacy 
in San Salvador, the capital of El Salvador and it has been able to carry out 
experiments and develop its pharmaceutical industries. Some of the 
experiments carried out in El Salvador’s laboratory have been compared to 
those carried out by British pharmacy students.543 Tragically the problem of 
lack of infrastructure and corruption has contributed to encouraging the trade 
in counterfeit medicines.544 In 2005, a WHO report showed that the business of 
counterfeit and fake drugs in the country generated economic losses to the 
country’s pharmaceutical industry to the tune of approximately $40 million.  
In 2001 Colombia’s National Institute for the Supervision of Foods and 
Medication  (INVIMA) discovered a thriving trade in Bosa, a poor 
neighbourhood in Bogota where more than 20,000 counterfeit tablets of flu 
druds, Dristan (a generic aspirin known as Dolex), and Ponstan 500, a popular 
painkiller of Pfizer were being produced. In 2000, Columbia confiscated 6 
million doses of counterfeit Voltaren, a Novartis anti-arthritic medicine. The 
fact that the  amount far exceeded the annual consumption of Voltaren in 
Colombia, signified that the fakes were created for export.545 Note that most 
counterfeit drugs are not produced for consumption in the country of origin, 
rather it is made for the purpose of export.  In 2004, the Association of 
Colombian Pharmaceutical Industries (ASINFAR) estimated that US$ 60 
                                                            
543 Ibid 
544 http://www.pjonline.com/Editorial/20000902/forum/ipsf_counterfeit.html (Accessed 16th 
April 2008) 
545 http://www.businessweek.com/magazine/content/01_25/b3737153.htm (Accessed 19th 
April 2008) 
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million, which represented 5% of the total annual market of drugs sold in 
Colombia were contraband, counterfeit or adulterated. The criminal trade in 
counterfeit is  so dangerous that Dr. Miguel Rueda, the General Director of 
INVIMA has received many death threats for trying to crack down on the 
activities of counterfeiters.  In 2001, Dr Rueda estimated that 10% of the $1.2 
billion worth of drugs sold in Colombia every year was counterfeit drugs. 
 
 6.4.3  Counterfeit Drugs: a Flourishing Business in Developing Countries 
in Asia 
Another major source of counterfeit medicines are countries in Asia. WHO has 
identified the “greater Mekong sub region,” which includes Vietnam, the Lao 
People’s Democratic Republic, Cambodia, China, Myanmar, and Thailand as 
the major sources of counterfeit drugs.546 China for example is the chief 
counterfeit manufacturing centre in the world.  In 2001 it was reported that 
China had 500 illegal factories where counterfeit medicines were being 
produced.547 That same year the China’s Research and Development-based 
Pharmaceutical Association estimated that about 8% of over-the-counter drugs 
sold in China were counterfeit.548 The productions of counterfeit drugs in china 
is so rampant that the drugs are manufactured from different locations ranging 
from one-room shacks in shanty towns to large, modern factories in the city. 
 
The exact data on the effects that  the production of counterfeit medicines in 
China has had on victims around the globe is difficult to ascertain, however the 
official Chinese estimate suggest that 100,000 people in China die every year 
from taking counterfeit drugs.549  In 2001, the Chinese authorities sealed off 
                                                            
546 Stephen Pincock WHO tries to tackle problem of counterfeit medicines in Asia. BMJ 
2003;327;1126-  doi:10.1136/bmj.327.7424.1126-a  
547 http://bmj.bmjjournals.com/cgi/content/full/327/ 7424/1126-a (Accessed 16th July 2008)  
548 WHO. 
http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/index1.html 
(Accessed  9th June 2008) 
549 DRUG BUSTERS. CSO MAGAZINE- NOVEMBER 2005.  
http://www.csoonline.com/read/110105/counterfeit.html (Accessed 16th April 2008) 
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1,300 factories whilst investigating a staggering 480,000 cases of counterfeit 
drugs worth $57 million.550  In 2006 fake drugs containing wrong active 
ingredients for  the antimalarial medicine, artesunate was traced back to an 
illegal factory on the outskirts of Puning, a city in Guangdong Province. In 
2006 and 2007 a factory in Yangtze Delta, China also sold counterfeit glycerin 
in Panama that ended up killing 120 people.551 
 
Although a research conducted by Professor Jin Shaohong, director of China’s 
National Institute for the Control of Pharmaceutical and Biological Products 
showed that the trade in counterfeit drugs in is reducing, the improvement has 
not been as much as the international community would like. His research 
showed that in 1998, 14% of drugs were estimated to be counterfeit; however 
by 2008 the percentage had fallen to 10.552  
 
Indonesia has also been on the headline news as one of the manufacturers of 
counterfeit medicines.  In 2005 Indonesia’s International Pharmaceutical 
Manufacturers Group (IPMG) approximated that counterfeit drugs represented 
25% of Indonesia’s $2 billion pharmaceutical market.553 In 2008, an 
international pharmaceutical industry group claimed that 40 per cent of all 
drugs sold in Indonesia may be counterfeit.554  Cambodia is also facing a 
similar public health crisis, in 2002 a Health Ministry survey conducted 
revealed that 13% of drugs on the domestic market were counterfeit or 
substandard, including anti-malaria drugs and antibiotics. In 2003, a WHO 
                                                            
550  Fackler M (2002 July 29) China’s fake drugs kill thousands. San Francisco Examiner 
551 WALT BOGDANICH and JAKE HOOKER Battle Against Counterfeit Drugs Has New 
Weapon: Pollen. February 12, 2008 
552 Asia’s dealy Counterfeit Drugs. June 5, 2008. 
http://www.feer.com/politics/2008/june/Asias-Deadly-Counterfeit-Drugs (Accessed 23rd 
January 2008) 
553 Counterfeit Medicines. Fact sheet N°275. 
http://www.who.int/mediacentre/factsheets/fs275/en/ (Accessed  12th March 2008) 
554  
Claims 40 per cent of Indonesia drugs counterfeit. Fri Jul 18, 2008 1:33pm AEST. 
http://www.radioaustralia.net.au/news/stories/200807/s2307503.htm (Accessed 11 March 
2008) 
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report revealed that Cambodia had 2,800 illegal pharmacists and 1000 
unregistered medicines on the market.555 Evidence suggests 33% of Artesunate 
(a major drug for malaria) sold in Cambodia, Thailand and Vietnam contained 
no active ingredients. The D&MD's Prescription Drug Counterfeiting report 
showed that of thirty medicines named in a list of drugs especially susceptible 
to counterfeiting, twenty-three are used in treating HIV/AIDS and cancer.556   
 
A WHO report showed that Laos had approximately 2100 illegal drug outlets, 
while in Thailand, substandard medicines account for approximately 8.5 per 
cent of the total market.557 In late 2006 and early 2007, the interim military 
government of Thailand issued compulsory licenses for three Western-owned 
pharmaceuticals. In each of its applications, the government claimed that the 
price of these drugs undermined its commitment to provide universal 
healthcare to its citizens, however this move makes the suspecting spectator to 
question if this will not lead to more counterfeit drugs in Thailand because of 
its weak regulatory agencies.  In 2003, The Philippine’s Bureau of Food and 
Drug (BFAD) reported that 30% of drug store outlets visited by food and drug 
deregulation officers carry and sell counterfeit drugs.  
 
6.6.4 Counterfeit Drugs from India 
India is a very important area that must be tackled if the fight against 
counterfeiting drugs can be successful in Nigeria. Apart from the similar 
colonial history which Nigeria and India has and the fact that they both passed 
the Patent Act , and which has been identified throughout this thesis. Nigeria 
derives most of its drugs from India. At a conference in Lyon, France, Dr Dora 
                                                            
555 http://www.who.int/entity/bulletin/volumes/81/12/ WHONews.pdf (Accessed 13th April 
2008) 
 
556 http://www.bioportfolio.com/cgi-bin/acatalog/Prescription_Drug_Counterfeiting.html 
(Accessed  2 March 2008) 
557 http://www.who.int/entity/bulletin/volumes/81/12/ WHONews.pdf (Accessed  1st April 
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Akunyili stated that most counterfeit drugs in Africa came from India.558 Thus 
a report by the European Commission (EC) alleged that of the 2.7 million 
counterfeit drugs seized by its customs department in 2006, India was the 
largest source of counterfeit medicines.559  In 2003, Mr Ranjit Shahani, 
President of the Organisation of Pharmaceutical Producers in India (OPPI), on 
the modus operandi of spurious drugs manufacturers in India pointed out that 
“India is fast becoming the capital for counterfeit drugs and accounts for one-
third of the counterfeit drugs produced worldwide”560 
 
 According to WHO, 35% of counterfeit produced in the world originate in 
India. Statistics show that only a few of the 15,000 generic manufacturers in 
India operate illegally, however this has put India on the top list of countries to 
watch out for when it comes to counterfeit production of medicines. In 2003, 
Nigeria threatened to ban all pharmaceutical products from India because most 
of the counterfeit drugs that were coming into the country originated from 
there.  
 
The Indian pharmaceutical industry has expressed fears that such a reputation 
could harm India as the supplier of inferior, counterfeit and adulterated quality 
drugs.561 One of the ways in which India has attempted to deter the production 
of counterfeit drugs has been to introduce the death penalty for selling fake 
drugs that cause grievous harm.562 The Indian Health Minister Sushma Swaraj 
said “Profiting from spurious drugs that might harm or kill innocent people is 
                                                            
558 Nigeria Calls for Convention Against Counterfeit Medicines. 16 November 2005. 
http://www.ip-watch.org/weblog/index.php?p=138&res=1280&print=0 (Accessed  4th March 
2008 ) 
559http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/Pharm
aceuticals/India_hub_of_counterfeit_drugs_EC/articleshow/2142855.cms (Accessed 4th 
March 2008) 
560 http://www.thehindubusinessline.com/2003/08/03/stories/2003080301260500.htm 
(Accessed 1st April 2008 ) 
561 Ibid 
562 India to introduce death penalty for peddling fake drugs BMJ  2003;327:414 (Accessed 
23 August 2007)  
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equivalent to mass murder,",563The committee recommended that the 
maximum penalty for the sale or manufacture of fake medicines that cause 
grievous harm or death should be changed from life imprisonment to the death 
penalty and that the minimum prison sentence for these offences should be 
increased from five years to 10 years. The committee has also called for higher 
fines for those convicted for trading in fake drugs.564 Dr Mashelkar said 
Penalties should be “severe, sure and swift,” , quoting from the `Technical 
Expert Group on Patent Law Issues'  report he had chaired three years ago. 565  
 
Like many Asia countries facing the threat of counterfeit medicines, one of the 
major problems that India has in combating counterfeits is the loop holes in 
domestic regulations. India lacks a federal drug agency its state regulators are 
often influenced by political considerations and plagued by corruption, a 
problem that many developing countries face. Nigeria has nevertheless begun 
serious work to eradicate the problem of counterfeit through NAFDAC which 
will be discussed in turn. 
 
6.7  NAFDAC 
NAFDAC was established as a Parastatal of the Federal Ministry of Health by 
the Decree No. 15 of 1993.566 Its role and duties included regulating and 
controlling the quality standards for foods, drugs, cosmetics, medical devices, 
chemicals, detergents and packaged water imported, manufactured locally and 
distributed in Nigeria. However in 2001, under the new leadership of Dr Dora 
Akunyili, NAFDAC’s role in the fight for access to genuine and authentic 
medicines and its war against counterfeit drugs dramatically changed the 
landscape of the fight against counterfeit drugs internationally. In 2009, Dr 
                                                            
563 Ibid 
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565 http://www.thehindubusinessline.com/bline/2007/07/16/stories/2007071651130300.htm 
(Accessed  6th April 2008 ) 
566 http://www.nafdacnigeria.org/ (Accessed 23rd March 2008) 
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Paul Orhii took over as Director General of NAFDAC and has continued to 
champion the fight against counterfeit medicines. 
 
In the 1990’s counterfeit drugs in Nigeria was a severe problem. Thus, Adeoye 
Lambo,the former WHO Deputy Director reported that 54% of drugs in 
pharmacies’ in Lagos were counterfeit drugs, a figure which rose to 80% in 
1991.567 However since 2001 the amount of counterfeit drugs in circulation in 
Nigeria has plummeted from a national average of over 41% in 2001 to 16.7% 
in 2006.568  NAFDAC has been a key instrument in the fight against 
counterfeit drugs and has sought to tackle the problem by using the following 
key eradication strategies.  
 
The first has been to tackle the “double standard” that exist 569 in some 
countries in the regulatory status of drugs. The double standards have allowed 
pharmaceutical industry to dump pharmaceuticals which are restricted or 
banned in developed countries.570 It is well known that some countries have 
stronger regulation for drugs consumed indigenously but have less stringent 
regulations for drugs exported to other countries. An example of the kind of 
double standard which may occur is the case of a combination medicine known 
as Deanxit (flupenthixol and melitracen) which was used for the treatment of 
                                                            
567 Ibid 
568 Prof.  Dora Akunyili. Keynote Address, NAFDAC at the International Conference of Heads 
of West African Drug Regulatory Agencies held at the ECOWAS Secretariat, Asokoro, Abuja, 
17th March 2006 
 
569 Double standards: in the regulatory status of pharmaceuticals enable the pharmaceutical 
industry to dump to third world countries medicines whose use is restricted or banned 
domestically. Numerous initiatives have been taken at the international level to tackle the 
problem, namely by the World Health Organisation. The European Community remained for a 
long time silent and promoted a laissezfaire policy, thereby giving carte blanche for the 
uncontrolled export of pharmaceuticals. However, a change of the European Community's 
attitude towards the export issue seems to be in the offing. 
570 Roger Bate, Kathryn Boateng.  Bad Medicine in the Market.  HEALTH POLICY 
OUTLOOK. June 20 2007. http://www.aei.org/publications/pubID.26368/pub_detail.asp and  
Nigeria leads fight against “killer’ counterfeit drug. WHO Report. Volume 84, Number 9, 
September 2006. 685-764. http://www.who.int/bulletin/volumes/84/9/06-
020906/en/index.html. KnujOn http://www.knujon.com/rx.html#imageonly  
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depression and anxiety.  The drug was rejected in Denmark twice by the 
Danish Medicines Authority but exported to countries with weaker regulatory 
authorities such as Sri Lanka.  The Danish authority did not need to give the 
exporters or importing country a certificate stating that it had been rejected by 
the pharmaceuticals in the Danish market.571 Thus the Danish Medical Agency 
(DMA) has been accused of operating “double standard” when it comes to the 
regulation of pharmaceuticals, hence a product of lower standard may be 
exported but not sold in Denmark. Kristen Myhr pointed out that what made 
the case more bizarre was the drug was also registered in other European 
countries like Switzerland, Spain, Italy, Austria and Belgium,572 and not just in 
developing countries. This kind of practice is possible in Europe because the 
regulatory position with regards to Good Manufacturing Practice (GMP) 
certification is not mandatory; consequently there is usually only a prospect of 
an examination of plants. The responsibility for quality and safety rest with the 
pharmaceutical companies, thereby making the industry self-regulatory.573 
Note that  European Community has promoted a policy of laissez-faire, and 
some have argued that this has given a leeway for the uncontrolled export and 
donation of banned or substandard pharmaceuticals.574 In contrast to this, in the 
US, all suppliers of Active Pharmaceutical Ingredients (APIs) are licensed and 
inspected by the Food and Drug Administration (FDA), although this increases 
the prices it also reduces the number of suppliers to those that can implement 
Good Manufacturing Practice (GMP)575 standards, and quality.576   
                                                            
571 Kristen Myhr [e- drug]  Double or dubious standards for regulation and export? 10 April 
2002 http://www.essentialdrugs.org/edrug/archive/200204/msg00035.php  
572 http://www.dsr.dk/sygeplejersken/  (Accessed 20th March 2008) 
573 Ibid 
574 Ruth Macklin “Double Standards in Medical Research in Developing Countries”  
Cambridge Law Medicine and Ethics (No 2) 
575.Good Manufacturing Practice (GMP) is defined as “That part of Quality Assurance which 
ensures that products are consistently produced and controlled to the quality standards 
appropriate to their intended use.” The principles and guidelines for GMP are stated in 
Directives; Directive 2003/94/EC for medicinal products and investigational medicinal 
products for human use. See also See Good Manufacturing Practices for Pharmaceutical 
Products (GMP), WHO Technical Report Series, No. 823, 1992, Annex 1, pp. 77-79 
576 Hevione head seeks level playing ground.  13/12/2004  http://www.in-
pharmatechnologist.com/news/ng.asp?id=56745-hovione-head-seeks 
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Consequently, statistics  show that in Europe, 70 per cent of the APIs used in 
medicinal products are sourced from plants based in countries in Asia that have 
perhaps never been inspected for GMP by a European Union official. This has 
put developing countries are at a disadvantage all round because they 
sometimes depend on inspection done in EU countries as many countries in the 
third world do not have strong regulatory authorities. Similarly the FDA in the 
US is required to certify all AIPs for consumption in the US, manufacturers 
that produce only for export are not inspected unless somebody asks for it. In 
order to counter the problem that come with pharmaceuticals “For export 
only”, the NAFDAC management has prohibited the importation of products 
marked “For export only” into Nigeria, and thus any product that cannot be 
consumed in its country of manufacture is officially prohibited from being 
exported into Nigeria.577 
 
In an attempt to ensure stricter registration procedures NAFDAC reports that it 
has set up collaboration with food and drug regulators in almost all continents 
in order to control pharmaceutical products that come into Nigeria578  
NAFDAC has also established serious communication with neighbouring West 
African countries’ Food and Drug Regulatory Authorities. It has done this  in 
order to monitor, share strategies and ideas to eradicate counterfeit is the sub-
region and prevent counterfeiters from establishing a haven and outlet into 
Nigeria or other West African countries.579 Dr Dora Akunyili’s work and 
vision has been commended by the international community and she has 
consistently urged an adoption of an international convention of 
pharmaceutical.  
 
                                                            
577 Prof.  Dora Akunyili. Keynote Address, NAFDAC at the International Conference of Heads 
of West African Drug Regulatory Agencies held at the ECOWAS Secretariat, Asokoro, Abuja, 
17th March 2006 
578 Ibid 
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NAFDAC has also attempted to tackle the problem of counterfeit medicines by 
strengthening its registration processes. NAFDAC has strengthened the 
registration process by outlining some organizational guidelines to ensure a 
strong and effective regulation scheme which will prevent the dumping of 
counterfeit or restricted pharmaceutical products. These guidelines include: all 
pharmaceuticals must comply with laboratory standards and inspection 
requirements before they are registered; all drugs on the Nigerian market must 
be registered again after every five years; all herbal medicine must also be 
registered again every year; all drugs in circulation in Nigeria must have a 
NAFDAC Registration Number that has been certified by NAFDAC to enable 
the public identify counterfeit drugs and finally so as to encourage transfer of 
technology, drugs can only  be imported for ten years period of which importer 
must begin producing locally.580 
 
NAFDAC has registered success in its campaign to eradicate counterfeit drugs. 
As of 2006, it measured its achievements by reducing counterfeits by 90% 
from what it was in 2001. Between April 2001 and July 2005, NAFDAC 
raided over 1000 illegal locations of counterfeiters and destroyed many of their 
outlets.581 The most notorious market for the production of counterfeit drugs in 
the East of Nigeria known as the Onitsha market is the headquarters of 
counterfeit drugs in Nigeria and has the biggest warehouses where counterfeit 
drugs are stored in Nigeria.  Whilst other counterfeit markets exist in Kano and 
Aba, Onitsha has posed the biggest problem for NAFDAC.  
 
                                                            
580 Prof. Dora N. Akunyili (D.G of NAFDAC) Strategies employed in combating Drug 
Counterfeiting in Nigeria, A workshop organised by World Health Organisation (WHO) in 
Collaboration with Italian Medicines Agency (AIFA) and the International Federation of 
Pharmaceutical Manufacturers and Association (IFPMA), held in Rome, Italy, 16th-18th 
February. 2006 
581Ibid 
581 http://ec.europa.eu/development/ICenter/Pdf/05-03_7%20Consultation_Rago.pdf  
(Accessed  12th February 2008)  
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
196 
 
Whilst trying to deal with the Onitsha problem, in 2002, NAFDAC closed 
down the Aba market for 6 months and the Kano market was sealed off in 
2004/2005 for a period of three months to halt the activities of counterfeit 
traders.  Although this caused a lot of hardship to the indigenous people of the 
states and the customers, NAFDAC was determined to put the safety and good 
quality of medicines first. Subsequently on 6 March 2007NAFDAC also 
successful closed down the Onitsha market. Some commentators have 
wondered why it took NAFDAC so long to deal with the counterfeit problem 
in Onitsha. Some of the reasons for the delayed were the size of the market  
and determination of the counterfeit criminals in the Onitsha market.  Onitsha 
market is one the biggest markets in Nigeria, and it has many accesses and 
outlets, so in order to avoid a gang war when closing down the market, 
NAFDAC needed to recruit a large and prepared security force  to raid the 
premises. Several days after the market closure, NAFDAC was able to 
apprehend and destroy a seven 20feet container of fake drugs and large 
quantities of packaging materials. Other fake labels for various products of 
highly reputable companies were seized, whilst an illegal clinic which 
produced fake injections and infusions was also destroyed.   
 
Another major accomplishment of NAFDAC in reducing the presence of 
counterfeit drugs in the Nigerian market has been the successful implemented 
and registration of drugs; at present the statistic of registered drugs in Nigeria 
stands at 89%.582 Thus in comparison to the level of unregistered drugs in 
2001, this is an enormous achievement.  
 
Another major accomplishment of NAFDAC in its fight against counterfeit 
drugs is the introduction of the Ahura Tru Scan which has made it easier to 
identify counterfeit medicines. The Ahura Tru Scan is named after Ahura 
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Scientific, its United States manufacturer. This device is a chemical 
identification hand machine. It puts accurate and traditional lab based 
instruments in portable systems and is designed for field use. The device is 
effective in making it possible to distinguish between genuine and counterfeit 
medicines.583  
 
 Another major improvement that NAFADC has achieved in the fight for 
access to safe and good quality drugs is to ensure that some drugs are obtained 
strictly on prescription. Thus the irrational use of drugs without prescription 
encourages drug counterfeiting.  Whilst this was not the case in the past, today 
all injections and sedatives in Nigeria can only be purchased on prescription. 
Kenya also faces the problem of counterfeit drugs infiltrating the markets due 
to its  practice of buying medicines without prescription. 584  The Kenyan 
population like many Nigerian practice a lot of self medication. Thus many 
drugs which are used in the treatment of opportunistic diseases including 
HIV/AIDS can easily be accessed by consumers over the counter. The harmful 
effects of this cannot be overstated,  some commentators have used the term 
manslaughter to describe the illicit lethal trade in counterfeit drugs, indeed, 
some have even called it murder. Dr Dora Akunyili described her outrage by 
declaring that “criminals are making these fakes in the full knowledge that 
their ineffective product might kill people who would otherwise survive [many 
infections and diseases].”585 Statistics show that 60% of the population practice 
self medication, especially in the rural areas where the lack of infrastructure, 
                                                            
583 Fake drug detection made easy. Daily Trust. Tuesday, February 2, 2010. 
584 Counterfeit drugs continue to flood markets 
Board warns of devastating impact of narcotics as trafficking continue unabated 
2 March 2007 - Zachary Ochieng 
Source: NewsfromAfrica 
http://www.newsfromafrica.org/newsfromafrica/articles/art_10823.html (Accessed 9 May 
2008) 
585 Prof.  Dora Akunyili. Keynote Address, NAFDAC at the International Conference of Heads 
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clinics and un-stocked hospitals force the communities to rely on “dukas” and 
kiosks. 
 
In order to better understand the seriousness of the problem of counterfeit 
medicines in Nigeria, a look at other African countries like Kenya and Liberia 
is necessary to show that Nigeria is not the only country in Africa facing the 
problem of counterfeit medicines in the region. The reason for choosing Kenya 
is that it has one of the most advanced generic industries in Africa and is  
regarded as a powerhouse for the manufacture and distribution of drugs in the 
sub-Sahara.. What happens in Kenya is therefore important in accessing the 
African situation.Kenya has a number of pharmaceutical companies that are 
producing medicines for the local population of Kenya.The local drug 
manufacturers is represented by the Industry Association and The Kenya 
Federation of Pharmaceutical Manufacturers. These association have 
pharmaceutical  companies such as Biodeal Laboratories Ltd, whose Managing 
Director is the Chairman of Association, Universal Limited, GlaxoSmithKline 
East Africa Limited, Ellys Chemical Industries Limited, Pharmaceutical 
Manufacturing Company Limited, Cosmos Limited, Regal Pharmaceutical 
Limited, Dawa Pharmaceuticals Limited, Beta Healthcare International 
Limited and almost 30 other manufacturers and a host of authorized firms for 
international brands and generic manufacturing. These companies come second 
only to South Africa in the Sub-Saharan Africa region in the manufacturing 
and distribution of drugs. This has made them a formidable force in the east 
and central Africa region.  
 
Despite commendable progress Kenya has made in developing its 
pharmaceutical companies to provide access to medicines for its local 
populations, a report by WHO showed that Kenya is still struggling with a 
growing network of counterfeit drug dealers. An assessment conducted by the 
National Quality Control Laboratories (NQCL) and the Pharmacy and Poisons 
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Board stated  that approximately 30% of all the drugs in Kenya are counterfeit.  
Further figures provided by the Kenyan Association of Pharmaceutical 
Industry, counterfeit pharmaceutical commodities account for roughly $130 
million annually in sales in the country.586  
 
The Pharmacy and Poisons Board, Kenya’s drug regulatory body which 
performs the same functions as NAFDAC in Nigeria was set up under the 
Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya as a parastatal 
of the Ministry of Health to tackle the trade in counterfeit;587 however it has 
not been as successful as NAFDAC in confronting the counterfeit criminal 
gangs in the country. The Pharmacy and Poisons Board mission statement is to 
regulate pharmacy through the following routes namely: manufacturing and 
trading in drugs and poison with the central aim of achieving the highest 
standard of safety, efficacy and quality of drugs, chemical substances and 
medical devices; and locally manufacturing importing, distributing, selling and 
using medicines to ensure the protection of the consumer.588  The Board has 
nevertheless found itself struggling because the Board is seriously understaffed 
with only 20 inspectors to monitor and control over 3000 chemists, pharmacies 
kiosks and dukas in the country. At the same time, Kenya is the hub of regional 
trade in East and central Africa, and this has served to attract drug dealers. This 
status quo is further compounded by Kenya’s slackness in supervising the flow 
of international drugs.589 
 
The trade in counterfeit drugs has continued to grow through the 
misrepresentation of products and identity. Some of which include 
misdiagnosis, misconduct, failures by physicians to examine charts, the 
                                                            
586 Around the world: reports of counterfeit medicines 
http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/index1.html 
(Accessed 14th March 2008) 
587Pharmacy and Poisons Board. Ministry of Health, Kenya on  
boardkenya.org/index.php?id=14   
588 Ibid 
589 OTC Healthcare in Kenya. http://www.euromonitor.com/OTC_Healthcare_in_Kenya 
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persistent dispensing of medications dangerous to fastidious health conditions 
and the dispensation of the wrong prescriptions by pharmacy personnel to 
patients.590   
 
On the other end of the spectrum is Liberia. The reason for choosing Liberia is 
not only is it neighbours with Nigeria but it too faces the problem of 
counterfeit medicines,  This along with the problem of poverty and civil  wars 
in the region have made the challenge of meeting the healthcare needs of its 
population near enough impossible to meet. Liberia is a small west African 
country with a population of approximately 3 million people.591 It was locked 
in a brutal civil war for fourteen years between 1989 until the signing of the 
Accra Comprehensive Peace (CPA) in August 2003. During that period more 
than 250,000 died and over a million people were displaced,  this figure 
included the hundreds of thousands of refugees who fled the country. During 
that time many of the hospital facilities were destroyed and looted. The war led 
to many trained and qualified health professionals fleeing the country to other 
neighbouring countries. This has in the long run led to a shortage of healthcare 
staff which has further compounded the public health crisis of the country. 
Before the war, there were 296 primary health care facilities of which 164 
were destroyed. Similarly there were 18 hospitals and presently only 12 
hospitals which are located in mainly urban areas exist.592 The effect of this is 
the clearly flourishing environment in which counterfeit trading can flourish. 
In the 1990’s a surge of “health care professionals” form the Democratic 
Republic of Congo (DRC) came into Liberia, eighty percent of the physicians 
                                                            
590 Health Care in Liberia: fake doctors, counterfeit drugs, and no alternative for patients By: 
Nyankor Matthew The Perspective. Atlanta, Georgia. February 7,  2007 
http://www.theperspective.org/articles/2007/0207200701.html 
591  Liberia: Health/Nutrition Sector report. WHO report 29 Nov 2003  
 http://www.reliefweb.int/rw/rwb.nsf/AllDocsByUNID/0be90e8ce8c5fe65c1256df700474ee0 
Prof.  Dora Akunyili. Keynote Address, NAFDAC at the International Conference of Heads of 
West African Drug Regulatory Agencies held at the ECOWAS Secretariat, Asokoro, Abuja, 
17th March 2006 
592 Africa Development Forum (ADF-V) Liberia Country Brief Presented by the Ministry of 
Youth & Sports November 2006  
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who came into Liberia from the 1990's to seek professional certification from 
the Angolan Physicians Association were impostor. Due to the lack of fake 
diploma detection mechanisms, these individuals were given certification to 
practice medicine have continued to practice medicine in the country.593  
 
Counterfeiting and medical imposters are not the only contributory factors to 
the lack of access to medicines in many sub-Saharan countries. In the case of 
Liberia the destructive nature of the prolonged civil war has had a catastrophic 
nature on Liberia's physical, social, political and economic infrastructure, as 
such its human development indicators mirrors the frightening stipulation of 
the population. Over 80% of Liberia's population is illiterate and lives below 
the poverty line.594 The unemployment rate exceeds 70%. Thirty-five percent 
of Liberians are malnourished, only 28% are fully immunized, 25% have 
access to safe drinking water, and only 36% have access to sanitation facilities. 
The prevalence of transmittable diseases such as HIV/AIDS, TB and River 
Blindness continues to escalate at an alarming rate.595 In Liberia, HIV/AIDS is 
estimated to affect 8.2% of the population between the ages of 15-49 years.  
According to the Ministry of health statistics, between 1986 and 2002, the 
AIDS cases increased among young people from 4.2% to 12.9%. The lack of 
knowledge, exacerbated by poverty, and multi-sexual behavioural practices 
continue to pose great challenges for the survival of young adolescents 
especially females who have been the main victims of rape and sexual abuse 
throughout the civil war.596  Female Genital Mutilation (FGM), teenage 
pregnancy, abortions and prostitution are closely associated with the healthcare 
problems facing Liberia and women in particular. These factors are all 
contributory factors to the successful trade in counterfeit drugs and criminal 
                                                            
593 According to the (Angola Press Agency, 2006-04-24) 
594 Liberia: Health/Nutrition Sector report. WHO report 29 Nov 2003 
 http://www.reliefweb.int/rw/rwb.nsf/AllDocsByUNID/0be90e8ce8c5fe65c1256df700474ee0 
(Accessed 20th June 2008) 
595 Ibid  
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activity. The international community and national governments are aware that 
efforts must be codified to arrest the spread of counterfeit drugs 
internationally, and  one of the most effective ways it has sought to do this is 
through the work of IMPACT. 
 
6.8     The Fight against Counterfeit  
 
The fight against counterfeit medicines and its destructive nature have led to 
various organisations been set up both internationally and by individual states. 
A good example of this is the primary universal partnership known as 
International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT)  
which was set up on 26 February 2006 by WHO to fight counterfeit drugs and 
mobilize attentiveness and action to tackle the issue of counterfeit medicines.  
At a conference to advance the global prevention, tracking and detection of 
counterfeit medicines, Dr Howard Zucker, the WHO assistant Director-
General for Health Technology and Pharmaceuticals said the purpose of 
IMPACT is to ensure that counterfeit medicines are “tackled not only through 
global efforts but also by a truly collaborative, cross-cutting approach 
involving medicine regulatory authorities, health professionals, enforcement 
officials, law-makers and industry.'597 This assertion demonstrates the 
imperative of the need to eradicate the plague of counterfeit medicines through 
a multi-sectoral approach. 
 
IMPACT is made up of 193 WHO member states on a voluntary basis and 
includes international organizations such as the World Bank, the World Trade 
Organisation and the International Federation of Pharmaceutical Manufacturers 
Associations, enforcement agencies such as Interpol, the World Customs 
Associations, patients' , national drug regulatory authorities, customs and 
police organizations, non-governmental organizations, associations 
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representing pharmaceutical manufacturers and wholesalers, health 
professionals and patients’ groups. These groups have come together with the 
sole aim of improving organization and coordination between countries so that 
eventually the manufacture, trading and selling of fake medicines can be 
eliminated. To accomplish this mandate, IMPACT has decided to focus on the 
following five key areas: legislative and regulatory infrastructure; regulatory 
implementation; technology and risk communication. 
 
IMPACT  held its first public meeting in Singapore, 13-15 February 2008 with 
the forum theme  "Combating Counterfeit Medicines: Where the Regulatory 
and Technology Roads Meet".598 In the meeting it was agreed that technology 
is imperative as one of the key ways of confronting counterfeiters. Advanced 
technology will help manufacturers upgrade their standards, and enable 
regulatory authorities strengthen the screening and testing of local and 
imported products.599  In March 2007, more than twenty technology companies 
responded to a call to support the fight against counterfeit medicines.600 
Speaking in her capacity as Chair of the IMPACT Working Group on 
Regulatory Implementation, Dr. Bernstein commented: "Anti-counterfeiting 
technologies are evolving fast and the field is an increasingly complex one. 
Pharmaceutical manufacturers and regulators have an interest to keep 
themselves informed about developments and this IMPACT Forum should 
provide a handy means of doing so." 601  
 
The US FDA. has recently recommended the use of Radio Frequency 
Identification Technology (RFID) as a way of tracing drugs. As such numerous 
pharmaceutical companies are experimenting with RFID and Optically 
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599 Pincock. S  (2003) WHO tries to tackle problem of counterfeit medicines in Asia. BMJ. 
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600Zucker, H. “WHO Coalition Examines Technology to Prevent Fake Drugs.” 
Emaxhealth.com. 19 Mar. 2007 
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Variable Devices (OVDs) or using Bar Codes or other technologies such as 
web portals that can help track and authenticate the drugs.602 Other RFID 
recommendations include putting electromagnetic chips and tags that have a 
unique serial number into cartons and individual drug products, and using anti-
counterfeiting technologies such as colour-shifting inks, holograms, and 
chemical markers built-in into a drug or its label.603  Many pharmaceutical 
companies have agreed that this is the way forward in ensuring that problem of 
counterfeit drugs is eradicated. By utilizing the broad partnership from health 
agencies to pharmaceutical manufacturers and distributors, IMPACT has  
proposed to help develop innovative solutions.  
 
Another key way in which IMPACT intends to halt the spread of counterfeit 
medicines is by putting in place regulatory reforms.604 In many countries, 
poverty and lack of political have created a market for counterfeit 
products.605IMPACT has sought to identify the means by which regulators can 
take action and implement ways to tackle counterfeit medicines. These 
measures include revised approaches to ensure that standards for quality, safety 
and efficacy are implemented and distribution chains are effectively controlled. 
Because regulatory oversights of pharmaceuticals are ineffective, especially in 
distribution channels. Coordinated action at the local level is essential between 
health authorities, police, customs, and judiciary institutions to ensure proper 
regulation, control, investigation and prosecution.606 Medicines need to be safe, 
effective and of good quality in order to generate the anticipated remedial 
effect. Guarantee these properties requires equipping skilled national drug 
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regulatory authorities with the necessary human and other resources to control 
the manufacture, importation, distribution and sale of medicines.607 IMPACT 
has pledged to help countries with weak regulatory systems to strengthen them 
by improving collaboration and drawing from the experience, capacity and 
resources of all IMAPCT stakeholders. 
 
Through enforcement, IMPACT asserts that it will help to identify and 
coordinate action between customs, police and the judiciary of different 
countries to monitor borders, track counterfeit goods and apprehend 
counterfeiters. By working with the World Customs Agency, INTERPOL, and 
informal networks of enforcement officers IMPACT aim to facilitate 
communication between enforcement and health authorities, improve 
international collaboration and develop appropriate mechanisms that will 
enable importing countries, especially in the developing world. This it is 
emphasized will trigger investigation and identification of the actual source of 
counterfeit medicines plaguing markets throughout the world.   
 
Risk communication, education and awareness programmes are also ways by 
which IMPACT is directing its efforts towards combating counterfeit drugs. 
IMPACT has resolved to identify and create the most coordinated and effective 
mechanisms required to respond and alert key audiences, stakeholders and the 
general public about counterfeits in communities all over the globe. 
Commentators have endorsed this approach by citing ways that this can be 
achieved namely by setting up information campaigns through radio and TV 
advertisements, banners, billboard adverts, publicity shows, events and even 
facebook.608 International information networks can also be created and 
reinforced to monitor the traffic of goods, exchange information, issue alerts 
from country to country and region to region. Increased public information is 
                                                            
607 Ibid 
608Counterfeit Medicines – The Global Hazards.  
http://www.pharmainfo.net/reviews/counterfeit-medicines-global-hazard 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
206 
 
essential for patients, dispensers, and doctors who have a right to know if there 
are suspect goods on the market but must also contribute to detecting 
counterfeits by reporting and helping to investigate suspicious cases.609 Special 
initiatives can also be launched to make internet users aware of the risks they 
run when purchasing medicines from unknown sources and to address 
consumers in extremely poor and rural areas where patients may be unable to 
make informed choices and may not be aware of their rights.610   
 
Given the disparities between the level of technological access in industrialized 
and developing countries, IMPACT plans to help facilitate the transfer of 
technology across both developed and developing countries. Technology it is 
asserted can contribute creative tools and in some cases leapfrog lengthy legal 
and administrative processes to provide faster solutions.  
 
In 2007, a working group at the WHO came up with a draft “The Principles 
and Elements for National Legislation against Counterfeit Medical Products”, 
it outlined the necessary legislative steps that must be taken if counterfeit 
medical products were to be addressed, and that was “through different bodies 
of legislation: on intellectual property protection and enforcement, on 
pharmaceutical and medical devices regulation and control, and criminal 
law”.611   
 
Some of the legal problems that have been identified is the fact that legal 
systems throughout the world are not well equipped to deal with the serious 
consequences of counterfeit medicines. The latter coupled with the fact that the 
penalties for counterfeiters are not severe enough have all encouraged the 
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611 The Principles and Elements for National Legislation against Counterfeit Medical Products 
in Lisbon, 12 December 2007. 
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existence of counterfeit trading throughout the world.612  IMPACT has asserted 
that stronger legislation will help empower those who have to deal with 
counterfeits and counterfeiters in the course of their work; namely, the police, 
customs officials and the judiciary. Laws in all countries need to enacted or 
reviewed to meet these global challenges that the world has had to contend 
with in making sure that access to authentic medicines is met. IMPACT has 
also pledged to focus on developing a set of principles for the establishment of 
appropriate legislation and penal sanctions including a clear legal definition of 
counterfeit medicines.613 
 
Another main organisations used to confront counterfeit medicines is the 
World Customs Organisation (WCO) which represents 171 customs 
administrations and is the main source of technical assistance to customs 
administrators. WCO has worked within WCO Standards Employed by 
Customs for Uniform Rights Enforcement (SECURE) to develop ‘Model 
Provisions for National Legislation to Implement Fair and Effective Border 
Measures Consistent with the TRIPS Agreement’.614 Despite the ambition of 
the WCO, critics have argued that some of the measures used are TRIPS plus. 
Some of which include having the ability to suspend counterfeit goods destined 
for export. Another critisim is that its definition ‘infringing goods’ exceed  
counterfeiting goods under Article 51 of the TRIPS Agreement. On the other 
hand the model provisions has been identified as lacking the authority to 
enforce policies that contradict the WTO.615 Indeed commentators have argued 
that the role of the WCO should be limited to training and capacity building of 
customs officials.616 
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The US Strategy on Targeting Organised Piracy (STOP) is co-ordinated by teh 
US government and seeks to encourage its trading partners to seize counterfeit 
goods at US borders. Their major outlets are to ensure that there are laws 
which protect IPRs and they are in turn enforced. To ensure that these laws are 
enforced the USTR is working in union with foreign governments through 
treaties, the promotion of best practices, technical assistance, the G8, the 
OECD, the US-EU summit, Asia-Pacific Economic Cooperation (APEC) 
forum and teh Security and Prosperity Patnership (Canada and Mexico).617 
Importantly too is the Anti Counterfeiting Trade Agreement (ACTA) which 
has been described as a response to "to the increase in global trade of 
counterfeit goods and pirated copyright protected works’.618  Accordingly, teh 
USTR has pointed out that teh agreement would not bring about changes to the 
TRIPs Agreement. It intends to set up a higher standard of enforcement that 
can be joined on a voluntary basis. Although the ACTA would address the 
problem of counterfeit products more than has been done so far, some have 
expressed concerns that it will require many signatories to undertake such a 
widescale expansion of customs and policing of goods and information.619 
The case for access to medicines for HIV/AIDS, malaria and tuberculosis 
requires that patients receive the correct authentic medication to treat their 
ailments and it requires that counterfeit medicines be fought on all levels. It 
also requires that collaboration be instigated on a national, regional and 
international level. It must include all stakeholders such  as patients, health 
professionals,  manufacturers, distributors, lawmakers and law enforcement 
agencies.  
 
                                                            
617  See Tekeste Biadgleng, E. And Munoz Tellez, V., 2008, The Changing Structure and 
Governance of Intellectual Property Enforcement, South Centre, Geneva, 
618 Ministry of Economic Development of New Zealand (2008). "On Anti-Counterfeiting 
Trade Agreement". 
619 Shaw, A., 2008, “The Problem with the Anti-Counterfeiting Trade Agreement (and what to 
do about it),” KEStudies. 
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6.9       Summary 
Many developing countries including Nigeria are saddled with both problems 
of neglected diseases and counterfeit medicines which contribute to preventing 
access to medicines. Nevertheless the fact that TRIPS Agreement has 
contributed to increasing the prices of medicines for the majority of the 
population cannot be ignore, still it cannot be blamed for the criminal activities 
of counterfeit traders nor the fact that some diseases are considered by MNC 
not to be profitable enough to invest in. It is therefore the responsibility of 
Nigeria and other developing countries to tackle the problem of neglected 
diseases and counterfeit drugs. One of the ways that Nigeria can get around 
this is by engaging in R&D for neglected diseases.  
 
By engaging in their own R&D, Nigeria will have the flexibility of setting its 
own agenda to research into neglected diseases that affect them rather than 
being at the mercy of pharmaceutical companies in the industrialised world 
who are reluctant to  conduct  R&D for diseases that affect poor people who 
cannot afford to pay for the medicines. In setting their own agenda, Nigeria 
will be able to concentrate on finding more anti-retroviral drugs, malaria 
medicines and other medicines for dieases which are peculiar to the indigenes 
but are not lucrative avenues for MNCs. Although it is true that some 
pharmaceutical companies have begun to conduct more R&D into neglected 
diseases and have provided some partnership initiatives to fight neglected 
diseases, some of these initiatives have not gone far enough in tackling many 
of the diseases that are exclusive to poorer counties such as dracunculiasis and 
chagas diseases.  
 
One of the ways in which Nigeria can conduct more R&D into neglected 
diseases is through partnerships between the local industries and the 
universities. Such partnerships are being undertaken all over the world 
especially between US universities and pharmaceutical companies. Only 
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recently AstraZeneca announced a strategic partnership with Peking University 
in China. Such partnerships are invaluable in the way that they  enhance local 
clinical research capabilities and speed up access to new medicines that may in 
turn benefit Nigerian patients. The Nigeria governments should also continue 
to use NAFDAC  to fight counterfeit drugs as a way of gaining access to 
medicines. Indeed one of the ways it may further deter such activities in 
Nigeria is by criminalising the production of counterfeit drugs or the sell of 
fake drugs that causes grievous bodily harm or death.620  Fines and severe 
penalty can also be used as a way of sending a clear signal that the Nigerian 
government will not condone such practices. 
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     PART III 
7 THE FLEXIBILITIES WITHIN THE TRIPS 
AGREEMENT EXPOSED  
7.1  Introduction  
Eight million people die every year for the price of going out with your friends 
to the movies and buying an ice cream. Literally for about $30 a head per year, 
you could save 8 million lives. Isn't that extraordinary? Preventable disease - 
not calamity, not famine, nothing like that. Preventable disease - just for the 
lack of medicines. That is cheap, that is a bargain. 
Bono 
 
Target 6b: Achieve, by 2010, universal access to treatment for HIV/AIDS for 
all those who need it. 
 6.5 Proportion of population with advanced HIV infection with access 
to antiretroviral drugs. 
Millennium Development Goals 
 
This chapter presents a critical analysis of the background of the Doha 
Declaration in light of the clarifications which it brought to the flexibilities 
within the TRIPS Agreement. When the Declaration was first adopted in 2001, 
many commentators praised it for being one of the most important 
achievements and victories for public health in developing countries. However, 
less than a decade after, many begun to question its achievement in bringing 
about access to medicines as it was intended to do. In the wake of the US and 
EU pressure to enforce TRIPS-Plus measures in regional and bilateral 
agreements, the cracks in the Doha Declaration had begun to show. For many 
countries like Nigeria who face consistent pressure to introduce a TRIPS plus 
regime the battle rages on.621  
                                                            
621 An example of TRIPS plus pressures from the EU include the  EU-West Africaxxiii EPA  
where West Africa was encouraged to  ratify or accede to UPOV (1991) and comply with 
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In examining the flexibilities in the TRIPS Agreement and the victory of the 
Doha Declaration, a detailed analysis of what compulsory licenses and parallel 
importation mean to developing countries and how successful they have been 
in using them will be carried out. This chapter will also look at the operation of 
compulsory licenses and parallel importation in developed countries in a bid to 
show the inequality of the multilateral trading regime that has been 
successfully implemented through the WTO. It will also carry out a detailed 
anaylsis of the way in which parallal imporatation has been interprettaed in the 
US courts in a bid to show whether or not the usage and interpretation of 
parallel importation by developing countries can be problemeatic\ 
 
7.2 What Brought About the Doha Declaration? 
The Doha Declaration on the TRIPS Agreement and Public Health (of 
November 14, 2001) was adopted in response to the outcry of developing 
countries and least developing countries that TRIPS had brought an end to the 
era of access to medicines. The Declaration sought to clarify and reiterate the 
options and flexibilities within the TRIPS Agreement that developing and least 
developing countries could take advantage of, in order to circumvent the 
unmistakable public health crisis that had arisen in the form of the HIV/AIDS 
epidemic in many developing countries.622  The first special discussion on 
intellectual property and access to medicines was spearheaded at the request of 
the African Group on 20 June 2001.623 Developing countries wanted 
reassurance that they could use compulsory licenses and parallel importation in 
                                                                                                                                                            
various provisions of the Budapest Treaty.  In Cotonou Agreement  2000, the parties are 
obliged to recognize the need to ensure adequate and effective protection of patents on plant 
varieties and on biotechnological inventions.  
 
 
622 Heimel. A.Y (2004). THE POWER OF A PATENT: THE IMPACT OF INTELLECTUAL 
PROPERTY IN THE FREE TRADE AREA OF THE AMERICAS AGREEMENT ON THE 
PLIGHT OF PRESCRIPTIONDRUG AVAILABILITY AND AFFORDABILITY IN CENTRAL 
AND SOUTH AMERICA. 16 Pace Int’l L. Rev. 447 
623 Sun. H ( 2004). THE ROAD TO DOHA AND BEYOND: SOME REFLECTIONS ON THE 
TRIPS AGREEMENT AND PUBLIC HEALTH. 15 Eur. J. int’l L. 123 
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the wake of strong pressures from pharmaceutical industry not to do so.624  It 
was therefore necessary to clarify that the flexibilities within the TRIPS 
Agreement could be interpreted in a way which would allow members to 
comfortably establish the link between intellectual property rights and access 
to medicines.625  
 
Zimbabwe issued a statement on behalf of the African Group which stated that 
“We propose that Members issue a special declaration on the TRIPS 
Agreement and access to medicines at the Ministerial Conference in Qatar, 
affirming that nothing in the TRIPS Agreement should prevent Members from 
taking measures to protect public health”.626 What appeared apparent was the 
fact that developing countries saw the need to have one voice if they wanted to 
be clear that they were prepared to take the necessary steps to protect and 
advance their fundamental interest in gaining access to medicines. The 
members of the Africa Group were headed by Barbados, Bolivia, Brazil, 
Dominican Republic, Ecuador, Honduras, India, Indonesia, Jamaica, Pakistan, 
Paraguay, Philippines, Peru, Sri Lanka, Thailand, and Venezuela.627 The 
African group was concerned that the public health problems facing many 
developing countries were escalating without a solution to the problem. One of 
the most worrying problems confronting them was how to halt the spread of 
the HIV/AIDS epidemic.  Sub-Sahara has one of the highest percentages of 
people who are living with HIV/AIDS and yet lack access to medicines 
because of the high cost of medicines; yet not a lot of countries from the sub-
                                                            
624 See WTO NEWS, 'Moore: Countries Must Feel Secure That They Can Use TRIPS' 
Flexibility'. 20 June 2001. Also note that there are other flexibilities within the TRIPS 
Agreement such as data exclusivity and novelty criteria, but the group of developing countries 
paid more attention to parallel importation and compulsory licensing. 
625 TRIPS Public Health', Submission by the Africa Group, Barbados, Bolivia, Brazil, 
Dominican Republic, Ecuador, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, 
Philippines, Peru, Sri Lanka. Thailand and Venezuela, 29 June 2001, IP/C/W/296. 
626 See WTO Council for Trade-Related Aspects of Intellectual Property Rights, Special 
Discussion on Intellectual Property and Access to Medicines 4, WTO Doc NO IP/C/M/31 
(Restricted) (July10, 2001) [on File with CJIL] 
627 Advance Copy (Unrestricted-IP/C/W/296), Council for TRIPS, 19 June 2001 (final text 
available at http://www.wto.org). 
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Sahara were present at the African group. The absence of many active Member 
states from the sub-Saharan region during the Doha Ministerial discussions 
raises some interesting questions about why they were also underrepresented at 
the GATT. 
 
The fact that HIV/AIDS is one of the leading causes of death in many 
developing countries  has led many to assert that developing countries were 
right to have been at the forefront at Doha demanding and calling for changes 
and clarifications on the flexibilities within the TRIPS Agreement which 
would in turn provide increased access to medicines. Developing countries had 
been accused of not asserting themselves during the Uruguay rounds, indeed 
most of them where seen as ‘quiet bystanders’ who lacked the expertise or 
political representation to partake wholly.628  Another explanation that has 
been pointed out that explains why many countries from the sub-Saharan were 
not appropriately represented at the GATT is the comparative lack of resources 
among developing country delegations in Geneva which has consistently led to 
underrepresentation.629 
 
The European Union for example administers local operations through 
democratic local governance, decentralisation and territorial development 
sometimes with the objective of developing and pursuing policy positions in 
international agreements. 630 By so doing, the EU as a bloc usually find that 
they have sufficient personnel to attend international meetings where 
specialized representation is needed. Many developed countries have always 
had a significant advantage over developing countries when it comes to being 
                                                            
628 Wilkinson R and Scott. J(2008)  Developing country participation in the GATT: a 
reassessment. World Trade Review  
629Abbott. F. M (2002)  THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO 5 J.Int’l Econ. L. 469 
630 Juergen K Binder, Peter Slits, Remi Stoquart, Dr. Jospeph Mullen  and Carlos Buhigas 
Schubert. Towards an EU approach to democratic local governance, decentralisation and 
territorial development. Background Paper. Project No. 2007/147439 – Version 1 See: 
http://www.deleri.ec.europa.eu/whatsnew/Background%20paper.pdf 
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represented at the WTO ministerial meetings. Whilst many developed 
countries tend to have permanent representatives at international organisations, 
developing countries on the other hand had very few delegates who were 
competent enough to be permanently situated at Geneva. Even when they were 
competent personnel, they are hardly permanently stationed in Geneva as they 
are usually other international institutions and meetings that required their 
attention.  
 
Regardless of the foregoing, it must be noted that international efforts have 
been made by several organizations to ensure that developing countries are 
fully represented at the WTO. Note that the Advisory Centre on WTO Law 
(ACWL) was established in July 2001 to give free advice on the WTO laws to 
all members of the WTO; and alleviate the difficulties faced by developing 
countries and LDC in gaining expert knowledge on the TRIPS Agreement.631 
Since 2004, the Agency for International Trade Information and Cooperation 
(AITIC) established in 1998 has been transformed into an intergovernmental 
organization to enable LDC gain from globalization through the multilateral 
trading system.632 Nevertheless when it comes to the responses of individual 
countries to the Geneva-capacity problem,633 a few developed countries have 
taken concrete actions to readdress the situation.634  Netherlands and Norway 
have also provided funding to help in the formulation of developing country 
                                                            
631 See Advisory Centre on WTO Law. How to Use the Services of the ACWL. A Guide for 
Developing Countries and LDCs. http://www.acwl.ch/pdf/how_to.pdf 
632 Business for Development. Fostering Trade through Private –Public Dialogue. A Business- 
Government Forum in Hong Kong. Hong Kong, China, 11-12 December 2005. 
http://www.intracen.org/hongkong/docs/Concept-Paper.pdf 
633   Abbott. F.M (2002)  THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO. 5 J.Int’l Econ. L. 469 
634 The U.S. government and U.S.-based IP private industries provided extensive training for 
foreign officials and nationals; Nigeria was one of participants in the program. Allison Areias. 
INTELLECTUAL PROPERTY TRAINING AND TECHNICAL ASSISTANCE 
PROGRAMS. http://usinfo.state.gov/products/pubs/intelprp/training.htm 
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policy papers, and assisted them in arranging a system where they can 
exchange views and opinions freely.635  
 
Developed countries on the other hand encompassing countries like Australia, 
Canada, Japan, Switzerland and the US have consistently aligned themselves 
together at the WTO.636  Characteristically, during the Doha rounds, the US 
took the US PhRMA position that patents do not lead to increased prices.637 It 
also reiterated that compulsory licence should be used restrictively, and 
asserted its position that the TRIPS should not be interpreted in a manner 
which would allow Members to establish its policy on parallel importation.638 
The emergence of a strong group of delegates from developing countries 
enunciating and advocating an intelligent position at the Doha declaration 
made a difference. Although initially it was not very clear which direction the 
pendulum would swing, the second Ministerial Council meeting on 25 July 
2001 was held, with a third and fourth meeting scheduled for 19 and 21 
September 2001.639 During the meetings the African group presented their 
paper to the TRIPS Council. Interestingly, observers have noted that the group 
of developing countries were more active at the Doha rounds because they had 
learnt their lesson from the Uruguay rounds. The price of being ‘ordinary 
observers’ at the Uruguay rounds were far too costly to repeat the same 
mistake again. For it had put the prices of medicines outside their reach by 
introducing the 20 year patent term which had put the prices of medicines 
outside their reach. 
 
                                                            
635 The Quaker United Nations Office (QUNO) has actively provided logistic support for 
developing country delegations. 
636 Sun. H ( 2004). THE ROAD TO DOHA AND BEYOND: SOME REFLECTIONS ON THE 
TRIPS AGREEMENT AND PUBLIC HEALTH. 15 Eur. J. int’l L. 123 
637  Ministerial Conference, Fourth Session, Doha, 9-14 November 2001, WT/MIN 
(01)/DEC/2, 20 November 2001. 
638 Abbott. F,M (2002)   THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO. 5 J.Int’l Econ. L. 469 
639A brief summary of the meetings can be found at http:// www.wto.org. 
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7.3  Demands of the Developing Countries during the Doha 
Declaration. 
Five major issues arose as the main crux of the African group’s demands. 
Firstly they wanted Public health to be considered in a broader context. They 
wanted HIV/AIDS, tuberculosis, malaria and other epidemic to be 
acknowledged as a serious health crisis.640 This was essentially the content of 
Para 1 of the Declaration on the TRIPS agreement and public health as adopted 
on 14 November 2001. Commentators have suggested that by demanding the 
recognition and significance of the public health problems facing the 
developing and least developed countries, the Doha Declaration broadened the 
scope of public health problems that developing countries could address. It 
also compelled Member states to confirm the relevance of the objectives 
(Article 7)641 and principles (Article 8)642 for the interpretation of the TRIPS 
Agreement. This was in accordance with the customary rules of interpreting 
public international laws based on Articles 31 and 32 of the Vienna 
Convention.643 Art 31 and 32 requires each provision of the TRIPs Agreement 
to be read in the light of the object and purpose of the Agreement as expressed 
in its objectives and principles.644  
 
Secondly, developing Members wanted the flexibilities available in the TRIPS 
Agreement such as compulsory licensing and parallel importation reiterated in 
                                                            
640 DOHA WTO MINISTERIAL 2001: TRIPS WT/MIN(01)/DEC/2. 20 November 2001 
Declaration on the TRIPS agreement and public health. Adopted on 14 November 2001 
641 Article 7 states that “the protection and enforcement of intellectual property rights should 
contribute to the promotion of technological innovation and to the transfer and dissemination 
of technology, to the mutual advantage of producers and users of technological knowledge and 
in a manner conducive to social and economic welfare, and to a balance of rights and 
obligations”. 
642 Article 8 states that “Members may, in formulating or amending their laws and regulations, 
adopt measures necessary to protect public health and nutrition, and to promote the public 
interest in sectors of vital importance to their socio-economic and technological development, 
provided that such measures are consistent with the provisions of this Agreement”. 
643 See Appellate Body Report, US – Gasoline, WT/DS2/AB/R, p.17 and Appellate Body 
Report, Japan – Taxes on Alcoholic Beverages, WT/DS8/AB/R, WT/DS10/AB/R, 
WT/DS11/AB/R, p.10.  
644 Gathii, J.T (2002) The Legal Status of the Doha Declaration on TRIPS and Public Health 
under the Vienna Convention on the Law of Treaties, 15 Harv. J.L. Tech. 296- 98  
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the Doha Declaration. It follows that the Doha Declaration was able to clarify 
that Article 31 of the TRIPS gave each Member the right to grant compulsory 
licences and the independence to determine the grounds upon which such 
licences are granted' (Paragraph 5(b) ). Impressively at the time the Declaration 
was also able to clarify that Members may grant  licenses not only during a) 
national emergency b) public non commercial use, c) anticompetitive practices, 
but had the autonomy to stipulate the grounds upon which such licenses may 
be granted. This was considered a major breakthrough.645The Doha 
Declaration went on to assure developing countries that they had the freedom 
to grant compulsory licenses in order to combat nearly all public health crisis, 
thus Para 5(c) allows each member dealing with public health problems 
including HIV/AIDS, tuberculosis, malaria and other epidemics to determine 
whether they are facing a national emergency or circumstances of extreme 
urgency. 
 
Thirdly, developing countries wanted the members of the WTO to 
acknowledge that despite the fact that enhanced patent protection leads to 
innovation in the development of new medicines, at the same time it increases 
the price of medicines beyond what the average patient in a poor country can 
afford.  Unsurprisingly, developing countries have always had serious concerns 
about whether patent protection encourages R&D on drugs for diseases that 
directly affect them.  To address this concern, developing countries attempted 
to address the lack of directive in the TRIPS Agreement to pharmaceutical 
companies to focus on R&D in diseases that affect poorer countries in the 
developing and least developing world. 
 
Fourthly, developing countries wanted to be given the assurance in Doha that 
they could adopt legislation in order to allow parallel imports without the 
                                                            
645  Matthew D (2004) The Decision on Implementation of Paragraph 6 of the DOHA 
Declaration on the TRIPS Agreement and Public Health: A Solution to the access to Essential 
Medicines Problem. 7 J. Int’l Econ. L 73 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
219 
 
consent of the patent holder. This stance genuinely epitomized the declared 
interest at Doha in helping developing and least developing countries obtain 
low-cost access to pharmaceutical medicines. Although this self-sufficiency to 
parallel import however is subject to the most favoured nations (MFN) and the 
national treatment provisions in Article 3 and 4 of TRIPS.646 Commentators 
have suggested that the authorization to permit parallel importation may be 
based on the consent of the patent holder; nevertheless the Doha Declaration 
does not elaborate on that. Paragraph 5(d) leaves each Member “free to 
establish its own regime for such exhaustion without challenge”, and that is the 
stance that most developing countries prefer to take. 
 
The fifth issue that the African group sought to resolve at the Doha Declaration 
was an extension of the transition periods for Members of the least developing 
counties to implement the TRIPS Agreement and pharmaceutical patent.647  
When the idea that the transition period for the implementation of the TRIPS 
Agreement be extended from 2006 to 2016, the United States sought an 
explanation as to why least developed countries might want to do this. The 
underlying principle for demanding such clarification was that such least 
developed countries were not required to implement the pharmaceutical patent 
protection until 2006 and therefore should not be concerned about the impact 
until then. Although the group succeeded in extending the deadline for LDC 
providing pharmaceutical patent protection and enforcing those rights until 1 
                                                            
646 Article 3:1 states that “Each Member shall accord to the nationals of other Members 
treatment no less favourable than that it accords to its own nationals with regard to the 
protection  of intellectual property, subject to the exceptions already provided in, respectively, 
the Paris Convention (1967), the Berne Convention (1971), the Rome Convention or the 
Treaty on Intellectual Property in Respect of Integrated Circuits”. Article 4 states that “With 
regard to the protection of intellectual property, any advantage, favour, privilege or immunity 
granted by a Member to the nationals of any other country shall be accorded immediately and 
unconditionally to the nationals of all other Members”  See also Haochen Sun. THE ROAD 
TO DOHA AND BEYOND: SOME REFLECTIONS ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH. 2004. Eur.J.Int’L.123 
647 Ministerial Conference, Fourth Session, Doha, 9-14 November 2001, WT/MIN(01)/DEC/2, 
20 November 2001. 
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January 2016,648 some thinkers have suggested that the transition period should 
not only be limited to pharmaceutical products but to all aspects of the 
Agreement.649 Further arguments along those lines suggest that even by 2016, 
it is uncertain whether LDCs and other low income countries should adopt the 
full range of the TRIPS Agreement. What has however been suggested is that 
each LDC or low income country be looked at on a case by case basis in order 
to avoid certain burdensome aspects of the TRIPS Agreement affecting 
countries adversely.650 Thus Constantine Michalopoulos writes that it is 
inappropriate to force LDCs and other low income countries to a fixed 
deadline. What developing countries need is the declaration by developed 
countries that technology transfer and technical assistance programs will be put 
in place to assist those countries towards economic and technical advancement.  
Technology transfer occurs when one firm transfer technology information 
from one firm to another, or from one country to another.651 Arguments have 
been also been put forward that the TRIPS Agreement fosters the slow flow of 
technology transfer to developing countries.652 Hence technology transfer has 
been identified as being an important aspect of sustainable development. The 
argument follows that for there to be successful transfer of technology 
emphasis should be laid on the transfer of technology from developed 
countries to developing and LDCs.653 In order for there to be sufficient transfer 
                                                            
648 Declaration on the TRIPS Agreement and Public Health, WTO Ministerial Conference, 
Fourth Session, Doha, Adopted on 14 November 2001, WT/MIN(01)/ DEC/2. 
649 Constantine Michalopoulos. Special and Differential Treatment of Developing Countries in 
TRIPS. 2000. Published by: Quaker United Nations Office (QUNO), Geneva, Quaker 
International Affairs Programme (QIAP), Ottawa Project undertaken with the financial support 
of the Government of Canada provided through the Canadian International Development 
Agency (CIDA) Available at http://www.quno.org/geneva/pdf/economic/Issues/Special-
Differential-Treatment-in-TRIPS-English.pdf 
650 Ibid 
651Keith Maskus. (1998)  The Role of Intellectual Property Rights in Encouraging Foreign 
Direct Investment and Technology Transfer.  Duke J. Comp. & Int'l L.  9: 109 
652Correa, Carlos. ( 2002.) Managing the Provision of Knowledge: the design of Intellectual 
Property Laws. In Inge Kaul et al, Providing Global Public Goods, Oxford University Press, 
New York  
653 Aaron Cosbey. The Sustainable Development Effects of the WTO TRIPS Agreement: A 
Focus on Developing Countries. International Institute for Sustainable Development. 
Winnipeg, Canada. 
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of technology, patent holders must set up factories in developing countries for 
domestic production.654 
 
Pharmaceutical companies however prefer to export their goods to other 
countries, rather than set up factories in the recipient countries.655656 Declaring 
the above, the successes of the Doha declaration must not be overlooked. By 
extending the dead line for the implementation of the TRIPS Agreement, to 
2016 least developing countries will be free to increase their own capacity to 
manufacture generic drugs or obtain low-priced drugs imported from other 
Members. The extension of the dead line gave LDCs the chance to adopt the 
necessary measures to use test data protection before the 2016 expiry date. In 
addition LDC now has until 2016 to propose and shape their national 
Intellectual property legislation in a way that will allow them to improve 
access to medicines by importing generic medicines and probably producing it. 
 
Developing countries seeking to make full use of the flexibilities within the 
TRIPS Agreement contend that data protection should not be used as a back 
door route to patent protection657. One of the concerns developing countries 
hoped to clarify at the Doha Ministerial meetings was whether Article 39 
establishes broad interpretations for national rules which allows member states 
to apply different types of protection or whether under Article 39 exclusive 
rights are given for test data.658  Before the TRIPS Agreement, countries had 
the option to choose whether to grant protection on test data or not, however 
Article 39.3 of the Agreement requires countries to protect test data against 
                                                            
654 Ibid 
655 Ibid 
656 See Ryan. M (1998)  Knowledge Diplomacy: Global Competition and the Politics of 
Intellectual Property, Brookings Institution, Washington DC, pp.67-72.  
Source: http://brookings.nap.edu/books/0815776535/html/ 
657 Abbott. F.M (2002) THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO. 5 J.Int’l Econ. L. 469 
658http://trade.busiaanessroundtable.org/trade_2006/wto/decision.html  
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“unfair commercial use”.659 The difficulty however remains that the term 
“unfair” commercial practice is not defined in the Agreement, the 
interpretation will depend on what the society believe it is at any particular 
given time.660 Additionally other language in Article 39 remains unexplained. 
Languages such as “new chemical entity”, “unfair commercial use”, 
“undisclosed test or other data” are open to interpretation. These shortcomings 
were not addressed at the Doha. Whilst some developed countries such as the  
 
US argue for a minimum period of exclusivity, this argument is not supported 
by the TRIPS Agreement For there to be access to medicines in accordance 
with the TRIPS Agreement, developing countries were aware that there has to 
adequate transfer of technology.  At the Doha ministerial meetings, developing 
countries expressed their disappointment that developing countries had not 
provided the incentives to promote technology transfer to assist their business 
and organizations in accordance with Article 66.2. Although some developed 
countries have provided different forms of technical assistance on IPR-related 
issues, some issues have arisen. Developed countries have been accused of 
providing unsuitable and unsafe technical assistance to them by advising 
countries to implement policies that are harmful to health.661.  For example, the 
US Agency for International Development (USAID) has been funding the US 
Commerce Department to provide technical assistance to Nigeria in re-writing 
its patent laws.662 The patent law draft legislation demanded for stronger 
intellectual property laws than TRIPS required. Such measures included laws 
                                                            
659  Humaira Mufti. Data Protection in compliance with Article 39 of the TRIPS Agreement: 
Draft Amendment to the Drugs Act 1976. WIPO National Seminar on Flexibilities under the 
TRIPS Agreement  
27-28th November, 2007. 
660 Ibid 
661 Médecins Sans Frontières Briefing Note . August 2003. ONE STEP FORWARD, TWO 
STEPS BACK? ISSUES FOR THE 5TH WTO MINISTERIAL CONFERENCE (CANCÚN) 
662 For more information on the shortcomings of WIPO technical assistance, see: MSF, 
Consumer Project on Technology, Oxfam International and Health Action International. 
“Conference Report: Implementation of the Doha Declaration on the TRIPS Agreement and 
Public Health. Technical Assistance—How to Get it Right.” March 2002. <www.accessmed-
msf.org>  
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to criminalisation patent infringement. Medecins Sans Frontieres objected to 
this stating that such a law would lead to more difficulty for the country 
gaining access to affordable generic drugs.663 Correa states that little or no 
action has been taken by developed countries to specifically implement their 
obligations under Article 66.2. 664  
 
Importantly, the Doha Declaration reaffirms the commitment of technology 
transfer made by developed country Members, whilst reiterating the need for 
developed countries to support and encourage technology transfer to least-
developed country members. The Ministers at Doha responded by setting up a 
Working Group under the patronage of the General Council to look at the 
relationship between trade and transfer of technology, in order to make 
achievable recommendations on steps that might be taken within the of the 
WTO to increase technology flows to developing countries. Ultimately the 
Doha Declaration was seen as a breakthrough for developing countries and 
their public health agenda, 665 thus it was the first time that international health 
and development was discussed at every level of the WTO governance.666  
 
Some commentators have suggested that the Declaration gave sufficient 
discretion to Member states in deciding how to counteract the negative effects 
of the TRIPS Agreement and its effect on prices.  Part of the rationale for such 
an assertion is based on the fact that the final text of the Doha Declaration has 
more similarities to the draft that the developing countries has proposed when 
                                                            
663 Schroeder.M (2003) Drug Patents Draw Scrutiny as Bush Makes African Visit.” The Wall 
Street Journal.  
664 Correa. C. (2002) 'Implications of the Doha Declaration on the TRIPS Agreement and 
Public Health'. WHO Health and Economics Policy Paper. EDM Series No. 12  at 36. 
665 Matthew D (2004) The Decision on Implementation of Paragraph 6 of the DOHA 
Declaration on the TRIPS Agreement and Public Health: A Solution to the access to Essential 
Medicines Problem. 7 J. Int’l Econ. L 73 
666 Mercurio. B. (2004)  TRIPS, Patents, and Access to life saving Drugs in the Developing 
World.  8 Marg. Intell. Prop. L. Rev. 211 
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compared to the developed countries draft.667 When one cast their mind back to 
the surrounding issues and events of 2001, it does perhaps seem unsurprising 
that the US government became so lenient towards the position of developing 
countries. One of such events was the tragic incident of the World Trade 
Centre. On 11 September 2001, several days before the second TRIPS Council 
meeting scheduled for 19 September 2001 was held, the World Trade Centre 
was attacked and bombed by terrorist claiming more than 5,000 US lives.668 
The Pentagon was also attacked and several days later a series of bio-terror 
threats in the form of anthrax attacks were carried out causing severe illness 
and deaths.669 The proximity between the World Trade Centre, the Pentagon 
attack and the bioterrorist attack led the United States to believe that the 
country might be under bioterrorist attack; this might resulted in an enormous 
public health emergency for North America.670 
 
The Canadian government reacted rapidly by issuing a compulsory licence to a 
Canadian generic producer on 18 July 2001. This effectively eroded the 
German pharmaceutical company Bayer's patent for the antibiotics, 
Ciprofloxacin. The compulsory licence was for a million tablets of 
Ciprofloxacin, which was at the time the most effective drug in treating 
anthrax.671  The United States followed suit, thus on 23 October by the 
Secretary of Health and Human Services (HHS) Tommy Thompson threatened 
Bayer with a compulsory license if it did not meet its demands for price 
                                                            
667 Hoen,  T.E (2002) TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A 
Long Way From Seattle to Doha'. 3 Chicago Journal of International Law  27, at 47-48. 
668 .S. Department of State. Office of the Historian, Significant Terrorist Incidents, 1961-2001: 
A Brief Chronology, www.state.gov/r/pa/ho/pubs/fs/5902.htm. 
669 American Anthrax Outbreak 2001. 
http://www.ph.ucla.edu/epi/Bioter/detect/antdetect_intro.html 
670 Abbott. F.M. (2002)  THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO. 5 J.Int’l Econ. L. 469 
671 See Harmon and Pear, 'Canada Overrides Patent for Cipro to Treat Anthrax', New York 
Times, 19 October 2001. The Canadian Government subsequently withdrew its decision after 
agreeing on the Monday to buy the tablets from Bayer. 
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reductions.672 Unsurprisingly, Bayer subsequently reduced the price of the 
product by half the price at which it had offered to supply the drug in the first 
place, thereby supplying it at 45 cents per Cipro pill for purchases under a 
separate government program (twice the price for the Indian generic 
equivalent).673   
 
Developing world was shocked at these developments. Whilst the US and its 
allies have threatened trade sanctions, withdrawal of economic benefits, and 
insisted on TRIPS plus standards in countries that attempt to grant compulsory 
license, here they were issuing compulsory licenses in a situation which they 
believed was a “national emergency”. To many the moral standing of the 
USTR was brought into question.674 Were the flexibilities within the TRIPS 
Agreement good for the US and Canada to use when they faced a public health 
emergency, but wrong when it came to developing countries using them? Were 
the lives of people in the developed world more important than the lives of 
people in the developing world? It seemed too many that there was in fact a 
double standard operating at the WTO.675 Whilst the United States had in the 
past issued over 100 compulsory licensing in antitrust cases and settlements, 
including cases of antibiotics, synthetic steroids and several biotechnology 
patents, they sought to prevent developing countries from using the same 
instrument. Other questions that arose out of the incident were whether the use 
of the flexibilities within the TRIPS Agreement would ensure that more R&D 
would be done for neglected diseases? These were indeed the questions that 
the African group and indeed the rest of the world pondered upon during the 
Doha Ministerial Conference. Frederick Abbot held that the result of the 
                                                            
672 Kristin Jensen, (23 October 2001.)Thompson May Seek to Void Cipro Patent If Talks Fail', 
Bloomberg News Service (Bloomberg.com), dateline Washington, DC,  
673  Russell Mokhiber and Robert Weissman (2001) MULTINATIONAL MONITOR 2001. The 
Ten Worst Corporations of 2001. Corporations Behaving Badly: The Ten worst Corporations 
of 2001.  
674 Haochen Sun. THE ROAD TO DOHA AND BEYOND: SOME REFLECTIONS ON THE 
TRIPS AGREEMENT AND PUBLIC HEALTH. 2004. Eur.J.Int’L.123 
675 Marwaan Macan-Markar. Bird Flu Brings Out Double Standards on Drug Patents. 
Published on Saturday, October 22, 2005 by the Inter Press Service 
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anthrax-cipro situation demonstrated plainly the common sense underlying the 
heart of the developing country draft declaration. 676He claimed that no 
responsible government with a choice would place the public health of its 
citizens below the interests of a few patent holders.677 
 
Panagariya has suggested that the events that caused the US government to 
express a willingness to grant developing countries concessions that it had 
previously guarded jealously were more than meets the eye.678  No sooner had 
the Declaration on TRIPS and public health been adopted that the cracks 
between the US position and the agenda of the developing country alliance 
(that patent protection should not hinder public access to affordable drugs) 
begin to show. The pharmaceutical industries began to seriously lobby the US 
government to reconsider its position and punish countries who failed to 
protect patented pharmaceutical products through its “Special 301” provisions 
of the US trade law. In 2002, under intense pressure from the pharmaceutical 
industry, the United States Trade Representative (USTR) added four new 
countries on its “priority Foreign Countries” with the possible threat of 
removing trade preferences and cutting development aid.679  The actions of the 
US pharmaceutical industry have raised criticism amongst academics and 
NGO’s.680 Some have questioned whether the US government considers the 
interests of associations such as PhRMA to be more important to the 
                                                            
676 Abbott. F.(2002)  THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND 
PUBLIC HEALTH: LIGHTING A DARK CORNER AT THE WTO. 5 J.Int’l Econ. L. 469 
677 Ibid 
678 Panagariya,  (2002) Developing Countries at Doha: A Political Economy Analysis', 25 
World Economy. 1205. 
679 See Maria Bystorm & Peter Einarsson, (2001) TRIPS – Consequences for Developing 
Countries: Implication for Swedish Development Cooperation 36, 37 , at 
http://www.grain.org/docs/sida-trips-2001-en.pdf 
680 See Drahos, P (2002)  Developing Countries and International Intellectual Property 
Standard- setting 14-18) at 
http://www.iprcommission.org/papers/pdfs/study_papaers/sp8_drahos_study.pdf 
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promotion and functioning of democratic institutions in developing 
countries.681     
 
7.4  Compulsory Licenses 
The issue of Member States capability to use compulsory licences has been a 
major cause of contention from the beginning of the TRIPS Agreement, 
nevertheless the availability of compulsory licenses as an option is not a new 
concept.  Article 5A(2) of the Paris Convention states that ‘Each country of the 
Union shall have the right to take legislative measures providing for the grant 
of compulsory licenses to prevent the abuses which might result from the 
exercise of the exclusive rights conferred by the patent”. Under Article 31k of 
the TRIPS a judicial or administrative ruling of anti-competitive practices also 
enables governments to issue a compulsory license without first seeking 
voluntary licenses, for domestic use or export. 
At the Doha Rounds compulsory licenses was one of the main issues that 
developing countries wanted addressed. Thus compulsory licenses have been 
identified as one of the best ways for lowering the prices of drugs below the 
original manufacturers’ price.  It works in a variety of ways namely; it allows 
the government to issue a licence to produce patented pharmaceuticals without 
the consent of the patent holder. It also allows a country to import generic 
version of the patented drug under Article 31. 682  
                                                            
681 Hernan L. Bentolila. Lessons from the United States Trade Policies to Convert A “Pirate”: 
The Case of Pharmaceutical Patents in Argentina. Yale Journal of Law & Technology. 2002-
2003. Available at http://www.yjolt.org/old/files/20022003Issue/Bentolila.pdf 
682 The text of the compulsory licensing provision reads, in relevant part:  
Where the law of a Member allows for other use of the subject matter of a patent without the 
authorization of the right holder, including use by the government or third parties authorized 
by the government, the following provisions shall be respected:  
(a) authorization of such use shall be considered on its individual merits;  
(b) such use may only be permitted if, prior to such use, the proposed user has made effort to 
obtain authorization from the right holder on reasonable commercial terms . . . . This 
requirement may be waived by a Member in the case of a national emergency or other 
circumstances of extreme urgency or in cases of public non-commercial use ...  
(f) any such use shall be authorized predominantly for the supply of the domestic market of the 
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The imported drug can be from a country in which the drug is not patented, or 
in a country where drugs are patented (in which case the exporting country has 
also to issue a compulsory license). Nevertheless the  following conditions 
must  be met: there has to have been adequate evidence that negotiations were 
made to obtain authorizations from the patent holder on reasonable commercial 
grounds (except in cases of public non-commercial use, situations of extreme 
urgency and national emergency) “within a reasonable amount of 
time”683which turned out to be unsuccessful.684 Although the term “reasonable 
commercial grounds” is open to interpretation, it allows each particular 
negotiation to be taken into account. Similarly, some commentators have 
suggested that the flexibility of Article 31(b) allows the issue of compulsory 
licensing if the patent holder deliberately delays negotiation to prevent the 
grant of a compulsory licence.685 Another key requirement of compulsory 
license is that the patent holder must be paid “adequate remunerations in the 
circumstance of each case, taking in to account the economic value of the 
authorization”.686 The provision that patent holders be paid adequate 
remuneration has been called into question by critics, on the basis that if the 
manufacturing pharmaceutical company that is being granted a compulsory 
licence has to pay a remuneration that is too high, it may defeat the entire 
purpose of the licence as compulsory licences are typically done to make the 
price of medication affordable. Some have also questioned what level of 
remuneration is ‘adequate’?687 To answer the question, some studies have 
                                                                                                                                                            
Member authorizing such use.. 
(h) the right holder shall be paid adequate remuneration in the circumstances of each case, 
taking into account the economic value of the authorization; . . . .  
683 Article 31(b) of the TRIPS Agreement  
684 Ibid. art 31(b)  The requirement to put forth reasonable efforts to negotiate a license with 
the patent holder can be waived by the Member in circumstances of national emergency or 
other circumstances of extreme urgency or in cases of public non-commercial use. 
685 Holger Hestermeyer. (2007)  Human Rights and the WTO. The Case of Patents and Access 
to Medicines. Oxford University Press.  
686 Ibid. art 31(h) 
687 J. Love, (2001) Compulsory License: Models For State Practice in Developing Countries, 
Access to Medicine and Compliance with WTO TRIPS Accord, Prepared for the United 
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suggested that between 2% and 15% of net sales is adequate remuneration. 
Ultimately member states have to provide the possibility of judicial review or 
other independent review of the legal weight of any decision relating to the 
authorization of use under Article 31 of the TRIPS Agreement.  
 
Important to note is that fact that compulsory licences are limited by scope and 
duration.688 If for example a compulsory licence was issued due to an 
epidemic, once the situation is over, the compulsory licence has to be 
terminated. The rationale for this is quite plain; the legitimate interest of the 
patent holder must be sufficiently protected. Secondly compulsory licences are 
non-exclusive and non-assignable; and thirdly and more controversial is the 
fact that compulsory licences are territorial.  Article 31(f) of the TRIPS 
Agreement states that it must be “predominantly for the supply of the domestic 
market of the member states”689 The word “predominantly” has been 
interpreted to mean: 50 percent of the use must be for use in the domestic 
market of the manufacturer and the domestic market has to be the most 
important market to benefit from the compulsory license. The important thing 
to note however is that since the coming into force of the TRIPS Agreement, 
the pharmaceutical industry in the developed world have questioned the use of 
compulsory licensing as a way of getting round the problem of high prices of 
medicines.  
 
This problem has been compounded for developing countries that have no 
manufacturing capacity, who have in turn presented the argument that the 
strings attached to the requirements of issuing a compulsory licenses presents a 
major setback for providing access to medicines. 690The controversy for 
countries without manufacturing capacities is centred on the fact that such 
                                                                                                                                                            
Nations Development Programme  at Para 2 
http://www.cptech.org/ip/health/cl/recommendedstatepractice.html  
688 Article 31(c) of the TRIPS Agreement 
689 Article 31 (f0 
690 Ibid 31 (f)  
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countries would be unable to take advantage of the compulsory licensing 
provision under Article 31(h), 691 thus any attempt to import pharmaceuticals 
from other countries would have been interpreted as a violation of the WTO 
Agreement.692 Attempts were made at the WTO Ministerial at Doha, Qatar in 
2001 to overcome the problem when the TRIPS Council held a special 
discussion on intellectual property and access to medicines and came to the 
conclusion that “nothing in the TRIPS Agreement shall prevent Members from 
taking measures to protect public health. And that the Agreement shall be 
interpreted and implemented in a manner that is supportive of WTO members’ 
right to protect public health by promoting access to medicines’. 693  At the 
request of the African group, the declaration emphasizes the importance of 
TRIPS’ role in protecting and promoting human rights.694 Specifically, Article 
5(b) of the Doha Declaration on the TRIPS Agreement and Public Health 
states that “Each member has the right to grant Compulsory licenses and the 
freedom to determine the grounds upon which such licenses are granted”.695 In 
what has been termed Paragraph 6 of the Doha Declaration, the WTO stated 
that “we recognize that WTO members with insufficient or no manufacturing 
capacities in the pharmaceutical sector could face difficulties in making 
effective use of compulsory licensing under the TRIPS Agreement.”696 The 
conflict was supposedly overcome on August 30, 2003 when a decision was 
reached permitting WTO member countries to waive its obligations under 
                                                            
691 Haag, T.A (2002) TRIPS Since Doha: How Far Will the WTO Go Toward Modifying the 
Terms for Compulsory Licensing? 84 J. Pat. & Trademark Off. Soc'y 945  
692 Ibid at 951-952 and Haochen Sun (2003)  A Wider Access to Patented Drugs Under the 
TRIPS Agreement, 21 B.U. Int'l L.J. 101  
693 See Declaration on the TRIPS Agreement and Public Health, Para 4, 
WT/MIN(01)DEC/2(Nov.20, 2001) asserting that TRIPS “can and should be interpreted and 
implemented in a manner supportive of WTO Members’ right to promote access to medicines 
for all”) available at http://www.wto.org/english/thewto_e/minist_e/mindecl_trips_epdf 
[hereinafter Doha Declaration] 
694 Sun Haochen, (2004) The Road to Doha and Beyond: Some reflection on the TRIPS 
Agreement and Public Health, 15 Eur. J. Int’l L. 123 
695 This is the developing countries' negotiating target in the Doha Conference. See C. M. 
Correa, Implication of the Doha Declaration on the TRIPS Agreement and Public Health 
(2002). 
696 Para 6 of the Doha Declaration  
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article 31(f) of the TRIPS Agreement in particular scenarios.697 The waiver 
allows countries to import generic698 copies of patented pharmaceuticals made 
in other countries under article 31(f) of the Agreement,699  however the 
provisions also puts the importing country at the mercy of the exporting 
countries. If a Member State with no manufacturing capacity wants to import 
generic medicines, it must find a Member who does not have patent on the 
medicines it wants to import.700 Commentators have argued that there are 
exceptions to the rule, for example the rule does not apply if the medicines are 
solely for export, nevertheless the criterion has been criticised as being unduly 
cumbersome and untidy.701  The difficulty of using compulsory licenses for 
developing countries which some have argued has never been resolved lies in 
the fact that the grant of a compulsory license solely to assist an importing 
Member is expressly prohibited under article 31(f) of the TRIPS Agreement. 
This has left developing countries with very few options on where to shop 
around when seeking to import from other countries using the option of 
compulsory licenses.  
 
                                                            
697 Press Release, WTO, Decision Removes Final Patent Obstacle to Cheap Drug Imports 
(Aug. 30, 2003), at http://www.wto.org/english/news_e/pres03_e/ pr350_e.htm (hereinafter 
WTO Press Release). 
698 Generic drugs are Copies of brand name patented pharmaceuticals. See Black's Law 
Dictionary 513 (7th ed. 1999). Generic drugs contain the same active ingredient, but not 
necessarily the same recipient substances (such as binders or capsules) as the patented drug 
marketed under a brand name 
699 While all WTO members are eligible to import under this decision, twenty-three developed 
countries announced that they will not use the system to import. These countries are: Australia, 
Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, 
Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, 
Switzerland, United Kingdom, and the United States of America. WTO, The General Council 
Chairperson's Statement, at http://www.wto.org/english/news_e/news03_e/ trips_ 
stat_28aug03_e.htm (Aug. 30, 2003) (hereinafter Chairperson's Statement). Other countries 
have stated that they would only use the article 31(f) exemption in cases of national emergency 
or extreme urgency: Hong Kong China, Israel, Korea, Kuwait, Macao China, Mexico, Qatar, 
Singapore, Chinese Taipei, Turkey, and United Arab Emirates. 
700 See Gopakumar, K.M (2004)  The WTO Deal on Cheap Drugs. A Cri-. tique, in: The 
Journal of World Intellectual Property 7) No. 1, 99-113. 
701 See Holger Hestermeyer. Human Rights and the WTO. The Case of Patents and Access to 
Medicines. Oxford University Press. 2007 
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It follows that some developing countries who have attempted to issue 
compulsory licenses have been faced with a lot of difficulty when attempting 
to use the device to access medicines. A typical case of this is the Thai 
government which has constantly been on headline news for flaunting patent 
rules. For example in November 2006, the Thai government issued a 
compulsory license for efavirenz (Stocrin), a Merck & Co. drug. In February 
2007, it announced that it would be issuing a compulsory licence for Kaletra 
and a number of other drugs used to treat cancer.702 In June 2007, the Thai 
Ministry of Public health also announced that it would be issuing a compulsory 
licence for an updated version of Kaletra known as Aluvia. Subsequently in 
October 2007, Thailand’s FDA completed the registration of the generic 
version of Aluvai manufactured by Matrix Laboratories in India.703 The Office 
of the U.S. Trade Representative responded harshly to the Thai proposal in its 
annual “Special 301” report.704 In the report Thailand was been placed on the 
Priority Watch List and accused of offering “weak protection against unfair 
commercial use of undisclosed test and other data” that were submitted by 
pharmaceutical companies seeking patent protection for their products.705  
 
A background of the relationship between US and Thailand is essential in 
understanding how they have differed on public health matters and the 
treatment of patent laws. Although the two have retained a close relationship 
since the end of World War II, and cooperated in many areas, including 
defence and security, countering illegal narcotics trafficking, trade 
                                                            
702 A LCORN, Keith (12 February 2007) Abbott offers price cut to thwart Thai compulsory 
license on Kaletra. Aidsmap.com 
703 Access to generic HIV/AID drugs increasing following Thailand’s decision to issue 
compulsory licenses, ealth official says. Shttp://www.news-medical.net/?id=38261. Published: 
Sunday, 11-May-2008 
704 2007 Special 301 Report. 
http://www.ustr.gov/assets/Document_Library/Reports_Publications/2007/2007_Special_301_
Review/asset_upload_file230_11122.pdf (Accessed 7th June 2008) 
705  Kaiser Daily HIV/AIDS Report. 
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=44603.  May 01, 2007. 
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liberalization, and fighting the war against international terrorism,706 they seem 
to differ on the subject of how best to approach the subject of public health and 
the usage of the flexibilities within the TRIPS Agreement. Thailand has 
continually been seen as a threat to intellectual property by the US, and many 
have asserted that this has ultimately hampered the trade relations in the long 
run.707  
 
Nimtri Tien-Udom, the director of Aids Access foundation in Thailand 
applauded the actions of the Public Health Minister Mongkol Na Songkhla for 
enforcing compulsory licensing for HIV medicines in the face of pressures not 
to do so from multinational corporations (MNC) in the US. Tien-Udom 
accused the United States for threatening access to medicines in Thailand.708 
Commentators have therefore argued that despite the fact that the option of 
compulsory license is available for the procurement of cheaper generic 
medicines as a substitute for expensive branded products, It t seems apparent 
that the option is not freely available as it was intended. 
 
In 1997, the South African government passed the Medicines and Related 
Substances Control Amendment Act No 90 of 1997 (Medicines Act) to allow 
compulsory licensing of patented AIDS drugs so that local companies could 
make and sell cheaper generic versions. The US hit back by imposing trade 
sanctions on South Africa, including denying it tariff relief on certain 
exports.709  Critics of a robust structure of intellectual property have argued 
that allowing compulsory license in developing countries like South Africa, 
Thailand and Nigeria where HIV/AIDS is a serious epidemic would not be a 
                                                            
706 Wayne M. Morrison. (2003) CRS Report for Congress. Thailand-US. Economic Relations: 
An Overview. March 28 
 http://www.us-asean.org/Thailand/thailand-RS21478.pdf  (Accessed 4th June 2008) 
707 TRIPS, AIDs and generic drugs. AVERT. http://www.avert.org/generic.htm  
708 Bangkok Post (4 May 2007) “AIDS activist lash out at US” 
http://www.bangkokpost.net/topstories/topstories.php?id=118506  (23rd October 2007) 
709 Somershwar Singh. Compulsory Licensing Good for US Public, Not Others. 
http://www.twnside.org.sg/title/public-cn.htm (Accessed 14 October 2007) 
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serious risk to the profits of the pharmaceutical industry and to research and 
development funding.  Their argument is sometimes based on the fact that 
developing countries are not really a threat to  the profits made by the 
multinational pharmaceutical industry as most of it comes from the developed 
countries.710 Their cry has fallen on deaf ears as the pharmaceutical companies 
in the west have been adamant on maintaining stout limitations on the usage of 
the flexibilities within the TRIPS Agreement. 
 
7.5 Parallel Importation 
Whilst the difficulty of using compulsory licenses has been highlight above, 
the usage of using parallel importation as a way of getting round the high 
prices of medicines has also presented its own problems. Although some have 
argued that it is easier for developing countries to use parallel importation as a 
way of accessing cheaper medicines, the complexities of using it is more than 
some scholars have led one to believe. Parallel import occurs where a patented 
product is placed on the market by the patent holder, in such a situation the 
patent holder has by right exhausted his patent rights and the buyer of the 
product can sell the product as he wishes. Paradoxically whilst Article 28 of 
the TRIPS Agreement grants the patent holder the absolute right to import or 
export his products wherever he wishes, Article 6 allows member states to 
decide whether parallel imports are permissible in their jurisdiction or not,711  it 
also allows member states to limit the patent holder's right under the 
exhaustion principle.712  In order words whether a patent owner can block 
parallel imports is a matter of national discretion713. Whilst most countries 
have clearly distinguished between national and international exhaustion, the 
                                                            
710 Ibid 
711 See Carlos M Correa (2000) Intellectual Property Rights, the WTO and Developing 
Countries: The TRIPS Agreement and Policy Option 62  
712 ) See Watal J (2001) Intellectual Property Rights in the WTO and Developing Countries. 
317  
713 See World Health Organization, Globalization, TRIPS and Access to Pharmaceuticals 4 
WHO Policy Perspective on Medicines No.3 (March 2001), available at 
http://www.who.int/mediciens/liberary/edm_ general/6pagers/PPM03%20ENG.pdf. 
[hereinafter TRIPS and Access to Pharmaceuticals] 
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issue of international exhaustion has sometimes raised some questions as 
different countries treat it differently. This has been made clear under Article 6 
of the TRIPS Agreement which states that “ For the purposes of dispute 
settlement under this Agreement, subject to the provisions of Articles 3 and 4, 
nothing in this Agreement shall be used to address the issue of the exhaustion 
of intellectual property rights”. As such the WTO Dispute Settlement system 
makes it clear that it is not in the business of addressing exhaustion doctrine 
disputes714.  
 
The way in which a country treats territorial exhaustion in its national 
legislations is a significant component of how it can regulate and limit its use. 
There are basically three types of exhaustion of rights namely, national, 
regional and international exhaustion. Under the national exhaustion, the 
exclusive rights of the patent holder ends upon the first sale of the products 
within a country, however the patent owner may be able to exclude parallel 
imports from other countries.715 Regional exhaustion operates by allowing the 
marketing of goods anywhere in a specific free trade zone or a customs union, 
such as the EC once the goods have been put on the market anywhere else in 
that region by or with the consent of the IP right holder.716 The IP right holder 
can, nevertheless, prevent the importation of these goods from outside the 
specified region.717 International exhaustion on the other takes place where a 
patent holder places his product in a foreign market and cannot prevent others 
from re-importing it into another country to be sold cheaper because he has 
                                                            
714 ) See World Health Organization, Globalization and Access to Drug, 24 (1999), available at 
htto://www.who.int/medicines/library/dap/who-dap-98-9-rev/who-dap-98-9rev.pdf. (visited 
Oct.7, 2002) [hereinafter Globalization and Access to Drug] (Mentioning that to improve the 
accessibility though parallel importation, members may establish that the exclusive rights of 
the patentee may not be claimed in cases where products marketed with that patentee's consent 
in any other countries are imported.) 
715 Maskus. K.E  (2001) Parallel Imports in Pharmaceuticals: Implications for Competition 
and prices in developing Countries. Final Report to World Intellectual Property Organization. 
April. http://www.wipo.int/about-ip/en/studies/pdf/ssa_maskus_pi.pdf 
716 Slotboom. M.M . (2005) The Exhaustion of Intellectual Property Right. Different 
Approaches in EC and WTO Law. The Journal of World Intellectual Property. Volume 6, Issue 
3.  
717 Ibid 
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already been rewarded through the first sale of the product. This doctrine is 
very important especially with pharmaceutical products, because the same 
patent products are usually sold at different prices in different countries. For 
example a report by JAAIDS showed that Roche’s rocephinea (branded 
version of Ceftriaxone was 58% cheaper in Colombia than in Nigeria, Glaxo’s 
Combiviral (association of ART+Lamivudine for HIV) was 43% cheaper in 
Guatemala than in Nigeria. Although the doctrine of exhaustion within the 
same country has already been established, the doctrine has remained a “grey” 
area.718  
 
Although the WTO tried to clarify the doctrine of international exhaustion in 
the Doha Rounds, there is no international consensus on what the rule should 
be. An extensive case study of the way different countries and trade blocks 
treat the doctrine will be undertaken below to help us discern the likely 
international direction that the future might go on the issue of parallel 
importation.  The US clearly distinguishes between national and international 
exhaustion. 719   A good example is  the US –Australia Free Trade Agreement 
(UAFTA) where an exhaustion provision is allowed but can be limited by 
contractual limitations.720 Note that in most FTAs , there is a general tendency 
to be TRIPS-PLUS. Nevertheless It is still  interesting to note that whilst the 
US are proponents of international exhaustion in its legal scheme for copyright 
and trademark721, it is in earnest disagreement about the international 
exhaustion of patents.  
                                                            
718 See Erlikhman, D (2003) Jazz Photo and the Doctrine of Patent Exhaustion: Implications 
to TRIPs and International Harmonization of Patent Protection, 25 Hastings Comm.& Ent. 
L.J. 307, 323-31 where Erlikhman reviews the patent exhaustion rules of the U.S., Japan and 
EU and showed that all of them have a national or regional exhaustion policy. 
719 A distinction may exist if the exporter is bound by express contract to sell outside the 
United States. In that case, U.S. rights would not be exhausted by the sale. See, e.g., Ariz. 
Cartridge Remanufactures Ass'n v. Lexmark Int'l Inc., 290 F. Supp. 2d 1034, 1043 (N.D. Cal. 
2003) 
720 US- Australia Free Trade Agreement (UAFTA) 
http://www.livingstonintl.com/tradenewsarticle.cfm?id=2842 Last Visited 11:12:05 
721 Cahoy, D (2005)  Patent Fences and Constitutional Fence Post: Property Barriers to 
Pharmaceutical Importation.  15 Fordham Intell. Prop. Media & Ent. L.J. 623 
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The issue of trademark for patented medicines is relevant because patent 
medicines are sold under trademarks; this makes it the more complicated. One 
of the most cited cases with regards to the international exhaustion in the US is  
Boesch v. Graff, which was decided by the Supreme Court as far back as 1890, 
even before the TRIPS Agreement722 Although not a case to do with patented 
medicines the principle behind the reasoning of the case is interesting. In this 
case, the plaintiff owned parallel patents for lamp burners in the US and 
Germany; he subsequently sued to keep the lamp burners lawfully purchased in 
Germany from being sold in the US. With regards to the German law at that 
time, a third party could manufacture and sell patented products so long as that 
party had done so before with the patent owner's submission of the patent 
application.723 The Supreme Court held that although the laws of Germany 
allow the selling of a product, this does not authorize the selling of "articles in 
the United States in defiance of the rights of patentees under a United State 
patent . . . . The sale of articles in the United States under a United States. 
patent cannot be controlled by foreign laws." 724The effect of this was the 
plaintiff could not prevent a third party from selling his patented lamp burners 
in Germany but could prevent a third party from importing the lamps lawfully 
sold in Germany into the US.725   
 
How far the Boesch rule extends, however, is debatable. A few years before 
the Boesch decision the District Court of New York in Holiday v. Mattheson 
held that parallel importation of patented goods first sold overseas under the 
authority of the patent owner did not infringe on the US patent.726  In this case, 
the owner of the patent sold his patented goods in England;727 the defendant 
                                                            
722 Boesch v. Gr ff, 133 U.S. 697 (1890). 
723 Ibid 
724 Boesch v. Graff, 133 U.S. 697, 702 (1890). 
725 Ibid 
726 Holiday v. Mattheson, 24 F. 185 (C.C.S.D.N.Y 1885) 
727 Ibid 
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obtained the goods in England and imported them back into the US.728 The 
defendant did not have the plaintiff's permission to import the patented 
product. Nevertheless, the court refused to grant the plaintiff an injunction.729  
The District Court reasoned that there was a presumption upon the sale of a 
good that the seller intended to give up his rights in the products sold; it would 
be therefore contradictory to allow the seller to restrict the buyer's use when no 
such restriction was made at the time of sale.730 The court held that the 
plaintiff's patent rights at home were exhausted after the goods were sold 
abroad. 731 The discrepancies in the court’s decision can also be seen in Curtiss 
Aeroplane v. United Aircraft.732  In this case the Court of Appeal for the 
Second Circuit pronounced that the US operates a policy of international rights 
of exhaustion.  A holder of US patents on aircraft components had licensed the 
British government to produce aircraft in Canada (for use in the First World 
War). After the war, the British government sold some of the aircraft it had 
produced to a third party that imported them into the US for resale. The Second 
Circuit held that the US patent holder, in consenting to the use of its patent for 
the manufacture of airplanes in Canada, had exhausted its right to control the 
importation of the resulting aircraft into the US 
 
Interestingly other US courts have distinguished a patent owner granting an 
exclusive license to a third party to practice a patent in a foreign country from 
the patent owner selling her product in another country.733   In Griffin v. 
Keystone Mushroom Farm, Inc., the District Court of Pennsylvania held that 
the Boesch doctrine against exhaustion applied even when the overseas first 
sale was authorized by the patent owner.734 In Griffin, the plaintiff held parallel 
                                                            
728 Ibid 
729 Ibid 
730 Ibid 
731 Ibid 
732 266 F. 71 (2d. Cir. 1920 
733 Griffin v. Keystone Mushroom Farm, Inc., 453 F. Supp. 1283, 199 U.S.P.Q. (BNA) 428 
(E.D. Pa. 1978);  
734 Ibid 
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patents on farm equipment in Italy and the US.735 He licensed his Italian rights 
to a company he formed to produce the equipment.736 The defendant purchased 
the equipment in Italy and imported it to the US.737  The defendant argued that 
allowing the plaintiff to stop the importation of the equipment would amount 
to a double recovery since the plaintiff had already received a royalty for the 
equipment from the Italian licensing agreement.738  The court disagreed, 
stating that the underlying principles governing patent law were to allow patent 
owners to exclude others from making, using and selling the patented 
invention.739  One method of exclusion is to grant licenses to only those 
entities that the owner wants to practice the patent.740 Allowing the defendant 
to import the equipment sold under the Italian license would thwart the patent 
owner's ability to exclude persons from practicing the patent in America.741   
Griffin restated the principle illustrated in Boesch, stating that the "sale of 
articles in the United States under a US patent cannot be controlled by foreign 
laws."742   Ruling for the defendant would breach that principle by allowing 
rights confirmed under an Italian patent to control the rights of an American 
patent holder.  
 
In Sanofi v. Med-Tech Veterinarian Products, Inc., the District Court of New 
Jersey clarified under what circumstances parallel imports infringe and who 
may bring an infringement action.743   In this case a pharmaceutical company 
in France sold an exclusive license to American Home Products for its US 
patent on acepromazine maleate, a tranquilizer for the treatment of animals.744 
Sanofi continued to produce and market the drug in Europe. The defendant 
                                                            
735Ibid 
736 Ibid at 1284 
737 Ibid 
738 Ibid 
739 Ibid 
740 Ibid 
741 Ibid 
742 Ibid 
743 75 
744 76 Sanofi, S.A. v. Med-Tech Veterinarian Prod., Inc., 565 F. Supp. 931, 220 U.S.P.Q. 
(BNA) 416 (D.N.J. 1983 
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purchased the drug in Europe and then imported it to the US. 745 Both Sanofi 
and its exclusive licensee, American Home Products, sued for patent 
infringement citing Boesch and Griffin.746 The court held that while American 
Home Products had a valid claim, its licensor, Sanofi did not.747  Discussing 
Sanofi's claim, the court distinguished Boesch and Griffin on the ground that 
neither of the plaintiffs in those cases had sold the product overseas.748 Sanofi 
sold the drug throughout Europe.749   Consequently, the court analogized 
Sanofi's case to Mattheson where the US patent holder sold the patentable 
articles overseas. 750  
 
Like the court in Mattheson, the District Court of New Jersey found that 
allowing Sanofi to impose restrictions against the defendant's use would be 
inconsistent with the defendant's expectation of full ownership.751 Moreover, 
the plaintiffs in Boesch and Griffin had authority to sell their product in the 
US.752 Here, Sanofi granted an exclusive license to American Home Products 
for all US sales. 753 Therefore, the court determined that it could not enforce an 
injunction on behalf of Sanofi, because Sanofi had no rights to sell the drug in 
the US.754 On the other hand, American Home had exclusive rights to practice 
the patent in the US. 755Thus, the defendant's lawful purchase of the drug from 
Sanofi in Europe did not give the defendant the right to ship it to the U.S. 
because Sanofi had no right to sell the drug in the US. A purchaser, though 
acquiring the "whole right of the vendor in the thing sold," 756still may only do 
with that product what the vendor could have lawfully done and acquires no 
                                                            
745 Id. at 937. 
746 Ibid 
747 Ibid 
748 Ibid 
749 Ibid at 937-38. 
750 Ibid 
751 Sanofi, S.A. v. Med-Tech Veterinarian Prod., Inc., 565 F. Supp. 931, 938 (D.N.J. 1983) 
752 Ibid at 939. 
753 Ibid 
754 Ibid at 939. 
755 Ibid 
756 Ibid 
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right greater than that possessed by the owner.757Thus, American Home's 
infringement claim was valid. The court also addressed the differences 
between exclusive and non-exclusive licenses.758  The court stated that a non-
exclusive license confers only the privilege to sell the patented product without 
infringing the patent. 759 Because the owner of a non-exclusive license could 
not prevent the patent owner from granting other licenses, he could not bring a 
claim for patent infringement.760 On the other hand, an exclusive license 
conveys the promise that others will be excluded from practicing the patent in 
the field of use for which the patent was granted.761 Consequently, the owner 
of an exclusive license may bring a claim against those who infringe upon it.762  
In sum, the courts have laid down the following rule: parallel imports are not 
infringing when the one authorized to practice the patent right domestically 
makes the first sale abroad. However, where the patent owner grants an 
exclusive license to practice the patent in the United States, the exclusive 
licensee's rights are not exhausted when another entity sells the product abroad. 
The important thing to note however is that while the Boesch decision may 
seem very odd in the context of modern intellectual property law as well as 
arguably discernible from many of the scenarios likely to occur with regards to 
pharmaceuticals imports, most courts in the US will address their case in 
accordance with Boesch or distinguish it basing its decision on technical 
grounds. The importance of Boesch cannot be understated as no other Supreme 
Court case has touched so specifically on the first sale doctrine.763  
In 2001, the U.S. Court of Appeals for the Federal Circuit  (CAFC)) court 
established to hear all patent appeals, which is also  responsible for articulating 
national patent rules deliberated on a groundbreaking case that brought the 
                                                            
757 Ibid 
758 Ibid at 939 
759 Ibid at 936 
760 Ibid 
761 Ibid 1t 937 
762 Ibid 
763 See Chisum, D.S (2001) Patents: A Treatise on the Law of Patentability, Validity and 
Infringement 16.03[2][a][iv] (2001) In the United States, the issue has arisen often with regard 
to trademark and copyright but relatively rarely with regard to patents. 
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subject of patent exhaustion back into the limelight.764 In  Jazz Photo v. 
International Trade Commission765  Jazz Photo, Fuji Photo Film contended that 
its patented "lens-fitted film packages" were being violated by US buyers who 
were using the originally provided first roll of film and  consigning the 
cameras to others who subsequently carried  out the necessary steps imperative 
to replace the film roll and its container.  Some US buyers were also replacing 
the batteries of cameras and replacing the film winding wheel and resetting the 
film exposure counter, resealing the outer case and adding new cardboard 
covers.766 Fuji Photo had initially sold the cameras with instructions that the 
film roll should not be removed after use and the entire camera should be 
returned to it for photo processing. Fuji instructed buyers that the camera 
should not be opened by the consumer because of the danger of electrical 
shock and that the camera would not be returned after photo processing was 
completed.767  
 
In a nut shell the case before the CAFC concerned the question of whether 
actions taken by third parties represented repair or reconstruction as a matter of 
US patent law. Under the applicable patent law in the US, a patent holder 
cannot prevent a third party from repairing a patented product that has been 
first sold, but may prevent the reconstruction of a product.768 Reconstruction is 
seen in the same light as making a new product, and therefore to be within the 
acts the patent holder may prevent. The International Trade Commission (ITC) 
decided that the acts performed by third parties constituted reconstruction, and 
that importation of the used and reconstructed disposable cameras should be 
                                                            
764 See Barfield C.E & Groombridge, M.A (1999)  Parallel Trade in the Pharmaceutical 
Industry: Implications for Innovation, Consumer Welfare, and Health Policy, 10 Fordham 
Intell. Prop. Media & Ent. L.J. 185, 190 (1999). 
765 264 F.3d 1094 (Fed. Cir. 2001), cert. denied, 536 U.S. 950 (2002). 
766 Mary Helen Sear: First Sale exhaustion clarified M.H Sears law Firm Washington D.C 
http://www.managingip.com/?Page=10&PUBID=34&ISS=12554&SID=471589&TYPE=20 
767 Ibid  
768 Ip-health] Fred Abbott on Jazz Photo case James Love james.love@cptech.org  
Tue, 4 Jun 2002 12:14:02 -0400  http://lists.essential.org/pipermail/ip-health/2002-
June/003097.html 
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generally prohibited. The CAFC disagreed with the ITC's legal analysis, 
holding that the acts performed by third parties constituted repair, and 
therefore were permitted as to disposable cameras that had been first sold. That 
is, the rights of the patent holders to exercise control over repair of the cameras 
had been exhausted when they were first sold. The CAFC held that Fuji could 
not prevent importation of cameras that had first been sold in the United States, 
exported for repair, and then re-imported. However, since US patent rights as 
to cameras first sold outside the US were not exhausted, importation of 
cameras first sold and repaired outside the US could be blocked. 
Commentators have expressed disappointment with the analysis and result of 
the CAFC on this case.  Lowe contends that the court did not adequately 
address existing US law on patents and parallel importation.769  The CAFC had 
failed to take note of the contrary pre-existing case law, therefore the Jazz 
photo case was seen as producing a very disappointing decision. It purported to 
dispose of a critical issue in US patent law without addressing the potential 
implications in respect to patented medicines first sold outside the US.770 The 
relevance of the above case law on parallel importation is very important in the 
access to medicine debate and on the flexibilities in the TRIPS Agreement for 
a variety of reasons. Firstly it show that even in the USA, the courts have 
struggled with the application and at times have had to reverse decisions made 
or like in the Jazz photo case clarify its position on parallel importation. 
Secondly, it also exposes the vulnerability that other developing countries or 
LDC who do not have the level of sophistication in which the courts have in 
the USA may be exposed to when it is called upon to interpret certain aspects 
of the TRIPS which they have little or no experience in dealing with. 
  
Whilst the US position on parallel importation is interesting, the courts in two 
countries who were the principal driving forces behind the TRIPS Agreement- 
Britain and Japan, have confirmed the legality of parallel importation of 
                                                            
769 Ibid 
770 Ibid 
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patented products in the absence of any indication to the contrary.771  English 
common law on patent expressly states that a patentee may impose limited 
conditions on selling his goods; an ordinary vendor of goods may not. The 
authority for this position was the judge’s reasoning in  National Phonograph 
Company of Australia Ltd. v. Menck where it was stated that “it is open to the 
patentee, by virtue of his statutory monopoly, to make a sale sub modo, or 
accompanied by restrictive conditions which would not apply in the case of 
ordinary chattels; ... the imposition of these conditions in the case of sale is not 
presumed, but, on the contrary, a sale having occurred, the presumption is that 
the full right of ownership was meant to be vested in the purchaser while ... the 
owner’s rights in a patented chattel would be limited, if there is brought home 
to him the knowledge of conditions imposed, by the patentee or those 
representing the patentee, upon him at the time of sale’ .772 The 1996 decision 
in Roussel Uclaf v Hockley 773 confirmed the English case law on exhaustion.  
In that case, a company received a licence to work a process patent in the 
People’s Republic of China for the formulation of insecticide.774  Roussel 
Uclaf SA (‘Roussel’), the patent holder, supplied the Chinese company with 
the chemical resulting from the patented process. The Chinese company resold 
the chemical on the international market. When the defendant, Hockley 
International Ltd (‘Hockley’), came into possession of a batch of that chemical 
in the United Kingdom, Roussel brought an infringement suit. It claimed that it 
had only given permission for the goods in question to be used in China and 
that it had expressly forbidden their re-export. In denying Roussel’s motion, 
the English Patents Court held: “It is the law that where the patentee supplies 
his product and at the time of the supply informs the person supplied (normally 
via the contract) that there are limitations as to what may be done with the 
product supplied then, provided those terms are brought home first to the 
person originally supplied and, second, to subsequent dealers in the product, no 
                                                            
771 Christopher Health. Parallel Imports and International Trade.  
772 National Phonograph Company of Australia Ltd. v. Menck , [1911] [28] R.P.C. 229, 248. 
773 Roussel Uclaf v. Hockley International, decision of 9 October 1995, [1996] R.P.C. 441 
774 [1996] RPC 441, 443 
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licence to carry out or do any act outside the terms of the licence runs with the 
goods”.775 The only exception to the rule would be in where there was a 
limited licence  imposed at the initial sale of the goods and even if Roussel had 
only granted the Chinese a limited licence, the limitation was not 
communicated to subsequent purchasers such as Hockley.  
 
By way of comparison, the Japanese Supreme Court stressed their position by 
emphasising the importance of international trade as its justification. In BBS 
Kraftfahrzeugtechnik AG v Racimex Japan KK; Jap Auto Products KK776 the 
Supreme Court of Japan had the opportunity to decide an important question 
concerning the parallel importation of patent-protected goods, which it did in 
an interesting way.777 It held that the rights of Japanese patent holders are not 
infringed by the importation into Japan of patent-protected goods placed on the 
international market by the holder of an equivalent patent in another 
country.778 This is provided that the holders of the patents in the different 
markets concerned are the same legal entity or licensees of the same entity. 
The case is of significance as it directly addresses the conflict between an 
intellectual property owner’s desire to maximise its profits by engineering 
variations in price for the same goods in different markets, and the desire of 
entrepreneurs to exploit those price differentials for their own gain.779 
 
The exhaustion principle under the European Community [EC] also exposes 
one to the value of parallel importation in the EC market. The principle is 
                                                            
775 Ibid 443 
776 Case No H-7 (O) 1988, dated 1 July 1997. An English translation of this judgment has been 
published at (1998) 29 International Review of Industrial Property and Copyright Law 331 
(‘BBS v Racimex Translation’). 
777 See Nanao Naoko, Koyama Takahiro and Sudo Hiromi, (1996) Decisions of Parallel 
Imports of Patented Goods 36 IDEA: The Journal of Law and Technology 567. 
778 http://www.austlii.edu.au/au/journals/MelbJIL/2001/7.html 
779 conflict causes recurring legal battles between intellectual property owners and arbitrageurs 
all over the world: see, e.g., Quality King Distributors, Inc v L’anza Research International, 
Inc, 523 US 135 (1998) (‘L’anza’), Zino Davidoff SA v A & G Imports Ltd (2000)  Ch 127 
(‘Davidoff’) and W R Cornish, Intellectual Property: Patents, Copyright, Trademarks and 
Allied Rights (4th ed, 1999) 47– 
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based on Article 28 and 30 of the EC. Article 28 states that “Quantitative 
restrictions on imports and all measures having equivalent effect shall be 
prohibited.”, whilst Article 30 states that “The provisions of Articles 28 and 29 
shall not preclude prohibitions or restrictions on imports, exports or goods in 
transit justified on grounds of . . . the protection of industrial and commercial 
property … A derogation from the principle of the free movement of goods is 
not . . . justified where the product has been put onto the market in a legal 
manner, by the patentee himself or with his consent, in the Member State from 
which it has been imported, in particular in the case of a proprietor of parallel 
patenes.”780 It follows that Article 28 has been interpreted to mean that 
governments of the EC Member States cannot hinder the importation of goods 
marketed in other EC Member States, even if these measures apply without 
distinction to domestic products and imported products from other EC Member 
States.781 The combined effect of Articles 28 and 30 EC based on the ECJ 
rulings asserts the prohibition of national exhaustion of IP rights, thereby 
establishing the principle of  regional exhaustion upon first-marketing by or 
with the consent of the IP right holder.782 
 
According to this principle, the IP right holder cannot prevent trading between 
EC Member States in products that have been marketed in the EC by or with 
the consent of the IP right holder. The ECJ has justified its interpretation of 
Article 30 EC, prescribing regional exhaustion of IP rights instead of national 
exhaustion, by referring to the object and purpose of the EC Treaty: “If [an IP 
right] is relied upon to prevent the marketing in a Member State of products 
distributed by the holder of the right or with his consent on the territory of 
another Member State on the sole ground that such distribution did not take 
                                                            
780 See Case 15/74, Centrajaam v. Sterling Drug [1974] ECR 1147, at § 10.  
781 See, for example, Case 8/74, Dussonviile, [1974] ECR 837; and Case 120178, Cusfis de 
Dijon, [1979] ECR 649. 
782 Consent is considered to exist when IP-protected products are marketed or sold by the IP 
right holder itself, by its subsidiary or affiliate, or, where the IP rights have been licensed, by a 
licensee: see Centmfuam, ibid, at 5% 18-21. 
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place on the national territory, such a prohibition, which would legitimize the 
isolation of national markets, would be repugnant to the essential purpose of 
the Treaty, which is to unite national markets into a single market . . .’’783  
 
The case for regional exhaustion  of patents has been validated by a 2000  EC 
Commission report  called a Proposal for a Regulation on the Community 
Patent.  Article 10 of that draft, titled “Community Exhaustion of the Rights 
Conferred by the Community Patent” provides that “The right conferred by the 
Community patent shall not extend to acts concerning the product covered by 
that patent which are carried out within the territories of the Member States 
after that product has been put on the market in the Community by the 
proprietor of the patent or with his consent, unless there are legitimate grounds 
for the proprietor to oppose further commercialization of the product.”784 
Having established the fact that the EC operates a regional exhaustion 
principle, the ECJ has not yet clarified whether EC Member States have been 
cleared to operate a system of international exhaustion.785 For an EC Member 
State to introduce the principle of international exhaustion, they must be trade 
agreement between the EC member state and a third country.786 The ECJ ruling 
on international exhaustion on trade-mark clarifies this. In Silhouette787 and 
Sebago788 the ECJ confirmed the rule on regional exhaustion; however some 
have argued that it accepted the possibility of international exhaustion being 
extended to third countries.789   
 
 
                                                            
783 Case 78/70, Deutsche Grammophon, 119711 ECR 487 
784 See COM (2000) 412 Final, Proposal for a Council Regulation on the Community Patent, 
O.J. 2000, C 337E/278 and press release of the EC Council of 3 March 2003, 6874/03 (Prase 
59), at p. 15 
785 Polydor v Harlequin Records Shops [1982] ECR 329. 
786 Ibid 
787 See Case C-355196, Silhouette, [1998] ECR 1-4799, at §§ 25-27. 
788 See Case C-173/98, Sebago, [1999] ECR 1-4103, at §§ 19 and 20 
789 See Article 7 of the Trade-Mark Directive. Available at 
http://europa.eu.int/comm/intern~_niarket/eu/indprap/tm/cxhaust.ht . For more discussion on 
this see Noor, M (1998) ECJ leaves Key Questions Unanswered. Managing Intell. Property 13  
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Having established the different options of parallel importation in developed 
countries, it is important to note that each developing country treats the issue 
of parallel importation of pharmaceuticals differently. Although Maskus notes 
that many developing countries disallow parallel importation790, India allows 
parallel importation under section 107Ab of its amended Patent Act 1970 Act. 
Section 107Ab states that the “importation of patent products by any person 
from a person who is duly authorised under the law to produce and sell or 
distribute the product shall not be considered as an infringement of patent 
rights”. In the case of Brazil,  the law on the parallel importation of products 
can be found in art. 43, IV of Brazilian Federal Law 9.279/96  which states that 
exhaustion of rights is deemed to occur only with respect to products placed by 
the patentee or with his consent in the internal market, similarly under art. 68 § 
4 if the patent owner imports his own products then third parties are entitled to 
carry out parallel importation. The case of American Home Products vs. 
Laboratório LDZ (subject to any higher Brazilian court judgment) is case law 
authority on parallel importation. In that case the defendant LDZ purchased 
Centrum vitamins in the internal market from an importer who was a trading 
company, the court held that the action should be brought against importer 
because the product had already entered into the local market.791 That being 
said a number of developing countries including Argentina, Thailand, and 
South Africa, recently have enacted laws permitting parallel imports of 
pharmaceutical products.792 
 
The importance of exploring the different approaches to parallel importation in 
different countries and economic blocs is important for developing countries 
                                                            
790 Keith E. Maskus.(2001)  PARALLEL IMPORTS IN PHARMACEUTICALS: 
IMPLICATIONS FORCOMPETITION AND PRICES IN DEVELOPING COUNTRIES. Final 
Report to World Intellectual Property Organization.  
791 Daniel Advogados. (2002) Brazil: Parallel Imports in Brazil. 20 May 2002. 
http://www.mondaq.com/article.asp?articleid=16266 
792  Keith E. Maskus. (2001) PARALLEL IMPORTS IN PHARMACEUTICALS: 
IMPLICATIONS FORCOMPETITION AND PRICES IN DEVELOPING COUNTRIES. Final 
Report to World Intellectual Property Organization. Draft. 
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that are yet to enact intellectual property legislation that will bring them in 
compliance with the TRIPS Agreement which gave developing countries like 
Nigeria a deadline of 1 January 2005 to comply. It shows the challenges that a 
country may have to face with gaining access to medicines through parallel 
importation depending on their health care crisis. In December 1997, the South 
African government amended its Medicines Act which gave the Minister of 
Health the right to legalize parallel importation of patented medicines in order 
to tackle the high prices of medicines. Even though this action was challenged 
in the South African Courts by the pharmaceutical companies, with much 
pressure from activist and NGOs, the case was dropped and today South Africa 
has the option to carry out parallel importation which some have suggested is 
an easier alternative to acquiring cheaper drugs than compulsory licensing.793  
 
Regardless of the foregoing, some commentators have pointed out the 
disadvantages of parallel importation leading to a decreased incentive for R&D 
into pharmaceutical products and the development for global diseases that 
affect the third world. One of the main disadvantages is the establishment of 
international exhaustion could lead to the collapse of the objective of price 
regulation.794 If patent-holder cannot confidently set prices near marginal cost 
in low-income markets where demand is highly price-elastic without the fear 
that these low prices could spill-over to other more potentially higher-priced 
markets, then the purpose of price discrimination could be defeated.795 
Pharmaceutical companies could therefore respond by attempting to set a 
uniform price throughout an economic bloc, Danzon and Wang points out that 
pharmaceutical have consistently attempted to set uniform prices in the EC to 
                                                            
793 Keith E. Maskus.(2001)  PARALLEL IMPORTS IN PHARMACEUTICALS: 
IMPLICATIONS FORCOMPETITION AND PRICES IN DEVELOPING COUNTRIES. Final 
Report to World Intellectual Property Organization 
794 PATRICIA M. DANZON. (2003)  Differential Pricing for Pharmaceuticals: Reconciling 
Access, R&D and Patents. International Journal of Health Care Finance and Economics, 3, 
183–205. 
795 Ibid  
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that effect.796 The failure of market division and the patent holders’ ability to 
maintain price differentials is a problem not only for re-importation into 
developing countries, but is equally a problem in developed countries like the 
US who have faced cross-border re-importation of prescription drugs from 
Canada.  
 
The US healthcare system has been heavily criticized with democrats calling 
for a free national healthcare system during the 2008 presidential election, the 
fact remains that when compared with the healthcare systems in the developing 
world, the US has a smaller problem.797 The US operates a health insurance 
scheme which enables people pay for medical expenses through privately 
purchased insurance, social insurance or a non-insurance social welfare 
program funded by the government,798 however the prices of pharmaceuticals 
in the US has continued to soar. The most vulnerable victims of the high prices 
of medicines are senior citizens who despite the fact they qualify for 
Medicare799  are unable to afford additional insurance for their prescription 
drugs.800  States such as Michigan who are near the Canadian border have 
                                                            
796 Danzon, P. M., Y. R. Wang and L. Wang. (2003). The Impact of Price Regulation on the 
Launch Delay of New 
Drugs: Evidence from Twenty Five Countries in the 1990s. Working Paper, The Wharton 
School. 
797 By Andrea Santiago What's Right with America's Healthcare System Physicians and 
Patients from Around the World Come to US for Highest Quality 
798 According to the United States Census Bureau, approximately 85% of Americans have 
health insurance. See Income, Poverty, and Health Insurance Coverage in the United States: 
2007." U.S. Census Bureau. Issued August 2008 
799 Medicare is a federal insurance program for people age 65 and older and certain disabled 
people. The Centres for Medicare & Medicaid Services (CMS) is the part of the United States 
Department of Health and Human Services that operates Medicare. The Medicare program 
consists of two parts, Medicare Part A (hospital insurance) and Medicare Part B (supplemental 
medical insurance). Part A covers hospital, skilled nursing facility, home health and hospice 
care. Part B covers doctors' services, outpatient hospital services, durable medical equipment 
and a number of other medical services and supplies. Medicare also provides limited coverage 
for preventive services.  See http://hiicap.state.ny.us/medicare/medicare.htm (last visited 
Dec.27, 2005) 
800 Senior citizens are the older population in the U.S. i.e. people over 65 years or older.  In 
2002 there were about 35.6 million senior citizens. Senior citizens represent 12.3% of the U.S. 
population, about one in every eight Americans. The number of older Americans increased by 
3.3 million or 10.2% since 1992, compared to an increase of 13.5% for the under-65 
population. However, the number of Americans aged 45-64 who will reach 65 over the next 
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found consonance in gaining access to cheaper medicines through border-
crossing and internet pharmacies. The most popular means of re-importation 
has been to travel over to Canada to purchase medications in individual 
quantities (note that practice is prohibited by the federal government if the 
individual is returning with a more than 90-day supply of prescription 
drugs).801  Drug clubs have also been set up to sell drugs sold in America that 
are exported to Canada and are then re-importation back to the U.S.802  In 
2003, it was estimated that  between one and two million US citizens purchase 
Canadian drugs over the internet, by phone, or through border-crossing.803 
Danzon has however asserted that trying to tackle the predicament faced by 
senior citizens in the US through parallel imports or external referencing to 
lower prices in other countries may not be the solution to gaining access to 
medicines in the long run because of the effects on R&D and the development 
of new chemical entities.804 Her argument assets that such actions will indeed 
affect lower income countries who will be at loss if pharmaceutical companies 
become reluctant to grant lower prices on medicines in other countries for fear 
that these lower priced products will  be re-imported into the US through 
referencing or parallel trade.805 
 
One of the detrimental effects of parallel importation on access to medicines 
has been its potential to facilitate counterfeit medicines entering the 
                                                                                                                                                            
two decades increased by 38% during this period.  In 2002, there were 20.8 million older 
women and 14.8 million older men, or a sex ratio of 141 women for every 100 men.  Since 
1900, the percentage of Americans 65+ has tripled (from 4.1% in 1900 to 12.3% in 2002), and 
the number has increased eleven times (from 3.1 million to 35.6 million). 
801 See generally Paul Egan, Michigan may buy Canada drugs, DET. NEWS, Oct. 1, 2003, 
available at http://www.detnews.com/2003/politics/0310/01/b01- 285866.htm. 
802 Ibid 
ju803 Kim Norris, Medications crossing the border spurring concerns over safety, DET. FREE 
PRESS, Nov. 24, 2003, available at http:// 
www.freep.com/money/business/cdrug24_20031124.htm. 
804  DANZON. P.A (2003) Differential Pricing for Pharmaceuticals: Reconciling Access, R&D 
and Patents. International Journal of Health Care Finance and Economics, 3, 183–205 
805 Ibid  
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marketplace.806  Although counterfeit drugs are discussed in the previous 
chapter, it will be slightly re-appraised here in light of its effect on exhaustion. 
However by far one of biggest counterfeit drug market in sub-Sahara is 
Nigeria; and most of the counterfeit drugs are imported from Asian countries 
such as china, India and Pakistan.807. As such a WHO report showed that 35% 
of counterfeit drugs in the world come from India.808The report also noted that 
the illegal business in counterfeit drugs makes up approximately 10 percent of 
the global medicines market and account for more than $32 billion in annual 
sales. 809 In 2001 Chinese authorities closed 1,300 factories and investigated 
480,000 cases representing counterfeit drugs with a value of $57 million 
Likewise a report by WHO in 2001showed  that more than one-third of 
products allegedly containing the anti-malarial drug artesunate in Cambodia, 
Laos, Burma, Thailand and Vietnam actually had no active ingredients.810  
 
A follow-up study in 2004 showed that the situation had worsened, with 99 out 
of 188 artesunate samples found to be counterfeit.811 The presence of 
counterfeit goods imported from other countries into Nigeria has a significant 
effect on parallel importation into neighbouring West African countries such as 
Benin, Chad, Niger and Cameroon as such West African countries buy their 
drugs from Nigeria.812 The ill effects of parallel importation encouraging 
counterfeit medicines are felt not only in developing world, but in the 
developed world.  
                                                            
806 Combating Counterfeit Medicines and protecting patients through a Partnership Approach. 
European Federation of Pharmaceutical Industries and Association.  
http://212.3.246.100/Objects/2/Files/Q&Acounterfeit20052.pdf 
807 Prof. Dora Akunyili, Counterfeiting Drugs and Pharmacovigilance – The study of adverse 
Drug Reactions on 25th May 2005 
808 Fact sheet N°275 Revised 14 November 2006 Counterfeit medicines 
809 See NAFDAC, Safeguarding the Health of the Nation. 
http://www.nafdacnigeria.org/globaltrends.htm. 
810 China's Killer Headache: Fake Pharmaceuticals. e-drug@usa.healthnet.org. Fri, 30 Aug 
2002 11:40:13 -0400 (EDT)  
811 Ibid 
812 Prof. Dora Akunyili, Counterfeiting Drugs and Pharmacovigilance – The study of adverse 
Drug Reactions on 25th May 2005 
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In September 2004, counterfeit Cialis, Eli Lilly’s medicine for the treatment of 
erectile disorder was found as part of a parallel import stock in the UK. Shortly 
after that Abbott’s Reductil counterfeit anti-obesity medicines were found in 
the legitimate parallel import supply chain.813 Similarly in 2007, the UK's 
Medicines and Healthcare products Regulatory Agency (MHRA) with 
assistance from Astra Zeneca Ltd had to recall parallel imports stock Lot 
65520 of Bicalutamide tablets 50mg sold as Casodex and supplied from France 
after counterfeit tablets were discovered in the legitimate supply chain.814 The 
fact that parallel trader have to repackage medicines before exporting them to 
other countries or regions  makes the likelihood of counterfeit trade more 
serious. Most of the incidents of safety in the supply chain of parallel imports 
have been deemed to involve human errors of different proportions. As such 
Packaging Gateway has pointed out that sometimes a medicine has to go 
through as many as 20-30 pairs of hands before it eventually reaches the 
patient.815 As such discriminatory and poor regulation of exports by exporting 
countries has been deemed to be one of the major reasons for counterfeit 
parallel imports into Nigeria.816  NAFDAC has therefore responded by banning 
the imports of pharmaceutical products into Nigeria marked FOR EXPORT 
ONLY. Their rationale is based on the fact that any product that cannot be used 
in the country of manufacture should be unacceptable in Nigeria. 
 
Despite the foregoing, the potential benefits of parallel importation in the 
access to medicines debate cannot be underestimated, people living in the 
developing world and even the developed world do benefit from parallel 
traders who purchase medicines at a lower price and sell them to patients at a 
lower price than the branded manufacturers would charge. Many observers 
                                                            
813 Diminishing the Risks of Counterfeit Drugs. Packaging gateway.com. 05 March 2005. 
http://www.packaging-gateway.com/features/feature18/ 
814 Drug Alert. Class 1 Medicine Recall. Action Now. EL (07) A/08. 1 June 2007. Ref MDR 
40-05/07 
815 Fact sheet N°275 Revised 14 November 2006. Counterfeit medicines 
816 Prof. Dora Akunyili, Counterfeiting Drugs and Pharmacovigilance – The study of adverse 
Drug Reactions on 25th May 2005 
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have affirmed the positive consumer welfare effect of making pharmaceuticals 
available at lower prices. The advantages of parallel importation to the access 
to medicines dilemma is further demonstrated in the fact that it is the only 
“flexibility” in the TRIPS Agreement that has been left to the discretion of 
each member states to choose whichever policy best suits them. Although 
some have argued that the fact that Article 3 TRIPS states WTO Members 
should accord to the nationals of other WTO Members treatment no less 
favourable than it accords to its own nationals with regard to the protection of 
IP rights, subject to certain exceptions is defeated when countries operate a 
national or regional exhaustion practice. This argument is baseless, as 
discrimination on the bases of exhaustion policies do not amount to 
discrimination based on nationality.817  Article 4 of the TRIPS Agreement also 
states that “any advantage, favour, privilege or immunity granted by a Member 
to the nationals of any other country shall be accorded immediately and 
unconditionally to the nationals of all other Members”, however the Doha 
TRIPS Declaration states clearly that the TRIPS Agreement does not prescribe 
any kind of exhaustion of IP rights. 
 
For many, including this author the way forward to maximize the usage of 
parallel importation would be to find ways to ensure that its potentials are 
maximized in fulfilling the role that it was intended for in the TRIPS 
Agreement. This can be done by making sure that parallel importation of 
authentic and genuine medicines are imported into the poorest developing 
countries and not re-imported into developed countries, whilst still ensuring 
that pharmaceutical companies are not deterred from investing into R&D for 
innovative medicines for all diseases including topical diseases. At present re-
importation of patented and generic products from 76 countries including 
                                                            
817Slotboom, M. M. (2003.) The Exhaustion of Intellectual Property Rights-Different 
Approaches in EC and WTO Law. Journal of World Intellectual Property 6(3):421-440.   
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China, India and South Africa are banned from being imported into the EU.818  
However the fact that regional exhaustion of patented products is a legitimate 
trade puts EU members in a better position to explore their internal market and 
promote access to medicines between their member states.  Malueg- Schwartz 
has recommended that countries should follow suit by implementing regional 
exhaustion as the key to achieving the optimal global policy on parallel 
importation.819  
 
Although the idea may seem farfetched at first, the creation of a single market 
within Africa may be the key to promoting trade and the access to medicines. 
That being said, there are various regional and economic trading blocs within 
the continent which promote regional exhaustion in the same way that the EU 
does. The African Intellectual Property Organisation (AIPO) or OAPI is one of 
them. It consist of 16 French speaking member states including Benin, Burkina 
Faso, Cameroon, Central African Republic, Chad, Republic of Congo, Cote 
d'Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, 
Niger, Senegal and Togo. The AIPO have a shared structure to protection 
intellectual property rights which allows parallel imports from within any 
AIPO state. Parallel imports from other third countries are however prohibited.  
Nevertheless the AIPO has many shortcomings when it comes to promoting 
parallel importation between neighbouring countries in Africa. For example a 
parallel trader from Togo cannot import medicines from Ghana to sell to 
consumers in Togo even if the pharmaceutical products were cheaper in 
Ghana.  Ghana on the other hand operates an international patent exhaustion 
policy; however its West African neighbour Nigeria operates a national patent 
                                                            
818 PATRICIA M. DANZON. (2003)  Differential Pricing for Pharmaceuticals: Reconciling 
Access, R&D and Patents. International Journal of Health Care Finance and Economics, 3, 
183–205 
819 Malueg, David A., and Marius Schwartz. (1994) Parallel Imports, Demand Dispersion, and 
International Price Discrimination. Journal of International Economics 37:167-196. 
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exhaustion policy with a ban on cheaper substances from India and China if 
domestically patented.820   
 
A regional alliance which might have formed a formidable force in dealing 
with intellectual property rights in West Africa is the Economic Community of 
West African States (ECOWAS). It comprises of 15 countries of which 
Nigeria is one of. Established in 1975 with the Treaty of Lagos, ECOWAS  
had the fundamental goal of achieving collective self-sufficiency in all fields 
including economic, transport, telecommunications, energy, agriculture, 
natural resources, commerce, monetary and financial questions, social and 
cultural matters.821  Interestingly, the Treaty of Lagos does not make any 
mention of intellectual property rights.  The African Union (AU) however 
seems like a more likely organisation which may achieve the realization of a 
harmonised intellectual property regime within Africa. The AU consists of 53 
states and is a successor of the OAU. It was established in September 1999 by 
the Heads of states and Governments of the African Union with the aim of 
promoting unity and solidarity as well intensifying co-operation on 
development.822 In a paper released in November 2006 titled “Establishing a 
PAN African Intellectual Property Organisation” (PAIPO) 2006,823 
participants called for African leaders to establish an umbrella institution on 
intellectual property that would fit all members. The goals of the PAN African 
Organisation on Intellectual Property would be to provide a means for all 
Member States to co-ordinate specialised intellectual property knowledge and 
services with a goal to promote innovation, industrial competitiveness and 
                                                            
820 The Use of TRIPS Flexibilities to Promote Pharmaceutical Production in Developing 
Countries24 October 2007“Pharmaceutical Production in West and Central Africa” BMZ-
GTZ-UNIDO Regional Workshop Dakar, Senegal ChristophSpennemann, Legal Expert, IP 
Team Division on Investment, Technology and Enterprise Development, UNCTAD. 
http://www.gtz.de/en/dokumente/en-Spennemann-TRIPS-flexibilities-2007.pdf 
821 Ibid 
822 AFRICAN UNION IN A NUTSHELL http://www.africa-
union.org/root/au/AboutAu/au_in_a_nutshell_en.htm 
823 Extraordinary Conference of the African Ministers of Council on Science and Technology 
(Amcost) 20-24 November 2006, Cairo, Egypt. 
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economic growth in Africa.824 Although the institution is already facing 
opposition from other intellectual property regional bodies such as ARIPO, the 
future will tell if an African regional union on intellectual property matters is 
the solution to the problems of parallel importation and compulsory licensing 
at least between one Member State and the other. 
 
7.6  Limitations of the Doha Declaration 
Most commentators who have written on the values, triumphs and disasters of 
the Doha Declaration have one thing in common, and that is the fact that 
despite the success of the Doha declaration, many issues remained unresolved 
with regards to health.  One of the key issues that remained unresolved at Doha 
was how to guarantee that countries with insufficient or no manufacturing 
capability in the pharmaceutical area could get medicines from  countries who 
had obtained a compulsory licences for the purpose of exporting medicines  to 
such countries with little or no manufacturing capabilities.  This setback 
steams predominantly from Article 31(f) of the TRIPS Agreement which states 
that compulsory licensing should be limited to situations where the 
manufacture is “predominantly for the supply of the domestic market”.825  
Whilst this kind of state of affairs would benefit developing countries such as 
India and Brazil who have laboratories and the man power to manufacture their 
own pharmaceuticals, it does not do poor countries that have a huge epidemic 
health crisis and no manufacturing capacity any favours.826 Thus Article 31(f) 
of the TRIPS Agreement in requires that pharmaceutical products 
manufactured under compulsory licensing would be "predominately for the 
supply of the domestic market."827  Although the African group pushed for this 
                                                            
824 Ibid 
825TRIPs, art. 31(f).  
826 Jean Bizet (France), The Trips Agreement and Public Health, Presented at Cancun Session 
of The Parliamentary Conference on The WTO (Sept. 9-12, 2003), at http://www.ipu.org/splz-
e/cancun/5b.pdf (last visited March 8, 2008) [hereinafter Cancun Session] 
827 See Press Release, WTO, Decision Removes Final Patent Obstacle to Cheap Drug Imports, 
at http://www.wto.org/english/news_e/pres03_e/pr350_e.htm (last visited March 8, 2005) 
[hereinafter Patent Obstacle]. 
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problem associated with Article 31 to be resolved at Doha, the difficulty could 
not overcome so easily. The Ministerial Council however promised through 
Paragraph 6 of the Doha declaration that they would endeavour to overcome 
the problem. Consequently Paragraph 6 states that “we recognize that WTO 
Members with insufficient or no manufacturing capacities in the 
pharmaceutical sector could face difficulties in making effective use of 
compulsory licensing under the TRIPS Agreement” the General Council were 
subsequently instructed by the TRIPS Council to come up with “an expeditious 
solution to this problem ..." by the end of 2002.  
 
Negotiations were held in Geneva throughout 2002 to no avail.  Despite the 
paramount hard work of the Chairperson of the TRIPs Council and all the 
WTO Members to come up with a solution, a decision could not be reached as 
to how best to resolve the problem.828  What became obvious however was 
some developed countries spear headed by the US had begun to backpedal on 
what had been promised at Doha. After harsh negotiations, the US Trade 
Representative was unyielding and this unequivocally led to the breakdown of 
discussions in the TRIPS Council on December 20, 2002. It must be noted 
however that even though all the 143 of the WTO trading partners had agreed 
to a compromise solution, the US alone refused to go along with the deal 
which doomed the Agreement to a deadlock situation. It was not until August 
20, 2003 that members of the WTO broke this gridlock over Paragraph 6 by 
signing another WTO agreement,829 titled "Implementation of Paragraph 6 of 
the Doha Declaration on the TRIPS Agreement and Public Health". 
 
                                                            
828 Declaration on The TRIPS Agreement and Public Health, Nov. 14, 2001 [hereinafter Doha 
Declaration], available at http:// www.wto.org/english/thewto_e/minist_e/min01_e/minde-
cl_trips_e.htm. 
829 See Press Release, WTO, Decision Removes Final Patent Obstacle to Cheap Drug Imports, 
at http://www.wto.org/english/news_e/pres03_e/pr350_e.htm (last visited March 8, 2005) 
[hereinafter Patent Obstacle]. 
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The Implementation of Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health is instrumental. 830 It waived countries obligation 
under Article 31 of the TRIPS Agreement, thus allowing WTO member states 
that are facing a public health crisis to export pharmaceutical products under 
compulsory license until a final resolution to paragraph 6 of the Doha 
Declaration could be found.831 A waiver was achieved using Article IX:3-4 of 
the WTO Agreement, which allowed the Ministerial Conference to waive a 
requirement imposed on a member state by the TRIPS Agreement in 
'exceptional circumstances'.832 For the second time the Doha Agreement was 
hailed as good news, the only conditions that were attached to it were that the 
Agreement be interpreted in good faith in order to deal with all diseases 
including HIV/AIDS, tuberculosis and malaria;833 and secondly the importing 
member states had the obligation to prevent medicines that were intended to be 
imported into their country from being diverted to other countries. In order 
words parallel importation for medicines procured under Art 31 to other 
countries were prohibited from being re exported to other countries. General 
Council Chairperson Carlos Perez del Castillo, Uruguay's ambassador 
reassured the pharmaceutical industry who were exceptional worried about 
diversions that, "Members recognize that the system that will be established by 
the Decision should be used in good faith to protect public health and, without 
                                                            
830 See Kelly A. Friedgen, (2002).  Comment, Rethinking The Struggle Between Health & 
Intellectual Property: A Proposed Framework for Dynamic, Rather than Absolute, Patent 
Protection of Essential Medicines, 16 EMORY INT'L L. REV. 689, 699 For a list of levels of 
Development in pharmaceuticals by country, see Phillip McCalma, The Doha Agenda and 
Intellectual property Rights. October 2002. 
http://www.adb.org/Economics/pdf/doha/McCalman.pdf 
831 Haag, T.A (2002) 'TRIPS Since Doha: How Far Will the WTO Go Toward Modifying the 
Terms of Compulsory Licensing?', 84(12) Journal of the Patent and Trademark Office Society 
945, Jacques H.J. Bourgeois and Thaddeus J. Burns, (2002) 'Implementing Paragraph 6 of the 
Doha Declaration on TRIPS and Public Health: The Waiver Solution', 5(6) Journal of World 
Intellectual Property 835 , at 839. 
832 See also Bourgeois and Burns, Ibid at 856. 
833 Correa, C.M (2003) TRIPS and Access to Drugs: Toward a Solution for Developing 
Countries without Manufacturing Capacity, 17 EMORY INT'L L. REV. 389, 390-391 at t 393 
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prejudice to paragraph 6 of the Decision, not be an instrument to pursue 
industrial or commercial policy objectives."834  
 
Like the Doha Declaration 2001, commentators and the international 
community welcomed the implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement as a step in the right direction for access 
to essential medicines; however they were still many criticisms levied against 
it. The US was accused of imposing burdensome conditions that would make 
the agreement unworkable.835 As a matter of fact Professor Brook Baker 
describes them as “cumbersome” and an “procedural labyrinth”836 One of the 
major encumbrances that have been pointed out by commentators is the 
procedural requirements that requires member states to alter and repackage the 
pill size and colours of the drugs. The catastrophic effect that these 
requirements have on access to essential medicines in developing countries is 
the financial burden that will accompany the adherence to the regulation.837 
Other difficulties that come with adhering to the rules of the Agreement are the 
administrative hassles connected with the prerequisite of having to notifying 
the WTO of every decision made with regards to compulsory licenses. 
Furthermore the Council must also review periodically compulsory licenses 
issued, this it is suggested will result in prolonged delays and prove to be 
                                                            
834 See WTO News, The General Council Chairperson's Statement, at http:// 
www.wto.org/english/news_e/news03_e/trips_stat_28aug03_e.htm (last visited March 8, 
2005) [hereinafter Chairperson's Statement]. 
835 See HIV Drugs for Africa Diverted to Europe, WASH. POST, Oct. 3, 2002 at A10; see also 
Naomi Klein, Bush's AIDS Test, The Nation, October 27, 2003, available at 
http://www.thenation.com/docprint.mhtml?i=20031027&s=klein (quoting Harvey Bale as 
saying that the Agreement weakens patents, will hurt corporate profits and will destroy the 
incentive for new research). 
836 Professor Brook Baker 
837 Godnick.. K (2007)  Profitability Versus The Public Interest: Is International Patent Law 
Hindering Third World Countries Access to HIV/AIDS Medication? Richard Journal of Law 
and the Public Interest. Spring 
http://law.richmond.edu/rjolpi/Issues_Archived/2007_Spring/Godnick.pdf and Duncan 
Matthew. WTO Decision on Implementation of Paragraph 6 of the Doha Declaration on the 
TRIPS Agreement and Public Health: A Solution to the Access to essential Medicines 
Problem. 7 J. Int’l Econ. L. 73. 2004 
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exorbitantly expensive for the governments of developing countries.838 The 
gifts and inadequacies of the Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health and its relationship 
with Article 31 of the TRIPS Agreement when it comes to access to medicines 
for developing countries are numerous. The WTO describes the resolution of 
the Paragraph 6 problem as removing the "final patent obstacle to cheap drug 
imports"839, however Pascal Lamy, the European Trade Commissioner 
interestingly said that “We all have to be very modest. We have solved about 
10% of the problem of access to medicines by developing countries." 840  
On December 6, 2005 the World Trade Organisation (WTO) members reached 
an agreement on the first ever amendment to the TRIPS Agreement. The 
agreement would make permanent the temporary waiver of Art.31(f) contained 
in the August 30, 2003 “WTO Decision on the Implementation of Paragraph 6 
of the Doha Declaration on the TRIPS Agreement and Public Health”.841 The 
amendment was in fact the first ever amendment to the TRIPS Agreement to 
directly allow WTO members to issue compulsory licences to export generic 
versions of patented medicines to countries with insufficient or no 
manufacturing capacity in the pharmaceutical sector. Nigeria for example was 
extremely active role in this Agreement, thus on March 31 2005 she explained 
to the TRIPS Council on behalf of the African Group that Art 31 needed to be 
                                                            
838 Matthews, D. (2004) WTO Decision on Implementation of Paragraph 6 of The Doha 
Declaration on the 
TRIPS Agreement and Public Health: A Solution to the Access to Essential Medicines 
Problem?, 7 J. INT’L 
ECON. L. 73  (citing World Health Organization Intellectual Property Rights, Innovation and 
Public Health: Report by the Secretariat (Geneva: WHO, 56th World Health Assembly 
Provisional Agenda 
Item 14.9, A56/17, 12 May 2003)). 
839 WTO: Decision removes final patent obstacle to cheap drug imports. 
[http://www.wto.org/english/news_e/pres03_e/pr350_e.htm]  
840 See Scott Miller, WTO Drug Pact Lifts Trade Talks - Landmark Deal Provides Medicines 
to Poor Nations, available at http://www.usvtc.org/WTO/WTO% 
20Drug%C20Pact%C20Lifts%C20Trade%Talks.htm; EU's Lamy Is Optimistic, WALL ST. J., 
Sept. 2, 2003, at A2. 
841 Duncan Matthew. (2006) From the August 30, 2003 WTO decision to the December 6, 2005 
agreement on an amendment to TRIPS:  improving access to medicines in developing 
countries? 2006. Intellectual Property Quarterly 
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modified and certain provisions eliminated.842    The provisions that needed to 
be eliminated amongst others included para.6 (ii) on regional patent systems; 
para.8 on annual reviews and para.9 on prejudice to other right.843. In my 
opinion, the presence of Nigeria at the Council meetings is important because 
Nigeria is a potential world power that needs to play a more active in world 
matters especially on public health issues of the sub-Sahara. The Agreement 
was however circulated to WTO members for formal adoption and a deadline 
was set for December 1, 2007. In 2008, the deadline for accepting the TRIPS 
agreement amendment was extended to 31 December 2009 or "such later date 
as may be decided by the Ministerial Conference.” 844 In a two-third of 
majority was however needed by members in order to accept a permanent 
amendment to the agreement and for it to be formally adopted. Regardless of 
the foregoing, one of the most decisive criticisms made against the successes 
of the Doha Rounds is the fact that it did not address the use of TRIPS plus 
measure used particularly by the US and EU to impose higher level of 
intellectual property protection than stipulated by the TRIPS Agreement. These 
TRIPS plus measures are usually in the form of bilateral and regional 
agreements, thus some have asserted that they have escalated the public health 
crisis in the developing world than the patent system. 
 
7.7  TRIPS Plus 
The United States has concluded a substantial amount of bilateral and regional 
free trade agreements with many developing countries. Each of these FTAs 
includes substantial obligations in the field of intellectual property rights that 
exceed those required by the TRIPS Agreement. Article 1 of the TRIPS 
                                                            
842 Ibid 
843 .  Minutes of TRIPS Council Meeting held on March 8-9 and 31, 2005, IP/C/M/47, June 3, 
2005.Art.7 
844  Amendment of the TRIPS Agreement – Extension of the Period for The Acceptance by 
members of the Protocol Amending the TRIPS Agreement. Decision of 18 December 2007. 
WTO WT/L/711. See also  David Cronin, EU Acceptance Of TRIPS Health Amendment Adds 
28 Members", Intellectual Property Watch (December 1, 2007), available at http://www.ip-
watch.org/weblog/index.php?p=856 
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Agreement states that “Members may, but shall not be obliged to, implement 
in their law more extensive protection than is required by this Agreement, 
provided that such protection does not contravene the provisions of this 
Agreement”. Most of the TRIPS plus measure have been aimed at increasing 
the level of protection for patent right holders beyond those given in the TRIPS 
Agreement, thereby reducing the scope or effective limitations on the rights 
and exceptions which establishes minimum substantive standards of protection 
and enforcement of IP rights for all WTO Members.845 Before the conclusion 
of the Uruguay rounds in 1994, the US had already began to use its special 301 
to pressurize Members states to implement TRIPS plus measures.  In 1988 
after a complaint by the Pharmaceutical Manufacturers’ Association (PMA) 
about the absence of effective patent protection for pharmaceutical inventions 
in Brazil; tariffs were increased to 100 percent on exports of more than 20 
pharmaceutical products from Brazil to the US.  This affected Brazil’s export 
trade by over $39 million.846 In the face of such enormous financial loss, Brazil 
who was one of the chief opponents to some of the measures in the TRIPS 
Agreement during the negation at Uruguay backed down, and encouraged 
other developing countries to do the same. 
 
Chile faced serious pressure from the United States to grant patent protection 
for its pharmaceutical products.847  During the 1980s, PMA put pressure on the 
Chilean government to grant patent protection to pharmaceutical products for 
twenty-five years. Although initially the Chilean government resisted pressure 
from the US, however in 1990 it  eventually succumbed to it and adopted a law 
                                                            
845 Sisule F Musungu and Graham Dutfield. Multilateral Agreements and a TRIPS plus World: 
The World Intellectual Property Organisation (WIPO). TRIPS Issues Papers 3. Published by: 
Quaker United Nations Office (QUNO), Geneva. Quaker International Affairs Programme 
(QIAP), Ottawa 
Project undertaken with the financial support of the Government of Canada provided through 
the Canadian International Development Agency (CIDA 
846 Watal. J (2002) Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for 
India Under the WTO TRIPS Agreement. The World Economy. Vol 23 , Issue 5 
847 Sell. K Susam  (2003) Private Power, Public Law. The Globalization of Intellectual 
Property Rights. The George Washington University. Cambridge University Press. 
http://assets.cambridge.org/97805218/19145/sample/9780521819145ws.pdf 
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providing patent protection for pharmaceutical products for a 15 year period. 
848 This action not only put the prices of essential medicines out of reach for 
the average Chilean citizens; it was also a forewarning of a global and 
internationally enforceable IP Agreement in the embodiment of the TRIPS 
agreement.  The bilateral treaty between US-Chile FTA came into force on 1 
January 2004. It required that Chile offer an extension to the 20-year term 
patent of patent holders by adding an additional five years to the length of 
protection. This puts access to affordable medicines such as HIV/AIDS drugs 
in jeopardy. In response to this a Chilean farmer Nicolas Garcia told the 
Washington Times (17/06/03) noted that it was indeed a “case of the biggest 
and strongest eating the smallest”.849Mexico like Chile came under similar 
pressure. By 1990 it had already agreed to introduce product patent for 
pharmaceuticals products and was already at the initial discussion stage of 
NAFTA.850  This resulted in it distancing itself from the camp of the resilient 
developing countries. Consequently by 1991 even before the TRIPS 
Agreement came into force, Mexico had already modernized its IP laws to the 
full approval of the US Trade Representatives (USTR).851 
 
By threatening bilateral trade sanctions against resilient countries, one by one, 
the US and its partners successfully undermined the developing countries 
resistance to the TRIPS Agreement. Other developing countries like China and 
Korea were placed on the priority watch list because of inadequate patent 
protection for pharmaceutical products.852 Other factor that made it impossible 
for developing countries to withstand pressure from the US was the fact that 
many developing countries were dependent on the US market. This coupled 
with political and economic pressure forced them to accept terms that did not 
                                                            
848 Ibid  
849 US –Chile. http://www.bilaterals.org/rubrique.php3?id_rubrique=20 
850 Ibid 
851 Ibid 
852 Blakeney, M (1996) Trade Related Aspects of Intellectual Property Rights: A Concise guide 
to the TRIPS Agreement, London : Sweet and Maxwell 
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adequately take into consideration their best interest.853   Although 
commentators have argued that developing countries gained access to the 
markets of industrialized states for their agricultural product and textile goods 
(which was part of the bargain of agreeing to the TRIPS Agreement), 854 it 
seemed that they remained opposed to the idea in principle.855   
 
The US president has been able to sign many FTA with other governments 
based on the 2002 Bipartisan Trade Promotion Authority Act856 which gives 
the him the power to conclude agreements with trading partners. The 
agreements are in turn presented to congress who then votes on the trade 
negotiations made by the president but in the real sense are not expected to 
amend or make any changes to the proposed agreement.857 Commentators 
have suggested that the Bipartisan Act legislation has been used to encourage 
TRIPS-plus agreements, and in so doing preventing access to medicines. The 
main section which the US has used to raise the level of intellectual property 
standard is Article 21012(b) (4) (A)(9i)(II) which explicitly states that “the 
provisions of any multilateral or bilateral trade agreements governing 
intellectual property rights that are entered into by the United States reflect a 
standard of protection similar to that found in the U.S law.858 
 
The Genetic Resources Action International (GRAIN) has identified at least 23 
negotiated bilateral and regional treaties between developed and developing 
world, in which the US required other member states to provide IPR protection 
that were greater than the minimum standard outlined by the TRIPS 
                                                            
853 See Kennedy .D and Southwick . J (2001),Trips in the political economy of international 
trade law: essays in honour of Robert Hudec , Cambridge, Cambridge University Press.  
854 Ibid 
855 Gervais, D (1998) The TRIPS Agreement: Drafting history and analysis. London: Sweet 
and Maxwell. Pg:18 
856 Bipartisan Trade Promotion Authority Act, Pub. L.No.107-210(2002) 
857 Abbot. F.M (2006)  Intellectual Property Provision of Bilateral and Regional Trade 
Agreements in Light of US Federal Law February  UNCTAD - ICTSD Project on IPRs and 
Sustainable Development. Issue Paper No 12 
858 Ibid 
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Agreement.859 The same report admitted that such agreements were affecting 
more than 150 developing countries at the time. Developed countries such as 
the US have continuously sought to fulfil the inadequacies of a lesser 
intellectual property protection at the multilateral level through bilateral and 
regional negotiations.860 For example the TRIPS Agreement clearly allows 
member states to exclude plants and animals from patent protection; however 
many of the negotiated bilateral agreements do not include such exclusions and 
require patents on biological inventions.861 The UN Convention on Biological 
Diversity (CBD) which states that countries own and should controls its 
genetic resources and that other countries cannot basically exploit such 
resources without prior consent from the owners.  Whilst the US government 
have threatened and punished countries who do not adhere to intellectual 
property rights which violate the rights of the patent holder, it does not seem to 
mind that the use of genetic resources are being misused by the same people it 
seeks to protect.862   
 
The irregularity of the multilateral system has seen MNC mainly in the US and 
the EU manufacturing pharmaceutical and agricultural products from 
genetically modified ingredients. These genetically modified ingredients 
include medicinal plants, soil microorganisms, animals and genes which 
belong to indigenous people in third world communities and have been used by 
MNC to make profits without the permission or remuneration to the owners.863  
Consequently in March 2006 in a case, “Out of Brazil: A Peanut Worth 
                                                            
859 Genetic Resources Action International (GRAIN), TRIPS plus” Through the Back Door 4 
(2001), available at http://www.grain.org/trips-plus-en.pdf (last visited February 2008) 
860 See David Vivas- Eugui. Regional and bilateral agreements and a TRIPS-plus world: the 
Free Trade Area of the Americas (FTAA) TRIPS Issue papers. Quaker United Nations Office 
(QUNO), Geneva. Quaker International Affairs Programme (QIAP), Ottawa International 
Centre for Trade and Sustainable Development (ICTSD), Geneva 
861 Ibid 
862 Tove Iren S. Gerhardsen.  Brazil Fights to Make Case for International Biodiversity 
Protection. Intellectual Property Watch. See http://www.ip-
watch.org/weblog/index.php?p=322 
863  Martin Khor. A Worldwide fight against bio piracy and patents on life. Third World 
Network. See http://www.twnside.org.sg/title/pat-ch.htm  Accessed 23 August 2008 
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Billions,”864  the US was exposed for using groundnut which originated from 
Brazil to treat disease-resistant tomato spotted wilt virus found in US peanut 
varieties since 1987.865 The genetic product is now being used in innovative 
peanut multiplicity in the United States and is projected to add at least $200 
million every year to the US market.  
 
The USA has since concluded free trade agreements with Israel866, 
Australia,867 Morocco868, and with Central American countries (CAFTA), 
including Costa Rica, El Salvador, and Guatemala, Honduras and 
Nicaragua.869. The Dominican Republic recently joined CAFTA. In all of 
them, specific provisions on IPRs are included. The USA has also signed FTA 
with the five nations of the African Southern Customs Union (SACU)870, 
including Botswana, Lesotho, Namibia, South Africa and Swaziland. A 
number of Middle-East countries including Bahrain871 have also signed FTA 
with the US. Panama, Colombia, Peru, Bolivia and Ecuador are also in FTA 
with the US,872 and negotiating several other FTAs with countries such as 
Thailand and Malaysia.873 Joseph Stigliz advised developing countries to be 
                                                            
864 Tove Iren S. Gerhardsen (2006)   Brazil Fights To Make Case For International 
Biodiversity Protect. Intellectual Property Watch. . 
865 Out of Brazil: A Peanut Worth Billions (to the US) " (available at http://www.edmonds-
institute.org 
866 The agreement was signed on April 22, 1985, but the final phase of the agreement was fully 
implemented on January 1, 1995. See text at: http://www.us-israel.org/jsourcae/USIsrael/ 
FTA_Text.htm 
867 The agreement was concluded on February 2004 and signed in May 2004. See: 
http://www.ustr.gov/new/fta/Australia/text/ 
868 Negotiations were concluded on March 2, 2004 and the FTA was signed on June 15, 2004. 
See the US–Morocco FTA at http://www.ustr.gov/new/fta/Morocco/text/index.htm 
869 CAFTA was signed in May 2004. See, 
http://www.ustr.gov/new/fta/cafta/text/index.htm 
870 The USA and the SACU launched negotiations for a Free Trade Agreement in Pretoria, 
South Africa, on June 2, 2003. It will be the first free trade agreement for the USA in Sub-
Saharan Africa and the first time that SACU nations would jointly negotiate such kind of 
agreement. This will be done under the framework of the African Growth and Opportunity Act 
871 Negotiations with Bahrain for a free trade agreement were launched on January 2004 and 
concluded on May 28, of the same year. See “Trade Facts” of March 2, 2004, available at the 
Office of the United States Trade Representative web site: http://www.ustr.gov 
872Negotiations with Colombia, Ecuador and Peru were launched on May 18 - 19, 2004 
873 IPR violations high on Bush visit agenda. Inter Press Service. 29 July 2008. 
http://www.bilaterals.org/article.php3?id_article=12808 
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cautious when entering into FTA and claimed that “bilateral agreements have 
been a disaster, for the developing countries and for the global trading 
system”.874 
 
Another FTA agreement worth mentioning is the US- SACU (Southern 
African Customs Union). The SACU compromises of five countries namely 
South African, Namibia, and Botswana. Lesotho and Swaziland, of which one 
(Lesotho) is recognized by the WTO as a Least Developed Country (LDC), 
meaning it has no obligations with respect to patents for pharmaceutical 
products until 1 January 2016. Mr Zoelick, former United States Trade 
Representatives who wrote the briefing paper  for the US-SACU FTA claimed 
that the paper would set out minimum standards of patent protection, similarly 
the Office of the USTR stated that the agreement will “bring new hope and 
prosperity to southern Africa and the United States [and] further drive regional 
growth and development, and provide for a common economic future”,875 
these assertions are doubtful as the US-SACU FTA demands standards that 
reflect IP protection that are similar to those found in US law be established.876 
The SACU countries would have to significantly strengthen their domestic 
enforcement procedures, strengthen measures in SACU countries that provide 
for compensation of right holders for infringements of intellectual property 
rights. They would also have to provide for criminal penalties under the laws 
of SACU countries that are sufficient to have a deterrent effect on piracy and 
counterfeiting. The irony of the US-SACU FTA lies in fact that the South 
African region already suffers tremendously from the HIV/AIDS epidemic and  
the high prices of the medicines for antiretroviral medicines has not made the 
situation any better.  Nevertheless the important thing to note is that the U.S.-
                                                            
874 Stiglitz: (30-08-2007) FTAs advantageous to US. The Edge Daily (Malaysia) |by Maryann 
Tan & Yong Yen Nie. http://www.bilaterals.org/article.php3?id_article=9510 
875http://www.ustr.gov/Trade_Agreements/Bilateral/Southern_Africa_FTA/Background_Infor
mation_on_the_US-SACU_FTA.html 
876 Jonathan Berger and Achal Prabhala. (17 February 2005) Assessing the Impact of the TRIPS 
PLUS Patent Rules in the Proposed US-SACU Free Trade agreement. Johannesburg, South 
Africa Draft http://www.who.int/hiv/amds/capacity/tza2_oxfamreport_pricing_financing.pdf 
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SACU FTA bilateral negotiations that was initiated in June 2003 came to a 
deadlock after a number of official meetings where the bilateral FTA 
negotiations were replaced by an effort to negotiate a framework agreement 
covering trade and investment with the hope that a bilateral FTA will be agreed 
upon in the future. 877 
 
The EFTA also attempted to sign a FTA with the SACU in November 2004; 
however the SACU rejected the European Free Trade Association’s (EFTA; 
which comprises Switzerland, Norway, Iceland, and Liechtenstein) proposal.  
South Africa-based public health group as well as the South African Minister 
of Trade Minister Mandisi Mpahlwa were aware that the EFTA’s proposed 
IPR provisions went beyond the requirements of the TRIPS Agreement.878 The 
TRIPS plus measures in the FTA  sought  to introduce a five- to ten-year data 
protection period for clinical test data, as well as a provision to potentially 
allow five-year patent extensions to brand-name drugs. This of course would 
"block and delay generic competition," thus hindering access to medicine. 
 
7.8  Is There TRIPS Plus in the ECP? If so is this the way Forward for 
Nigeria? 
Although slow but major IP reforms are underway, the EU has been seeking 
rapid changes to the IP laws in Nigeria through regional treaties with 
ECOWAS. 879 One of the reasons for this is to push for reforms that they have 
previously not been able to get through multilateral agreements at WTO and 
                                                            
877 The Congressional notification letters were available online at http://wwww.ustr.gov/Trade 
Agreements/Bilateral/Southern Africa FTA/Section Index.html. 
878 Southern African Countries Reject “TRIPS PLUS” FTA Negotiation. ICTSD. 2004  See 
http://ictsd.net/i/publications/7481/  
879 The Economic Community of West African States (ECOWAS) is a regional group of 
fifteen West African countries, founded on May 28, 1975 with the signing of the Treaty of 
Lagos. Its mission is to promote economic integration. Member states of ECOWAS are Benin, 
Burkina Faso, Cape Verde, Côte d'Ivoire, The Gambia, Ghana, Guinea, Guinea Bissau, 
Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone, and Togo. 
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WIPO.880  For example in  2006 and 2007, the EU through the European 
Commission attempted to complete what it called the comprehensive 
Economic Partnership Agreements (EPAs) with the 79 member African, 
Caribbean and Pacific (ACP) group of countries.881 The major thrust of this 
change was its Global Europe strategy, which states that, “[t]he EU should 
seek to strengthen IPR [Intellectual Property Right] provisions in future 
bilateral agreements and the enforcement of existing commitments ...,”882 . The 
target was to conclude comprehensive agreements to meet the 2007 goal for 
bringing the EU’s preferential trade arrangements for goods with ACP 
countries into conformity with the World Trade Organization’s (WTO) 
General Agreement on Tariffs and Trade (GATT).883  
 
Although Teddy Sseezi Cheeye argues that by signing the EPA, Europe would 
be “pressurizing its former colonies [into] signing an enslaving trade 
agreement”,884 the agreement is a goods-only interim agreement; hence some 
commentators state that it presents a chance for ACP countries to organize 
themselves if and when it decides to negotiate on IPRs in future EPAs. The 
objective of this is so that they can ensure that they do not compromise their 
                                                            
880 Dalindyebo Shabalala with contributions from Marcos Orellana, Nathalie Bernasconi-
Osterwalder and Sofia Plagakis (April 2008).  Intellectual Property in European Union 
Economic Partnership Agreements with the African, Caribbean and Pacific Countries: What 
way Forward after the Cariforum EPA and the interim EPAs?. Centre for International 
Environmental Law 
881 Update: Interim economic Partnership Agreements. 19 December 2007.  
http://trade.ec.europa.eu/doclib/docs/2007/november/tradoc_136959.pdf 
882 European Commission “Global Europe: competing in the world” EU Policy Review, 
October 4, 2006 (available at 
http://EU.europa.eu/trade/issues/sectoral/competitiveness/global_europe_en.htm), Section v. 
883 2 The deadline came about because of a 2001 waiver from the WTO that was obtained by 
the EU and ACP regarding 
the Cotonou Agreement, allowing for the continuation of the preference regime but only until 
the end of 2007. The preference regime largely excluded Latin American countries who 
objected to what they argued was unfair discrimination between similarly situated developing 
countries. Beyond that date, the EU would not have been allowed to continue the preference 
regime without establishing a regional trade agreement under Article XXIV of the GATT. The 
waiver is “European Communities — the ACP-EC Partnership Agreement, Decision of 
November 14” WTO Document Number WT/MIN(01)/15, available at 
http://www.wto.org/English/thewto_e/minist_e/min01_e/mindecl_acp_ec_agre_e.htm. 
884 There is No Need for the Continent to Sign EPA. The Monitor (Kampala) Column 26 
November 2007 
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position in multilateral forums and that any IPR provisions in EPAs actually 
reflect their interest. Oxfam argues that the signing of the interim EPAs has 
inevitably increased the complications of future intellectual property 
negotiations.885  The CARIFORUM – EC EPA (the EPA text) acknowledges 
that access to medicines is imperative. This is reiterated in Article 139.2 of the 
IPRs section, which emphasis the right to take measures to protect public 
health and nutrition in Art 8 of the TRIPS Agreement.  
 
In 2007, Nigeria refused to sign a separate interim agreement with the EU 
through ECOWAS.886 The European Commissioner for Trade, Mr Peter 
Mandelson responded by saying that Nigeria is “sitting like an elephant in the 
middle of the road”. Although this was said to denounce Nigeria’s position, 
some observers have chosen to see this as a positive sign that a developing 
country has refuses to be bullied into signing an EPA that will pose a serious 
major challenge to their ability to gain access to cheap medicines.887  
OPINION analysis of Mandelson’s comments that Nigeria is sitting like an 
elephant in the middle of the road when she refused to sign EPA is interesting 
in signalling the angle that the country hopes to play in future multilateral 
agreements. OPINION states that the “elephant indeed is a prestigious animal 
at least, for its size and gait, but more importantly for the ornamental value of 
the tusk. Whether it is walking, standing, or sitting, one fact is clear - it cannot 
be moved easily from one position to another against its will. This indeed is 
Nigeria’s position as far as the EPA is concerned. Nigeria appears to be the 
only country within the ACP bloc that can sit and stand tall before any other 
(colonial headmasters inclusive) or even withstand any form of ferocious 
                                                            
885  Ibid  
886  For full text (in French) see http://www.acp-eu-trade.org/library/files/Cote-d-Ivoire- 
CE_FR_071207_bilaterals.org_APE-d-etape.pdf. 
887Chibuzo Nwoke. (Posted 21-05-2008. ) Nigeria: Country to lose $478.4 million revenue to 
EPA.. Institute of International Affairs. 
http://www.bilaterals.org/article.php3?id_article=12164&var_recherche=nigeria 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
272 
 
pressure from any kind of oppressor in the face of negotiations”.888 Article 
46.1 of the text states that “Without prejudice to the positions of the Parties in 
multilateral negotiations, the Parties recognize the need to ensure an adequate 
and effective level of protection of intellectual, industrial and commercial 
property rights, and other rights covered by TRIPS…in line with the 
international standards with a view to reducing distortions and impediments to 
bilateral trade”. This signifies that countries are well within their rights to 
refuse to negotiate on certain parts of Intellectual property rights. 
 
In responses to pressure to sign TRIPS plus agreements in bilateral and 
regional agreements, the Centre for International Environmental Law argues 
that ACP countries need to refrain from further negotiating on intellectual 
property in EPAs. The rationale for this is that the addition of any TRIPS-Plus 
intellectual property provisions in the EPAs will dramatically alter the whole 
scene of international intellectual property negotiations for a country like 
Nigeria. It has been suggested that during the interim Nigeria will be better of 
concentrating its resources on carrying out a full national policy impact 
assessment that would involve retrospective, concurrent or prospective health 
impact assessment of any intellectual property agreements.889. The imperative 
of the urgent need to amend Nigeria’s IP Laws to take full advantage of the 
TRIPS Agreement and flexibilities in the form compulsory licensing and 
parallel importation is understandable, however Nigeria must factor into their 
national legislations their level and pace of development, whilst enacting 
legislations that are public health friendly. Nevertheless Article 44 of the EPA 
text in relation to what is next for ECOWAS urges the parties to conclude a 
global EPA between the West Africa region and the EU before the end of 
2008, whether the agreement will be concluded remains to be seen 
                                                            
888  Nigeria: EPA - Reasons Why Nigeria is a Sitting 'Elephant' Leadership (Abuja) OPINION 
18 November 2007. http://allafrica.com/stories/200711190348.html. Accessed 12 June 2008 
889 Health Impact Assessment in Development Policy and Planning. Report of an Informal 
WHO Consultative Meeting. Cartagena, Colombia. 28 May 2001. WHO/HDE/HID/02.4. See 
http://www.who.int/mediacentre/events/HSD_Plaq_02.4_def1.pdf Accessed 28 June 2008 
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7.9  Summary  
The search for access to medicines after the TRIPS Agreement was signed in 
1994 has led to different alliance. While one camp praised it for ensuring that 
MNC companies would continue to invest in R&D for NCES, the other camp 
saw it as an end to public health. So when the Doha Declaration came about in 
2001 bringing with it clarifications that developing countries could use the 
flexibilities within the TRIPS Agreement to gain more access to medicines, 
many developing countries welcomed it as a breakthrough in the fight to 
ensure that the Agreement did not affect public health in a negative way. 
Nevertheless some issues remained unresolved. Firstly the issue of lack of 
manufacturing capability was not resolved by the TRIPS Agreement or the 
Doha declaration, indeed many developing countries do not have the 
manufacturing capacity to take advantage of compulsory licences as stipulated 
in the agreement because their pharmaceutical industries are not advanced 
enough. They must therefore rely on other countries that have manufacturing 
capacity in order to reap the benefits of compulsory licenses. 
 
The issue of Trip-plus has also been left unresolved by the TRIPS Agreement. 
Developing countries therefore have to contend with pressures from countries 
in the EU and the US to raise IP standards beyond a level that is helpful for the 
development of their economies. Although Nigeria has withstood the pressure 
to become TRIPS-plus, it is also equally important that it amends its laws to 
become TRIPS –compliant. As such it is the responsibility of the Nigerian 
government to ensure that it enacts legislations that are public health friendly, 
which also fosters an environment where local pharmaceutical industries can 
thrive and begin to manufacture their own medicines as well as using parallel 
importation and compulsory licences where necessary. 
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8 THE PHARMACEUTICAL INDUSTRY AND 
ESSENTIAL MEDICINES 
 
8.1  Introduction  
Without drugs, a health service has no substance and no credibility. Every 
effort to ensure that the right drugs are available where they are most needed in 
the primary health care system, at prices that are realistic, demands an alliance 
between a sovereign government and the pharmaceutical manufacturer. 
Dr Hiroshi Nakajima, WHO’s Director-General 1989 
 
A love for tradition has never weakened a nation; indeed it has strengthened 
nations in their hour of peril. 
Winston Churchill 
 
There is no medicine like hope, no incentive so great, and no tonic so powerful 
as expectation of something better tomorrow. 
Orison Swett Marden 
 
When the World Health Assembly convened in 1975, it introduced the concept 
of essential medicines and national drug policies. By October 1977, the World 
Health Organization (WHO) had produced the first Model List of Essential 
Drugs. The vision that WHO had was to ensure that people all over the world 
have access to the essential medicines that they need; that the medicines are 
safe, effective, of good quality, prescribed and used rationally.890 The report of 
the UK Working Group on Increasing Access to Essential Medicines in the 
Developing World recommended that pharmaceutical companies provide 
medicines at near to production cost for HIV/AIDS, TB and malaria to 
countries who cannot afford to purchase them. Since the realization that access 
                                                            
890 Essential Medicines and Pharmaceutical Policies (EMP) http://www.who.int/medicines/en/ 
Accessed 19 May 2007 
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to medicines is a fundamental human right that many people in poorer 
countries lack because of the high prices of medicines, the pharmaceutical 
industry has been consistently blamed for this status quo. This position has 
been further reinforced by the TRIPS Agreement which makes it difficult for 
people to obtain cheap generic versions of patented drugs and allows patent 
holders to set prices which are prohibitively expensive. 
 
The purpose of this chapter is therefore to show that pharmaceutical MNC and 
their emphasis to maintain a strong patent system are not the only reasons to 
blame for the lack of access to essential medicines. There are other factors that 
have contributed to the situation. Some of these factors include a lack of 
commitment by governments in developing countries to invest in 
pharmaceutical local companies that will enable them to become self 
sufficient; a lack of investment in primary health care systems; inappropriate 
use of medicines; corruption, lack of education and failed government national 
policies. In order to achieve the above stated goal, this chapter will also carry 
out an evaluation of the pharmaceutical industry with major emphasis on two 
developing countries namely Nigeria and India.  
 
The reasons for choosing these two countries are that both countries have a 
similar history; they are both former colonies of Britain; they both have a rich 
tradition of traditional medicines, they are both facing a health care crisis with 
relation to HIV/AIDS, they both have the right to health as a provision in their 
constitution. Both countries have a huge population; in 1970 both countries 
passed the Patent Act. Most antiretroviral medicines that are used in Nigeria 
come from India. Most pharmaceuticals set up in Nigeria have affiliations with 
India e.g. Ranbaxy, most counterfeit medicines come from India, both 
countries have a high level of poverty but more importantly Nigeria has a lot it 
can learn from India in how to make their pharmaceutical industry self-
sufficient.  
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Whilst India has been successful in developing its pharmaceutical industry and 
providing medicines for majority of its population and a large proportion of the 
population of the developing world, Nigeria is still struggling to for its 
pharmaceutical industry to become self-sufficient and provide medicines for its 
population  A case study of the Indian pharmaceutical companies is therefore 
important for a variety of reasons: it is important to show the reader that it is 
possible to take advantage of a country’s traditional medicines to provide more 
access to medicines; it is important to show the reader that Nigeria can learn 
from India  key resolutions that will enable the Nigerian pharmaceutical 
industry to become self-reliant and prosperous.  The purpose of this chapter is 
not to transport the Indian analysis to the Nigerian situation, but to learn 
important elements of how a government that is determined to strengthen its 
primary healthcare can succeed with the right national policies. 
 
8.2  Proximity between India and Nigeria  
India has the highest population of people living with HIV/AIDS in the world. 
Presently there are over 5.7 million people who are infected with the 
HIV/AIDS in India.891  The National Commission on Macroeconomics and 
Health (NCMH) has warned that India's noncommunicable disease burden is 
set to rise from 1804.34 cases per 0.1 million in 2005 to 2636.31 cases per 0.1 
million in 2015.892  Likewise Nigeria also has a high population of people 
living with HIV/AIDS with statistics showing that Nigeria has third highest 
number of people living with the disease. In 2007, estimates showed that 2.4 
million people were infected with HIV/AIDS.893 Nigeria and India both have 
                                                            
891 HIV Policy Fact Sheet. http://www.kff.org/hivaids/upload/7312-03.pdf  2006. Accessed 18 
November 2007 
892 See One-day National Consultation o Access to Medicines in India, CENTRE for Trade and 
Development. http://www.centad.org/events_32.asp and UNAIDS, 2006 Report on the global 
AIDS epidemic 
893 Globalhealthreporting.org 
http://www.globalhealthreporting.org/countries/nigeria.asp?collID=11&id=953&malID=956&
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the right to health enshrined in their constitution; nevertheless both countries 
have been identified by the National Intelligence Council as two of the five 
countries most likely to bear the heaviest burden of HIV infection by 2010.894 
Interestingly while India has managed to develop its pharmaceutical industry, 
Nigeria on the other hand has not been so successful and is still lacking behind 
in the developing its pharmaceutical industry. Indian has a thriving generic 
industry which produces half of the generic medicines used in many 
developing countries. When the deadline for India to adhere fully to the TRIPS 
Agreement came in 2005, many feared that this would be the end to cheaper 
generic medicines, but this has not been the case. The Indian pharmaceutical 
industry continues to grow and provide access for medicines for many 
developing countries that do not have manufacturing capacities.  
 
India and Nigeria have had a close relationship for some time now. Apart from 
its similar colonial past, India has also been instrumental in providing cheaper 
genetic ARV’s to the Nigeria government to enable them meet their obligation 
in providing access to medicines to its populace. For example in 2002, the 
Nigerian government entered into an ambitious programme to supply 10,000 
adults and 5000 children with ARVs within a year.  An initial $3.5 million 
worth of ARVs were imported from India and delivered at a subsidized cost of 
$7 per person. Although the programme suffered a setback in 2004, when it 
encountered a shortage of drugs, where some people did not receive treatment 
for a period of three months, the programme was later resumed when another 
$3.8 million worth of drugs were ordered. India has also set up pharmaceutical 
manufacturing facilities in Nigeria, indeed Ranbaxy one of the biggest 
manufacturing companies in India has a manufacturing facility in Nigeria. 
                                                                                                                                                            
tbID=955&hivIC=954&malIC=960&tbIC=959&map=958&con=Nigeria&p=1 Accessed 15 
June 2007 
894 Journalists Against AIDS in Nigeria: www, Nigeria-aids.org - In 2002, the National 
Intelligence Council identified five countries expected to bear the heaviest burden of HIV 
infection as India, China, Nigeria, Ethiopia and Russia. 
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A comparative analysis of the evolution of government policies and 
legislations regarding the growth of the pharmaceutical industry in India and 
Nigeria may therefore be useful in identifying clues as to why Nigeria is still 
struggling to develop its pharmaceutical industry despite being one of the 
richest countries in Africa and at one point the 5th largest oil producer in the 
world.  
 
8.3   Evolution of the Modern Pharmaceutical Industry: A History of 
the Pharmaceutical Industry 
The pharmaceutical industry is one of the largest and most firmly established 
manufacturing industries in the world.895 One of the chief roles of the 
pharmaceutical industry is providing medicines. Indeed medicines are 
considered to be extremely important because they are the most important 
determinants of the health of every nation. The innovation, progress and 
successful use of medicines has enhanced many people’s quality of life, and in 
many cases reduced the need for surgical operations, reduced the amount of 
time spent in hospital and saved many peoples’ lives.896   
 
Looking back at how far medicines have come in changing the landscape of 
what qualifies for good health requires an analysis of the evolution of 
pharmaceutical Multinational corporations (MNC). Merck is one of the oldest 
pharmaceutical MNC in the world. It was first established in 1668 by Friedrich 
Jacob Merck. However it did not begin large scale production until 1827 when 
Merck began intense industrial production. It went further to establish its roots 
in the United States in 1891 and from there emerged some of the most 
                                                            
895 Facts and Statistics from the Pharmaceutical Industry.  The Association of British 
Pharmaceutical Industry. http://www.abpi.org.uk/statistics/section.asp?sect=1  
896 House of Commons Health Committee - The Influence of the Pharmaceutical Industry.  
Fourth Report of Session 2004-2005. Vol 1. HC 42-I [Incorporating HC 1030-i-iii] Published 
on 5 April 2005 by authority of the House of Commons. London: The Stationery Office 
Limited 
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successful and innovative medicine used throughout the world today.897  Only 
recently on 12 October 2007 - Merck announced that the U.S. Food and Drug 
Administration approved ISENTRESS the first medicine which in a new class 
of antiretroviral drugs.898 The significance of such discoveries by the 
pharmaceutical industry to the access to medicines debate can therefore not be 
ignored. Indeed it shows the strong links in which patents have to the western 
world and why it is only natural that most of the developed world has 
successfully transformed into not only accepting the TRIPS Agreement but 
also applying it to their national laws. This has in turn ensured that firstly the 
pharmaceutical industries in developed countries thrive and that access to 
medicines is made more readily available to the population. 
 
The roots of the modern pharmaceutical (MNC) can also be traced back to 
Felix Hoffman who invented aspirin in 1897. Hoffman had worked for a 
German Chemist known as Bayer, and was later issued a U.S. patent for the 
drug (No. 644,077) in 1900.899 The need to invest in continuous innovative 
medicines can also be traced back to the advent of WWI where the huge R&D 
demands of the war required that the scientific community invest in rapid 
technology.900 WWII brought with it even further advances in health methods, 
but the most dramatic single medical advance was probably the successful 
production of penicillin by Florey and Chain in 1948. Penicillin was 
considered a breakthrough in medical industry because for the first time there 
was a pharmaceutical product that had the twofold effect of killing bacteria and 
inhibiting their growth. Penicillin worked against a wide range of pathogenic 
micro-organisms, including pneumococcal, streptococci, gonococci, 
                                                            
897  AGGRASTAT® (tirofiban HCI) Used to decrease chances of clots after certain cardiac 
events. CANCIDAS® (caspofungin acetate) used to treat Aspergillus fungal infection and 
RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)] used to treat Hepatitis-B. See 
http://www.cogforlife.org/merckproducts.htm 
898 FDA Approves ISENTRESS™ (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase 
Inhibitor 
http://www.merck.com/newsroom/press_releases/product/2007_1012.html 
899 This made Bayer the first known  pharmaceutical MNC 
900 Calder. R (1962) The Life Savers, London: Hutchinson & Co. p. 20 
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meningococcal, the clostridium of tetanus, and the syphilis spirochete. It was 
also been used to effectively treat fatal diseases such as subacute bacterial 
endocarditic, septicaemia, gas gangrene, gonorrhoea, and scarlet fever.  
 
Other innovative medicines were also developed during the 1950s, however by 
the 1960s these medicines began to be mass produced and marketed in many 
parts of the world. Some of these medicines included high blood pressure 
drugs, and tranquilizers (Haloperido and chlorpromazine) for psychiatric 
medication.901  By the 1970’s cancer drugs became the highlight of innovative 
discovery in the medical world. The continuous demands for such 
groundbreaking medicines meant that by the mid-1980s, small biotechnology 
companies were struggling for survival. The formations of mutually beneficial 
partnerships with larger pharmaceutical companies were therefore necessary 
and this led to a host of corporate buyouts of the smaller companies. The 
growth of MNC was further accelerated when pharmaceutical manufacturing 
became concentrated, with a few large companies holding dominant positions 
throughout the world and few companies producing medicines within each 
country.902 Interestingly when HIV/AIDS was discovered in the 1980’s the 
pharmaceutical industry was already on the path to becoming regulated and 
transformed, a process which was enhanced by the discovery of new DNA 
chemistries and technologies for analysis and computation.   
In the case of HIV/AIDS which has become a priority area of R&D for the 
many pharmaceutical companies, the discovery of antiretroviral drugs has 
turned HIV/AIDS from a deadly and fatal disease into a controllable and 
manageable one.903 Although HIV/AIDS was discovered in 1983, it took four 
years before GlaxoSmithKline discovered the first antiretroviral drug 
                                                            
901    
902  Chaudhuri. S ( 2005)  The WTO and India’s Pharmaceutical Industry. Patent Protection, 
TRIPS and Developing Countries. Oxford university Press 
903http://216.239.51.104/search?q=cache:gmX3iJH0YgAJ:www.ifpma.org/documents/NR543
/GPF_HIV_leaflet_final.doc+evolution%2Bpharmaceutical+industry%2Bantiretroviral%2Baid
s&hl=en&ct=clnk&cd=2&gl=uk 
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(zidovudine or AZT), which was approved by the FDA in 1987. From that time 
until now significant progress by the pharmaceutical industry to ensure that 
people gain access to medicine can be measured by the number of companies 
manufacturing antiretroviral medicines. Thus by 2000, six major MNC namely 
Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, 
Merck, and Roche were producing antiretroviral medicines.904 Although there 
are many pharmaceutical companies spread out all over the world. The top 
pharmaceutical MNCs are based in developed countries, particularly in the 
United States, European Union and Japan.  The importance of discussing the 
evolution of the pharmaceutical MNC is to show that the practice as the world 
knows it today has evolved mainly from Europe and the US, their role in 
determining the future direction of R&D can therefore not be ignored. For 
medicines to be invented and cures found for diseases, the industry must 
collaborate and share information.                                                                                                                     
 
 
8.4 Leading Pharmaceutical Companies in the World ($ Billions) 
2005Rank 2004Rank Company/Country 
2005 Global Pharma 
Sales ($ B) 
%Growth 
1 1 Pfizer (U.S.) $44.3 <4%> 
2 2 
GlaxoSmithKline 
(U.K.) 
$34.0 +8% 
3 3 
Sanofi-Aventis 
(France) 
$32.3 <5%> 
4 7 Novartis (Swiss) $25.0 +16% 
5 6 Astra-Zeneca (U.K.) $24.0 +12% 
6 4 Johnson & Johnson $22.3 +1% 
                                                            
904http://216.239.51.104/search?q=cache:gmX3iJH0YgAJ:www.ifpma.org/documents/NR543
/GPF_HIV_leaflet_final.doc+evolution%2Bpharmaceutical+industry%2Bantiretroviral%2Baid
s&hl=en&ct=clnk&cd=2&gl=uk 
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(U.S.) 
7 5 Merck (U.S.) $22.0 +2% 
8 N/A 
Roche* (Swiss + 
Chugai) 
$15.7 N/A 
9 9 Wyeth (U.S.) $15.3 +10% 
10 8 Bristol-Myers Squibb $15.3 <1%> 
11 11 Eli Lilly (U.S.) $14.7 +12% 
12 10 Abbott Labs (U.S.) $14.0 +16% 
13 13 Amgen (U.S.) $12.0 +13% 
14 14 Boehringer Ingelheim $10.8 +2% 
15 15 Takeda (Japan) $8.5 +3% 
16 N/A Astellas (Japan)** $8.0 N/A 
17 16 Schering-Plough (U.S.) $7.6 +18% 
18 18 Bayer (Germany)*** $7.6 +18% 
19 N/A Daiichi Sankyo**** $7.3 N/A 
20 17 
Schering AG 
(Germany) 
$6.3 +3% 
21 22 Genentech (U.S.) $5.5 +46% 
22 25 
Novo Nordisk 
(Denmark) 
$5.4 +1% 
23 19 Eisai (Japan) $4.8 <5%> 
24 20 Teva (Israel) $4.7 +10% 
25 21 
Merck KGaA 
(Germany) 
$4.6 +21% 
26 24 Otsuka (Japan) $3.3 <11%> 
27 29 Forest Labs (U.S.) $3.2 +19% 
28 26 Baxter International $3.0 +11% 
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(U.S.) 
29 31 
Akzo Nobel 
(Netherlands) 
$2.9 +21% 
30 32 Altana (Germany) $2.8 +27% 
 
Source: Pharmaceutical Executive, May 2006 
 
These pharmaceutical companies carry out intense production and marketing 
of pharmaceuticals products at a level which has never been seen before in the 
world.905 Statistics show that since the 1970s, a small amount of approximately 
50 pharmaceutical companies accounted for more than two-third of the world 
production and export.906  Between 1997 and 2003 pharmaceutical sales 
increased by over 12 percent annually. Likewise global production in 
pharmaceutical products grew from $70 billion in 1975 to $300 billion in 
2000. 907  In 2004, the total global sales for pharmaceutical product were 
estimated to be in the region of $550 billion, this represented a 7 % increase 
from 2003.908  The evolution of the pharmaceutical industry has brought with it 
a dominance of the industry by a small number of MNCs who exert 
extraordinary financial power. Statistics show that the total worth of Pfizer, 
GlaxoSmithKline, Merck, AstraZeneca and Aventis909 are worth more than the 
entire income of Mexico or India and twice that of the entire income of sub-
                                                            
905 Silverman, Milton and Philip R. Lee (1974) Pills, Profits and Politics, Berkeley and Los 
Angeles: University of California Press. pp. 1-6 
906 Mossialos, E., P. Kanavos and B Abel-Smith  (1994), The Pharmaceutical sector in the 
European Union –an overview’, in E Mossialos, C. Ranos and B. Able-Smith (eds, Cost 
Containment, Pricing and Financing of Pharmaceuticals in the European Community – The 
Policy Makers’ View, London: LSE Health and Pharmetrica SA, pp 18-87 
907 Ballance, R., J. Pogany and H. Forstner (1992)  United Nations Industrial Development 
and Organisation  
(UNIDO) (eds) The World’s Pharmaceutical Industrial, Aldershot, U  (1992: 22-23, 29) 
908 Bill Trombetta (2005). For the fourth year in a row, Pharmaceutical Executive slices and 
dices the numbers to learn who's really on top see  
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=177964 
909 The leading Pharmaceutical companies in the world in order of ranking (2003) are Pfizer, 
GlaxoSmithKline, Merck, Johnson & Johnson, Aventis, AstraZeneca, Novartis and Bristol-
Meyers Squibb 
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Saharan Africa.910  Similarly a single product of Pfizer - Lipitor sold twice the 
total drug sales in India for all the products and companies in 2003;911  thus 
statistics also show that the top 50 pharmaceutical MNCs accounted for 74.6 
per cent of the world market in 2003.912  
 
Some of the factors that have enabled pharmaceutical MNCs to acquire such 
financial powers are Mergers and Acquisitions (M&A) in the EU and the US913 
which began an intense wave  in the 1980s and 1990s. Most of the top 
pharmaceutical companies in 2003 are the result or one or more horizontal 
mergers.914 For example Glaxo-SmithKline’s antecedents consist of Glaxo, 
Welcome, SmithKline French and Beecham, similarly Aventis is a 
consolidation of Hoechst (German), Rhone-Poulenc (French), Rorer, Marion, 
Merrill, Dow (US); Pfizer on the other hand is the combination of Pfizer, 
Warner-Lambert, and Pharmacia and Upjohn.915  
 
Consequently between 1988 and 1992, there were 760 M&As in the 
pharmaceutical and biotech industries world-wide of which the total value 
exceeded $47 billion.916 The pharmaceutical-biotechnology industry has 
become progressively more united over the past 15 years and sales have grown 
considerably. By 1985 the 10 largest pharmaceutical companies accounted for 
approximately 20 percent of worldwide sales, however by 2002 the total 
                                                            
910 Julian Borger, Industry that stalks the US corridors of power, the Guardian, February 13 
2001. Oxfam 2001a, p.11 citing UNDP, Human development Report, 2000 
911 IMS World Review, 2002 and Pharmaceutical Executive, May 2003 
912  Pharmaceutical Executives, May 2004 
913 Pugtach 
914  
915 Patricia M. Danzon, Andrew Epstein and Sean Nicholson (2004) . Mergers and 
Acquisitions in the Pharmaceutical and Biotech Industries. The Wharton School  University of 
Pennsylvania 
http://hc.wharton.upenn.edu/danzon/PDF%20Files/Mergers&AquisitionsInPharma&Biotech.D
anzon&Epstein&Nicholson_May04.pdf and Hall, Bronwyn H.(1999) Mergers and R&D 
Revisited, mimeo.  
Hall, Bronwyn H., (1988) The Effect of Takeover Activity on Corporate Research and 
Development. In Auerbach, Alan J., ed., Corporate Takeovers: Causes and Consequences. 
Chicago: University of Chicago Press. 
916 PhRMA (2003: 81, Table 9) 
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amount of worldwide sales had risen to 48%.917 The significance of mergers 
lay in that for pharmaceutical companies who have to face patent expirations 
and cracks in its follow-on products, merging with another company that has a 
channel but lacks adequate marketing and sales capacity to adequately launch 
its own drugs may create value.918  Other benefits of merger are that they offer 
the potential for cost cut in administration, consolidation of R&D expenditure, 
greater market access in the sense of increased specialized treatment, offsetting 
the negative effect of declining revenues on net profits and generating the 
economies of scale in the longer run.  
 
Interestingly enough whilst a lot of people talk about M&A, there are actually 
two separate concepts. Mergers take place when there is a combination of two 
companies; acquisitions on the other hand take place when there is a takeover 
of one company by another. An acquisition may either be affable or 
aggressive. In the former case, the pharmaceutical company may cooperate in 
negotiations; in the latter case, the takeover target may be unwilling to be 
bought or the target's board will have no prior knowledge of the offer. One of 
the largest pharmaceutical acquisitions to take place in modern times has been 
Glaxo’s hostile acquisition of Burroughs Wellcome in 1995. Glaxo’s financial 
strength at the time was measured by the amount of sales it was making at the 
time. Thus between 1980 and 1994 Glaxo’s sales had increased from £618 
million to £5,656 million. This growth was led by the best selling prescription 
drug in history, Zantac (a peptic ulcer treatment that was launched in 1981). 
For much of this period, Zantac accounted for over 40 percent of Glaxo’s sales. 
Wellcome’s sales also showed that between 1986 and 1994, its market 
increased from £l,005 million to £2,662million. Its leading product, Zovirax (a 
                                                            
917 Danzon,  P.M , Andrew Epstein and Sean Nicholson. Mergers and Acquisitions in the 
Pharmaceutical and Biotech Industries. May 2004. The Wharton School  University of 
Pennsylvania 
http://hc.wharton.upenn.edu/danzon/PDF%20Files/Mergers&AquisitionsInPharma&Biotech.D
anzon&Epstein&Nicholson_May04.pdf 
918 Ibid 
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treatment for genital herpes and shingles first sold in 1982) accounted for over 
40 percent of its sales and was the fourth best-selling drug in the industry for 
much of the 1990s. During the bidding Glaxo discouraged any competing bids 
by offering cash and stock that were 49% higher than the closing price of 
Wellcome’s shares, this put other bidders off and led to a somewhat undisputed 
acquisition.919   Even so by 1997, the US patents on both Zantac and Zovirax 
had expired, and Glaxo and Wellcome were faced with the challenges of a 
changing industry environment and the decline of their major sources of 
growth. By combining two firms with similar financial powers and targets 
GlaxoWellcome created over $2 billion in stock market 
As has been discussed above, M&As have been a key factor in the expansion 
and corporate strategy of pharmaceutical companies in the 20th century.920 
Statistics show that between 1990 and 2000, more than $250 billion worth of 
assets had been acquired in over four hundred deals involving a pharmaceutical 
or biotech company.921 These mergers and acquisitions have considerably 
augmented the company sizes of many pharmaceutical companies, putting the 
total value of business carried out by pharmaceutical companies during that 
time at approximately $1 billion.  
 
With regards to patented products however, pharmaceutical MNC face serious 
competition from generic based companies. The Generic Competition 2007-
2011 report predicts that between 2007 and 2011, there will be expiration of 
patent protection on at least 52 major drugs in the US. This it is asserted will 
have a clear impact of the loss of revenue and the growth for the patent 
orientated pharmaceutical companies and threaten over $100 billion worth of 
revenues generated by patent orientated companies in the US and Europe.922 
                                                            
919. Hilzenrath. D.S  (1995)  Glaxo Bids $14 Billion for Rival Wellcome; British Firm Would 
be Biggest in Drug industry. Article from: The Washington Post.  
920 Rozens, A. (2006). Wall Street Expects Merger Recor. Associated Press Online.. 
921 David J Ravenscraft and William F. Long. (2000)  Paths to Creating Value in 
Pharmaceutical Mergers. In Mergers and Productivity (National Bureau of Economic 
Research Conference Reports) (Hardcover)  by SN Kaplan. Chicago University Press  
922 Generic Competition 2007-2011. URCH February 2007 
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Statistics show that the most affected will be the loss of patent on Lipitor 
between 2010 to 2012.923 
 
8.5  Generic Pharmaceutical Industry 
Generic companies have the advantage of not incurring the significant risks 
and costs associated with R&D for innovative medicines. Generic companies 
are smaller in terms of capital, funding, asserts, scope of operations, diversity 
and specialization when compared to pharmaceutical MNC.924  One of the 
advantages that they have is that they are flexible and this allows them to 
specialize in specific market areas, such as gene or cell therapy as well as 
working with MNC at various stages of R&D.925   
 
The rise of the generic industry can be traced back to The Drug Price 
Competition and Patent Term Restoration Act of 1984, which is commonly 
known as the Hatch-Waxman Act.926 The Act was a milestone in the hub of 
generic trade in the US and effectively promoted generics while leaving 
untouched the financial incentive for R&D. 
 
Whilst there are many supporters of the rise of the generic industry, there are 
opponents to the rise of the generic industry. Most of these opponents base 
their arguments on the fact that the rise of the generic industry will hurt 
innovation by preventing adequate patent protection is the lifeblood of 
biomedical research.927 The Hatch-Waxman Act is therefore significant in that 
it allows generic companies to gain FDA marketing approval by discarding the 
                                                            
923 Ibid 
924 Ballance, R., J Pogany and H Forstner (1992), United Nations Industrial Development and 
Organization (UNIDO) (eds) The World’s Pharmaceutical Industries, Aldershot UK and 
Brookfield, US: Edward Elgar 
925 Commission on the European Communities, Economic Advisory Group (1985), The 
Community’s Pharmaceutical Industry, Brussels 
926 Grabowski, H., and J. Vernon.( 1992)  Brand loyalty, entry and price competition in 
pharmaceuticals after the 1984 Act. Journal of Law and Economics 36:331-50. 
927 Eli Lilly's challenge of generic provision stirs debate 
Drug Store News,  Sept 22, 2003  by Michael Johnsen 
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requirement of carrying out clinical trials and allows the generic companies to 
simply submit bioequivalence.928  The Hatch-Waxman Act has all the same 
been criticised for granting a 30-month stay to firms that file suit against 
generic manufactures that challenge their patents. The controversy of this 
provision steams from the fact that pharmaceutical companies have used the 
provision to keep generics off the market by protecting their drugs with extra 
patents of poor quality, filing lawsuits to protect the patents even when the 
lawsuit will be lost, but getting the extra market exclusivity anyway. 
The importance of the generic pharmaceutical industry has continued to grow 
and it has continued to provide access to cheaper medicines. MSF reports it 
relies on affordable generic antiretroviral drugs (ARVs) from India to treat 
over 80% of the more than 100,000 people receiving treatment in MSF 
projects.929 Between 1989 and 1992 generic market share increased from 47% 
to 72%.930  The US generics Market in 2004 was also reported to be worth over 
$18bn.931 The importance of the generic industry towards meeting the 
healthcare needs of the global populace is evident in that in Britain for 
example, more than 66% of all prescription drugs are generics.932 Some GP 
surgeries prescribe more than 90% of generic medicines to their patients.933 
Globally, In 2006, generic medicines were prescribed to patients in 
approximately 50% of cases globally and represented a total of 10% of sales of  
the entire pharmaceutical market.934 Statistics has also shown that between 
2004 and 2006 the sale and popularity of generics drugs grew faster than 
                                                            
928Donald O Beers. (2004)  Generic and Innovator Drugs: A Guide to FDA Approval 
Requirements. Aspen Pub.,. 6th Edition  
929 Promoting Generic Competition. http://www.accessmed-msf.org/main/hiv-
aids/introduction-to-hivaids/promoting-generic-competition/ 
930 Grabowski, H., and J. Vernon. (1996). Longer patents for increased generic competition in 
the U.S. PharmacoEconomics 1O:llO-23. 
931 The World’s Top Ten Generic Companies 
932 Pharmaceutical Industry Issues. 
http://www.abpi.org.uk/publications/publication_details/pharidustryissues-bk040113/pii8.asp 
933 Ibid  
934 Booming US Generic Drug Market 
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branded935 patented drugs. As  result In 2006  the US government saved an 
estimated $10.2 Billion. 
 
The usefulness of generics as an alternative to patented medicines was also 
established when in 2001, the Greater Access to Affordable Pharmaceuticals 
Act (GAAP), bipartisan legislation was introduced. The Act was intended to 
provide Americans with more choices when buying their medicine by ensuring 
that all safe and effective pharmaceuticals are made available to them in a 
timely manner and not kept off the market because of reasons that were 
unjustifiable. The author of the Act Senator McCain stated that by easing the 
entry of generic alternatives to the marketplace, the legislation could save 
consumers $71 billion over ten years.936  With such optimism it is no wonder 
the report “Booming US Generics” has reported that unbranded generics will 
account for approximately 19% of the US pharmaceutical market by 2011,937 
further pointing to the development of the US generic pharmaceutical 
industry.938 What this proves is that the prices of medicine do affect 
availability not just in third world countries, but also in the industrialised 
world. If a country like the US, which is one of the most advanced countries in 
the world need more access to generic medicines, it is fair to argue that 
developing countries need such access as well.  
 
The generic pharmaceutical companies have continued to grow at an alarming 
rate and are now major competitors of patented MNC. Indeed some of the top 
pharmaceutical companies in the world are generic orientated. An evaluation 
of the financial might of some generic companies below will give the reader an 
                                                            
935 The brand name is chosen by the manufacturer, usually on the basis that it can be 
recognised, pronounced and remembered by health professionals and members of the public 
936 Grabowski, H., and J. Vernon. (1996). Longer patents for increased generic competition in 
the U.S. PharmacoEconomics 1O:llO-23. 
937 Booming US Generic Drug Market 
938 To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy. By 
United States Federal Trade Commission, Federal Trade Commission, United States. DIANE. 
2003 
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insight into the level of competition that generic companies bring to the 
pharmaceutical industry. For example, Teva is a generic orientated 
pharmaceutical company based in Israel, its consumer base is mostly in the US 
and EU, thus over 80 percent of its sales are carried out in the West939    
 
As of 2008, Teva was estimated to be worth over $38 billion and had an annual 
sale of more than $9 billion.940 Teva specializes in developing, manufacturing 
and marketing generic and pioneering human and active pharmaceuticals 
ingredients, it also concentrates its R&D on animal health pharmaceutical 
products. In September 2008, Teva announced that it had signed an agreement 
to set up a primary generic pharmaceutical company with Kowa Pharma Co., 
Ltd in Japan.941 Teva-Kowa Pharma Co., Ltd has pledged to pull the 
marketing, R&D, manufacturing and distribution capabilities of each company 
to become a broad based supplier of high quality generic pharmaceutical 
products for the Japanese market and reach sales of $1 billion by 2015.942  
 
The Brazilian generic industry is another market which has been crucial in the 
fight towards access to medicines. In 1997, Brazil embarked on an on an 
ambitious program to locally manufacture expensive affordable versions of 
expensive patented medicines. The competition from generic medicines 
brought prices down by over 90% in some cases.943 By 1999, the Brazilian 
government introduced new generics laws which legitimized pharmaceuticals 
                                                            
939 Script Magazine 1993, 40-41; Aizenberg 2000 
940 Lewis Krauskopf. Reuters. Makers of generic drugs likely to keep jumping the gun on 
patents.  Accessed 16 January, 2008 
941 Kowa is responsible for sales and marketing of innovative drugs and focuses on promoting 
cardiovascular drugs, such as treatment drug for hypercholesterolemia "Livalo tablet" and 
hypertension drug "Olmetec tablet" through its wholly owned subsidiary, Kowa 
Pharmaceutical Co. Ltd. In addition, Kowa has focused on lifestyle diseases (arteriosclerosis, 
kidney disorder and diabetes) as main strategic therapeutic area for research and development. 
942 Calisha Myers.  Teva and Kowa Announce Strategic Partnership to Create a Leading 
Generic Pharmaceutical Company in Japan. http://www.fiercebiotech.com/press-releases/teva-
and-kowa-announce-strategic-partnership-create-leading-generic-pharmaceutical-co 
943 Paul Davies. (2001) New Trade Agreement for the Americas Jeopardizes Brazil’s 
Acclaimed Generic AIDS Drug Program. FOR IMMEDIATE RELEASE. ACT-UP . 
215.731.1844 
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companies to legally produce generic drugs that were copies of patented 
drugs.944 The legislation made many MNCs uncomfortable about the 
emergence another stronger generic industry, however many NGO’s were 
pleased with the fact that consumers in Brazil would be better off in 
manufacture or purchasing generic versions of expensive patented drugs. The 
influence of the Brazilian generic manufacturer continues to grow, by 2004 it 
was producing 11.6% of all drugs in Brazil. The Brazilian generic industry is 
expected to take over 20% of the entire drug market by 2009.945 Faced with 
such huge competition Patented oriented  MNCs have  responded by seeking to 
secure their position in the generic markets through setting up coalitions with 
generic companies, by so doing regulating the level of competition that they 
face. Many MNC have also set up their own generic units,946 for example 
Merck’s generic-drug division has nearly 5,000 employees.947  Pfizer was also 
been reported to be moving into generics.948 
 
Although an in-depth study of the Indian generic pharmaceutical industry will 
be carried on later in this chapter, it is important to note that another key 
generic industry which has the threatened the patent based pharmaceutical 
industry with competition is the Indian generic pharmaceutical industry. Most 
Indian generic companies have the added advantage over their counterparts in 
developed countries of producing bulk and formulation medicine at 
approximately 10-20% of the cost of production in the west. 949  The report 
                                                            
944 Generic Drugs in Brazil Are a Hard Pill for Big Pharma to Swallow. Section Especial. (Jan 
16, 2006) 
http://wharton.universia.net/index.cfm?fa=viewArticle&id=1086&language=english&specialI
d= 
945 Ibid 
946 Faigen, N. (1993), The multinational threat in the generic market, Scrip Magazine, April, 
pp. 13-14 
947 The German drugmaker Merck to sell generic-drug unit to Mylan. Published May 13, 2007. 
http://www.iht.com/articles/2007/05/13/business/merck.php 
948 Jacob Goldstein. Pfizer. October 16, 2008. http://blogs.wsj.com/health/2008/10/16/pfizer-
goes-generic and Lewis Krauskopf. Reuters. Makers of generic drugs likely to keep jumping 
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called “Booming Pharma Sector in India” predicts that exports from India 
pharmaceutical companies will grow at 18.5% between 2007 and 2011950. 
According to the report, one of the key reasons for the predicted growth will be 
the expirations of many product patents.951 The growth of the generic industry 
can therefore not be underestimated in their role of providing more access to 
medicines and its potential to dominate the pharmaceutical industry in the near 
future after the expiration of certain patents, it is with this background in mind 
that the next section seeks to explore the Nigerian pharmaceutical industry and 
the pharmaceutical practice in Nigeria. 
 
8.6  The Origins of the Nigerian Pharmaceutical Industry and Practice  
The origins of pharmaceutical laws and practice in Nigeria can be traced back 
to the Lagos Pilotage and Harbour Ordinance which was enacted in 1878. This 
Ordinance established the control and supervision of medicines and medical 
treatment on ships when the ships docked in the Lagos harbour.952 However it 
was not until 1887 that Dr R Zacchaeus opened the first pharmacy store for 
Europeans in Lagos.953 During that time people who trained to handle drugs 
were called “dispensers”. Such dispensers functioned as dispensers of 
medicines, sanitary officers, medical aids and anaesthetics in operating 
theatres.954 Subsequently, the Hospital Ordinance 1881, and the Ereko 
Dispensary Rules of 1889 were further enacted in support of the early laws 
controlling pharmacy and pharmaceuticals.  Indeed, some sceptics have argue 
that the practice of pharmacy in Nigeria did not begin as a well defined health 
care area of specialization, this suggest that whatever pharmaceutical training 
there was existed from the necessity to provide assistance to expatriate medical 
                                                            
950 RNCOS. Booming Pharma Sector in India, Aug, 2008 
951RNCOS. Booming Pharma Sector in India, Aug, 2008 
952 HISTORY OF PHARMAVY REGULATION IN INGERIA. Pharmacists Council of Nigeria. 
2001. Lindoz Products Limited, Lagos, Nigeria. 
953 Adenika FB.(1998)  Pharmacy in Nigeria. Panpharm Ltd, Lagos, Nigeria 
954 Daily Times (Nigeria), 8 Jan 1975. 
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officers who were at the time their colonial masters.955 What this also indicates 
is that because the industry was more centred on providing the healthcare 
needs of its colonial masters as opposed to its local indigenes, it would later 
struggle with the future responsibility of enacting a new philosophy where the 
health care needs of own populace would be cared for. 
 
As the colonial masters settled into Nigeria, the number of dispensers and 
medical stores increased and this brought about a need to regulate the 
pharmaceutical industry and practice. Early legislation was therefore enacted 
in the form of  the Pharmacy Ordinance No8 of 1902. The Ordinance sought to 
control the sale and distribution of drugs and poisons and was restricted to 
Lagos, Calabar, Opodo, Warri, Forcados and other areas that were declared by 
the Governor in Council.956 In 1923, the Poison & Pharmacy Ordinance was 
enacted to control the sale and distribution of drugs and poisons in Nigeria. 
Under the Ordinance the Board of Medical Examiners was established and had 
the sole responsibility of controlling the training of medical assistants and the 
supervision of training dispensers and chemists. However it was not until 1925 
that a Medical College was set up in Yaba, Lagos. The College consisted of the 
School of Medicine and the School of Pharmacy. In 1936 another Poison and 
Pharmacy Ordinance was enacted which made major improvements on the 
1927 Ordinance which had already been passed. This Ordinance increased the 
membership of the board, standardised the syllabus, and curriculum of Chemist 
and Druggists Diploma and the issuance of Dispensers Certificate. The 
Ordinance also established the Pharmacy Board of Nigeria. The Pharmacy 
Board of Nigeria was crucial in the sense that it consisted of representatives 
from the Nigerian Union of Pharmacist (NUP) and the Association of 
Dispensers which were to later form the Pharmaceutical Society of Nigeria 
(PSN).  
                                                            
955  https://tspace.library.utoronto.ca/bitstream/1807/3173/1/pr03010.pdf Accessed  25 
November 2008 
956  HISTORY OF PHARMAVY REGULATION IN INGERIA. Pharmacists Council of Nigeria. 
2001. Lindoz Products Limited, Lagos, Nigeria. 
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Note that today the PSN is one of the most important bodies in the directing  
pharmaceutical practice and research in Nigeria. The relevance of the origins 
of the pharmaceutical practice in Nigeria in relation  to India cannot be lost on 
the reader. Indeed as will become evident below like Nigeria, India began to 
practice orthopaedic medicine in the 19th century and passed its first Indian 
Patent act in 1856. Like India, Nigerian’s pharmaceutical industry and 
pharmacy practice was based on providing medicines for its colonial masters. 
The comparison is therefore important in discerning why the problems of the 
pharmaceutical industry in Nigeria failed to become self sufficient and why  
the Indian pharmaceutical industry has thrived. 
 
The PSN  was also in charge of granting licences to sellers of patent and 
propriety medicines and making sure that facilities were drugs and poisons was 
sold were inspected.957 Subsequently, in 1947 the School of Pharmacy Zaria 
was established in the North of Nigeria, which is also affiliated with the 
Ahmadu Bello Teaching Hospital, one of the most renowned teaching hospitals 
in Nigeria today. In 1958, another Ordinance known as the Poison and 
Pharmacy Act 152 was enacted and this gave the Pharmacy Board of Nigeria 
additional powers to regulate the examinations for certificates and to keep a 
register of  pharmaceutical chemists and pharmaceutical premises. The 
consecutive evolution of legislation was a clear indication that pharmacy laws 
and the pharmaceutical industry were constantly evolving. The Nigeria 
government was desperately seeking to consolidated the regulation of drugs 
and revolutionize the healthcare delivery system, but this proved not to be an 
easy task.  
 
After Nigeria gained its independence in 1960, the Pharmacist Act No 26 was 
passed in 1964.  The 1964 Act was crucial because it amalgamated the 
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regulation and control of all pharmacist affairs including the profession. 
Further development led to the Food and Drugs (Lagos) Act 1965 and the 
Foods and Drugs Act (Commencement) Order was enacted in 1967 to control 
the importation of drugs and other products into Nigeria.  By 1969, the first 
national pharmaceutical inspectors’ workshop was organised by the PBN in 
Lagos, it continued to operate so that by 2001 zonal pharmaceutical inspectors’ 
workshops were set up in Kaduna, Jos and Enugu. Consequently after that, the 
control of industrial chemicals was taken over by NAFDAC which has been 
discussed in an earlier chapter.  
 
8.6.1 Problems of the Pharmaceutical Industry  
The Nigerian pharmaceutical industry as far back as its history goes has been 
saddled with serious problems such as limited local input in production in 
terms of raw materials, machinery and technical manpower. The industry has 
also faced the problems such as lack of infrastructure, lack of electricity, water, 
roads, communication and information technology. Another major setback for 
the Nigerian pharmaceutical industry has been the lack of (R&D) by its local 
industry into the discovery and development of medicines which are peculiar 
to diseases that affect the country. The development and role of the 
pharmaceutical industry has followed the pattern of other British colonies and 
has historically been in line with the developments in Britain,958 however the 
industry has seriously fallen short of its expectation to produce critical input in 
agricultural raw materials, intermediate chemicals from the nations’ 
petrochemicals and engineering infrastructure for the pharmaceutical 
industry.959 
 
A study carried out in 1971 revealed that there were ten local manufacturing 
companies in Nigeria, and that most of the drugs used were imported from 
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959 Fredrick Adenika. Paper on “Nigeria’s pharmaceutical industry  -an agenda for survival in 
the 1990s and beyond” 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
296 
 
abroad. The development of the pharmaceutical industry was lunched with the 
Food, Drug and Cosmetic Decree No. 35 of zd1974.960  The Decree took effect 
in 1976 and formed the basis for setting up the nation’s Food and Drug 
Administration (FDA) department of the Ministry of Health. The Decree 
sought to regulate manufacturing practices, quality control, advertising of 
drugs to protect consumers’ from fake and counterfeit products, and gave the 
FDA wider powers to inspect and control the industry. Findings showed that 
by 1976, the number of indigenous companies producing drugs had risen to 15, 
and were providing only 5% of the total drugs consumed in Nigeria, although 
by 1984, the number of pharmaceutical companies manufacturing medicines 
for the local population had further risen to 26, they were only  producing 20% 
of the total amount of medicines consumed. 
 
8.6.2 Nigeria’s National Health Plan  
Nigeria came up with its first National Health Policy in 1986. The policy stated 
that its aim was to achieve a level of health which would allow all Nigerians to 
achieve socially and economically productive lives by 2000. Obviously, this 
objective did not materialize because the World Health Report 2000 showed 
that Nigeria had a disability adjusted life expectancy (DALE) of 38.3 years and 
its health system was ranked at 187, one of the worst in sub-Saharan Africa.961 
The National Health Policy also stated that the Nigerian government had the an 
overall obligation of establishing a comprehensive health care system, based 
on a primary health care that is promotive, protective, preventive, restorative 
and rehabilitative. This they stated should be available to every Nigeria to 
enable them have a level of productivity that would ensure a degree of social 
well-being that would be suitable for an enjoyment of living.  This goal could 
not be achieved because the basic health service delivery is run by the states 
and local government which are not adequately quipped with enough revenue 
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and resources to fulfil such obligations as the bulk of government revenues is 
retained by the federal government.962 
 
In the same way that the Nigerian Primary health care is based on a three tier 
government system namely  the federal, state, and the local government 
authorities (LGAs); the Nigeria Healthcare system is divided into three main 
sectors. The first sector is the primary healthcare which is the local government 
responsibility and oversees the healthcare clinics, health centres and 
community health workers.  The second sector which is the secondary 
healthcare system which is run by the state and oversees the general hospitals 
in the 774 local government areas and other secondary health care providers 
and thirdly the tertiary healthcare system which is the Federal government 
responsibility. The tertiary healthcare system consists of teaching and 
specialist hospitals and there is at least one in all 36 states including the 
Federal Capital territory. Some private hospitals with specialist services are 
also included in the Tertiary health care system of Nigeria.  The Nigerian 
Constitution of Nigerian gives state governments and LGAs the principle 
responsibility for providing basic services including primary health care. This 
primary health care is based on the Bamako initiative of 1987 and stipulates 
the following obligations: namely that primary health care must seek to 
encourage community participation in primary healthcare services; and aim to 
increase the availability of essential medicines and other health care services. 
Regardless of the Bamako initiative, evidence suggest that the initiative has not 
been very successful due to a variety of reasons: there has been a lack of 
community participation in setting charges for drug; funding for essential 
medicines is limited because the bulk of LGA health funds are allocated to 
staff salaries, thus a survey done in Kogi state in 2000 showed that LGA spent 
approximately 78% of health care expenditure on salaries. Similarly in Lagos, 
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65% of health expenditure was used to pay staff salaries.963 The same study 
showed that whilst malarial drugs were available in more than 60% of the 
facilities surveyed, they was no equipment for testing for malaria in more than 
90% of the facilities. This suggests that medicines are simply administered if 
malaria was suspected, further pointing towards the irrational use of 
medicines.964 Thus for there to be rational usage of drug, patient must receive 
medications that are appropriate to their clinical and medical needs in doses 
that treat specific medical problem, for an adequate time and at the lowest 
possible cost to them and their communities.965  
 
 In a study carried out by the Nigerian Ministry of Health, it was revealed that 
the average number of medicines per prescription was only 4.7.966  In another 
survey carried out on the rational use of ARV in Nigeria, it was revealed that 
the labelling of ARV which should include the name of the ARV, name or 
code of patient, frequency and duration of administration was unsatisfactory in 
86% of cases.967 As some cases the suitability of medicines administered was 
as low as 2% in diarrhoea prescriptions, and 10% in cases of acute respiratory 
tract infection. Similarly in cases of mild to moderate pneumonia only 21% of 
medicines were correctly prescribed. Because of the foregoing, the irrational 
use of drugs has been identified by WHO as one of the major cause of lack of 
access to medicines.968 Indeed whilst the rational usage of medicines is very 
important in the access to medicines debate because although drugs have the 
power to heal, it also has a potential to cause harm and prolong illness if 
administered in the wrong way for the wrong illness. 
                                                            
963 Adeniyi, J., O. Oladepo, and A. Soyibo ( 2003) Survey of Primary Health Care Service 
Delivery in Lagos and Kogi: A Field Report.”Mimeo, African Regional Health Education 
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964 Ibid  
965  Ibid 
966 Baseline Assessment of the Nigerian Pharmaceutical Sector (2002) Federal Ministry of 
Health in collaboration with the World Health Organization.  
967 Situation of ARV DRUG USE IN NIGERIA. (November 2003).  The Federal Ministry of 
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968 How to develop and implement a national drug Policy.  (1988) World Health Organization. 
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8.6.3 Nigeria’s National Drugs Policy 
National Drugs Policy and is a guide line for developed and developing 
countries alike. The objectives of a national drug policy for the purpose of this 
chapter are threefold: firstly to ensure the availability and adequate supply of 
most useful drugs at reasonable prices to the general populations; secondly to 
provide adequate governmental control in ensuring drug quality and ensure the 
safety in use and handling by all and thirdly to stimulate the growth of local 
pharmaceutical manufacturing industry which will provide medicines for the 
general population as well as compete in local and international markets 
thereby resulting in the balancing of trade.969 
 
The Nigerian National Drug Policy was enacted in 1990 and sought to make 
the Nigerian pharmaceutical industry self reliant. The main aim of the Nigerian 
National Drugs Policy was to reduce the high level of dependence on foreign 
sources for finished drug products. In the 1970s and 80’s, Nigeria begun on a 
path to lessen the level of dependence on imported pharmaceuticals and 
provide medicines for its general population through their local manufacturing 
industries, these gains have however been  short-lived. Although it is important 
to note that the most superb year when Nigeria recorded that its pharmaceutical 
local industries was providing 25% of the medicines needed was in 1984,. By 
1987, that amount had dropped to a low of 20%.  Thus Fred Adenika 
commented that “It is obvious that after 1984, the gains made since the mid-
seventies in increased local production are being eroded by a wave of 
increased importation”.970  In another paper delivered in March 1984 titled 
“Developing appropriate strategies for local manufacturer”, Frednika noted 
that ‘Faced with mounting opposition to our self-reliance programmes, it is 
clear that our nations in West Africa will, above all, need strong political will, 
                                                            
 969 Fred B. Adenika. Principles of Essential Drugs Management. 1992. Published by 
Shaneson C.I. 
970  Adenika FB.(1998)  Pharmacy in Nigeria. Panpharm Ltd, Lagos, Nigeria 
 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
300 
 
at the national level, we must develop and enforce these policies despite local 
professional and commercial opposition.  At the international level, we need 
the political will to co-operate among ourselves and end today’s ‘drug 
colonialism’. We require astute, effective and loyal leadership which can 
match those of the developed countries, and indeed surpass them in single –
minded dedication to our cause”. 
Bearing the above stance in mind the Nigerian National Drug policy 1990 
sought to: 
1. To ensure that - drug research and development is an essential 
component of health research which is itself an important feature of 
most of the strategies for achieving the goals of a national health 
policy. 
2. To produce more high-level research scientists and technicians in the 
area of drug research and development so that by 2000 shortage of 
people with such skills and expertise would no longer constitute a 
handicap to the national effort on local production. 
3. To achieve the objective of full local capacity in drug manufacture, 
exploratory and development research into local raw materials as 
sources of new drugs ...[shall] be pursued as a major drug research 
objective. 
4.  
The National Drug policy’s objectives in reaching the above goals are outlined 
in Article 1(I)  and it states that its aim is to  “make available at all times in all 
sectors of the health care system adequate supplies of drugs which are 
effective, affordable and safe, are of good quality”. Despite the above goals, 
Nigeria is still struggling to meet  its National Drugs Policy  objectives and has 
remained heavily reliant on imported medicines. Thus the 2007 BMI estimates 
showed that imported pharmaceuticals accounted for  54% of the Nigerian 
market.971  
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Pharmaceutical R&D are the backbone of any the self-reliant nation, many 
commentators have therefore suggested that the prospect for R&D in Nigeria is 
enormous . Thus despite the setbacks that the Nigeria pharmaceutical industry 
has faced in becoming self-reliant, in 1987 it managed to set up a National 
Institution for Pharmaceutical Research and Development (NIPRD) in Abuja. 
The Institution is one of the most  advanced  organizations in Nigeria that 
engages in extensive R&D. NIPRD has sought to work with traditional 
medicines, receipts and formulas in a bid to advance R&D in the country. 
Accordingly in 1986, Professor Bona A Obiorah stated that “the Key to 
Nigeria’s Pharmaceutical industrialization lies in the bush”.972 This statement 
was made because of the rich pharmacopoedie collection that Nigeria has 
collected over the years. The advantages of this in propelling the Nigerian 
pharmaceutical industry forward in becoming a major competitor in creating 
NCE cannot be overstated, thus according to WHO, 80% of the world’s 
population uses medicinal plants for the treatment of diseases.973  A survey 
carried out by UNCTAD showed that 33 % of drugs produced by the 
industrialised countries are plant derived and that if microbes are added 60% of 
medicinal products are of natural origin.974 Whilst approximately 400 
compounds derived from plants are currently being used in the preparation of 
medicines, higher plants (higher plants are plants in the kingdom Plantae that 
have specialized tissues for conducting water, minerals, and photosynthetic 
products through the plant) have been identified as the future of drug 
development.975 Statistics also show that the total global sales of plant derived 
drugs in 2002 were estimated at $13.7billion. Evidence  also suggests that 
plant derived drugs accounts for 50% of the global drug market.976  Indeed 
                                                            
972 Adenika FB.(1998)  Pharmacy in Nigeria. Panpharm Ltd, Lagos, Nigeria 
973 Frances O. A. Ajose, Some Nigerian plants of dermatological importance. International 
Journal of Dermatology. Vol 46 Issue s1, pg 48-55 
974 UNCTAD 
975 Farnsworth and Morris (1976) 
976 BCC Research Report ID:BIO022C, Published: February 2003, Analyst: Andrew 
McWilliams 
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Obafemi Awolowo once stated that the prospects are great for finding new 
drugs from plant; the chances are even greater in developing countries where a 
lot of plants used in traditional medicines are yet to be checked. A survey 
carried out in Dermatology Clinic, Lagos State University Teaching Hospital 
(LASUTH), Ikeja in Lagos suggested that 65% of patients had applied herbal 
medicines before going for consultation.977 
 
The objectives of the national drugs policy are imperative in pushing forward 
the Nigerian pharmaceutical industry agenda, however the wealth of herbs and 
plants in Nigeria will also play an important role in the successful 
implementation of the national drugs policy if the healthcare delivery system is 
to be refurbished. It is with this background that the Indian National Drug 
policy will be explored in the next section to discern any similarities that may 
enable one to discern what direction Nigeria should take if it is revamp its goal 
of making the pharmaceutical industry independent and ensuring that it gains 
access to medicines.  
 
8.6.4 Essential Drug List (EDL)/ Nigeria’s Essential Drugs List  (NEDL) 
 The WHO essential drug list was conceived in 1975 by the World Health 
organisation but was complied and promulgated in 1977. Since then it has been 
consistently updated every two years and the current version was updated in 
March 2007.978 Also note that the NEDL which consisted of 205 essential 
drugs when it was published in 1986 was updated in 1996 to 484 drugs.979 It 
was last reviewed in 2003. The list of essential medicines has been very 
important in the access to medicines debate and has doubled from 186 in 1977 
to 320 in 2002. With regards to HIV/AIDS, WHO’s EDL contains medicines 
in three classes of antiretroviral  for the treatment and prevention of HIV 
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978 Ibid 
979 Baseline Assessment of the Nigerian Pharmaceutical Sector, (2002)  Federal Ministry of 
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(including treatment for the prevention of mother-to-child transmission and 
post exposure prophylaxis).980    
 
An EDL must reflect the pattern of diseases a country faces by taking into 
consideration the health care facilities available; the training and experience of 
the health care personnel; financial resources available and the genetic, 
demographic and environmental factors.981 The first Nigerian essential drug 
list (Fed.Government’s NEDL 1986) contained 204 drugs, the drugs were 
listed by generic names, dosage, forms and strength.982 Some of the drugs 
listed were probably obtained from WHO Model lists at the time, however the 
Minister of Health  Ransome Kuti stated in an interview that “we developed 
our own essential drugs list. We know our patterns of diseases, and we have 
listed the drugs we need for each diseases and we produced our national 
essential drugs list”.983 
 
The NEDL has outlined four main guideline as the foundation of its strategy 
namely: to develop and affordable and sustainable supply of safe drugs; 
improve the skills of health workers in providing drugs; change the harmful 
practices of patients; and strengthen institutional capacities to undertake 
essential drugs programs.984 The background of the NEDL reveals some 
important factors that has formed the basis of the national drug policy. Thus at 
the time that the essential drug list was compiled, Nigeria was facing major 
problems within its health care delivery services. There were acute shortages 
of both preventive and curative drugs especially in the public health sector. 
This was further aggravated by the rapid increase in population and the rapid 
                                                            
980 WHO list of Essential Medicines 15 List  March 2007 
http://www.who.int/medicines/publications/EssMedList15.pdf. The three antiretroviral 
medicines on the EDL are Nucleoside/Nucleotide reverse transcriptase inhibitors, Non-
nucleoside reverse transcriptase inhibitors and Protease inhibitors  
981 HOW TO DEVELOP AND IMPLEMENT A NATIONAL DRUG POLICY. WHO. 2ND 
EDITION. 2001 
982 See Nigerian National Drug Formulary and Essential Drugs List, 1986. 
983 Kuti. O Ransome . National Drug Policy in Nigeria.  
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decline of economic resources. The Federal Ministry of Health was therefore 
given the task to set up an Essential Drugs working Group that would organize 
workshops for all states and selected LGA’s to make sure that this policy was 
implemented from the local grass root level.  
 
The Federal Ministry of health was able to engage the commitment of WHO 
and the World Bank financial aid and by doing this set up an assistance 
program through WHO that would manage the preparatory process of 
NEDL.985 Subsequently the preparatory process was done in collaboration with 
the Essential Drugs Unit in the Department of Primary Health Care (DPHC) 
who began a series of studies on logistics, training, quality assurance, local 
production and public education for establishing the NEDL.986 The Ministerial 
Committee on the Reorientation of curricula in Medicines and the Dentistry 
and Pharmacy on the Essential Drugs Concept was also set up to assist the 
federal government come up with ways to ensure a “total implementation” of a 
comprehensive curriculum on the Essential Drugs Concept in all relevant 
institutions of health training.987  Through the long history of  the evolution of 
the Nigeria’s essential drugs policy and programmes, there has been a 
precedents of several attempts made to improve and rectify failed policies that 
have handicapped the advancement of the healthcare delivery system.   It is 
therefore important to note that the advantages of the EDL in promoting the 
access to medicines is to ensure that:  “essential drugs … are available at all 
levels of the health care system” and guarantee that access to health care is a 
human right. Hestermeyer states that “by their very nature, human rights have 
the potential to reach all human behaviour’ and thus governments and 
international agencies have an obligation to see that this right is progressively 
                                                            
985 WHO Technical Reports, Series , No. 615.   
986 Adenika. Fredrick B  (1992) Principles of Essential Drugs Management.  Shaneson C.I. 
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987 The Committee concluded their work in 1989. The Committee was headed by Prof. B.D 
Musa and Prof H. O Obianwu had several other university teachers in medicine and pharmacy, 
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realized. Having a list of essential drugs is therefore an essential step in 
ensuring that people have access to it. 
 
The EDL is also useful to developing countries in their search for access to 
medicines and in ensuring that drugs are specified by their international non-
proprietary name or generic equivalent without reference to the brand name. 
The importance of this lies in that it makes it easier for accurate and 
comprehensive information to be given on all drugs in the essential drugs lists. 
Hence the NEDL has also been instrumental in ensuring access to medicines 
and making it easier for pharmacist, dispensers, or prescribers to familiarize 
themselves with the pharmacological properties of the drugs; and enabling 
them to make more accurate judgment on the type of prescription to use on 
patients thereby improving rational use. The NEDL has also made it easier for 
NAFDAC to formulate strategies to evaluate the quality of medicines as well 
as ensuring the regular inspection of factories to ensure that they are 
complying with the guidelines for good manufacturing practices (GMP).988  
Indeed another major advantage of the NEDL has been its reduction in the 
number of drugs in circulation in the health care system which has ensured  
easier organization of the procurement, storage, and distribution of drugs. For 
example in Nigeria, procurement in public health facilities and the National 
Health Insurance Scheme is limited to medicines listed in the EDL.989 
 
8.6.5 Supply Systems 
The availability of a proper drug supply system has been identified as a vital 
factor in the quest for access to essential medicines in Nigeria. WHO states 
that “a good supply system requires an interaction between the public and 
private sector that will guarantee that public funds available for drug purchases 
are used effectively to maximize access, to obtain value for money, avoid 
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waste and ensure an economy of scales”.990 A good supply system also 
requires good pharmaceutical procurement practices991; publication of price 
information on raw materials and finished products as well as prevention of 
waste, theft and the disposal of unwanted or expired drugs.992   
 
A good supply system is particularly relevant in the case of Nigeria as some of 
the major deterrents of access to medicines are expired medicines, counterfeit 
medicines, poor procurement that is centred on state central medical stores and 
the irrational use of medicines. A survey carried out in 2006 by the Ministry of 
Health on six state medical stores revealed that only three of the stores were 
functional. The survey also revealed that public CMS procurement was 500% 
higher than NGO procurement.  
For developing countries to have a good supply system, WHO has outlined 
four basic principles for good pharmaceutical procurement,993 which are listed 
below: the most cost-effective drugs must be procured in the right quantity; 
reliable suppliers of high-quality products must be selected to ensure timely 
delivery; procurement and distribution systems must achieve the lowest 
possible total cost. The procurement and distribution should take four main 
components into consideration: (1) the actual purchase price of drugs, (2) the 
hidden costs of the product due to poor product quality (3) poor supplier 
performance or short shelf-life, (4) inventory holding costs at various levels of 
the supply system (5) operating costs and capital loss by management (6) 
administration of the procurement and distribution system.994 
 
With regards to providing medicines for HIV/AIDS, most of the goals of the 
ARV programs in Nigeria have been to provide a constant supply of drugs to 
                                                            
990 How to develop and implement a national drug policy( 2002) WHO. 2nd edition 
991 Operational Principle for Good pharmaceutical Procurement. World Health Organization.  
WHO/EDM/PAR/99.5. http://www.who.int/3by5/en/who-edm-par-99-5.pd 
992 How to develop and implement a national drug policy. 2002. WHO. 2nd edition 
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patients in a timely and cost effective manner while minimizing drug 
expiration of drugs; however the drug supply system has not been 
ineffective.995 A survey by the Ministry of Health revealed several problems 
with regards to the supply system of ARV in Nigeria. The survey listed the 
following as major distractions to the supply chain: lack of communication 
between the central supply system and the local centres;996  centres stocking 
expired ARVs, centres running out of ARVs. Thus expired drugs were also 
found to be a major problem in the supply system of ARV in Nigeria. The 
three ARVs on the NEDL most suitable to the health needs of people living 
with HIV/AIDS in Nigeria - Nevripine, Stavudine and Lamivudine have 
problems with supply coordination. In the baseline assessment by the Ministry 
of Health (2003), 64% of the health facilities surveyed had expired drugs.  
7,188 packets of Nevirapine were found to be expired in 50% of health 
facilities, 2,934 packets of Stavudine were found to be expired in 27% of 
facilities, while 6,553 of Lamiviudine were found to be expired in 31% of 
facilities.997 The total amount of wasted funds for these ARV was $146,717 
and 19,953,510 in naira. 
 
Affordability also poses a serious problem with patients gaining access to the 
supply chain of medicines.  Affordability is usually measured by comparing 
the cost of medicines with daily wages of the lowest paid government 
worker.998 Presently, the minimum wage of a Nigerian is set at 5,500 (naira) 
per month, which is an equivalent of $11.3 per week.999 A person earning the 
minimum wage in Nigeria has to work for 0-6 days to procure one month’s 
supply of drugs from the government health facilities. He would have to work 
for 30-90 days for an equivalent supply of ARVs from the private sector. 
                                                            
995 Situation of ARV Drug Use in Nigeria. November 2003. Published by The Federal Ministry 
of Health in collaboration with the World Health Organisation. 
996 Ibid 
997 Ibid 
998 Ibid 
999 Ibid 
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Naturally, brand medicines for all medicines in the NEDL are higher than their 
generic equivalent (see table below).1000 However evidence suggests that 
generic medicines were up to 825% more expensive in Nigeria than in other 
countries.1001 
 
Additional problems included the fact that some centres stocked first line triple 
therapy despite the fact that second line therapies were available at the central 
medical stores.1002 Data Recording in many health facilities were also found to 
be inadequate. ARVs were being dispensed to patients without keeping 
detailed record of prescriptions, stock cards and patient data.  Funds for 
procurement were also being delayed, especially when it came to subsequent 
purchase of medicines, the situation was made more dire because success of 
many ARVs are based on follow up medication. All these were evidence of a 
failed drug supply system 
 
Another major problem which has blocked the supply system of medicines in 
Nigeria has been the lack of a National Health Act to back up the National 
Health Policy. This problem has meant that there is no health legislation 
describing the national health system, defining the roles and responsibilities of 
the three tiers of government and the stakeholders in the system. This has led 
to confusion, duplication of functions and sometimes lapses in the performance 
of essential public health functions. On a positive note however, a long awaited 
National Health Bill was passed in May 2008, which improved the 
coordination of the healthcare system.  According to the bill, a primary 
healthcare development fund is to be established to ensure that basic healthcare 
facilities are provided under the NHIS. The bill organised healthcare funding 
in order to prioritise goals more efficiently. Meanwhile, problems of corruption 
                                                            
1000 Ibid 
1001 Medicines Prices in Nigeria. Prices People Pay for Medicines. Published by the Federal 
Ministry of Health in collaboration with World Health Organisation, DFID, EU and the Health 
Action International March 2006.  
1002 Ibid 
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in the healthcare system are still crippling the healthcare system with various 
allegations of corruption being levied. In April 2008, the Health Minister 
Grange Adenike Grange and the Minister of State for Health Gabriel Aduku 
were sacked after an investigation by the Economic and Financial Crimes 
Commission (EFCC) revealed that 300million naira had been misallocated and 
embezzled.  
 
8.6.6  The Present Status of the Nigerian Pharmaceutical Industry and 
Practice  
In October 1977, at the 50th Anniversary Conference of the PSN held in Lagos, 
Fred Adenika urged more pharmaceutical companies to engage in the local 
manufacture of drugs. “No nation can truly control what it does not make; if 
Nigeria wishes to have real control over the drug needs of its populace, it must 
organise and produce the drugs” Remarkably, the drug industry in Nigeria 
experienced some growth in local drug manufacture (from 5 companies 
supplying 5% of national requirement in 1979 to nearly 70 companies 
supplying about 50 % of national requirement in 1995). Many indigenous 
pharmaceutical industries such as: Berewa Pharmaceutical Limited, Biode 
Pharmaceutical Industries Ltd, Bond Chemical Industries Ltd, Continental 
Pharmaceutical Limited, Emceea Limited, Emzor Chemist, Kafal Industrial 
Enterprise Ltd, Leady Pharmacy Ltd, Leo Melos, Link World Nigeria Ltd, 
Mopson Pharmaceutical Industries Ltd, Oily Chemists Ltd, Rajrab Limited, 
Tisco Industries Ltd, Toki Dabur Production Ltd, Vofmed Nigeria Limited 
sprung up and are manufacturing and producing medicines for some 
percentage of the population.  
 
In the 1980s, the need to ensure the availability of the much needed drugs in 
Nigerian hospitals at affordable prices led to hospital pharmacists becoming 
more interested in the manufacture of drugs within the hospital system. The 
introduction and acceptance of clinical pharmacy into the practice of pharmacy 
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in Nigeria in the 1980s led some hospital pharmacists to be involved in clinical 
activities including drug information service and unit dose dispensing. 
However, unlike many developed countries, the involvement of pharmacists in 
Nigeria in the application of the emerging roles has not been impressive. In a 
survey conducted in 2002, only 18.2% of 119 pharmacists practicing in Nigeria 
stated that they applied most of the 52 suggested practice standards obtained 
from round one discussion by the Delphi panel of pharmaceutical care experts 
in their settings. Although pharmaceutical care has become a preferred mode 
of practice, most pharmacists in Nigeria still hardly offer significant patient-
oriented services.  
 
The Nigerian pharmaceutical industry has prospects, but its R&D efforts have 
been limited to isolated endeavours of individual scientists in universities, with 
little cross-pollution and without central guidance.1003 Some of these 
pharmaceutical scientists are outstanding and internationally recognised but the 
nation as a whole has achieved very little that is concrete in this field.1004 The 
international pharmaceutical companies in Nigeria had therefore shunned local 
medicinal research. This has impacted negatively on the Nigerian 
pharmaceutical industry because research is the springboard for growth of any 
modern pharmaceutical industry.  Because it is a costly low-yield process, each 
nation must first clearly define its research goals and then purse them 
systematically. The first generation of Japanese scientists were educated 
mainly abroad, and then returned home to produce the next generation of 
pharmacist who formed the nuclei of important research centres in Japan (this 
is why they were a strong force at the Uruguay round) subsequently 
generations developed into a formidable scientific community. The process 
took 50 years and today Japan produces virtually all the drugs it consumes and 
is a world leader in drug discovery. Nigeria when compared to countries that 
have succeeded in developing their manufacturing industries do not have clear 
                                                            
1003 Adenika FB.(1998)  Pharmacy in Nigeria. Panpharm Ltd, Lagos, Nigeria 
1004 Ibid 
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cut goals (this will become clearer below when the development of Indian 
pharmaceutical industry is examined). Nigeria has fallen behind in the prospect 
of it being able to produce critical input in agriculture raw materials, 
intermediate chemicals from the nation’s petrochemicals, machine tools and 
engineering infrastructure for the pharmaceutical industry.  These problems 
have not only retarded the industry‘s technical advancement but have also 
threaten its sources of supply and its survival. Despite government efforts to 
promote domestic manufacturing, Nigeria remains heavily reliant on imported 
pharmaceuticals. 
 
 The National Drug Policy sets a target for 70% of the country's demand for 
drugs to be met by local industry. However, in 2007 BMI estimated that 
imports supplied 54% of the market. On the whole, domestic players do not 
appear ready to manufacture high tech products  so Nigeria can expect imports 
to remain dominant. Indeed, domestic drugmakers seem to be increasingly 
looking to diversify into consumer health products, most likely in response to 
the difficult operating environment in their core market. In January 2008, both 
Fidson Healthcare and Neimeth Pharmaceuticals announced they were to 
launch consumer health lines. Neimeth revealed it would do this through two 
newly created subsidiaries - one concentrating on food and pharmaceuticals, 
the other on herbal remedies.  The Nigeria Pharmaceuticals and Healthcare 
Report provides independent forecasts and competitive intelligence on 
Nigeria's pharmaceuticals and healthcare industry.  The market was estimated 
to be worth US$278mn in 2007 and it should grow at around 5% year-on-year, 
reaching US$369mn by 2012.1005 These forecast are indeed optimistic, but how 
far reaching this prediction will be remains to be seen. 
 
 
                                                            
1005 Nigeria Pharmaceutical Market Should Grow at around 5% Year-on-Year Reaching 
Us$369Mn by 2012. 2008-04-23 10:07:21 – http://www.pr-inside.com/nigeria-pharmaceutical-
market-should-grow-r552361.htm 
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8.7  Background of the Indian Pharmaceutical Industry  
India has one of the most powerful pharmaceutical generic industries in the 
world. As a matter of fact, it is one of the few countries where western MNCs 
do not control its pharmaceutical industries.1006   India has a $7 billion drug 
market and is the fourth biggest drug market (in terms of volume) in the 
world;1007  it has 24,000 drug manufacturers, approximately 500,000 chemists, 
and provides medicines to at least a million people in 200 countries.1008  Before 
the British colonial rule in India which lasted from 1858 to 1947, only local 
indigenous medicines were used in India;1009  however the East Indian 
Company brought with it new modern bulk medicines and introduced new 
patent laws in India.1010  The British rule brought with it the first Indian patent 
Act of 1856 which was enacted based on the recommendations of Lord 
Macaulay Law Commission.1011 In 1859 another amendment was enacted 
introducing exclusive privileges for the making, selling, licensing and using 
inventions. These initial legislations gave patent holders a 14 years exclusive 
privilege period.1012 For a young India pharmaceutical industry, the tenure was 
too long and allowed no opportunity for the indigenous firms to grow.1013 
Many indigenes were concerned about the high prices of medicines and  the 
                                                            
1006 Ibid -Chaudhuri. S.  
1007 Saritha Rai, (24 Mar 2005) India Adopts Patent Law Covering Pharmaceuticals, N.Y. 
TIMES, Mar. 24, 2005, available at http://www.nytimes.com/ (search "NYT Since 1981" for 
"India patent law pharmaceuticals"; then follow "INTER Interview with Ranjit Shahani, 
President, Organization of Pharmaceutical Producers of India (Mar. 2, 2005), available at 
http:// www.pharmabiz.com/article/print.asp?articleid=26475NATIONAL BUSINESS; India 
Adopts Patent Law Covering Pharmaceuticals" hyperlink and  
1008 Indrajit Basu (Jan. 11, 2005)A Brave New World Indian Drug Industry, WASH. TIMES. 
available at http://www.washtimes.com/upi-breaking/20050111- 114414-9131r.htm 
1009 Raj in Hindi/Urdu means Rule.  This refers to the British rule between 1757–1947 of the 
Indian Subcontinent, or present-day India, Bangladesh, Pakistan, and Myanmar, during which 
period these lands were under the colonial control of Britain as part of the British Empire. 
1010 The first patent law in India, enacted in 1856, was assented to by the Governor General 
on February 28, 1856. First Indian Patent Law, Intellectual Property Rights (Tech. Info., 
Forecasting & Assessment Council (TIFAC)), Jan.-Feb. 2002, at 1, available at http:// 
www.tifac.org.in/do/pfc/pub/jan02.pdf. 
1011 Ibid 
1012 Srividhya Ragavan,( Accessed Jan. 28, 2003). Patent Amendments in India in the Wake 
of TRIPS, CASRIP Newsletter (Univ. of Wash. Sch. of Law), Winter 2001, available at 
http://www.law.washington.edu/casrip/newsletter/newsv8i1Ragavan.pdf This Act was 
"modelled on the same lines as the British Patent Act of 1852." Id. 
1013 Ibid 
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renowned Indian Chemist, Prafulla Chandra Ray set up the Bengal Chemical 
and Pharmaceutical Works (BCPW) in 1892 and began the manufacturing of 
the British Pharmacopoeia which was previously imported.  This was indeed 
the origins of what was to later become one of the most vibrant third world 
pharmaceutical industries in the world. Ray went further to revitalize the use of 
robust indigenous drugs, which were traditionally prescribed by “medicine 
men”; and like in the case of Nigeria, a system for collecting the formulas, 
prescription and putting them into circulation in the market.  And for the first 
time there was an ordered system of marketing indigenous medicines in 
modern day India. 
 
However in 1911 the very famous Patent and Design Act was passed repealing 
earlier enactments and entrenching the patent system into the Indian structure. 
Although the Patent and Design Act was seen by critics as suiting only the 
needs of the British colonial masters.  The 1911 legislation coupled with the 
establishment of several medical schools by the British brought about a culture 
of producing modern drugs and subsequently paved the way for a thriving 
pharmaceutical culture that exists in India today. What became apparent at this 
point was the fact that like in the case of Nigeria, the colonial masters were 
paving the way for what direction the future pharmaceutical industry would 
take. Thus Ray observed with unease that the local raw materials were being 
exported to foreign countries and imported back to India as finished products 
at extremely high prices.1014 
 
Like many Asian countries with long civilization histories, India has always 
had a reasonably well-organized system of medicine, known as ayurveda, 
which is several centuries old, thus the direction for the restructuring   of  
indigenous medicine foreseeable and projectable.1015  Indeed the need to 
                                                            
1014 Ray, Prafulla Chandra (1932), Life and Experiences of a Bengali Chemist, Calcutta: 
Chuckerverthy Chatterjee & Co. 
1015 Ibid 
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organise a pharmaceutical industry which was self reliant was at the forefront 
of government agenda.  Consequently in 1919, the Bengal Community was 
established; it consisted of a group of leading physicians and scientists who 
came together with the aim of attaining medical self sufficiency in India.  By 
1939 when WWII began, indigenous firms produced approximately 13 percent 
of the medical requirement of India.1016 By a remarkable turn of events by the 
end of the war in 1945 indigenous firms were producing 70 percent of the 
country’s pharmaceutical needs.1017 The reason for this was remarkable; the 
war had diverted the attention of MNC from importing medicines into India, 
1018 The India pharmaceutical industry was therefore given a chance to set up 
its own local firms to respond to their own medical needs and this enabled 
them to become self-sufficient. New indigenous  pharmaceutical companies 
such as the Indian Process Chemical Laboratory, Unichem and IndoPharma 
were established.1019 Also worth noting is the fact that indigenous firms also 
revived the use of ayurvedic drugs which, in effect, enlarged the range of drugs 
available to modern doctors. Many of these drugs such as Kalmegh and 
sarpaganadha (used to suppress high blood pressure) are still used today.1020 
 
By 1947 when India gained its independence it had to a large extent become 
self-sufficient, indeed it sought to take full control of it drug expenditure and 
set about this setting up several law commissions. These law commissions has 
the task of proposing  legal reforms to realize national objectives. High on the 
list of legal reforms were efforts to improve “the standard of living of the 
people by efficient exploitation of the resources of the country”, which 
                                                            
1016 Pharmaceutical Enquiry Committee (1954), Report of the Pharmaceutical Enquiry 
Committee, New Delhi: Government of India, Ministry of Commerce and Industry. S.L. 
Bhatia was the chairman of the Committee 
1017 Ibid 
1018 Ibid 
1019 Ibid -Chaudhuri pg 24 
1020 Ibid 
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included the traditional systems of medicines.1021  Between 1948 and 1950, the 
Tek Chand Committee also known as the (Patent Enquiry Committee) was set 
up.   The committee was quick in noting that MNCs had been given wide 
powers under the old patent systems. The system allowed all inventions made 
by any "manner of manufacture"  to be patentable,1022 and this enabled  owners 
of vague patent provisions being granted patent rights beyond the scope of 
their invention.1023 The Tek Chand Committee was also instrumental in 
recommending the incorporation of compulsory licensing into India Patent 
laws. Note that by 1950, the law was amended but it made no substantial 
changes in the realm of providing access to medicines for the Indian 
population.1024  
 
8.7.1 India’s National Drug Policy 
The first Indian national drug policy 1978 emerged from the Hathi Committee 
recommendations which was set up in 1975 to investigate the connection 
between MNCs and indigenous pharmaceutical companies.1025 The main 
objectives of the Hathi report were to strengthen R&D activities in the country, 
issue licenses for the formulation of only 117 essential drugs that were 
essential for the treatment of diseases which were prevalent in India. The Hathi 
report also suggested the dissemination of drug information to both prescribers 
and consumers, the development of self-reliance in drug technology, reduction 
in the level of importation so as to encourage the development of the domestic 
sector. Finally the report asserted that in order to ensure that drugs are easily 
available and accessible at a reasonable price, the State Trading Corporation 
                                                            
1021 The Planning Commission was set up in March 1950 by a resolution of the Government 
of India. Planning Comm'n, 1st Five Year Plan intro., available at 
http://planningcommission.nic.in/plans/planrel/fiveyr/default.html (last visited Jan. 8, 2006) 
[hereinafter 1st Five Year Plan]. 
1022 Banerji, S. (2000) The Indian Intellectual Property Rights Regime and the TRIPs 
Agreement, in Intellectual Property Rights in Emerging Markets 47, 57 Clarisa Long ed 
1023 Ibid at 66 
1024 Ibid 
1025 Ministry of Petroleum and chemicals, Report of the Committee on Drugs and 
Pharmaceutical Industry (Hathi Committee Report), Delhi, 1975 
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(STC) government must begin a process of importing raw materials, pooling 
them together and re-distributed them to manufacturers.1026  
 
Since then the 1978 Indian National Drug Policy  has been revised three times 
in 1986, 1994 and 2002. What was striking in the Hathi report was that like the 
Nigerian National drugs policy, the Indian drug policy sought to: ensure the 
availability of essential life-saving medicines at reasonable prices; strengthen 
quality control and promote the rational use of drugs; encourage investment in 
new technologies and cost-effective production; and strengthen the indigenous 
capacity for production of drugs and most importantly ensure self-reliance. 
Whilst the characteristics of both national drug policies are similar to many 
other countries, the fact that Nigeria and India have an almost identical policy 
makes the case for Nigeria to follow in the footsteps of India if it is become 
self sufficient and conquer the access to medicine problem. 
 
Self reliance for the Indian pharmaceutical industry was the cornerstone of 
India’s national policy. Thus the government planning commission Third Plan 
states that “special emphasis has to be placed on industries such as steel, coal, 
oil, electric power, machine building and chemicals...(as) the development of 
these industries is an essential condition of self-reliant and self-sustained 
growth”1027  The Hathi Committee noted that MNCs “activities (such as 
finished drugs being imported, marketed and formulation drugs1028  being 
imported in bulk1029and repackaged locally) were carried on without investing 
                                                            
1026P K Sarkar.( Accessed 12 June 2007)  A Rational Drug Policy. Indian Journal of Medical 
Ethics.  http://www.issuesinmedicalethics.org/121di011.html  
1027 Third Five Year Plan, New Delhi, Planning Commission, Government of India, 1961, p 24 
1028 "formulation" means a medicine processed out of, or containing without the use of any one 
or more bulk drug or drugs with or pharmaceutical aids, for internal or external use for or in 
the diagnosis, treatment, mitigation or prevention of disease in human beings or and, but shall 
not include - any medicine included in any bona fide Ayurvedic (including Sidha) or Unani 
(Tibb) systems of medicines.; any medicine included in the Homeopathic system of medicine; 
and any substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) 
do not apply;  
1029“ Bulk drug" means any pharmaceutical, chemical, biological or plant product including its 
salts, esters, stereo-isomers and derivatives, conforming to pharmacopoeial or other standards 
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in factories or employing technical personnel’.1030  By pointing out specific 
concerns that the Indian pharmaceutical industry was facing in becoming self-
reliant was crucial and made the difference in whether concrete actions would 
be taken in the future to ensure that the national drug policy was implemented 
or not. 
 
One of the most significant points that the Hathi Committee recommended was 
that foreign drug companies should not be given any preferential treatment 
under the Foreign Exchange Regulation Act 1973 (FERA) and Industrial 
Licensing Policy Committee of February 1973 (ILPIC). Under FERA, all 
corporate bodies with 40% or less of foreign holdings were considered 
indigenous bodies. The Hathi Committee believed that reducing foreign equity 
in companies in India to 26% foreign equity would be reduced. One of the 
examples that the Haiti Committee  cited in support of its recommendation 
was, where if a company owns 10% or more in foreign equity, they are 
considered foreign. Likewise in Canada if a foreign company owns more than 
5% in foreign equity it is considered foreign.1031 
 
India was clever enough in discerning that foreign MNC were only interested 
in marketing formulations under brand names in order to maximise profits as 
opposed to the production of the less profitable bulk drugs.1032  Thus before 
India become self reliant,  80% of total formulations drugs such as antibiotics, 
vitamins, antirheumatics, analgesics and cough syrups were being sold by 
MNCs and hardly any bulk medicines including Tetracycline and Aspirin were 
being sold by foreign MNC was evidence of this 
 
                                                                                                                                                            
specified in the Second Schedule to the Drugs and Cosmetics Act, 1940 (23 of 1940), and 
which is used as such or as an ingredient in any formulation; 
1030 Ministry of Petroleum and chemicals, Report of the Committee on Drugs and 
Pharmaceutical Industry (Hathi Committee Report), Delhi, 1975. P87. 
1031 Benjamin Cohen, Multinationals and Asian Exports, New Haven, 1975, p 9 
1032 Ibid 
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India’s experience with MNCs is useful in establishing why Nigeria has never 
been able to attain self sufficiency in the pharmaceutical industry. India 
introduced industrial policy restrictions which required MNCs to accelerate 
their activities. The policy required that unless bulk drugs are produced in 
specified quantity, MNC could not expand their activities in formulations. 
What later appeared evident was that MNC were willing to undertake 
production in India when they found it profitable to take advantage of India’s 
low costs and outsourcing their global requirement of off patent drugs.1033 
Nigeria on the other hand has never sought to take the kind of drastic actions 
that the Indian has  taken, the fact that the Indian pharmaceutical industry is the 
4th largest producer of medicines in the world in terms of volume is testament 
of the hard work and dedication that successive governments have placed in 
ensuring that medicines is a priority for its population of 1 billion people.1034 
 
8.7.2 Disadvantages of the Indian Indigenous Firms pre-1970 and How 
they were Overcome 
The pharmaceutical indigenous firms in the India had initially operated at a 
disadvantage in the sense that the advent of colonialism brought about the 
denigration of traditional systems of medicines in India. A Drugs Enquiry 
Committee had been set up in 1931 and the report noted that because the 
British controlled trade, they could obtain a superior variety of medical plants 
at cheaper prices to be exported back to Europe, whilst the indigenous firms 
were left with the inferior ones for local production.1035  Restrictions were 
placed on the movement of domestically produced spirituous preparations 
between one province to another, however imported spirituous preparations 
                                                            
1033 Chaudhuri. S (2006) THE WTO and India’s Pharmaceutical Industry. Patent Protection, 
TRIPS, and Developing Countries. Oxford University Press 
1034 Srividhya Ragavan. The In equals of Uruguay. University of Oklahoma College of Law. 
http://jay.law.ou.edu/faculty/sragavan/Docs/PPT%20Folders/Inequals%20of%20Uruguay.ppt
m 
1035 Drugs Enquiry Committee (1931), Report of the Drugs Enquiry Committee, 1930-1931 
Calcutta: Government of India. 
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could be distributed anywhere in India once the custom duty was paid at the 
point of entry.1036  
 
The Indian government took the important step of setting up the Ayyanger 
Committee which was named after Justice Rajagopala Ayyangar, head the 
committee in 1957. Between 1957and 1959, the Ayyangar Committee also 
known as the Committee on the Revision of the Patents Law was set up. The 
findings and reports of the committee were useful in laying down the 
foundations of the Indian Patent Act 1970. The Committee proposed that India 
should diverge away from incompatible patent policies of industrialized 
nations.1037 The Committee also affirmed that a patent regime is an 
unconditional requirement to facilitate and advance industrialization, as long as 
it is designed "with special reference to the economic conditions of the 
country, the state of its scientific and technological advance, its future needs 
and other relevant factors." 1038 The report is significant for the following 
reasons: firstly the report led to the improvement and growth of the 
pharmaceutical industry in India and set the stage for making India’s 
pharmaceutical industry one of the strongest generic providers today 
 
Secondly the Ayyangar report resounded one of the core national goals of the 
Indian Constitution which can be found in Article 21 which guarantees the 
right to life including the right to good health,1039  and social and economic 
rights.1040 Thirdly the Ayyangar report was revolutionary because it recognized 
that public health concerns need to be balanced with business interests. 
Fourthly the Ayyangar Committee specifically examined issues that are were 
later discussed during the TRIPS negotiation such as whether patenting food, 
                                                            
1036 See Indian Bare Acts: THE SPIRITUOUS PREPARATIONS (INTER-STATE TRADE 
AND COMMERCE) CONTROL ACT, 1955. 
1037 N. Rajagopala Ayyangar, Report on the Revision of the Patents Law P 8 (1959)  
1038 Ibid 
1039 Indian Constitution, art 21 
1040 Indian Constitution Pmbl. 
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chemical, and pharmaceutical inventions will affect developing countries 
ability to gain access to such products; and whether compulsory licensing can 
enable accessibility while at the same time promoting innovation.1041 The 
Ayyanger report not only made significant recommendations but was a 
premonition of the many the challenges that the Indian indigenous 
pharmaceutical industry would have to overcome in order to become self 
sufficient. 
 
The Ayyangar Report argued that a patent policy giving absolute monopoly 
power to MNC would deny majority of the Indian population access to 
medicines.1042  What made the Ayyangar Report innovative was that it 
advocated the adoption of a patent regime with an intense logic of 
accomplishing national goals.1043 The report concluded that giving unregulated 
monopoly rights went against the right to good health guaranteed under the 
Indian Constitution;1044  and concluded that the development of a local 
pharmaceutical industry in India was the only way that India could compete 
with MNC whilst meeting their local needs.1045  
 
8.7.3  Product Patents and not Process Patents 
The Ayyanger Committee favoured a ban on process patent because it believed 
that granting product patents to food and pharmaceuticals would prevent 
majority of the population access to the vital products and contravene the 
constitutional right that Indians have to life and good health. 1046 In order to 
support their logic the committee examined  the historic evolution of patents 
                                                            
1041 N. Rajagopala Ayyangar, Report on the Revision of the Patents Law P 8 (1959) 
[hereinafter Ayyangar Report]. 
1042 Banerji, S (2000)  The Indian Intellectual Property Rights Regime and the TRIPs 
Agreement, in Intellectual Property Rights in Emerging Markets 47, 57 .Clarisa Long Ed 
 at 69 
1043 Ayyangar Report 
1044  Krishna, V. R (2002)  Patent Law-Patently Unfair?, The Hindu, at Opinion Section 
1045 Ibid 
1046 Banerji,. S (2000) The Indian Intellectual Property Regime and the TRIPs Agreement, in 
Intellectual Property Rights in Emerging Markets 63 Clarissa Long ed. 
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on chemicals and foods in other developed countries.  The Ayyanger 
committee recommended that India draw on examples of how other 
industrialised countries has developed their own pharmaceutical industries, 
citing the example of the German patent Law of 1877. The German patent law 
of 1877 prohibited product patent for chemicals in other to develop its 
pharmaceutical industry and stimulate research, and in less than 30 years the 
chemical industry had grown to be self-sufficient.1047 Similarly the French Law 
of 1844 prohibited the patenting of products for food and medicine, although 
other chemical products could be patented. The Belgium Patent Law of 1854 
employed the French style and as a matter of fact Italy, Spain, Sweden and 
Japan excluded patent on medical products and were all able to develop its 
pharmaceutical industry.1048  
 
The Ayyangar Committee noted that "such important articles of daily use such 
as medicine or food which are vital to the health of the country should be made 
available to everyone at reasonable prices."1049 The Ayyangar Committee 
therefore suggested that product patents should not be granted in critical areas 
like food and medicines. It recommended that exclusive rights to the process of 
production would accelerate research in developing alternative processes. Thus 
the committee also asserted that process protection could lead to increased 
diversity of products at competitive price.1050  
 
Subsequently, the Ayyangar Committee sought to redress the problem of 
foreigners not working their inventions locally with Compulsory license.1051   
It recommended that the government should maintain the right to revoke 
                                                            
1047 Ayyangar Report 
1048 Ibid 
1049 The Ayyangar Committee discusses the Sargant Report and § 38A of England's Patents 
and Designs Amendment Act of 1919, which marked an introduction to restrictions on patent 
protection for food and to process patenting. Section 38B(2) introduced compulsory licensing 
of patents relating to food substances 
1050 Ibid 
1051 Ibid pt. V. 
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patents whenever they are not worked locally and issue compulsorily license 
for patents when the patent owners decline to license them. 1052 The committee 
based its assessment on the  works of Sir Walterscheid, who stated that Queen 
Elizabeth I made an effort "to stimulate domestic production of both raw 
materials and a wide variety of manufactured goods previously imported from 
abroad" by granting patents.1053 The history and development of British patents 
and the model of compulsory licensing was important in the recommendations 
of the Ayyangar Committee.1054  
 
In the case of Britain, the Ayyangar Committee was able to observe that 
compulsory licensing has been an important concept in the development of 
intellectual property rights in England. India should therefore follow the same 
direction if it wanted to observe the same progress in its development. 
Ayyanger therefore pointed out that “though the U.K. has been one of the 
major industrial countries of the post-war world, she clings with tenacity to the 
provisions regarding compulsory working." 1055 The Committee noted that, 
compared to the policies of the United Kingdom between 1907 and 1919, India 
remained underdeveloped even in 1947, thus justifying the need to include 
compulsory licensing provisions.1056 Thus compulsory licenses have been 
historically seen as an option in promoting industrialization in many developed 
countries. The Ayyangar report was relevant in the way that it sought to 
replicate how developed countries had succeeded in developing their 
pharmaceutical industry 
 
 
 
                                                            
1052 Ibid p.125. Impartial arbitrators will decide what royalties are payable for such licenses. 
1053 Ibid at 1261 (quoting Edward C. Walterscheid, The Early Evolution of the United States 
Patent Law: Antecedents (Part 2), 76 J. Pat. & Trademark Off. Soc'y 849, 855 (1994)). 
1054 See Chapter 3 for a more detailed analysis of this 
1055 Ibid P. 133 
1056 Ibid P 135 
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8.7.4 Indian Patent Act 1970 
The Indian Patent Act, 1970 is crucial for a variety of reasons; firstly it 
abolished product patents on drugs and in so doing removed the monopoly 
power of MNCs in India; secondly it allowed indigenous pharmaceutical 
companies to produce patented drugs, thirdly it granted patents to inventor for 
a limited period of time, giving them monopoly rights and allowing them  to 
exclude of others from using their invention,  and fourthly it served as an 
imperative tool in developing and preserving the generic competence of the 
country. Interestingly the initiative of the process regime that was epitomised 
in the 1970 Patent Act was borne back in 1959. The key objectives of the Act 
were to boost the domestic development of pharmaceuticals at the expense of 
foreign corporations which enabled the pharmaceutical industry to become 
self-reliant. The 1970 Patent Act also sought to put in place a variety of 
protectionist measures: to assist the development of an independent Indian 
pharmaceutical industry; to make new pharmaceuticals cheaply available to the 
Indian public; to encourage local process development followed by bulk 
pharmaceutical production; to reverse the negative pharmaceutical balance of 
payments by stimulating exports; and to encourage original pharmaceutical 
R&D in India.1057  
 
The creation of a process patent pharmaceutical regime in the Patent Act 1970 
excluded patent protection of the final product. This was an important 
development because it meant that  a MNC inventing a new drug could only 
patent the process of manufacturing the new drug and not the final product1058  
1059  In order words only one method or process best known to the patentee 
                                                            
1057 Patents Act, 1970, 27 INDIA A.I.R. MANUAL 450 (1979) India is not a signatory to the 
Paris Convention. However, under § 135 of the Patents Act, India recognizes the priority date 
of the matter disclosed in the application prosecuted originally in a convention country. 
Section 135 also requires that the patentee file an application in India within twelve months of 
a PCT application. 
1058 For the provisions, see The Patents Act, 1970 (New Delhi, Ministry of Law and Justice and 
Company Affairs, Government of India) See section 5 & 8 of the Act. 
1059 The Patents Act of 1970 reads as follows: 
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could be patented.1060 Another important feature of the 1970 Act that came into 
effect in 1972 was its special provision on drugs and foods manufactured under 
chemical processes.  The life of the drug and food patents was reduced from 16 
years to five years from the date of sealing OR reduced to 7 years from the 
date of filling complete specification, whichever one came first.1061 For all 
other patents the limit was set for a period of 16 year.  
 
The significance of the 1970 Act was that it ensured that indigenous 
manufacturers were able to manufacture new drugs immediately if they could 
use an old process of manufacture or new process that was not mentioned by 
the Patentee. The ingenious companies were thereby free to reverse-engineer 
medicines. This resulted in sometimes the same products being produced by 
several manufacturers who could each hold a patent for different processes of a 
patent. 1062 1063  
 
Section 87 of the Patent Act 1970 was significant in the sense that it liberated 
the Indian pharmaceutical industry and drove it into becoming more self-
reliant. Section 87 of the Act stated that process patents for the manufacture of 
food, medicine, drug, and chemical had to be endorsed with the “license of 
                                                                                                                                                            
(1) In the case of inventions- 
a. claiming substances intended for use, or capable of being used, as food or as 
medicine or drug, or 
b. relating to substances prepared or produced by chemical processes 
(including alloys, optical glass, semi-conductors and inter-metallic compounds), 
no patent shall be granted in respect of claims for the substance themselves, 
but claims for the methods or processes of manufacture shall be patentable. 
Patents Act of 1970 § 5. 
1060 Borkar S.K (1974) Patent Act 1970 and its Effect on the Drug Industry in the Country’, 
IDMA Annual Publication, Bombay: Indian Drug Manufacturers Association.  
1061 Chaudhuri. S (2006)The WTO and India’s Pharmaceutical Industry. Patent Protection, 
TRIPS, and Developing Countries. Oxford University Press 
1062 Ragavan, S  (2006)  Of the Inequals of the Uruguay Round. Marquette Intellectual 
Property Law Re view, Vol. 10. No 2 
1063 The process patent provisions contravene the product patent regime envisioned under 
TRIPs, which stipulates that Members shall ensure patent protection "for any inventions, 
whether product or processes, in all fields of technology.” Article 27 of TRIPs requires 
member countries to establish a product patent regime. Hence, the process patent provisions 
contravene Article 27. 
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right” after three years from the grant of a patent.1064 What this meant was that 
even before the three year from the date of sealing expires, the Controller of 
Patent had the power to grant a compulsory license and fix the rate of royalty if 
he thought it was “necessary or expedient in the public interest”, see section 86 
of the Patent Act 1970.1065 These “licenses of right” were issued on the same 
terms as a compulsory license.  The only difference is that it was the 
government responsibility to request the licenses of right as opposed to third 
parties.  Compulsory licenses and licenses of right were significant in the way 
that they enabled other parties to gain a manufacturing license without the 
patentee’s consent.1066 The Indian government found the usage of these 
licenses efficient in enabling them intervene if the patents were not worked to 
the benefit of the indigenous people.1067  This had very far reaching 
implications, because after the Patent Act 1970 was passed anyone could ask 
for a compulsory license and be granted one.  
The 1970 Patent law also imposed artificially low royalty ceiling on 
compulsory licenses. Under section 88, the maximum payment of royalties for 
license under the Act was set at 4 percent of the ex-factory sales; this was 
much lower than those of other countries. For example the United Kingdom 
fixed a maximum limit of 40 percent, whilst the US does not even have a 
maximum limit.1068  The Patent Act also required tests on innovative drugs to 
be carried out in the public domain.  Local indigenous companies could then 
use the information to produce their own medicines thereby avoiding costly 
expensive clinical trials. All the indigenous companies had to prove to the 
Director General of Health Services was that the medicines in question were 
the bioequivalent; this automatically entitled him to register the pharmaceutical 
                                                            
1064 Section 87(1) 
1065 Section 97 of the Patent Act 1970 
1066 Section 88 of the PATENT ACT 1970 
1067 Article 27(1) of TRIPS stipulates that patent rights shall be enjoyed "without 
discrimination as to the place of invention, the field of technology and whether the products 
are imported or locally produced."  
1068 Redwood. H (1994) NEW HORIZONS IN INDIA: THE CONSEQUENCES OF 
PHARMACEUTICAL PATENT PROTECTION 17  
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as generic.1069 Of course many indigenous companies took advantage of the 
liberal environment and explored various processes for manufacturing drugs to 
the great disappointment of many MNC.  
 
The Indian Patent Act began the revolution of developing the Indian 
pharmaceutical industry which has enabled the country provide medicines for 
over 70% of its population. Despite this extraordinary achievement, some 
critics have argued that the policies initiated in the 1970s and 1980s to regulate 
MNC have been withdrawn since the 1990’s. Industrial licensing has now been 
abolished for all bulk and formulation medicines.  Other reversal of polices 
include the fact that all production of drugs are now open to the public and 
private sector, and more importantly MNC are permitted to have 100% foreign 
equity.1070 Indeed critics  have consequently argued that the gains of the Patent 
Act has been further  reversed by the advent of the TRIPS Agreement in 1995 
and the coming into force of the Agreement in developing countries in 2005 
which forced India to provide patents for both process and products if it is was 
to comply with the TRIPS Agreement.1071  
 
8.8 Nigeria’s Patent and Design Act 1970 
Ironically the same year that  India passed its revolutionary Patent Act, Nigeria 
enacted its Patent and Design Act  into law and published as chapter 344 of the 
Laws of the Federation of Nigeria 1990. Unlike the Indian Patent Act 1970, the 
Patent and Design Act  made no significant progress to the pharmaceutical 
landscape in Nigeria, neither did it alleviate the public health crisis facing the 
country.1072  
 
Under the Act, a patent could be granted for a product or process for a period 
of 20 years on condition that the annual renewal fees is paid for the duration of 
                                                            
1069 Ibid 
1070 Working Group of Drugs and Pharmaceuticals 2001, p. 60 
1071 The Patents (Amendment) Act, § 5, Acts of Parliament, 2005 (India). 
1072 Cap 334 Law of the Federation of Nigeria, 1990. Hereinafter called “the Act”. 
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the patent.  The important thing to note about the act is that it does not exclude 
from patentability innovative pharmaceutical products or processes. Indeed 
Chapter 344 (2) (c) “states that an invention is capable of industrial application 
if it can be manufactured or used in any kind of industry, including 
agriculture”, and can therefore be patented’.  Interestingly the Patent and 
Design Act does not guarantee that a patent granted to a patent holder is valid, 
thus Section 4(4) of the Act provides that “Patents are granted at the risk of the 
patentee and without guarantee of their validity”. In my opinion this provision 
went a long way in revealing the uncertainty of the times with regards to the 
validity of national policies and legislations. The Patent and Designs Act was 
therefore not aimed at promoting R&D, nor was it aimed at making the 
pharmaceutical industry self-reliant. Some commentators have blamed the 
uncertainty of the time on the presence of military regimes in Nigeria.  
 
Nigeria has had a very troubled history of military regimes since it gained its 
independence from Britain in 1960. Beginning in 1966, Nigeria has had eight 
military regimes succeeded, which was interspersed between the fourth and 
fifth military regime by a return to civilian rule with the Second Republic 
between October 1979 and December, 1983. The final military regime left 
power on May 29, 1999. Critics have also argued that some of the provisions 
in the Patent and Design Act 1970 were lifted from the English patent law  and 
applied to the Patent and Design Act without judging whether it would 
promote the Nigerian industrial climate or not.   
 
Another provision in the Patent and Designs Act 1970 that is disturbing is the 
fact that section 1(1)(b) of the Patent and designs Act 1970 states that an 
invention will still be patentable if it is an improvement on an already patented 
invention. This section clearly does not leave any scope for boost the domestic 
development of pharmaceuticals. Indeed the Patent and Design Act had no 
protectionist policies that would have assist the development of an independent 
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Nigerian pharmaceutical industry, encouraged local process development or 
encouraged original pharmaceutical R&D in the country.1073  
Schedule 1 of the Patent and Design Act deals with compulsory licenses, and 
makes provisions for the non-working of patents. It gives statutory rights to the 
Nigerian government to authorise the use of patents for the service of 
government agencies.1074 The provisions state that four years after the filling of 
a patent application or at the least three years after a patent is granted, an 
application for compulsory licence can be made to the High Court of Lagos 
State and granted.1075 The provision stipulates that the court can issue a 
compulsory licence if the following criteria are met. Firstly the applicant must 
prove that the patented invention though capable of being worked in Nigeria 
has not been worked, secondly the applicant must prove that the working of the 
patented invention in Nigeria is insufficient to meet  the local demand  for the 
patented product; thirdly the applicant must prove that the importation of the 
patented product is preventing the local working of the patent and fourthly the 
applicant will have to prove that the patentee has refused to grant licences on 
reasonable grounds and this has adversely affected the development of 
commerce in Nigeria. When compared to the Indian Patent Act 1970, the 
criteria that had to be proved before a compulsory license can be granted 
appear to be very cumbersome, if not near impossible for individuals or small 
business to prove. Nevertheless it is important to note that no compulsory 
license was ever issued under the Patent and Design Act.  
 
Although the Patent and Design Act 1970 is still the authority on patents in 
Nigeria today, Nigeria was supposed to have amended its intellectual property 
                                                            
1073 Patents Act, 1970, 27 INDIA A.I.R. MANUAL 450 (1979) India is not a signatory to the 
Paris Convention. However, under § 135 of the Patents Act, India recognizes the priority date 
of the matter disclosed in the application prosecuted originally in a convention country. 
Section 135 also requires that the patentee file an application in India within twelve months of 
a PCT application. 
1074 S.K date-Bah. (1981) Transfer of technology to Nigeria and the Patent and Designs Act 
1970. Journal of African Law, vol. 25, No. 2.  
1075 See s.1 of Schedule 1. 
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laws by 1 January 2005 to conform to the TRIPS Agreement in the same way 
that India has done, but January 2005 passed with no legislation emerging from 
the National Assembly.1076 
 
In 1991, the Nigerian Law Reform Commission took on the task of amending 
the Patent and Design Act. It recommended extensive amendments to the 
existing patent law and modifications to the administration of the IP laws in 
general. On the strength of those recommendations, a draft decree on Industrial 
Property (including patents) known as the Industrial Property Decree1077 was 
drafted. Incidentally, this draft was never enacted into law.  
 
The Nigerian Law Reform Commission draft is nevertheless important for a 
variety of reasons, it reveals the direction that the law makers intend on taking 
in their bid to promote intellectual properties as well as whether they intend to 
create a climate which will encourage innovation and R&D. With regards to 
the access to medicines debate both the 1970 Act and 1991 Draft can be said to 
be inadequate for three reasons, firstly they both failed to lay strong emphasis 
on enacting laws that would promote public health in the face of the 
HIV/AIDS epidemic and other opportunistic diseases, secondly both laws do 
not take advantage of the flexibilities available within the TRIPS Agreement, 
namely compulsory license and parallel importation;  and thirdly are not aimed 
at fostering the growth of the pharmaceutical industry.  
 
In 2002, the Minister of Commerce inaugurated the Intellectual Property 
Commission to establish a legal framework to harmonise and amend 
Nigerian’s Intellectual Property rights laws and bring it up to date with the 
TRIPS Agreement, however by January 2009  no new intellectual property 
laws has been enacted. Indeed many lawyers I spoke to in Nigeria said they did 
not know of any intellectual property Commission and if it existed it did not 
                                                            
1076 Cap 334 Law of the Federation of Nigeria, 1990. Hereinafter called “the Act”. 
1077Industrial Property Decree No. 10 of 1991. 
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have an office. Regardless of the foregoing the bottom-line remains that The 
Patent and Design Act 1970 is out-dated and should be considered obsolete. It 
does not promote R&D  in the country, it practically offers no protection to the 
patent holder, the compulsory licenses and parallel importation clauses in the 
Act are impracticable and unfavourable to the Nigerian government, it does not 
encourage the pharmaceutical industry to grow and does not comply with the 
TRIPS Agreement 
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9   CONCLUSION AND RECOMMENDATIONS: WAY 
FORWARD FOR NIGERIA  
   
 The Federal Government of Nigeria has a lot of grounds to cover in the quest 
for access to medicine for its citizens; nevertheless one of the factors that 
become clear in this research is that the TRIPS Agreement cannot be blamed 
entirely for the lack of access to medicines in many developing countries. 
Indeed Nigeria can take advantage of the flexibilities of compulsory licenses 
and parallel importation in the TRIPS Agreement to ensure that it gains access 
to medicines in the short and long term.  
 
Whilst the high prices of medicines which is one of the effects of the TRIPS 
Agreement contributes to the exorbitant prices of some medicines, other factors 
remain equally important to rectify before the problem of access to medicines 
can be resolved. Nigeria should seek to put in place infrastructure, electricity, 
good transportation systems, technical assistance to existing laboratories and 
guidance on setting up new laboratories for improved medical/ scientific 
research and diagnosis and ensure that the most vulnerable people in society 
such as women, children and PLWHA are protected by the law. One of the 
ways of ensuring that that such people are protected is by equipping these 
people with education and ensuring that these people know their rights as 
citizens of the Federal Republic of Nigeria.  
 
Nigeria should therefore initiate and reaffirm policies and national laws that 
will protect the fundamental human rights of its citizens and in so doing ensure 
that ordinary people have access to the most basic primary health care.  
 
Another key issue that became clear in this thesis was the fact that access to 
medicine cannot be achieved substantially by over-dependence on 
expensive foreign pharmaceutical drugs that are out of reach for most people 
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suffering from diseases like HIV/AIDS.  Indeed what became obvious was that
access to medicine for Nigerians can be enhanced when local pharmaceutical 
industry, traditional medicine, healthcare, and national infrastructure are 
developed and improved.  
 
Nigeria should therefore seek to gain access to medicines by acknowledging 
that the TRIPS Agreement has an important part to play in the social fabric of 
the nation and that due process of law can be followed to achieve the quest. It is 
with the foregoing that the following legal frameworks and policies are r
recommended as the way forward for Nigeria to improve access medicine for 
the people:  
 
Nigeria should seek to become TRIPS compliant as soon as is possible by 
amending its outdated patent laws.  
 
The new patent legislation should contain a clause that protects pharmaceutical 
products as well as limiting patent protection to new chemical entities. The 
legislation should also limit the scope of patentable products to avoid frivolous 
or ambiguous claims and evergreening.  
 
The new patent legislation should ensure that it permits generic manufacturers 
who are already producing generic new drugs can continue to do so 
uninterruptedly. The legislation should also ensure that it does not put in place 
unnecessary legal requirements that will end up deterring local companies that 
may be interested in producing generic medicines.  
 
The new patent legislature should ensure that it incorporates the flexibilities 
available in the TRIPS Agreement into the new law. Flexibilities such as 
compulsory licences and parallel importation can facilitate local production of 
generic drugs and promote FDI.  
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The Nigerian government should also ensure that it sets up a patent office for 
the registration of patent applications apart from the Nigerian Industrial 
Property Offices which presently does not have a website or an office.  
 
The government should seek to make the pharmaceutical industry more self-
reliant. The Nigerian government should adopt national policies that promote 
R&D into NCEs. This will include tax cuts, custom duty exemptions and other 
government incentives for bringing new drugs and medicines unto the market.  
   
The pharmaceutical industry should also be encouraged to develop its 
manufacturing capacity in generic medicines and ensure that it perfects the act 
to reverse engineering of medicines when the patent on them expires. 
 
The Nigeria government should tackle the problem of lack of electricity, 
telephone, water, and transport as a matter of urgency in order to encourage FDI 
and ensure that indigenous companies are able to operate their factories and 
engage in R&D.  
 
The fight against counterfeit trade through NAFDAC should be continued and
sustained with the enactment a new law criminalising trading in counterfeit 
drugs in Nigeria in order to deter criminals from selling fake drugs. 
 
Indeed the quest for access to medicines is a complex issue that requires a 
multi-sectotal approach. Nevertheless I have attempted to show that whilst the 
TRIPS Agreement can always be put at the forefront of the access to medicines 
debate, the Nigerian government will be more successful in tackling the 
problem and saving lives if it focuses on enacting laws that will enable the 
country to have a focus on intellectual property laws which will go a long way 
in ensuring that the search for access to medicines is attained.  
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